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Abstract 
Risk-benefit assessment for decision-making based on evidence is a subject of continuing 
interest. However, randomised clinical trials evidence of risks and benefits are not always 
available especially for drugs used in children mainly due to ethical concern of children being 
subjects of clinical trials. This thesis appraises risk-benefit evidence from published trials in 
children for the case study; assesses the risk-benefit balance of drugs, proposes a framework 
for risk-benefit evidence synthesis, and demonstrates the extent of its contribution. 
 
The review shows trial designs lack safety planning leading to inconsistency safety reporting, 
and lack of efficacy evidence. The General Practice Research Database (GPRD) data was 
exploited to synthesise evidence of risks of cisapride and domperidone in children with 
gastro-oesophageal reflux as a case study. Efficacy data are only available through review 
evidence. 
 
Analysis of prescribing trends does not identify further risk-benefit issues but suggest the 
lack of evidence has led to inappropriate prescribing in children. Known adverse events are 
defined from the British National Formulary and quantified. Proportional reporting ratio 
technique is applied to other clinical events to generate potential safety signals. Signals are 
validated; and analysed for confirmatory association through covariates adjustment in 
regressions. The degree of associations between signals and drugs are assessed using 
Bradford Hill’s criteria for causation. Verified risks are known adverse events with 95% 
statistical significance, and signals in abdominal pain group and bronchitis and bronchiolitis 
group.  
 
The drugs’ risk-benefit profiles are illustrated using the two verified signals and an efficacy 
outcome. Sensitivity of input parameters is studied via simulations. The findings are used to 
hypothetically advise risk-benefit aspects of trial designs. The value of information from this 
study varies between stakeholders and the keys to communicating risks and benefits lie in 
presentation and understanding. The generalisability and scope of the proposed methods are 
discussed. 
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1. Introduction 
Safety of medicines is an important subject and has received considerable attention in 
medical literature as well as in the media. It is mostly the public media that act as the 
mediator between scientific risk-benefit research and the wider public. For some drugs 
however, there is no robust evidence in the form of clinical trials of the risks or the benefits to 
justify their use in certain population or for certain indications. This is particularly true for 
drugs used in children. This may be due to the infeasibility to carry out experimental studies 
for various reasons. Standard observational studies are performed to study the evidence of 
risks and benefits as alternative but they are not free from issues. This thesis evaluates and 
proposes a coherent approach to the assessment of the risks and benefits assessment of 
medicines. 
 
1.1 Benefit and risk in safety of medicines 
Every medical research project involving human subjects should be preceded by careful 
assessment of predictable risks and burdens in comparison with foreseeable benefits to 
the subject or to others (World Health Organisation, 2000). 
 
Principle 16 of the Declaration of Helsinki offers a much more generous approach and 
requirement compared to Hippocrates’ long-held principle in medicine:- 
 
‘Primum non nocere’ (First of all be sure you do no harm) (Hippocrates, 460-370BC).  
 
This rigid philosophy is apparently too ideal for the real world and has never been achieved 
(Pirmohamed, 2003) – some compromise have to be made. 
 
Risk and benefit are the two components in the risk-benefit assessment of drug therapy. The 
assessment of risk and benefit is not only valuable to the manufacturers and drug regulatory 
agencies, but also to the patients/carers themselves. Researchers recruiting participants to 
clinical trials also need to be able to clearly explain and justify the risks and benefits of trial 
drug for the participants to make informed decision. 
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1.1.1 Introduction to benefit and risk 
Benefit is defined as the magnitude of a positive outcome without reference to its probability 
of occurrence, (Weijer, 2000). There is a terminology issue. Weijer argues that the correct 
terminology is “potential benefits” when comparing to risks. I will not however make a 
distinction between the two, but rather use them interchangeably for the simple reason that 
people are more familiar with the term “risk-benefit” than “risk-potential benefit”. In 
biomedical research, (potential) benefits of a drug therapy must be assessed together with the 
probability of its occurrence and the risks to establish the efficacy and safety profile. A 
positive outcome alone must never be used to label a drug as beneficial.  
 
Risk is a very broad subject. In general, risks can be classified into four categories: physical – 
causing bodily harm; psychological – causing emotional distress; social – causing social 
stigmatisation; and economic – impact on financial cost (Weijer, 2000). The collective 
definition is an unwanted or negative outcome. Here I only focus on risks in biomedical 
research in relation to drug use. 
 
Risk is a multidimensional concept of probability and magnitude of harms to research 
participants (Weijer, 2000). One must consider the magnitude of a reaction, and the 
probability of it occurring. For example, in a nested case-control study looking at risk of fatal 
and non-fatal self-harm in first episodes of depression following use of antidepressants, the 
incidence rate of non-fatal self-harm is 2,894 in 100,000 person-years and the incidence rate 
in fatal self-harm is 62 in 100,000 person years (Martinez, 2005). When only considering the 
impact of the individual event, fatal self-harm causes more concern than non-fatal self-harm 
(although one might argue otherwise); but taking the probability of occurring into account, 
non-fatal self-harm may cause more concern as it is 50 times more likely to occur than fatal 
self-harm. 
 
Drug use operates in a heavily regulated environment. Drug regulations vary between 
different countries as determined by individual country perspective on the drugs. In the UK, 
the Medicines and Healthcare Products Regulatory Agency (MHRA) is responsible in drug 
marketing authorisation and post-marketing pharmacovigilance. In the context of drug 
regulation, a favourable risk-benefit ratio or minimal risk must be established to conclude that 
a drug is safe and beneficial for use in human. The methods of judging risks and benefits vary 
and can be very subjective.   
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1.1.2 Adverse drug reactions as risks 
‘Adverse drug reaction’ is not an easy concept to define; and usually the definition is 
contextualised on the situations where it is used. In a survey, 56 different definitions of 
‘adverse drug reaction’ were found used in 76 hospitals (Case, 1986). The definition that I am 
going to use in this thesis is that from the MHRA: 
 
An adverse drug reaction (ADR) is an unwanted or harmful reaction experienced 
following the administration of a drug or combination of drugs, and is suspected to be 
related to the drug. The reaction may be a known side effect of the drug or it may be 
new and previously unrecognised (Medicines and Healthcare Regulatory Agency, 
2008).  
 
For this definition to hold, correct administration of the drug is assumed (SNAPP/NES, 
2005a).  
 
1.1.3 General classifications of adverse drug reactions 
Adverse drug reactions could be immunologic or non-immunologic (Riedl, 2003). 75%-80% 
of ADRs are caused by predictable non-immunologic reactions, whilst the other 20%-25% 
may or may not be caused by unpredictable immunologic reactions (Riedl, 2003). Whilst the 
unpredictable immunologic reactions are associated with a person’s immune reaction, such as 
haemolytic anaemia from penicillin; the predictable non-immunologic reactions cause more 
concern about risk of the drug itself. Examples of non-immunologic reactions are: dry mouth 
from antihistamines (Riedl, 2003); and respiratory adverse reaction from oral NSAIDs 
(Underwood, 2008a). 
 
ADRs of the non-immunologic type are commonly classified into two main categories: Type 
A and Type B (Table 1.1). However, it has been argued that all drug effects are dose related 
and the classifications into immunologic and non-immunologic, type A and B are inadequate 
(Aronson, 2003).  
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Table 1.1: Characteristics of ADR types 
Type A Type B 
Predictable Unpredictable 
Usually dose dependent Rarely dose dependent 
High morbidity Low morbidity 
Low mortality High mortality 
Responds to dose reduction Responds to drug withdrawal 
e.g. low blood pressure with antihypertensive; 
haemorrhage with warfarin 
e.g. anaphylaxis with penicillin; skin rashes 
with antibiotics 
Adapted from Introduction to Paediatric Pharmaceutical Care (SNAPP/NES, 2005b) 
 
Alternative classifications of ADRs have been suggested based on dose, time and 
susceptibility (DoTS) (Aronson, 2003). The DoTS classification extended the standard dose-
response curve to include time of reaction as well as patient’s susceptibility to the reaction. 
We address dose-response relationship through the analysis of the effect of cumulative dose 
on ADRs; time-response relationship is dealt by framing the clinical events within a specified 
period after drug prescription; and the time period specified is considered based on 
susceptibility of an average child to ADRs from cisapride or domperidone. We only use these 
classifications as guidance criteria for capturing adverse events on the dataset but proposed 
our own working definitions of ADRs (Chapter 8). 
 
1.1.4 Prevalence of ADRs in children 
It is difficult to estimate the prevalence of ADR in the general population but some studies 
conducted in hospital patients offer a general idea of this burden. A prospective observational 
study (Pirmohamed, 2004) involving 18,820 patients over 16 years old admitted into two 
hospitals in Merseyside showed that about 6.5% (95% CI 6.2%-6.9%) hospital admissions 
were directly caused by ADRs. Of those admitted due to ADRs in the two hospitals, 2% had 
died. A meta-analysis of prospective studies in hospitalised patients in the United States 
found that 0.32% of patients died from serious ADRs after being admitted (Lazarou, 1998). 
 
Excess practice of off-label medicine use has been claimed to be responsible for many cases 
of ADRs in children particularly (Choonara, 2004; Cuzzolin, 2006; Ufer, 2004). Estimates of 
about 16%-62% off-label drug use was observed in hospitals versus 11%-37% in community 
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settings. Furthermore, about 55%-80% off-label drug use was observed in neonatal wards 
(Pandolfini, 2005). The younger the patient, the higher is the rate of off-label drug use. 
 
1.1.5 Off-label drug prescribing in children 
Off-label prescribing or prescribing drugs outwith their marketing authorisation to children is 
common due to lack of clinical trials in the younger population. Marketing authorisations are 
rarely obtained for drug use in children. The correct formulation of these drugs when used in 
children is thus questionable.  
 
In paediatric population, altering dose is the most common practice when prescribing off-
label drugs (Pandolfini, 2005). Doses for children are often determined by body weight, and 
occasionally by body surface area (Joint Formulary Committee, 2008). Due to its 
unidimensional approach, scaling dosage using body weight is less accurate than using body 
surface area, which correlates more with many physiological phenomena such as 
measurements of organ size, fluid compartment volumes, and assays of blood concentrations 
(Joint Formulary Committee, 2008; Lack, 1997). However, dose rescaling has disadvantages: 
it is not simple enough for routine use, and errors are often made in dose calculations (Lack, 
1997). The reason for having complicated formulae and excess use of off-label medicines in 
children is simply because appropriate clinical trials have not been conducted in children to 
address this issue; therefore no appropriate dosage has been determined.  
 
The second most common practice in paediatric drugs prescribing is to prescribe a drug for 
indications outside its marketing authorisation (Pandolfini, 2005). Although the use of off-
label drug is not promoted, the Medicines Act (1968) does not prohibit the practice, 
recognising informed off-label drug use is often necessary in treating very sick children (Joint 
Formulary Committee, 2008).  
 
There is increasing awareness that this ‘tradition’ should be discouraged; instead good quality 
research should be encouraged before use of drugs becomes an established part of paediatric 
practice. Drugs pharmacokinetics and pharmacodynamics in children may not be the same as 
in adults; for example, younger children may require higher doses per kilogram weight than 
adults due to higher metabolic rates. The nature and cause of illnesses and ADRs may also be 
different between children and adults (Joint Formulary Committee, 2008). Ignoring these 
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issues may expose children to greater (unknown) risks when treated with off-label drugs than 
the risks they may actually experience as subjects of clinical trials.  
 
 The reasons for this dearth of trials in children varied, and include perceived ethical issues in 
studying children, practical barriers, and financial constraints related to relatively small 
market in children. This induces the difficulties of conducting risk-benefit assessments of 
drug treatments in children because good clinical trials evidence is scarce. 
 
Recognition of the challenges to provide evidence of efficacy and safety of drugs in children 
has resulted in various initiatives. The Medicines for Children Research Network (MCRN) 
was established to promote and support drug clinical trials in children. In 2007, the EU 
legislation specified that companies marketing new drugs should provide a Paediatric 
Investigative Plans (PIP) prior to approval by the European Medicines Agency (EMA). 
National Service Framework Standard 10 also addresses medicines in children as priority. 
 
1.2 The motivations for the study 
The motivation for this study
1
 revolves around the issues of safety in medicines and risk-
benefit assessment of clinical evidence. Although it is widely recognised that adverse drug 
reaction is a huge burden to public health, clinical trials planning in general (not only in 
children) do not often properly address this issue at the time of protocol development. 
Sometimes, ADRs do not explicitly form part of the study’s aims.  
 
Adverse events details are often omitted from planned clinical trial protocols and the strategy 
for collecting them is often left to chance reporting. In general, this may be acceptable as it is 
very difficult to pre-specify which adverse events might be observed. But because there are 
various approaches in defining, analysing and reporting of risks and benefits of drugs, a 
systematic evidence-based safety planning is possible. A safety plan too general may lead to 
under-reporting of adverse events thus leads to biasness when a drug is compared to 
alternatives, and to inconsistency in study findings and reporting, as reviewed in Chapter 5.  
 
                                                 
1
 This PhD study is a work initiated when I was working with the Wolfson Institute of Preventive Medicine at 
Queen Mary, University of London. The registration of the PhD and its work are transferred to Imperial College 
London when I moved to the Imperial Clinical Trials Unit with Professor Deborah Ashby in December 2008. 
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The more challenging question is the evidence-based risk-benefit assessment of these drugs 
for use in decision-making in children. Many drugs used in children are prescribed outwith 
their license, where there is no robust evidence of efficacy or safety. Prescribing off-label 
drugs generally implies that the prescribers feel that the off-label drug is beneficial therefore 
are less likely to actively monitor or report any unknown potential adverse events. There is 
increasing awareness in the need for clinical trials in children to provide more robust 
evidence of efficacy and safety of drugs use in this population. However, the lack of safety 
knowledge about the trial drugs being used in children is still a major ethical hindrance for 
these trials to take place. Where there is known to be insufficient safety evidence for a drug 
that would be used in trial, it begs the question that the trial is at all safe to conduct. 
 
Because there have already been experiences in prescribing off-label drugs to children in the 
primary care, there are useful clinical data available on the efficacy and safety that may help 
make future trials safer. In the UK, a valuable source for such data is in the GPRD which I 
introduce in Chapter 2 as an alternative source of evidence for risks and benefits. 
 
An example of this situation is introduced in detail in Section 1.4; and is used as the case 
study in this thesis.  
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1.3 Research questions, objectives and contributions of the study 
There are two themes of risk-benefit to this thesis that form the research questions: 
(1) The retrieval and verification of risks and benefits evidence 
(2) The integration and communication of risks and benefits evidence 
 
Two main objectives are set in this thesis to answer the first research question: 
(1)  to investigate the quality of available clinical trials evidence of risks and benefits of 
drugs use in children; and 
(2) to investigate the feasibility of information retrieval (data mining) of the evidence of 
risks and benefits for off-label drug prescribing in children in a routine healthcare 
database as an alternative source of evidence 
 
More specific objectives are addressed in Chapter 8 when they are applied to the case study 
(Section 1.4). 
 
The objectives for the second research question are: 
(1) to investigate the available quantitative methods of integrating risks and benefits 
evidence for use in clinical decision-making; 
(2) to build a general framework for risk-benefit assessment where clinical trials evidence 
may be insufficient or unavailable for future decision-making; and 
(3) to demonstrate how the evidence of risks and benefits from this study can be 
propagated to decision-makers 
 
The contribution of this study includes the structured approach offered by the final 
framework (Chapter 10) to risk-benefit evidence synthesis; and the value of information this 
study adds to inform decision-makers about the current evidence of risks and benefits of the 
drugs in children. 
  
Part I: Introduction 
Chapter 1 | 39  
 
1.4 Background to case study 
There are concerns about conducting clinical trials in children with off-label drugs that have 
neither been proven to be safe nor proven to be effective in children. One particular example 
is the treatment for gastro-oesophageal reflux disease (GORD) in children with domperidone 
(see Chapter 4). 
 
There is no well proven treatment for gastro-oesophageal reflux disease (GORD) in children 
despite being common problems in the clinics. Domperidone is already seen as “routine care” 
in the hospitals and the general practices. Domperidone is unlicensed for this use (Paediatric 
Formulary Committee, 2008), and there is insufficient evidence that treating GORD in young 
children with domperidone is actually beneficial (Pritchard, 2005). The prescribing of 
domperidone in the UK has greatly increased in recent years following the withdrawal of 
another off-label drug widely used to treat GORD, cisapride, in 2000 due to serious 
arrhythmic adverse events. Due to lack of clinical trials evidence, its use is only supported by 
the experience of healthcare professionals prescribing them over the years. 
 
As domperidone has been used off-label in children for the treatment of gastro-oesophageal 
reflux for many years, data on its use are readily available to form the basis investigations on 
its risk-benefit balance. A source where this information is collected is in primary care as 
addressed earlier. It is acceptable to assume that sick children (usually by parents/carers) are 
taken to see the general practitioners presenting some complaints. These children are then 
prescribed with some medications to be taken over a period of time for the complaints where 
applicable. The complaints and prescriptions that take place are recorded by the GPs onto the 
patients’ medical record which is stored on the practice database. Assume now that the 
children experience some adverse events whilst on the drug therapy – which might or might 
not be related to the drugs given – are then taken back to see the GPs. Again, the complaints 
during that clinic visit are also recorded. Although GPs may be responsible for the 
prescriptions, they may simply be continuing the treatment initiated in the hospitals for these 
children. 
 
Initiatives such as the General Practice Research Database (GPRD) exist to make primary 
care data available for research and are supported by GPs. About 500 general practices in the 
United Kingdom contribute their data to GPRD. GPRD ensures that the data from the general 
practices are of high quality and before making them available for research. 
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A double-blind randomised placebo-controlled trial “Treating Refluxing Infants: efficacy and 
safety of Domperidone” (TRI-Domp) has been planned to seek the definitive answer to 
whether the prescribing domperidone in children to treat GORD is appropriate. TRI-Domp is 
a double blind randomised placebo-controlled clinical trial of efficacy and safety of 
domperidone in children 0-18 months old led by Dr. Nick Croft. TRI-Domp recognises the 
need for a domperidone trial in infants because of the issues previously discussed. 
 
An opportunity has arisen at the time when TRI-Domp was proposed. The MHRA was 
looking to commission a study to explore the potential use of the GPRD database in 
automated safety signal detection. An exploratory study Gastro-Oesophageal Reflux 
Medicine – Evidence for Trials (GORMET) was proposed, commissioned and set up. 
GORMET is a collaborative study with the MHRA
2
 under their level IV license which started 
in January 2007 and ended in December 2009. The study explored potential use of GPRD 
data in automated signal detection for the assessment of drug safety with focus on cisapride, 
domperidone and metoclopramide as used in the primary care in children under 18 years old. 
For simplicity and also because metoclopramide is not a popular drug for the treatment of 
GORD, the results from metoclopramide analysis are not presented in this thesis but can be 
found in the full GORMET report (Mt-Isa, 2010). 
 
GORMET is a retrospective observational study. The overall aim of GORMET was to 
explore whether the information held in the General Practice Research Database (GPRD) can 
be used to inform future trials of medicines in children; in particular to directly inform TRI-
Domp on the safety aspects of the trial.  
  
                                                 
2
 Disclaimers 
 
MHRA Funding/Publication Acknowledgement: GORMET was funded by the MHRA Pharmacoepidemiology 
Research Programme (project number SDS011) and the Executive Summary will be published in full on the 
MHRA website. 
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In terms of safety assessment, GORMET explicitly seeks the information on drug safety to 
decide:  
(a) whether the proposed trial (TRI-Domp) is needed and safe to conduct;  
(b) if so, what are the important safety parameters; and  
(c) what is the expected risk-benefit profile for the trial. 
 
GORMET observed that there were more cases of intolerability and allergies for cisapride as 
recorded by the GPs compared to domperidone and metoclopramide. This was probably due 
to well-publicised warnings that were coming out during the years when it was used therefore 
prompted the GPs to be more vigilant in monitoring true clinical intolerance. GORMET 
identified two raised signals for potential ADRs for cisapride (not associated with the reasons 
for cisapride withdrawal), ten for domperidone, and three for metoclopramide. If a GPRD 
safety study is useful for drugs that are used off-label, it is anticipated that it would be of 
greater use when a drug is licensed and its use is well documented. 
 
The data and results from GORMET are used as the backbone to this thesis to illustrate using 
a topical question a general framework for risk-benefit decision-making based on evidence. 
The applications to the case study through GORMET are presented in Part II of this thesis.  
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1.5 Structure of thesis 
Throughout the thesis, I use “we” to refer to the joint decisions made as part of the GORMET 
study team, of which I was also a member. This is to emphasise that this work was 
collaborative, and that the decisions about the designs and discussions had been made 
collectively as a group. Otherwise I use “I” to reflect my own contributions (after consulting 
my supervisors) to this thesis. 
 
This thesis is structured in four parts. Part I is the prologue which includes this chapter and 
two other chapters as the introduction to this study. Chapter 2 discusses the different sources 
of evidence for risks and benefits of drugs available to the decision-makers. These are clinical 
trials evidence, spontaneous reporting evidence, epidemiological studies evidence, systematic 
review evidence, and evidence from routine healthcare data. The most suitable data source 
identified fit for this purpose is the General Practices Research Database (GPRD) for the 
reasons described in Sections 1.2 and 1.4. The background to GPRD and issues surrounding 
it including the quality of the data, and the clinical classifications system available are also 
discussed. 
 
Chapter 3 is the last chapter in Part I. It introduces the statistical methods used in this thesis. 
The methods of meta-analysis used in the review in Chapter 7 are discussed. The underlying 
design principles of observational studies are then discussed. A cohort study design can 
measure risks in terms of incidences, risks ratio, and odds ratio; whilst a case-control study 
design can only validly measure odds ratio. These measures of risks can be obtained from 
regression procedures such as Poisson and logistic regression, which I use in this thesis. 
Signal detection methodology in data mining applied in this thesis is described. I then present 
the Bradford Hill criteria for causation; and discuss the quantitative approaches to risk-benefit 
assessment in decision-making. Because this thesis approaches the problem using both 
classical and Bayesian technique, I give a short account on these two schools of statistics. 
Although Bayesian statistics have grown in popularity in the application in medical statistics 
lately (Ashby, 2006), most of the analyses in this thesis are classical. This is because in large 
dataset such as GORMET data, classical analysis offers better practical inference to Bayesian 
analysis. In this thesis, Bayesian analyses are performed when the models required cannot be 
easily formulated using classical methods. This chapter finally discusses statistical power and 
sample size determination for a trial. 
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Part II is the applications of the methods to case study as partly investigated through 
GORMET. Chapter 4 first reviews the epidemiology of the medical condition in children to 
understand its public health importance. I discuss scientific background to GORD from the 
literatures, review the burden of the condition in the population of children, its symptoms, 
and the management and treatment options currently available. In Chapter 5, I review the 
extent of safety planning and reporting in clinical trials of cisapride and domperidone in 
children to learn about the quality of available trial evidence. The purpose of this narrative 
review is to highlight the lack of evidence for cisapride and domperidone arising from current 
practice of trial planning and reporting. 
 
Trends analysis of drug prescribing is presented in Chapter 6. It is particularly important to 
learn about how the trends of drug prescriptions changed over time and whether there are any 
new issues arising. This is achieved through the analysis of prescribing data on the GPRD 
dataset. Trends analysis also demonstrates the importance of dealing with this topic for 
domperidone at this point in time, where the prescription rates in children are increasing 
despite the lack of evidence of efficacy or safety. 
 
Chapter 7 assesses the quantitative evidence of risks and benefits from clinical trials of 
cisapride and domperidone in children through meta-analysis. The evidence found is not 
sufficiently robust to inform the risk-benefit balance for or against the use of cisapride and 
domperidone in children. The quantitative review demonstrates there is a need to investigate 
further evidence from alternative sources to establish the risk-benefit balance for these drugs 
when used in children, where GPRD data is found to be a rich and suitable source. 
 
Chapter 8 then investigates alternative evidence to contribute to risk-benefit assessment of 
cisapride and domperidone in children through the use of GPRD data. Known risks
3
 are 
defined from the information in the British National Formulary (BNF). Information on 
known associated risks is useful, and can increase sensitivity in detection of unknown risks. 
“Unknown risks” by definition are risks that have not yet been recognised to be associated 
with a (drug) treatment. In pharmacoepidemiology/pharmacovigilance, these are known as 
‘signals’. The sensitivity of a signal detection algorithm is increased when the numerator and 
denominator are not inflated by risks that are already known. Because signal detection 
                                                 
3
 Known risks are risks which have already been identified previously for associated (drug) treatment; or 
otherwise specified. See Section 8.3.1 for the definition used in this study. 
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algorithm can only mathematically determine the signals, a two-step validation procedure is 
proposed here to incorporate clinical viewpoint. The signals are only disproportionate events 
in terms of relative frequency. Their degree of associations to the drugs are raised but are still 
not fully quantified. In order to learn more about the association to the drug, a confirmatory 
association analysis is carried out under a case-control study design for each validated signal 
from the previous step. The relationship of the signals to the exposure drugs and other 
covariates is explored further. The Bradford Hill Criteria for causation introduced in Section 
3.8 are adopted to discuss the degree of association of each signal. To determine causality 
with certainty is not an easy task. Therefore, the causality framework is used to focus the 
thinking in discussing whether a signal is likely or unlikely to be caused by the drugs.  
 
Part III is dedicated to the second theme of this thesis which is in the integration and 
communication of risks and benefits evidence. Known adverse events that are statistically 
associated with cisapride and domperidone and the signals verified to have some likely causal 
relations to the drugs are then taken forward as risks attributes in the quantitative risk-benefit 
assessment in Chapter 9. Examples of how the quantitative approaches described in Section 
3.9 to be applied in real life evidence data are illustrated using the verified signals. 
 
Chapter 10 summarises the framework developed in the earlier chapters for the assessment of 
risks and benefits based on evidence. I describe how the risk-benefits evidence from this 
study can be disseminated into TRI-Domp. I then discuss the value of information from this 
type of study from several perspectives: patients/carers, healthcare professionals, researchers, 
regulators, and pharmaceutical companies. The use of visual displays in communicating the 
idea of risks and benefits also discussed. Finally I discuss the difficulties and challenges 
associated with risks and benefits assessment and their communication. 
 
Part IV is the last part of this thesis. I discuss the generalisability, strengths and limitations of 
this study in Chapter 11. Some suggestions for further research are made; and some related 
ongoing studies are discussed to provide a wider overview of the future direction for risk-
benefit research in medicines. 
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2. Sources of evidence-based risks and benefits 
2.1 Introduction 
History teaches that something can be learnt from the past. This also applies to evidence of 
risks and benefits, where evidence are collected, archived and studied in a number of ways. 
However, the quality of different sources of evidence and their relevance to different 
purposes vary; and some are considered better than the others. In this chapter, I discuss in 
general five sources that can provide evidence-based risks and benefits in some sense of 
chronological order: 
1. Clinical trials (Section 2.2) 
2. Spontaneous reporting (Section 2.3) 
3. Epidemiological studies (Section 2.4) 
4. Systematic reviews (Section 2.5) 
5. Routine healthcare data (Sections 2.6 and 2.7) 
 
Efficacy and safety studies start in pre-clinical laboratory settings, be it molecular studies or 
animal studies. Molecular studies are performed on tissue samples, blood, or urine from 
people with certain disease e.g. cancer versus normal samples. In molecular drug studies, the 
efficacy of experimental drugs or chemical compounds is the main objective. Safety is of less 
concern as there could be no direct harm to humans. Animal studies take place after 
molecular studies to give further insight into the compounds and its mechanism of actions. 
Despite some major ethical issues in animal testing, drug authorities require extensive 
toxicity data from animal studies before clinical testing can start to ensure that it is safe 
enough for human. (Non-human) Animal studies can also potentially give insight into the 
disease mechanisms, as well as efficacy and treatment effects of drugs. The guideline for 
conducting animal research in the UK is available from The Royal Society (The Royal 
Society Animals in Research Committee, 2004). There are still many issues in using pre-
clinical animal studies to inform clinical trial design (Murray, 2010); from ethical issues, to 
translation to humans (Murray, 2010), and low methodological (Bebarta, 2003) and reporting 
standards (Kilkenny, 2009). Pre-clinical studies however are beyond the scope of this thesis 
and will not be discussed further. 
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2.2 Clinical trials 
A clinical trial is a planned experiment involving patients, designed to elucidate the most 
appropriate treatment for future patients with a given medical condition (Pocock, 1983) by 
comparing a new or different types of treatment against the best currently available treatment, 
should there be one (British Medical Research Council, 2008). 
 
The largely forgotten 1944 Patulin trial is regarded as the first decently conducted clinical 
trial (Chalmers, 2004; Hart, 1991). It was a large scale trial involving 1,348 participants from 
offices, factories and two schools in the UK to test the efficacy of patulin – a metabolic 
product of penicillium patulum mould which grows on apples – as a cure for common cold. 
 
Harold Raistrick initially supplied patulin to W.E. Gye, the director of the Imperial Cancer 
Research Fund’s laboratories, for testing as cancer treatment. Infected with severe cold at that 
moment, Gye douched his nasal passages with the drug and found that his nose cleared within 
an hour. He repeated it with a tenth of the strength twice more that day and recovered the 
following morning. He then tested the drug on his friends and colleagues who also found it 
helpful with their cold. This leads to larger trials in the navy (Hopkins, 1943), and the army 
(Stansfeld, 1944). The trials yielded conflicting results: Navy trial significantly favoured 
patulin; the army trial showed a small difference in favour of placebo (Chalmers, 2004). 
 
In the hype of the excitement for the cure for common cold, the large scale Patulin trial was 
proposed to the MRC by Therapeutic Research Corporation (manufacturer of patulin) in 
October 1943. Treatment allocation in the Patulin trial was cleverly concealed from the 
knowledge of participants and medical personnel (‘double-blind’) by having two containers 
with patulin (labelled R and T) and two containers with just the buffer solutions (labelled Q 
and S). This scheme is superior in reducing allocation bias and error than having only one 
container of each. A treatment allocation mimicking a randomisation was achieved by an 
effective alternation scheme to divide the participants equally into two groups (Hart, 1991). 
Unfortunately, the Patulin trial killed the excitement when it concluded that patulin was not 
an effective treatment for common cold (Patulin Clinical Trials Committee, 1944); they 
found placebo significantly better at treating common cold at three weeks but dismissed this 
as irrelevant finding; and the last of its kind (Hart, 1999). 
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In 1947, MRC ran a second trial to evaluate streptomycin in tuberculosis which allocated 
patients to treatment of either streptomycin or placebo using a random number sampling 
technique. The streptomycin trial is widely regarded as the first randomised clinical trial but 
weak in design as it was unblinded (Hart, 1999). 
 
Both the Patulin and streptomycin trials demonstrate novel approaches to clinical trials, 
although one lacks of what another has. Taking the best approach in both, we have a double-
blind randomised controlled (clinical) trial (RCT) – which is largely received as the gold 
standard in clinical trials in order to obtain conclusive evidence. However, to get a drug 
approved for specific use is not a one-step process but is a rather longer process involving 
different stages and resources. 
 
In Section 2.2.1, I describe the conventional approach to clinical trial designs where new 
drugs are tested through a series of distinct experiments. The conventional approach can take 
very long time and involving many subjects from start to finish, and can be regarded as 
conservative. However, to this day, many pharmaceutical companies still employ this 
conventional approach to clinical trials. More innovative approaches are available to address 
the limitations of the conventional approach, and are described in Section 2.2.2.  
 
2.2.1 Conventional approach to clinical trial designs 
Traditionally, when a new drug is discovered, it goes through three phases of clinical trials 
before it is licensed for use in general population – conventionally referred to as Phase I, 
Phase II, and Phase III. A few years into its use in ‘real life’ environment, a post-marketing 
evaluation (Phase IV) takes place. 
 
Phase I clinical trial evaluates the safety of the drug in human. The drug is tested on a small 
number of healthy volunteers, usually adults less than 45 years old, before it is tested in a 
more vulnerable population of those with the disease it is designed to treat. In Phase I, the 
maximum tolerated dose is established by cautiously increasing administered doses. 
Physiological (or psychological) changes are observed for any abnormalities. In some cases, 
with aggressive treatment e.g. for cancer, the patients are used instead. 
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Phase II trial tests the drug in a larger group of patients following a successful safety 
evaluation in Phase I. A few hundred participants with the medical condition it is meant to 
treat are given the drug to test its efficacy for the medical condition. Safety of the drug is also 
evaluated. The test on Gye himself, his friends and colleagues is a Phase II trial. Phase III 
trial took place following a positive outcome in Phase II. 
 
Phase III aims to evaluate whether the new drug is superior in terms of efficacy and safety in 
treating a particular medical condition when compared to the best available treatment at that 
time or a placebo, if there were none. It involves a much larger group of patients as the 
differences to detect may be small. Phase III takes longer than phase I and II; and requires 
patient randomisation.  The patulin trials (Hopkins, 1943; Patulin Clinical Trials Committee, 
1944; Stansfeld, 1944) are illustration of phase III clinical trial. A successful Phase III trial 
will determine if a new drug should be licensed for marketing, but this is not always the case 
– European Medicines Agency (EMA) approved 9/18 anti-tumoral drugs without going 
through a Phase III trial (Garattini, 2008). Current European legislation also does not require 
that a new drug is compared with other drugs already available for the treatment so long as 
quality, safety and efficacy of the new drug can be demonstrated; making it difficult to 
properly evaluate the efficacy a new drug in comparison with currently available drug for the 
same medical condition (Garattini, 2008). 
 
Even if a drug did go through Phases I to III of clinical trials, it is still not sufficient to 
evaluate all the risks associated with a drug. The use of a drug in the general population is not 
the same as when it is used in a controlled clinical trial setting. For example, many efficacy 
and safety of drugs are not tested in children but are still widely used in this population. 
Therefore, the post-marketing or Phase IV trial is now a more common practice compared to 
the 1970s, with an increased focus on children (Steenburg, 2006).  
 
Phase IV trial is conducted after a drug has been licensed for use; to learn more about the 
adverse drug reactions previously missed during the earlier phases. In some cases, it is also 
performed to develop new treatment uses for a drug; or to compare with other treatments for 
the medical condition (The Association of the British Pharmaceutical Industry, 2003). 
However, under the current pharmacovigilance system, Phase IV trial is not a compulsory 
obligation of the drug manufacturers. It has been argued that some changes in the current 
regime are required to ‘significantly tighten the evidentiary requirements’ of the safety of a 
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drug by making Phase IV trial an obligation of the manufacturer when necessary (Steenburg, 
2006). Steenburg argues in his paper (Steenburg, 2006) that Merck should be required to 
conduct a Phase IV trial to evaluate safety of Vioxx® when used in the general population. 
This was sparked by the finding in VIGOR study (Bombardier, 2000) of a five-fold increased 
risk of heart attacks in those on Vioxx® treatment compared to naproxen. The need for the 
trial was clear but never took place, demonstrating how earlier phases of trials were unable to 
observed certain drug safety issues, and how it managed to slip through current system. Not 
only it is important in adults drug trial, Phase IV trial in children should also be mandated for 
new drugs provided that the drug is used, or likely to be used widely in the population 
(Steenburg, 2006). 
 
The conventional trial designs by phases do not always work in real world due to demands 
and limited resources. For example, a drug might be required urgently for chronic diseases or 
for some untreatable diseases (e.g. HIV/AIDS or some cancer), access to new drugs are being 
pressured by patient groups. These have received response from the regulators through the 
introduction of schemes to allow faster access to drugs like the conditional marketing 
authorisation in the EU (Willis, 2007). Marketing authorisation can be awarded at the end of 
phase III trial conditional on the fulfilment of phase IV commitments; or it could also be 
dependent on a successful phase II trial as suggested by the 2006 Cooksey Review which is 
being implemented by NICE (Chalkidou, 2007). More close collaboration among 
stakeholders was called for, identifying the need for more innovative clinical trial designs to 
help making the time taken from drug development to getting them to the market shorter 
without compromising their efficacy and safety. 
 
2.2.2 Innovative approaches to clinical trial designs 
Many aspects of clinical trial designs have evolved over the decades with the endeavours to 
improve the efficiency, and to deal with some of the drawbacks of conventional clinical trial 
designs by phases. An innovative design that is gaining momentum in drug development is 
the adaptive trial design, originated back in the 1970s (Efron, 1971; Simon, 1977; Wei, 
1978), and is described here in brief. The term “adaptive design” is often used loosely but can 
best be described as a trial design that uses accumulating data in order to decide how a live 
trial is to be modified without undermining its validity and integrity (Gallo, 2006).  
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There are many types (or techniques) of adaptive designs which are reviewed in greater 
details elsewhere (Chow, 2008). Adaptations usually employed to clinical trial designs can be 
classified into three broad categories: prospective, concurrent, and retrospective (Chow, 
2008). ‘Prospective adaptation’ includes but not limited to adaptive randomisation, stopping 
trial early due to safety issues, “dropping the losers”4, and sample size re-estimation. 
‘Concurrent adaptation’ refers to ad hoc modifications to trial design and includes but not 
limited to amendments to inclusion or exclusion criteria, changes to dose regime, changes to 
initial hypothesis, and changes to trial endpoints. ‘Retrospective adaptations’ includes but not 
limited to modifications to statistical analysis plans prior to trial database lock, and 
unblinding of treatment codes during the trial. 
 
At the initial trial design stage, only the prospective adaptations could be determined in 
advance. Four adaptive randomisations procedures were compared against balanced 
randomisation
5
, and each other (Berry, 1995). The robust Bayes procedure
6
 trumps over 
simple balanced randomisation, J. Bather
7, the ‘two-arm bandits’8, and play-the-winner9 
procedures. Adaptive randomisation procedures are not free from drawbacks, and some have 
been criticised (Armitage, 1985; Simon, 1977), such as assignment bias, treatment balanced 
by covariates, the appropriateness of using classical/frequentist analysis on the results, the 
timing of response in trials, and the problems with obtaining informed consent due to the 
nature of adaptive trials (Berry, 1995). 
 
An adaptive design allowing for premature stopping of the trial is the sequential design where 
stopping boundaries are determined at the initial trial design and adopted at pre-specified 
interim analysis if the results were beyond the boundaries (Chow, 2008). A seamless phase 
II/III design is a special form of sequential design where the conventional phase II and phase 
III clinical trials are seamlessly integrated (Inoue, 2002). The design circumvents the 
                                                 
4
 “Dropping the losers” is a design adaptation where a treatment comparison (including dose or duration 
regimes) is found to be inferior to other treatments in the trial during the trial conduct, and consequently 
dropped from being tested further in the trial. 
5
 Participants are randomised in equal numbers to treatments 
6
 Based on dynamic programming and is similar to play-the-winner procedure (see 9), but all accumulated data 
up to the point of analysis is used to determine the current best treatment for the next allocation (Berry, 1995). 
7
 The first two participants are randomised with equal probabilities trial treatments (in the case of two treatments 
comparison). Subsequent participants are randomised based on the probability of observed responses at that time 
point (Bather, 1985). 
8
 Participants are randomised to a treatment based on the probabilities that it is superior to the comparative 
treatment at that time point from the accumulated data (Thompson, 1933). 
9
 The first participant is randomised with equal probabilities to a treatment. The next participant is allocated to 
the same treatment if it were successful; otherwise the comparative treatment is allocated (Robbins, 1952). 
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weakness of phase II trials which are often being analysed as underpowered phase III trials. 
Through the seamless phase II/III design, participants are randomised to treatments 
throughout. During the “phase II” part of the trial, interim analyses were made repeatedly in a 
set time interval to determine whether the trial is to stop early, to continue with phase II, or to 
proceed to phase III. If the latter is decided, phase III begins as an extension of phase II.  
 
The concept of seamlessly integrating phase II and III has been taken upstream with the 
proposal to combine phase I and II (Whitehead, 2007; Whitehead, 2010). In the phase I/II 
combination design, both efficacy and safety data are collected from doses that appear to be 
safe focussing on those that provide benefits, until sufficient benefit data has been collected. 
This design allows continuous monitoring of efficacy and safety distributions at various 
treatment doses. Sufficient data can be collected safely and efficiently to make early phase 
trials’ analysis more informative (Whitehead, 2010). 
 
The advantage of these innovative sequential designs is that it saves time and resources by 
allowing all data to be used in analysis and decision, and by allowing continuous accrual of 
participants to the trial (Inoue, 2002). Less number of participants has to be recruited 
compared to the split conventional designs. Consequently, these designs ensure that fewer 
participants are exposed to the inferior treatment, and that more trial participants would 
benefit from the superior treatment. 
 
Advancing the research into innovative clinical trial designs is one of the agenda of the FDA 
Critical Path Initiative which was launched in March 2004 to address six public health 
challenges in developing, evaluating and manufacturing new drugs (FDA, 2004; FDA, 2006). 
As a result of the Opportunities List call, a guideline for the industry was published on 
adaptive designs (FDA, 2010). Some concerns about the multiplicity issues arising from the 
application of adaptive designs in drug trials prompted the FDA to publish strategies to 
approach the related issues that matter to the regulators (Wang, 2011). 
 
2.2.3 The essence of clinical trials 
Clinical trials (in human) are run to establish the efficacy of medicines, and to assess its 
safety when used in the target population. The efficacy of a drug is often predictable from its 
pharmacology (based on pre-clinical testing), and methodologies for studying efficacy are 
Part I: Sources of evidence-based risks and benefits 
Chapter 2 | 52  
 
well established (Pocock, 1983). The Steering Committee of the International Conference on 
Harmonisation (ICH) produced some important statistical elements to consider in clinical 
trials in their guideline on statistical methodology (E9) commonly known as the ICH-E9 
guideline (Lewis, 1999). On examination of ICH-E9 guideline, the focus is mainly on the 
efficacy. Evidence of efficacy comes in various forms such as laboratory measurements of 
biomarkers, visual analogue scales, and psychometric health instruments scores. By contrast, 
safety of a drug is often far less predictable and often further complicated by underlying 
diseases and/or drugs interaction. The methodologies for studying safety in trials are not as 
well developed. ICH-E9 does value safety as an important element in clinical trials, but it 
also addresses the complexity and the lack of consistency of safety assessment and reporting 
in clinical trials (Lewis, 1999). 
 
2.3 Spontaneous reporting through the Yellow Card Scheme 
Running a Phase IV clinical trial is not the only way to learn about the safety of a drug use in 
the general population. In many countries, spontaneous reporting systems have been set up 
for this purpose. In the UK, MHRA and the Commission on Human Medicines (CHM) run 
the spontaneous adverse drug reaction reporting scheme called the Yellow Card Scheme 
(YCS). It acts as an early warning system for unrecognised adverse drug reactions identified 
through the use of medicines in the general population and is claimed to be the best suspected 
adverse reaction reporting scheme in the world.  
 
The scheme started in 1964 as a result of the thalidomide tragedy. It was managed by 
Subcommittee of Adverse Reactions of the Committee on Safety of Drugs (later replaced by 
the Committee on Safety of Medicines under the Medicines Act 1968). In the first decade of 
the scheme started, 3,000 to 5,000 reports were received each year. Of these, about three-
quarters were received on a business reply card – the ‘yellow card’ – which has given birth to 
its name. Only doctors, dentists and later coroners were allowed to submit reports on 
suspected adverse reactions following drugs use then. Figure 2.1 shows the number of 
Yellow Card reports received since the scheme started up to year 2002. 
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Figure 2.1 Chronicle of total annual Yellow Card reports 
 
Graph extracted from Pharmacovigilance in the UK website on 28/06/2010 (University of Liverpool, 2010) 
 
The Yellow Card Scheme as we know today has undergone some necessary changes from the 
original scheme started over 40 years ago to reflect changes in the current healthcare system. 
The major improvement was made in 1991 when the database was enhanced with a new 
computer system known as ADROIT (Adverse Drug Reactions On-line Information 
Tracking). ADROIT stores the image of the actual Yellow Card report as well as the details 
of the report. Other changes include expanding the list of professions who could report an 
adverse event through the scheme. Not until 1997 were pharmacists added to the list. Nurses, 
midwives and health visitors had been added to the list of profession who could report in 
2002; realising their increasingly important roles in the healthcare system. Nurses, for 
example are in an excellent position to report any suspected adverse drug reactions as they 
have close contacts with patients. Since nurses began using the scheme, the reporting of 
ADRs has doubled (Hunt, 2003). More recent changes include allowing direct reporting 
through the Yellow Card Scheme by the patients themselves, parents and carers of the 
patients if they suspected an adverse drug reaction after taking a medicine. Reports now can 
be made online through the MHRA website or through the post by completing a patient or 
healthcare professional reporting form (downloadable from MHRA website). 
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The Yellow Card Scheme plays very important role in pharmacovigilance in the UK. This is 
because: we can only gain limited information on efficacy and safety of new drugs from 
clinical trials; new drugs are approved for marketing in shorter time; the increase use of over-
the-counter drugs; and the economic costs of sudden drug withdrawals due to adverse drugs 
reactions (ISDB, 2005).  
 
Up to 2002, there were around 500,000 suspected ADRs reported via Yellow Card Scheme 
and the system has helped to identify many previously unidentified ADRs, e.g. Quixil and 
neurotoxic reactions, Vigabatrin and visual field defects and Kava-kava and hepatoxicity 
(CSM/MCA, 2002). Through the scheme, rare reactions could be identified and studied 
which otherwise would have been missed. However, a high level of specificity is expected 
due to the nature of the scheme. The scheme is particularly useful at learning about safety of 
medicine (licensed or unlicensed) use in children. Estimates from MHRA showed 8% of the 
Yellow Card report between 1997 and 1998 were for children (Nandy, 2004) and data from 
year 2000 showed about 43,000 of the total reports were for children (Clarkson, 2002). With 
the size of data available on children more research on paediatric drug safety using Yellow 
Card Scheme data is anticipated in the future (Wong, 2005). 
 
Some limitations of the scheme had been reported in various studies, and listed below. 
 
1. A common issue is under-reporting of ADRs. This may be a consequence of 
healthcare professionals not recognising an ADR or not reporting it (Belton, 1997; 
Crombie, 1984). In UK general practices, less than 10% of ADRs were reported 
(Lumley, 1986). Some of the reasons given were the reaction was too trivial, already 
well-known or the causal relationship was uncertain. Patients themselves may be 
reluctant or hesitant to report a suspected reaction which may be an ADR either 
directly to the scheme or by visiting the hospital or their general practitioners. The 
reasons may be the same as those given by GPs and might be personal or 
psychological like being afraid having other people passing judgements. 
 
2. The use of Yellow Card Scheme data in research is also limited and careful 
considerations must be given when disseminating the results (other than it has to be 
read and approved by MHRA before submission for publications). The Yellow Card 
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Scheme data cannot be used to determine the incidence rates of ADRs as both 
numerators and denominators are incomplete (Clarkson, 2002; Sacristán, 2001). 
 
3. The quality of the data is variable in the sense that some important signals are missed 
or delayed (Clarkson, 2002). Patient-reporting of ADRs could help improve the 
delayed signals and provide earlier detections. This was demonstrated in the suspected 
reactions to paroxetine where patients tended to report on average 273 days earlier 
than doctors reported the same reaction (Egberts, 1996).  
 
4. It has also been reported that Yellow Card Scheme is poor at detecting long latency 
reactions (Rawlins, 1995).  
 
5. It is also difficult for spontaneous reporting mechanisms to detect signals and sound 
the alarm when drugs simply increase the frequency of commonly occurring medical 
conditions (Brewer, 1999). 
 
6. High level of specificity is also expected due to the nature of the scheme. This is 
because more concern patients or carers of patients would report more events, 
including those that are not related to the drugs taken. It is also possible that a patient 
takes multiple drugs at the same time and reported wrong drug-event pair when 
spontaneously reporting adverse events to the YCS.  
 
Despite what it seems as a never-ending list of limitations of the scheme, it is a valuable 
system to have for pharmacovigilance. It provides a source and platform allowing more 
detailed investigations of suspected adverse drug reactions. 
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2.4 Epidemiological studies 
Epidemiological studies are mainly divided into two types: cohort studies (Breslow, 1987) 
and case-control studies (Breslow, 1980). The methods offer good alternatives to clinical 
trials when conducting clinical trials is infeasible. This might be due many issues including 
limited funding, limited time and resources, and for ethical reasons. 
 
Because epidemiological studies are observational by definition, no active intervention is 
made therefore certain issues that are considered unethical can be studied. A well-known 
epidemiological study is the 50-year long British Doctors Cohort to study the association 
between smoking and mortality (Doll, 1954). The study demonstrates that unethical issue for 
clinical trial like smoking intervention can be studied. 
 
Another practical use of epidemiological study design is demonstrated using the case study 
when risk-benefit evidence from clinical trials are insufficient to support the use of off-label 
drugs or to support planned clinical trial. It also demonstrates that evidence of risks and 
benefits for drugs that are no longer on the market can also be studied. Chapter 3 described 
the mechanics of epidemiological study designs. 
 
2.5 Systematic reviews and meta-analysis 
In addition to or in place of evidence from primary studies, systematic reviews and meta-
analysis can be used to inform the design of new clinical trials. A systematic review is an 
“overview of primary studies that used explicit and reproducible methods” (Greenhalgh, 
1997), which may or may not include meta-analysis. Meta-analysis is a “statistical procedure 
that integrates the results (or evidences) of several independent studies considered to be 
combinable” (Egger, 1997). Many systematic reviews address both qualitative and 
quantitative (including meta-analysis) evidence of a research question from primary studies. 
Bandolier (Bandolier, 2007) refers to these types of systematic reviews as mixed-method 
systematic review (Hemingway, 2009). 
 
Systematic reviews are usually a requirement before conducting any trial to investigate the 
available evidence whether they are sufficient or insufficient, and whether the need for new 
trial is clear. Meta-analyses, on the other hand, are not usually a requirement when planning a 
new trial but carrying out a meta-analysis would be able to quantitatively address the research 
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question of interest. For example, meta-analysis may reveal conflicting evidences from 
primary studies, as well as show the building up of evidence via cumulative meta-analysis as 
first illustrated in one meta-analysis of therapeutic trials for myocardial infarction (Lau, 
1992). Although cumulative meta-analysis is useful, its use comes together with the issues of 
multiple testing, as well as other issues associated with meta-analysis such as publication 
bias, selection bias, etc.  
 
One source for a collection of systematic reviews is in the Cochrane Library of the Cochrane 
Collaboration (The Cochrane Library, 2010) set up to support and to promote evidence-based 
decision-making for healthcare. Cochrane Library is well known for the comprehensive high 
quality reviews (known as Cochrane Reviews) which are regarded as having better average 
quality than reviews published elsewhere (Jadad, 1998; Moher, 2007; Shea, 2006). On top of 
that, it also stores summaries of other high-quality reviews published elsewhere, and citations 
and abstracts of individual controlled trials in the Cochrane Central Register of Controlled 
Trials; and is still evolving (Starr, 2009).  
 
Quantitative evidence from systematic review of different studies is usually enhanced 
through the application of meta-analysis which combines results from individual studies to 
give a more robust estimate of the results. Methods of meta-analyses are described in Section 
3.4. 
 
2.6 Routine healthcare data 
In the UK, healthcare data are routinely collected when patients see healthcare professionals. 
In the primary care (general practices), data are kept on the practices’ electronic databases for 
the purpose of managing patients care. Initiatives to make these data available for research 
are in place, where GPs contribute their data to public organisations for research purpose. 
 
Our case study data are contributed by the General Practices Research Database (GPRD) 
under the Medicines and Healthcare Regulatory Agency UK license for an exploratory 
research on its potential use for safety data mining of off-label medicines (see Section 1.4). 
Therefore, this section is dedicated to describing GPRD in greater detail, as well as 
acknowledging alternative routine healthcare databases available in the UK.  
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2.6.1 Introduction to GPRD 
GPRD in the UK is well-known for being a very large collection of primary care data. 
MHRA claims that GPRD is the world’s largest computerised database of anonymised 
longitudinal patient records from primary care (GPRD, 2008). GPRD database is now a 
globally accepted resource for research in medicine, public health, epidemiology and 
pharmacoepidemiology as well as pharmacoeconomics. Over 550 research papers have been 
published in peer-reviewed journals to date. 
 
2.6.2 History 
To manage day to day work in his Essex practice, Dr. Alan Dean first developed a data-entry 
system to record clinical events of his patients comprehensively. Due to its success, he then 
decided to commercialise it. The aim was to develop an automated clinical research database 
on 4 million patients, representative of UK GP population. This gave birth to VAMP (Value 
Added Medical Products Ltd) Research Databank in June 1987. The database was made 
available for post-marketing surveillance to pharmaceutical companies. Despite the 
usefulness and its potential, it was not successful commercially because of its unstructured 
data entry fields. However, Reuters had taken an interest in the database, only to recognise its 
potential. 
 
VAMP Medical was the original software used by contributing GPs. It was text based 
practice management software developed using Microsoft Disk Operating System (MS-
DOS). The database was renamed to GPRD in 1994 when it was donated to Department of 
Health after VAMP Ltd was acquired by Reuters Health Information. The management of 
GPRD had then become the responsibility of Secretary of State’s Statistics Division, operated 
by the Office of National Statistics (ONS). Reuters still continued in the interest of the 
provision of practice management software. Reuters launched Microsoft Windows-based 
Vision software in 1995 to replace VAMP Medical. This has become the only software used 
by the GPs in the GPRD scheme. UK Health Ministers decided that GPRD should be self-
financing and introduced license system. The commercial fee to having an access to GPRD 
was £500k per annum. In spite of this, the license fees did not generate enough revenue for 
GPRD to load and integrate the data collected; resulting in several years of data collected but 
was not available to researchers. In 1999, Cegedim, a European healthcare and research 
company, acquired Reuter’s practice management software business and renamed it In 
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Practice Systems (InPS); their website is available at http://www.inps4.co.uk. Cegedim 
hastened the migration from VAMP to Vision as Millenium approached. The situation 
worsened when many practices trying to upgrade at the same time. The future of GPRD was 
then doubted. 
 
From October 1999 onwards, the Medicines Control Agency (MCA) took over the 
management and operations of the database. With the priority to make data available to 
researchers in mind, MCA invested £3millions to secure GPRD’s future viability and utility. 
The work began on the “Full feature GPRD” or “FF-GPRD” in short. FF-GPRD has 
considerably enhanced features compared to the former GPRD databases and has been 
available since 2001. MCA now sits under the umbrella of the newly created Medicines and 
Healthcare products Regulatory Agency or MHRA in April 2003.  
 
The GPRD database is now a widely accepted resource for research in public health, 
medicine, epidemiology and pharmacoepidemiology as well as pharmacoeconomics with 
over 550 research papers published in peer-reviewed journals to date.  
 
2.6.3 Data availability and structure 
Up until July 2008, GPRD data warehouse comprises 487 practices with 433 up-to-standard 
practices and about 3.66 million active patients. ‘Up-to-standard’, or    , is a date marker in 
the database indicating the first date by which a practice continuously complied with 
minimum standard for completeness and quality of data recording in accordance with GPRD 
Recording Guidelines. In addition, GPRD also holds data for further 2.79 million previously 
registered patients making a total of 6.46 million patients usable for research purposes 
(Figure 2.2). The database covers about 5.5% of the UK population. 
 
The data consist of a core dataset which includes demographic information, registration 
details, and all clinical and prescription events for the cohort of patients; and optional data 
modules which contain additional data on these patients including adverse drug reaction 
details, immunisation details, and lifestyle information (body mass index, weight, height, 
smoking, etc.). In addition to patient-level data, we also acquired practice-level data which 
consists of the age and sex denominators, and practice-level information (Figure 2.3). 
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Figure 2.2: Practice and patient populations in GPRD 
Source: http://www.gprd.com/_docs/GPRDPracticePatientPopulationsJul2008.pdf  (accessed on 08/09/2008). 
 
Figure 2.3 GPRD data structure 
 
Adapted from GPRD website (GPRD, 2008)  
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2.6.4 Quality of data 
The Medicines and Healthcare products Regulatory Agency who manages the database is 
very strict about data quality. Several measures are in place to implement this. Data are 
checked on receipt to ensure any time gaps are detected prior to loading onto the database, 
find the cause of the gaps and attempt recollection of data. The audit sequence number of 
incoming collection is also compared with the last collection date sequence loaded on the 
database for every practice. 
 
Data completeness is measured at practice and patient levels. At practice level,     identifies 
up-to-standard practices fit for research.     criteria include percentage of acceptable 
patients, monthly prescription rates, and percentage of prescriptions with medical indications, 
death rates and recording of deaths. Each practice satisfying the criteria is assigned a     
date.     was first assigned in 1987. 
 
Several validation studies on GPRD were conducted reporting acceptable level of 
completeness (Walley, 1997). 75% of all consultations, 95% of prescriptions, and 30-70% of 
diabetic complications were recorded in GPRD data when compared to 13 general practices 
database (Nazareth, 1993; Walley, 1997). 
 
The quality of the data we extracted from GPRD for this study is described in Chapter 6. 
 
2.6.5 Clinical data coding on GPRD 
2.6.5.1 The Medical Dictionary for Regulatory Activities (MedDRA) 
The Medical Dictionary for Regulatory Activities (MedDRA) is a clinically-validated 
international medical terminology used by regulatory authorities and the regulated 
biopharmaceutical industry. The terminology is used through the entire regulatory process: 
from pre to post-marketing, and for data entry, retrieval, evaluation, and presentation. EU 
Clinical Trials Directive indicated that MedDRA should be used for conduct of clinical trials 
and for pharmacovigilance from 1 May 2004 in order to move toward global harmonisation. 
MedDRA is updated bi-annually with input from subscribers. The dictionary contains more 
than 66000 terms at lowest level which allow greater specificity; ~18000 preferred terms 
representing unique medical concepts; and less grouping of higher hierarchy terms. MedDRA 
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is to be used for coding of adverse drug reactions, signs and symptoms, procedures, 
indications, and medical and social history; but not for the purpose of recording prescriptions. 
 
2.6.5.2 The Read Clinical Classification codes 
Read clinical classification codes were first developed by Dr. James Read, a general 
practitioner in Loughborough in the 1980s. The Read clinical classification contains 5 alpha-
numeric characters in the five byte version set, and has a hierarchical structure. Each 
successive level adds more specificity to the concept it represents. At each level, the character 
could be a lowercase letter (excluding o and i), an uppercase letter (excluding O and I), or a 
number 0-9, in total 58 characters giving a theoretical maximum of 656,356,768 codes. In 
1990, the Secretary of State acquired Read codes for the NHS to streamline computerised 
medical records. The codes have evolved since it was first acquired, and is still evolving. The 
scope for Read clinical classification extends to drugs and appliances.  
 
Read codes only just became standard coding for general practices in GPRD in 1998. Prior to 
that, most general practices participating in the GPRD used the Oxford Medical Information 
System (OXMIS) clinical classification codes. 
 
2.6.5.3 The Oxford Medical Information System (OXMIS) codes 
The Oxford Medical Information System was developed in the mid 1970s for recording of 
clinical events in general practices. The OXMIS coding scheme was based on the 
International Classifications of Disease (ICD)-8 codes. The codes did not have hierarchical 
structure. It was typically arranged by alphabetical order for easy indexing by the GPs. The 
codes composed of a “core” structure which could be traced back to corresponding ICD-8 
codes. However, this core component of OXMIS might or might not be exactly the same as 
its corresponding ICD-8 code; where some ‘random’ alterations were implemented including 
truncation of digits, prefixes, and suffixes. As OXMIS codes are not hierarchical in structure 
and the resources to understand its structure is very limited, it is harder to be used for signal 
generation. Painter (2009) gives a good overview of OXMIS codes; and also proposed a 
mapping technique using the UMLS Metathesaurus (UMLS, 2010) to allow mapping of the 
unstructured OXMIS terminologies to other coding systems (Painter, 2009). Potentially, data 
coded with OXMIS would not be wasted if automated matching could be carried out. In the 
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GPRD case study data, roughly 30%-60% of coded clinical events were OXMIS prior to full 
migration onto the Read codes system. Unfortunately, I am not fortunate enough to 
experiment with this technique due to time constraints and limited resources. 
 
2.6.5.4 Other coding system 
It is important to note that, at the time this report is written, the NHS is in the process of 
migrating fully to SNOMED CT® (Systematised Nomenclature of Medicine Clinical Terms) 
as the standard for the NHS Care Records service. All concepts available in Read clinical 
classification are covered under SNOMED. Mapping information is also released by the NHS 
Connecting for Health with Read codes and SNOMED CT UK edition (NHS Connecting for 
Health, 2009). I have not explored the effect of this migration to the methodology proposed 
in this thesis, but anticipated that there would not be any major issues if the proposed 
framework were to be used because the mapping information is available. 
 
2.6.6 Ways to obtain access to GPRD data 
GPRD data can be obtained either as datasets, through commissioned research or reports, or 
through secure online access. Medical Research Council also signed an agreement with the 
MHRA allowing UK academic researchers to access GPRD at no cost. It is a very popular 
and cheap way to conduct a research using GPRD data among academic researchers but 
datasets are only limited to 100,000 patients, and for up to 50 approved proposals per year. 
All research protocol will be evaluated by Independence Scientific Advisory Committee 
(ISAC) to make sure they comply with the scientific quality standard that has been set. Any 
ethical issues arisen especially those requiring direct patient involvement needs an approval 
from the Multi-centre Research Ethics Committee (MREC). This process is illustrated in 
Figure 2.4. 
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Figure 2.4 Extraction of GPRD dataset under MRC agreement (©Crown Copyright 2007) 
 
(Extracted from ISAC presentation during the GPRD training day 2007 by Tarita Murray-Thomas) 
 
2.7 GPRD alternatives 
GPRD is not the only electronic healthcare data warehouse available in the UK which could 
be used for the purpose of this study. The choice to use GPRD as data source was made 
because GORMET is commissioned by the MHRA to evaluate the potential of its GPRD 
database to provide evidence of safety where clinical trials evidence are lacking. Before 
describing alternative electronic healthcare data warehouses available in the UK, I first 
comment briefly on the clinical IT systems that are commonly used for recording routine 
healthcare data in the general practices. 
 
In the GPRD, participating general practices use Vision/INPS software to record their 
patients’ data. Vision is a leading provider of clinical systems for Windows in the UK. About 
95% of UK primary care trusts and health boards (INPS, 2010). Main competitors are the 
EMIS (EMIS Online, 2010a), iSoft (iSOFT Group Ltd, 2010) and GPASS (but no longer 
available after EMIS took over the primary care management system in Scotland in May 
2010). All software provide comprehensive computerised systems to record information on 
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patients efficiently and structurally. This includes incorporating Read Clinical Classification 
Codes to record clinical events.  
 
The variation of the different systems has been studied in terms of number of Read codes 
choices displayed by each system when a search is performed (Tai, 2007). The study found 
that EMIS, iSOFT, Vision, and GPASS present on average of 35.2, 18.8, 13.0, and 12.7 
codes selections respectively. The four systems present longest list of codes selection when 
searched for “depression”. However, the impact of having shorter code lists on data quality 
and efficiency of data entry need to be properly studied to be able to fairly compare the 
systems. The study recognises that the different systems promote diversity rather than 
consistency of clinical coding, but the latter is usually sought for (Tai, 2007). 
 
Whilst Vision has its own competitors, GPRD has QResearch, THIN, and MEMO along 
other smaller ones as competitors. 
 
2.7.1 QResearch 
QResearch is probably the main competitor to GPRD. It is a not-for-profit company run by 
academics research team at the University of Nottingham in collaboration with EMIS with 
data dated back to early 1990s (EMIS Online, 2010b). Currently the database contains 
anonymised records of around 12 million patients from 602 participating practices spread 
throughout the UK (Qresearch, 2010).  
 
QResearch website listed seven special features of the database: 
a. Socio-economic details of each patient’s postcode are available on the database. 
b. The data extracted from the database do not contain any strong patient or general 
practice identifiers to protect patients’ confidentiality. 
c. Unlike the GPRD, patients from QResearch participating practices can opt out. 
d. The database will be open to academic researchers with ethical committee approval 
from the Trent Multi-centre Research Ethics Committee. 
e. The researchers will only be provided with patient or practice level data they required 
specific to their research 
f. QResearch carefully controls the costs of use of the data to allow the scheme to fund 
itself whilst giving good access to academic researchers. 
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g. Analyses are undertaken to ensure data are accurate and complete. The analyses are 
made available for morbidity analyses. 
 
QResearch has contributed to many aspects of public health in the UK and worldwide. One 
popular tool developed is the QRISK
®
1 calculator to predict the risk of cardiovascular 
disease (CVD) using the risk factors. QRISK
®
1 is validated against the Framingham CVD 
algorithm and the Scottish ASSIGN score (Hippisley-Cox, 2007). The newer version, 
QRISK
®
2 allows additional covariates adjustment particularly ethnicity to the prediction 
algorithm (Hippisley-Cox, 2008). Later addition to the risk calculator is the QDScore that 
calculates the risk of type II diabetes in England and Wales (Hippisley-Cox, 2009). QRISK
®
2 
and QDScore calculators are freely available on their website (ClinRisk, 2010).  
 
The Health Protection Agency (HPA) collaborates with QResearch to operate QSurveillance
®
 
National Surveillance System based on primary care data. QSurveillance
®
 is the largest 
surveillance system of its kind in the world, monitoring over 100 clinical indicators for 23 
million people from almost 4000 EMIS practices in the UK. HPA publishes weekly health 
protection reports of near real-time infections in primary care using QSurveillance (HPA, 
2010) including pandemic flu. 
 
From February 2008 QResearch is involved in a new European project, EU-ADR, to develop 
an integrated data mining algorithm for early detection of ADRs using clinical records and 
biomedical data sources (EU-ADR, 2010). The project is being developed to overcome the 
shortcomings of spontaneous reporting databases, and to provide solid basis for large-scale 
monitoring of drug safety. EU-ADR is designed to give special attention to patient groups not 
usually involved in clinical trials because of ethical or practical reasons like pregnant women, 
children, and the elderly. The project is expected to finish in July 2011. 
 
2.7.2 The Healthcare Improvement Network (THIN) 
THIN is a collaboration between the University College London (UCL) Primary Care and 
Public Health, and Infection and Public Health departments, InPS and the Epidemiology and 
Pharmacology Information Core or EPIC (Cegedim, 2010). THIN is essentially similar to 
GPRD but on a smaller scale with about 6.9 million patients (2.9 million active) and about 40 
million patient-years data from around 386 general practices using Vision clinical IT system. 
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This covers around 6% of UK population. The database started prospective data collection in 
September 2002, but some contributing practices have data back to 1987 (Lewis, 2007). Data 
are fully anonymised, processed and validated by EPIC. 
 
The database has four standardised data area and one linked file per practice (UCL PCPH, 
2010). The descriptions of the four data area are listed in Table 2.1 below. 
 
Table 2.1 THIN data area 
Data area Description 
Patient Age, sex, and date entering and leaving the practice 
Medical Medical diagnoses data including referrals to hospitals and specialists. 
Diagnoses are recorded in Read codes. 
Therapy Prescriptions data and events leading to withdrawal of a drug or 
treatment. Prescriptions are recorded using Multilex codes issued by First 
Databank which can be easily linked back to the BNF. 
Additional 
health data 
Vaccinations and prescription contraceptives; as well as other 
miscellaneous information such as smoking, weight, immunisations, 
birth, death, pregnancy, and laboratory results. 
Postcode 
variable 
indicators 
Postcode-linked area-based socio-economic, ethnicity and environmental 
indices 
Adapted from UCL PCPH homepage (UCL PCPH, 2010) 
 
The practices that contribute to THIN may also contribute to the GPRD. A validation study of 
THIN against GPRD has been conducted (Lewis, 2007). The study includes 255 general 
practices, of which 147 had previously (or concurrently) contributed to GPRD and 108 were 
new practices. The validation study concludes that data collected outside GPRD is as valid as 
data collected as part of GPRD. 
 
Access to THIN data for research is granted through the South East Multi-centre Research 
Ethics Committee. Because of the similarity to the GPRD, THIN also shares the strength and 
weakness of GPRD database (see Section 2.6). 
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2.7.3 Healthcare Informatics Centre (HIC) 
The Health Informatics Centre is a partnership between University of Dundee Epidemiology 
and Biostatistics Unit, NHS Tayside, and Information Services Division of NHS National 
Services Scotland (ISD). HIC was formerly known as MEMO (Medicines Monitoring Unit). 
Of the three GPRD alternatives, HIC is the smallest and most locally focus. HIC database 
contains about 400,000 patients essentially 100% coverage of Tayside population (HIC, 
2010). In 2009, NHS Fife has agreed to contribute their data to HIC, in effect doubling the 
size of the database to 800,000 patients or about 16% of Scottish population.  
 
HIC anonymised data include prescriptions, hospital stays, diagnoses, procedures, laboratory 
tests results, and death records. The data are stored on secure servers on the NHS network 
with access limited to authorised personnel only. Requests to use HIC data for research are 
granted by the Tayside’s Committee on Medical Research Ethics; and NHS Caldicott 
Guardians if the research were to take place externally (outside Mackenzie Building where 
HIC is based). For many clinical indicators, HIC population is largely representative of the 
UK population, therefore evidence from HIC would also be generalisable nationally. 
 
2.8 Discussion 
Various sources of evidence on risks and benefits of medicines are available in the UK as I 
presented in this chapter. Each one has its own strengths and limitations to the type and 
quality of evidences it can provide for risk-benefit decision-making. Rather than viewing the 
different sources as rivals, it is best viewing them as complementing each other in providing 
evidence of risks and benefits. 
 
Many other studies have used the various sources to learn about efficacy and safety of drugs 
treatment. This study thus explores novel use of routinely collected primary care data stored 
in GPRD to learn about unknown safety issues of drugs treatment when clinical trials 
evidence is sparse. 
 
We have learnt that there are many sources of evidence for risks and benefits of drugs. In 
order to synthesise evidence systematically and robustly, Chapter 3 describes the methods we 
use. 
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3. Methods 
3.1 Introduction 
As the two themes of this thesis (Section 1.3) are the retrieval and verification, and the 
integration and communication of risks and benefit evidence, this chapter reflects them. This 
chapter is intended to introduce the methods in general, although references to the case study 
are made at various points. The more specific methods and models used in analyses are 
presented in the respective chapters where they are applied. 
 
Sections 3.2 and 3.3 describe cohort study and case-control study designs respectively. 
Section 3.4 introduces the methods of meta-analysis used in the quantitative review in 
Chapter 7. Sections 3.5 to 3.8 introduce the methods relating to improving the evidence of 
risks and benefits research using large longitudinal observational data. 
 
Section 3.9, in different subsections, introduces methods for integrating the evidence of risks 
and benefits that are considered to be of high certainty through the application of formal 
quantitative risk-benefit assessment methods. 
 
Section 3.10 gives a short introduction to Bayesian statistics and Section 3.11 briefly 
discusses power and sample size determination. 
  
Part I: Methods 
Chapter 3 | 70  
 
3.2 Cohort study design 
A cohort study is where a group of subjects is studied, usually, to establish an association 
between a possible risk factor (exposure) and a medical condition (outcome). At its simplest, 
group of subjects, some with the exposure and some without, is selected to form two cohorts. 
The two cohorts are observed for a few years (between 3 to 20 years) to see whether they 
develop the condition. The number of participants with the outcome of interest is counted in 
each cohort and compared. The amount of exposure is also recorded for each participant. 
 
3.2.1 Features of cohort design 
Cohort study does not only apply to observational studies, but also to interventional study. 
For an interventional drug study – as we have seen in the patulin trial(s) in Section 2.2– a 
group of subjects with the condition is chosen and ‘exposed’ to a treatment drug of choice 
and a control drug (or placebo) by random allocation. Similar to observational study, the 
participants are followed up over several years, but may not be as long, to see whether the 
treatment drug works. The outcome here would be an improvement in quality of life, which 
must be specifically defined before the study starts. 
 
What I just described is commonly termed the ‘prospective (cohort) study’; but it is not the 
only way to conduct a cohort study. A cohort study could also be conducted retrospectively. 
The principle is exactly the same as a prospective study but the approach is different. This 
design makes use of the many longitudinal databases already available (e.g. GPRD). One 
defines a starting point in the data to identify subjects with and without the exposure. A 
timeframe to allow for the development of the outcome is also specified. The outcomes 
observed within the timeframe in the exposed and unexposed cohorts are counted. 
 
The key property of a cohort study is that the maximum numbers of subjects with and without 
the exposure are fixed when the study begins. However some may be lost during follow-up. 
In many clinical trials, the exposures are collected continuously at different time points 
during the period of the cohort study to take into account the real world scenario when 
exposure status in some people may change. The changes of exposure status may change for 
many reasons including personal e.g. stopping smoking, or environmental e.g. change in 
pollution level. The changes in exposure status may affect the final outcomes. Outcomes are 
also sometimes collected continuously to obtain more accurate estimates of the association 
between the exposure and the outcomes in study population.  
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The most common statistical measures used in reporting a cohort study – odds ratio, risk 
ratio, incidence rates – are all valid. The advantages of a cohort study are: a well-designed 
study can minimise biases; and several outcomes from the same exposure can be studied at 
the same time. The disadvantages are: it takes a long time to complete; and expensive. 
 
3.2.2 Selection of controls 
Controls are the group of people who are not exposed to the drug of interest in a particular 
study. They are used as the comparison or reference group when studying the effects 
(efficacy or safety) of drugs. A standard way of selecting controls (usually for prospective 
studies) is to “split” a sampled population based on their exposure as illustrated in Figure 3.1.  
 
In a retrospective cohort study such as for our case study, the process is somewhat reversed 
beginning with selecting people with the disease of interest. The controls are usually selected 
by matching potential controls on some characteristics (e.g. age and sex) of the people in the 
exposed group. Matched cohort offers the advantage of having exposed and unexposed group 
with balance characteristics therefore reduces bias in comparison. This is a similar process to 
case-control design sampling (Section 3.3). Throughout this thesis onwards, the control group 
in cohort studies is referred as the “unexposed” children or group to avoid confusion with the 
“controls” in the case-control context (Section 3.3.2). 
 
Figure 3.1 A standard cohort study sampling process 
  
Sampled 
population 
Ineligible 
for study 
Eligible for 
study 
Exposed 
group 
Unexposed 
group 
Study population All 
population 
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3.3 Case-control study design 
A case-control study, as its name suggests, is a retrospective study design. A group of 
subjects with the outcome (cases) and another group of subjects without the outcome 
(controls) are selected. By asking the participants or looking at their historical data, number 
of subjects with the exposure is counted in each group and is compared. The standard case-
control design may results in inappropriate selection of comparison group (see Section 3.3.2), 
thus a matched approach is usually preferred. 
 
3.3.1 Features of matched case-control design 
A case and a control are matched on some specified criteria, usually age and sex. This is to 
ensure that the comparison is fair. The comparison need not always be one-to-one (   ). 
Some case-control studies are designed as     comparison, where    . 
 
The key property of a case-control(s) study is that the numbers of subjects with, and without 
the outcome are fixed when the study begins. Only odds ratio is valid when reporting the 
analysis of a case-control study. The advantages are it is cheaper and quicker compared to a 
cohort study; and more than one exposure for an outcome can be studied at the same time. 
The disadvantages are it is subjected to more biases, and more complicated controls selection 
compared to a cohort study. 
 
A case-control study can also be carried out in an ‘audit-style’ by selecting cases and controls 
from a large longitudinal database. This is known as the nested case-control study design as 
the cases and controls are nested within the same cohort. It has the added advantage of 
minimising the difference in life-style patterns and environmental factors because they come 
from the same population. Because the data prior to the outcome is consistently recorded for 
every subject (there is no reason to assume otherwise), information bias is also minimised. 
 
3.3.2 Selection of controls 
In conducting a case-control study, controls selection normally poses the greatest challenge 
especially when the study involves recruiting participants. The source of controls can be 
biased because they are systematically different from the cases. For example when selecting 
controls for GORD cases in a hospital unit, controls selected say from gastroenterology unit 
with no GORD may be subjected to bias because the patients may have too similar symptoms 
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to GORD therefore any associated risk factors may be masked. Selecting controls from a 
different unit may bias comparison if the controls are sicker or healthier. To sample controls 
for these cases from general population is also bias because the cases would then be 
compared against very healthy controls. In these situations, the two groups to be compared 
would be – as quoted by Sir Austin Bradford Hill (see Section 3.8) – ‘in pari materia’. 
Therefore, a good practice of controls selection for case-control studies is through criteria 
matching. Figure 3.2 illustrates the general process flow of a matched case-control study 
sampling. 
 
Figure 3.2 A standard matched case-control study sampling process 
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3.4 Meta-analysis 
Meta-analysis is a complex subject and has attracted much interest. It has been studied 
extensively in other literatures, with many other ongoing studies addressing different 
methodological aspects of meta-analysis. It is a method that is already established to be of 
great value to evidence synthesis for decision-making i.e. policies are not made based on a 
single study (Spiegelhalter, 2004a).  
 
The results from many studies are combined in a meta-analysis by weighting the evidence 
usually by the fixed effect inverse-variance method giving more weights to studies with 
smaller variances; or random effect methods of DerSimonian and Laird to additionally allow 
for varying treatment effects across studies (DerSimonian, 1986). The standard meta-analysis 
can also be adjusted for the effects of covariates in regressions framework. Methods of meta-
analysis in health research are used to combine clinical evidence from comparable studies 
e.g. the cohort studies, the case-control studies, or randomised clinical trials. Different type of 
evidence may also be combined but must be done with caution with respect to the quality of 
data and the associated biases. The cross design synthesis is a flexible method proposed to 
deal with combining different type of evidence (GAO/PEMD, 1992); and the confidence 
profile method proposes strategies for dealing with biases in meta-analysis (Eddy, 1989) – 
both are out of scope of this thesis. 
 
The more advanced applications of meta-analyses include indirect treatment comparisons 
(Higgins, 1996), and network meta-analysis for indirect treatment comparisons (Lumley, 
2002) and its extension the mixed treatment comparisons (Lu, 2004). The network of 
evidence (Figure 3.3) is exploited in both. 
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Figure 3.3 lllustration of the network of evidence in the indirect treatment comparison (A and B) and the 
mixed treatment comparison (A, B and C) 
 
Study A provides direct comparison of treatment 2 to treatment 1. 
Study B provides direct comparison of treatment 3 to treatment 1. 
Study C provides direct comparison between all three treatments. 
 
Indirect treatment comparison (ITC) allows studies of different treatments but share the same 
outcome and common comparison group to be compared indirectly (Lumley, 2002). Figure 
3.3 illustrates that in the presence of evidence A and B only, the comparison of treatment 2 
and 3 can be made indirectly by fixating on the common comparative treatment 1. If study A 
provides a direct treatment effect  ̂   and study B provides a direct treatment effect  ̂  , then 
the indirect estimate of the treatment effect between 2 and 3 is  ̃    ̂    ̂  . The 
estimated variance of the difference is simply    ( ̃  )     ( ̂  )     ( ̂  ); where 
   ( ̃  )     ( ̂  ), the observed variance, due to the indirect use of evidence. The method 
is simple in construction yet very powerful in application given that sensible assumptions are 
made, and appropriate models and parameters are chosen.  
 
Mixed treatment comparison (MTC) is an extension of the ITC where there might also be 
studies that directly compare the two treatment of interest. In the presence of evidence A, B 
and C (Figure 3.3), the reasonable meta-analytic model is the mixed treatment comparison 
because evidence C now provides direct comparison of treatment 2 to treatment 3 (in fact 
between all three treatments). MTC further adjusts for having studies directly comparing the 
three arms, as in evidence C in Figure 3.3. The model formulations and variance-covariance 
matrix for MTC are extended to K-comparisons to accommodate the multiple treatment 
comparisons within one study  (Lu, 2004). The application of MTC is naturally implemented 
within the hierarchical Bayesian framework (Lu, 2004).  
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MTC relies on the assumption that direct and indirect evidence to be combined are consistent. 
A simple method to assess inconsistency (or consistency) of evidence in a triangle network 
(three treatments only) is using the Bucher’s ‘back-calculation’ method (Bucher, 1997; Dias, 
2010). The discrepancy measure ̂    ̂    ̃   is defined, with variance    ( ̂  )  
   ( ̂  )     ( ̃  ). The null hypothesis test of no inconsistency ( ̂    ) between direct 
and indirect evidence can be inferred on the test statistic      ̂   √   ( ̂  ) against the 
standard normal distribution for comparison of any two treatments   and   (Dias, 2010). 
Another more computer-intensive method to check for consistency – the ‘node-splitting’ 
method – is also described in the same paper (Dias, 2010) but it is not used or described in 
this thesis since there is only one trial that provide direct evidence and there is no single trial 
that compares all three treatments. Therefore, the added complexity in node-splitting method 
would not greatly contribute to more valuable inference in this case. 
 
I apply ITC and MTC to the systematic review data of cisapride and domperidone in children 
to explore the evidence of risks and benefits (Chapter 7). Inconsistency between the direct 
and indirect evidence of domperidone against cisapride is examined using Bucher’s back-
calculation method. The models used are shown in Section 7.3.3. Cumulative meta-analyses 
are also performed to show how evidences based on clinical trials of the drugs over the years 
have been building up. The issue of bias in meta-analysis is addressed but not corrected for in 
the model as methods in meta-analysis in informing clinical trials design are beyond the 
scope of this thesis. 
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3.5 Definition of time at risk  
When dealing with longitudinal data such as routinely collected healthcare data for study of 
risks and benefits of drugs use, the definitions of timeframe to search for associated evidence 
are crucial. Timeframes vary for different drugs in different groups of patients, therefore need 
to be clearly defined in advance specifically for each study. The practice is critical to the way 
data would be extracted and handled. However we did not specify timeframe in advance 
because the aim of the case study was exploratory in nature.  
 
Figure 3.4 shows various timeframes for different scenarios which are described thoroughly 
in Section 3.5.1 and 3.5.2 for exposed and unexposed patients respectively. The different 
scenarios provide allowances to errors and inconsistency of data recorded through the general 
practices, as well as biological and practical response to the drugs in the population. 
 
Figure 3.4 Diagram for definition of time at risk for exposed and unexposed patients 
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3.5.1 Time at risk for exposed patients 
There are many ways to look at the data in terms when patients are exposed to a drug. It is 
important to define time at risk as this will later determine how we should search for adverse 
reactions (see Chapter 6). We consider three scenarios, in the increasing order of total time at 
risk we observed in the data: 
 
Scenario 1: A specified length of time after the last prescription for each patient 
The logic behind this is that when a patient was no longer prescribed with a drug, it is 
possible that (i) the patient is cured, or (ii) the patient experienced adverse reactions 
following the consumption of the drug. This scenario assumes (ii), which means that the 
patient stopped taking the drug because of a suspected adverse reaction. Suppose that T2 
is the last prescription for any patient (Figure 3.4); then the time at risk for that patient is 
simply defined as          days (a risk period j) where    is an arbitrary number of 
days chosen for its clinical relevance.    could be a constant length of time e.g. one week 
or two weeks (let’s call this    ), or a variable length of time of the actual (recorded) 
prescription duration (let’s call this    ); and     <    .    could also be a mixture of the 
two,          as will be explained in scenario 3. The total time at risk is the sum 
of     , time at risk for patient   (         ) at  
   prescription (      ). 
 
Scenario 2: A specified constant length of time after each prescription for each patient 
Scenario 2 extends the definition of      in scenario 1. Figure 3.4 illustrates time at risk 
for a patient with two prescriptions. If T0 is the date of first prescription, and T2 is the 
date of the second prescription, then                 and              
   where   is an arbitrary constant length in days. For patient    with   prescriptions (  
 ), the total time at risk is simply          .   is defined to be short, to reflect the 
immediate effect, and strictly less than the actual (recorded) duration of a particular 
prescription. The logic behind this is that an adverse reaction could occur either 
knowingly or unknowingly immediately after taking the drug. We specifically put 
“knowingly or unknowingly” in the definition because an adverse reaction could happen 
“knowingly” but the patient or carer of the patient decided that there was more benefit of 
the drug than the risk, therefore chose to continue taking them; or “unknowingly” that an 
adverse reaction had happened therefore continue taking them. The total time at risk is 
then         .  
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Scenario 3: The length of time each prescription was prescribed for, plus a specified 
constant length of time after the end of each prescription period 
The third scenario is an extension of the first two where we assume that an adverse 
reaction could happen at any time within the duration when a patient was taking the drug, 
not just restricted to immediate effect. A short period of time,  , is then added to the end 
of each risk period as some adverse reactions may occur after a patient had taken the last 
pill. Some calculated prescription durations extend across the next prescription. Using 
Figure 3.4 as an illustration, assume that    was the former prescription which lasted to 
   . There was another prescription at TS which lasted to TE. In this situation, we assume 
that the former supply stopped at the next prescription date. We therefore assume that the 
exposure time in this situation was (     )  (     ). This scenario also allows us to 
characterise the exposure in the exposed cohort in terms of cumulative dose. The longer 
risk period has another advantage in a way that it gives more chance for the healthier 
matched unexposed children to visit the GP, thus enable us to capture more events in the 
unexposed children group. Total observation period is then         , where      is now 
composed of prescription duration plus a constant. We set the constant to be seven days. 
 
3.5.2 Definition of time at risk for unexposed patients 
Time at risk for unexposed patients are matched to those of exposed. Arrows A-E in Figure 
3.4 illustrate the situations of how the unexposed data compares to that of exposed, when we 
take into account the “reliability” of unexposed data. We defined “data reliability” as follows. 
Supposed that the shaded area bounded by T0 and T1 is the length of time a matched exposed 
patient was at risk; then this will be the maximum time at risk for the unexposed, which will 
be determined in situation A-E. These situations apply in all three scenarios above. 
 
Situation A 
Unexposed data is reliable for the whole period when its matched exposed data was at 
risk. ‘Whole period’ here refers to any one prescription (which naturally extends to 
having reliable data from first to the last prescription).  
Then,     (         )       (       )   
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Situation B 
Unexposed data is reliable from the beginning of a risk period in its matched exposed 
patient but become unreliable before the period has elapsed.  
Then,      (         )       (       )  
with   (         )     (       ) and   (         )     (       ). 
 
Situation C 
Unexposed data is reliable only after the beginning of a risk period in its matched 
exposed patient but is unreliable throughout the risk period.  
Then,      (         )       (       )  
with   (         )     (       ) and   (         )     (       ). 
 
Situation D 
Unexposed data is reliable only after the beginning of a risk period in its matched 
exposed patient and become unreliable before the period has elapsed.  
Then,      (         )       (       )  
with   (         )     (       )  and   (         )     (       ). 
 
Situation E 
Unexposed data is unreliable throughout a risk period in its matched exposed patient.  
Then,      (         )     
with   (         )     (       ) and   (         )     (       ); 
or with   (         )     (       ) and   (         )     (       ). 
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3.6 Regression models for associations 
3.6.1 Fixed effects Poisson model for cohort studies 
Assuming a fixed effects model, we fit 
   (   )     ∑       
 
    (               ) 
   (               ) is added to the model with the coefficient constraint to 1 to give 
incidence rates. The likelihood is conditioned on the sum of the outcomes in the panel 
(matched cohort). This model assumes that the observations are independent within and 
across the panels. We fitted this model whenever the random effects model failed to 
converge, otherwise random effects model is fitted. This might not be a thoughtful 
justification for the model choice, but rather it was for simplicity due to time constraint and 
the amount of work involved. We admit that by using better modelling techniques, we would 
get better estimates of the risks but we left this exercise for further investigations.  
 
3.6.2 Random effect Poisson model for cohort studies 
Suppose the random effect of the matched exposed-unexposed group is identified by   , then  
  (     |  )  
        
 
  
 
for      
(          ) where         matched groups,          clinical events,     are 
the fixed effects covariates vector,   is fixed effects regression coefficients vector, and,     
are covariates to the random effects. We fit  
   (   )     ∑       
 
    (               )     
This model assumes the random effects    is independent and identically distributed such 
that      (   ). It is also possible to assume that          (    
 ). Our exploratory work 
suggests that choice of underlying distribution for    does not affect the results. We choose 
log-Gamma distribution because the likelihood maximisation procedure in Stata 10 
(StataCorp, 2007) runs faster than when assuming a Normal distribution. 
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3.6.3 Conditional (fixed effects) logistic model for case-controls studies 
For the case-controls studies, we used the conventional approach of fitting conditional 
logistic regressions for    (              ) against     (independent variables containing 
log-doses and indicators for prescription of other drugs where appropriate), where   
         were the observations within sets          . Suppose that the observed number 
of successes (ones) for the dependent variable in the i
th
 group was given by     ∑    
  
     
and            in the matched controls group i. We then fit the model of the form: 
   (  )   ∑{∑           (  (      ))
  
   
}
 
   
 
where      (  | ∑        
  
   ), and   (      )   ∑    (∑        
  
   )      where     is 
equal to 0 or 1 with ∑        
  
    and    is the set of all possible combinations of 
                 zeros.  
 
3.7 Signal detection and validation 
A large proportion of time on this thesis was spent on evidence data mining exercise to detect 
signals of adverse events. A “signal” is defined as a clinical event with elevated association to 
a drug that is flagged up for further investigation. This definition will be used whenever 
signals are mentioned in this thesis.  
 
In pharmacovigilance, signals are generated using data mining algorithms based on 
disproportionate drug-event pairs on the database. These signals are generated statistically 
without clinical alertness (nonclinical) initially, and are subsequently used to focus the efforts 
of clinical experts to provide clinical judgements when faced with such difficult tasks 
(Hauben, 2003).  
 
The introduction to Chapter 8 describes some data mining techniques that have been used for 
a number of pharmacovigilance organisations. So far, no literature directly compares the 
performance of the different methods for real-time pharmacovigilance activities. This might 
be due to limited resources and priorities. Proportional reporting ratio (PRR) method (Evans, 
2001) is a simple disproportionality method akin to relative risks, with the advantage of being 
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easy to implement and easy to understand in comparison to other more complex 
disproportionality methods.  
 
Table 3.1 shows the concept of PRR with specific reference to how the method is used in the 
case study (see Section 8.3.2). The PRR associated with a clinical event given available 
dataset with incidence rates         in a     table (Table 3.1) is calculated as: 
    
 
   
 
(   )
⁄  
 
The process is resource-intensive in practice because PRR for every clinical event-drug pair 
on the entire database is calculated. I only restrict the PRRs calculations in the case study for 
the two drugs of interest – cisapride and domperidone. 
 
Table 3.1 Calculation of Proportional Reporting Ratios (PRRs) 
 Exposed patients Unexposed patients 
Read code of interest
a
 present 
during drug risk period
 
p q 
All other Read codes present 
during drug risk period 
r s 
a
 We do this for every truncated Read code 
 
3.8 Bradford Hill criteria for causation 
Sir Austin Bradford Hill first proposed a set of criteria to assess cause and effect in 1965 
(Hill, 1965), which is still remarkably pertinent in current work in epidemiology (Ashby, 
1998; Ward, 2009). Many papers have described the criteria thoroughly (Ashby, 2008) 
including in the Presidential Address landmark paper of Royal Society of Medicine’s Section 
of Occupational Medicine (Hill, 1965). I describe the nine criteria in the context they are to 
be used in this thesis and formulate appropriate questions that are useful when addressing 
them. First, to clarify, this set of criteria is intended to move from observing association 
between drugs and adverse events by considering nine aspects of associations before making 
a verdict of causation (Hill, 1965). 
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(1) Strength of association 
This is the magnitude of the association described by incidence rates or odds of an 
adverse event in those exposed to drug versus those not exposed to drug. Absolute 
difference of the measures of risks can be used but relative measures such as 
incidence rates ratio and odds ratio are more informative in this context (Hill, 1965). 
However, ratios should be accompanied by their baseline risks in order to make sense 
of the strength of association. The question to be answered when dealing with the first 
criterion is: “What are the incidence rates/odds of an AE being observed when no 
treatment is given, and how much does this change when a treatment is 
administered?” 
(2) Consistency 
The second criterion is a check on whether the evidence have been observed 
repeatedly in different settings e.g. by different people, in different places, under 
different circumstances, and at different times (Hill, 1965). The idea behind this is 
simple that is: “Is there multiple evidence of association between the drug and the 
observed AE from other sources?” 
(3) Specificity 
The association is only specific if it were limited to specific group of patients using 
specific drug for the same disease i.e. there is no association between the drug and 
other mode of experiencing the same AE but must not be over-emphasised because 
other underlying factors may also contribute to the observed association (Hill, 1965). 
This also implies absence of confounding effect when assessing specificity. An AE 
may also have more than one cause, which also needs to be considered. So it is 
important to ask: “How specific is the AE observed to the drug given the population 
and the time period it was observed in?” 
(4) Temporality 
It is a criterion to address the timeline of drug use and the observed AE. An event 
simply cannot be caused by a drug if the drug were only used after an event had 
already occurred. Then we simply ask “When was the drug taken and when did the 
AE occurred?” 
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(5) Biological gradient 
In many drug safety and efficacy assessment, biological gradient data are available. 
This criterion refers to the dose-response relationship of a drug to the AE. Therefore 
we ask: “Does higher doses of the drug associate with more of the AE observed at 
lower doses?” 
(6) Plausibility 
It is helpful if the suspected causation is actually biologically plausible (Hill, 1965). 
However, the plausibility is also dependent on the biological knowledge of the day, 
thus an AE must not be dismissed too light-heartedly because it just appears too odd 
(Hill, 1965). It may help to ask: “How plausible or implausible, or otherwise 
probable, is the observed AE to be caused by the drug treatment?” 
(7) Coherence 
The natural history and biology of the disease, the observed AE, and the drug 
prescription should all fit the facts already known about the epidemiology of the 
disease, AE and drug. Similar trends of the disease, AE and drug prescription provide 
over time provides a good indicator for coherence. We seek to answer: “To what 
extent our knowledge about the epidemiology of the disease-drug-event agree or 
disagree with the AE being observed from the drug use in the disease population?” 
(8) Experimental evidence 
Drug experiments on human are performed in a controlled clinical trial setting. 
Clinical trials, when properly carried out (see Section 2.2), would provide the 
strongest support for causation hypothesis (Hill, 1965). Evidence from randomised 
controlled clinical trials is often classified as the gold standard. The question is thus: 
“Are there any strong evidence of association of the AE from clinical trials on the 
drug use in the population with the same characteristics to those in our data?” 
(9) Analogy 
Sometimes it is fair to judge the causation of an AE by analogy (Hill, 1965). 
Additional to the eight earlier criteria, when similar AE have been observed with 
another drug use, the observed AE could also contribute to the verdict of causation. 
So: “What analogy can support the causation of the observed drug-AE association?” 
 
The Bradford Hill criteria for causation is applied to the observed AE signals obtained 
through data mining to judge whether the use of the drug could potentially be causal to the 
AE (Section 8.5).  
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3.9 Formal approaches for quantitative risk-benefit assessment 
Commonly practised methodologies for assessing risks and benefits in decision-making 
process in medicine have been reviewed in greater detail elsewhere (Guo, 2010; Phillips, 
2010b). Broadly, they are divided into quantitative and non-quantitative methods. Non-
quantitative methods are too subjective (and too philosophical) therefore are not applied in 
this work and will not be discussed.  
 
Probability is a measure of chance that a true parameter   would be observed. Therefore 
probability is based on a single parameter (with the exception of conditional probabilities). 
More detailed discussion on probability can be found in many textbooks (Miller, 1999; 
Parmigiani, 2002a; Spiegelhalter, 2004a). 
 
Utility is a function of the consequences of a decision   if the true parameter is  , therefore is 
based on two parameters (with the exception of conditional utilities). Utility is more specific 
to the decision-makers or the stakeholders; and often valued differently. Good discussions on 
utility functions are available in many textbooks (Berger, 1985; Garthwaite, 2002; 
Parmigiani, 2002a). 
 
The usefulness of utilities in risk-benefit assessment is the subject of a long standing and 
continuing debate (Spiegelhalter, 2004a). I describe in this section some of the emerging 
quantitative risk-benefit assessment approaches based on utilities, and some that are not. 
They are discussed further with applications to case study in Chapter 9 and demonstrated the 
reasons utility theory has not lived up to its promise when it comes to trading off risk and 
benefit for decision making (Phillips.L.D., 2005).  
 
3.9.1 Number needed to treat approaches 
The idea of measuring number of patients who need to be treated to prevent one patient from 
an adverse outcome e.g. a disease or to observe a benefit (e.g. improvement in GOR 
symptoms) has been suggested and termed number-needed-to-treat (NNT) (Laupacis, 1988). 
The NNT measure is derived from probabilities of events such as incidence rates in the two 
treatment groups of interest. Mathematically NNT follows the geometric (waiting time) 
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distribution with mean      where       is the probability of “success”10 associated 
with a treatment.  
 
Let           be the probability of successes in the general population and those underwent 
treatment   to prevent disease   respectively. Then          represents the “excess” 
probability of a successful treatment i.e. the absolute risk reduction. Using    as the 
parameter for the geometric distribution, it will be necessary to treat on average      patients 
to prevent one occurrence of disease   – which is the NNT (Schulzer, 1996). 
 
The opposite of NNT was also suggested and termed number-needed-to-harm (NNH). The 
calculation of NNH parallels that of NNT, with the aim to observe an adverse event   with 
probability  . When considering a drug, it is common to consider multiple AEs. A method of 
combining these has been proposed (Guyatt, 1995; Guyatt, 1999), where under independence 
assumption of the AEs,     ∑ (       )
 
    for AE   (       ). The reciprocal of    is 
then called T-NNT or the NNH. A treatment is then favourable if  
   
   
   i.e. more patients 
are needed to be on treatment to observe an occurrence of adverse event than to observe a 
successful treatment. Of course, the benefit and harm in question should be valued equally for 
the ratio to be at all meaningful. 
 
Schulzer and Mancini (1996) presented a visual representation for use in the assessment of 
risk and benefit by introducing some mutually exclusive marginal events based on the 
probabilities         (Schulzer, 1996). The diagram is rectangular with unit area which is 
segmented into the marginal events (Schulzer, 1996). Of these marginal events, two are of 
special interests named as ‘unqualified success’ (uqs) and ‘unmitigated failure’ (umf). Under 
independence assumption of        : 
       (    ) 
          
 
    characterises the probability of having the a successful treatment without any adverse 
event; and     characterises the probability of having adverse events when the treatment is 
not successful. These formulations in effect penalised the NNT and NNH, thus the 
                                                 
10
 The outcome of interest is observed. 
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reciprocals of     and     produce larger numbers need to be treated (or to be harmed) 
compared to unadjusted measures taking into account both risk and benefit outcomes 
simultaneously. The reciprocal of     is known as the AE-adjusted NNT (AE-NNT) 
(Mancini, 1999). The major limitation of AE-NNT is that it does not take into account the 
relative importance of multiple AEs or the benefit of the outcome (Holden, 2003). The T-
NNT method (Guyatt, 1999) could overcome the problem but does not adjust for AE in the 
same way; it compares whether      -       . 
 
The use of patient-preferences or user-preferences weights to different AEs (or benefit 
outcomes) has been proposed by means of relative values (RV) adjustment (Guyatt, 1999). 
RV is calculated from utilities of AEs and the utilities of the disease of interest based on 
patients response obtained from standard-gamble or time trade-off approach: 
 
   
     
               
 
(Guyatt, 1999) 
   
     
                                    
 
(Guo, 2010) 
 
RV-NNH is used in the same way as T-NNT; and is calculated as: 
        {∑(       )     
 
   
}
  
 
 
Other variants of NNT methods are available: for example cost-adjusted RV-NNH model 
(Guyatt, 1999); length of survival time to consider whether a treatment is worthwhile 
(Silvestri, 1998); and disease impact number and population impact number indexes to give 
perspective of the population (Attia, 2002; Heller, 2002).  
 
Because of the simplicity in calculations and in communicating the results, NNT/NNH 
measures are popular among clinicians (Holden, 2003). However due to the lacking of good 
statistical properties, NNT has been criticised (Hutton, 2000), in particular when    
       ; therefore NNT is undefinable or uninterpretable when there is no treatment 
effect. Guyatt’s adjustment with relative values has been suggested to overcome one of the 
weaknesses of NNT/NNH (Guo, 2010), but the RV adjustment threatens the logical 
Part I: Methods 
Chapter 3 | 89  
 
soundness of NNT measure (Phillips, 2010b). Phillips (2010) argues in decision theory, the 
product of probability and utility is the expected utility, and not a probability (Phillips, 
2010b). (See section 9.4 for further discussion on NNT) 
 
3.9.2 Minimum Clinical Efficacy approach 
The principles of minimum clinical efficacy (MCE) were first introduced as a means of 
selecting between high and low dose chemotherapy for the adjuvant treatment of breast 
cancer (Djulbegovic, 2000; Holden, 2003). MCE weighs risk and benefit in search of the 
minimal therapeutic benefit threshold at which a treatment is still worth administering. The 
uniqueness of MCE is that it takes into account the natural characteristics of the disease in 
general population using untreated group. 
 
Holden (2003) showed the following derivation of MCE: 
Let               be no treatment, new treatment and standard treatment respectively. Let    
be the risk of disease   in    for        . The efficacy of    relative to    is defined as 
   
     
  
  
and similarly for   . Epidemiologists of course would recognise this measure as the ‘relative 
risk reduction’ of    relative to   . 
 
Now let           be the risk of an AE   among those treated with           respectively. 
Similar to NNT in Section 3.9.1,    is warranted over    if the risk reduction of   using    
compared to    is greater than the excess risk of   induced by   , thus: 
                
      
     
  
  
            
     
  
 
 
Therefore the new treatment should only be considered if the efficacy is at least the same as 
the old treatment option plus the risks differences of AEs relative to the risk of disease of 
interest in the untreated group.  
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MCE can be adjusted to accommodate multiple AEs and relative values as in RV-NNH, and 
can be written as: 
      ∑
(    [       ])
  
 
   
 
where             are the risk and relative value of  
   AE in    compared to the disease of 
interest. 
 
When comparing an active treatment    with no treatment   ,    simplifies to: 
        
     
  
 
             
         
where                . Thus it shows that MCE is only useful when comparing two 
active treatments. 
 
MCE is not widely used in epidemiology and very rarely used for R-B assessment when 
compared to NNT (Holden, 2003). However, the statistical properties and the distribution of 
MCE has not been studied (Holden, 2003) and its use is based solely on MCE point estimate. 
As it bears resemblance to RV-NNH model, it also shares some of its weaknesses including 
the inability to handle uncertainty in the measurement of risk and benefit (Guo, 2010) – also 
see Section 9.4.2. Phillips (2010) pointed out that the use of MCE method may also lead to 
failures of logical soundness of the estimates (Phillips, 2010b). 
 
3.9.3 Benefit-Less-Risk Analysis approach 
The initial Benefit-Less-Risk Analysis (BLRA) was proposed to combine risks and benefits 
into a single measure by subtracting risks from benefits using weights assigned to one of five 
categories (Chuang-Stein, 1991). The five categories (Chuang-Stein, 1991) are shown in 
Table 3.2. 
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Table 3.2 Five categories of the BLRA 
1. Efficacy without 
side-effects 
2. Efficacy with side-
effects 
3. No efficacy and no 
side-effects 
4. No efficacy with 
side-effects 
5. Side-effects leading to withdrawal 
 
Mathematical models are then derived from these weights. Chuang-Stein (1991) proposed 
three models for combining the weights    and probabilities of being in the  
th
 category    for 
categories         (Chuang-Stein, 1991): 
 
(a) Linear score: 
  ∑    
 
   
 ∑    
 
   
 
(b) Ratio score 
   
(∑ (    )
 
   )
 
∑ (    )
 
   
      
(c) Composed 
ratio score 
   
    
    
 (
    
         
)
 
      
 
Weights can be chosen to imply equal spacing (importance) of the five categories (Table 3.2) 
for example                       and probabilities can be regarded as 
coming from a multinomial distribution with    (       ) subjects in category   with   
subjects in the treatment group (from example given by George Quartey at Roche in an 
unpublished internal report). Risk-benefit profiles for drugs option are then compared using 
standard statistical techniques, e.g. Student’s t-test. 
 
A follow-up publication (Chuang-Stein, 1994) extends the BLRA method to overcome the 
limitations of the earlier approach (Chuang-Stein, 1991) when collapsing the safety data into 
five crude categories could result in substantial loss of information. She proposed to treat 
adverse events according to body functions and introduced the risk-adjusted benefit measure, 
  . The new BLRA approach, which is favoured to the previous one, involves the following: 
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(1) Organise safety data into body functions. Several (say   (       )) body functions 
e.g. cardiovascular and gastrointestinal are defined to be important body functions 
that are affected by the treatment. The total number of body functions considered 
should be adequate but not overwhelming. 
(2) Score the risk in each   class. The score can be levels of severity of the adverse event 
in that body function, say    (         ( )), where higher level indicates worse 
state.  
(3) Build the risk component from   . Define    as the weight in body function   relative 
to the other body functions – seriousness of AE. Then define          with 
∑     ( )    . It is obvious that     can take into account patient-preference. Hence 
the combined risk component for individual   is defined as: 
   ∑∑        
 ( )
   
 
   
            {
                                            
                                                                  
 
(4) Define benefit outcome. This can be for example change from baseline, a binary 0/1 
response, ordinal scale, etc. Let    be the benefit for patient  . 
(5) Discount the benefit. The benefit    is the adjusted by the risk component calculated 
in (3) above through a proportionality constant: 
  
          
  imposes penalty on the benefit of the treatment due to treatment-induced adverse 
events.   
  can be negative values when the benefit is small compared to the AEs, 
hence suggesting the risks outweigh the benefits for the treatment for that patient. 
(6) Compare risk-adjusted benefit measures.   
 ’s for different treatments can then be 
compared using standard statistical techniques e.g. t-tests. 
(7) Run sensitivity analysis. The values of   is varied to assess its impact on the 
treatments comparison. 
 
3.9.4 Clinical Utility Index approach 
This section is based on the 2010 review paper of the Clinical Utility Index (CUI), where 
CUI and its applications were discussed more thoroughly (Ouellet, 2010).  
 
CUI is defined as an integrated measure of risk-benefit, which can be quantified over the 
entire exposure range. It was originally proposed by Rowland and Tozer as a therapeutic 
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index for the assessment of new drugs (Ouellet, 2010) and its use may still be optimal in the 
context of new drug development. The use of CUI is divided into within a drug and between 
drugs. Its use within a compound focuses on finding the optimal dose-response index; whilst 
the focus for between compounds is the relative value at therapeutic dose. 
 
Generally, CUI is used to determine the utility of a drug in a population, but it has been used 
to determine individual utility (Jonsson, 2005). On a slightly different perspective, CUI was 
also used for economic evaluation of once-a-day dosing antiretroviral drug in order to justify 
its market share over time (Poland, 2001).  
 
There are four key aspects to CUI (Ouellet, 2010): 
(1) Exposure-response analysis of safety and efficacy outcomes is undertaken to 
understand the relationship among the attributes of exposure and the response. 
(2) Definitions of clinically meaningful differences are crucial as for any other clinical 
experimental designs. The CUI is then defined as the sum weighted utilities i.e. 
     ∑      
 
   ; where    is the weight of attribute   relative to one another, and 
   is the utility of attribute  .  
(3) Selection and weighing of attributes is a critical and difficult task which is faced in 
any utility-based method. The challenge is to find an agreement on the selection of 
attributes and to rank their importance for use in the analysis model. This is achieved 
through consolidation of experts’ opinions and past data if available. 
(4) Quantification of uncertainty and sensitivity analysis as final checkpoint. Uncertainty 
around CUI particularly when responses are obtained from a small sample is assessed 
commonly via bootstrapping, Monte Carlo simulation, or assessment of posterior 
distributions under Bayesian framework. Sensitivity analysis are performed to address 
the impact on decision when there were changes in the final utility equation selected, 
the choices of weights and utility parameters, or the dose-response functions. It also 
assesses which attributes matter or redundant to the assessment and decision. 
Sensitivity analysis of CUI can be performed to assess the utility index in different 
scenarios e.g. in different population or from a different perspective. 
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3.9.5 Desirability Index approach 
Desirability Index (DI) originates from the field of industrial process control, where using 
desirability functions one can determine how desirable certain outcomes or attributes are in a 
system (Harrington, 1965). Desirability functions (    ( ( )) for drug  ) range on a 
closed interval [0,1], and are combined into an index, DI, by geometric averaging (geometric 
mean) i.e.    (∏   ))
 
   )
    for attributes         of drug     Any functions that map 
to [0.1] can be used. Weighted sum can also be used to combine DFs. Renard (2009) pointed 
out that in risk-benefit assessment of drugs, geometric mean DI has the desirable properties: 
 
“If one of the product’s properties is completely unacceptable, 
the product as a whole is unacceptable” (Renard, 2009) 
 
Renard (2009) sees desirability index for drug   with DFs      and      for efficacy and 
safety respectively as 
  ( )      (    ( ))
  
     (    ( ))
  
 
and suggests that CUI is a special case of DI when (1) both efficacy and safety outcomes are 
normalised, (2)    
 
   
       
 
   
, (3)     ( )           ( )     , and (4) 
weighted sum is used to combine the DFs. 
 
3.9.6 Time trade-off approach 
The popular time trade-off metrics are the quality-adjusted life years (QALY) and disability-
adjusted life years (DALY). QALY (and DALY) is a multi-attributes utility where health 
states for each attribute are scored and rated. Weights are assigned to each attribute to reflect 
their relative importance. Because the weights are based on life-years trade-off, it 
circumvents some of the difficulties in choosing weights like for other models. 
 
QALY model has also been extended to include patient-preference values, which is known as 
the relative value adjusted life-years (RVALY). RVALY is calculated from relative utilities 
derived from patients’ response to certain attributes of risks and benefits (Lynd, 2004). The 
natural extension of RVALY in quantitative decision-making is given in a framework of 
Incremental Net Benefit (INB) (Garrison, 2007).  
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Let  (  )      (  ) be the efficacy for treatment           respectively in RVALYs unit 
(QALY or DALY can also be used), and let  (  )      (  ) be the risk for           
respective also in RVALYs unit. Then, 
 
    ( (  )   (  ))  ( (  )   (  )) 
 
INB describes the “net” health benefit of a treatment after the risk induced by the treatment 
has been discounted.  
 
3.9.7 TURBO approach 
The concept of Transparent Uniform Risk Benefit Overview (TURBO) model proposed by 
Dr. Willem Amery at the Belgium Janssen Research Foundation was described in the 
appendix of CIOMS IV report (CIOMS Working Group IV, 1998). TURBO model is based 
on two dimensions – risk (“R”-factor) and benefit (“B”-factor). In each dimension, Amery 
(1998) suggested for any given treatment, two most important attributes to be taken into 
account in the scoring (CIOMS Working Group IV, 1998): 
                 
                 
   {         } is associated to the most important or severe adverse event (AE), and 
   {     } represents additional risk e.g. the second most important AE. The scales of 
          are determined qualitatively for example based on probability (frequency) and 
severity of the AE. Similar,    {         }        {   } are the primary benefit of the 
treatment and the ancillary benefit respectively. 
 
In general the second attribute in each dimension, acts as a “correction” to the first. Amery 
(1998) essentially proposed to combine multiple (two in his proposal) attributes of risks and 
benefits in their respective dimensions under linear additive assumption. One can see the 
restrictions (     )  (     ) as implicitly weighing or taking into account the 
correlations between the two attributes within each dimension. In principle, under the current 
proposed model, there is no reason why further attributes in each dimension cannot be added, 
or why the scale for each attribute cannot be modified e.g. on continuous scale or by having 
more ordinal categories. Assuming independence between attributes, the R-factor and B-
factor are then simply   ∑   
 
          ∑   
 
    respectively.  
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The transparent (“T”) score is then determined from the R-factor and B-factor as a single 
point on a TURBO diagram where   {             } is plotted against   {             }. 
An example of TURBO diagram (Figure 3.5) and the postulated
11
 T-scores are given in 
CIOMS IV report (CIOMS Working Group IV, 1998). 
 
Figure 3.5 The TURBO diagram 
 
(TURBO diagram extracted from Appendix E of CIOMS Working Group IV report (CIOMS Working Group 
IV, 1998)) 
 
TURBO is a simple multi-criteria analysis model, but was criticised as lacking in the 
‘theoretical foundation’ of the Multi-Criteria Decision Analysis model (Phillips, 2010b). The 
approach is very qualitative and too simplistic for use in regulatory decision-making 
(Phillips, 2010b). 
 
3.9.8 Decision trees approach 
Decision tree is tree-like diagram with branches of decision, uncertain events, consequences, 
and multiple criteria describing the consequences (Phillips, 2010b). The models are derived 
from decision theory, and operate by decomposing complex problem into its elements. 
Probabilities and utilities about relevant pieces are then assessed and reassembled (Phillips, 
2010b). It works on the basis of three theorems that: 
  
                                                 
11
 T-scores can be further defined but it is unclear on how to do so. 
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(1) probabilities exist, 
(2) utilities exist, and 
(3) options with the highest expected utility should be most preferred 
 
Each option on the decision tree is assessed by multiplying the associated probabilities and 
utilities along a “consequence” branch to give the expected utility which then gets evaluated.  
 
A simple example of a decision tree is shown in Figure 3.6 for choosing whether to take folic 
acid supplement during pregnancy (Ashby, 2000; Spiegelhalter, 2004a). Let  (  ) be the 
expected utility for taking decision   (      ),    be the probability of chance event given 
  , and    be the cost associated with   , then, 
                        (  )       (    )       
 
and, option    is then preferred to option    if  (  )   (  ). By substituting the expected 
utilities and rearranging the inequality, the relationship between utilities in the decision tree 
to NNT when cost was involved can be expressed as (Ashby, 2000): 
    
 
     
 
     
     
  
 
Figure 3.6 Decision tree of folic acid supplements for pregnant women 
 
(Reconstructed from Spiegelhalter et al. (Spiegelhalter, 2004a) with the square representing a decision, hollow 
circles representing chance events, and solid circles representing the utilities) 
 
  𝜋  
No NTD 
No supplement 
d1 
Supplement 
d0 
𝜋  
NTD 
  𝜋  
No NTD 
𝜋  
NTD 
Decision Event? Utility of consequences 
U1 – c0 
U0 – c0 
U1 – c1 
U0 – c1 
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3.9.9 Multi-Criteria Decision Analysis approach 
The idea of multi-criteria decision analysis (MCDA) is so natural and attractive (Figuera, 
2005) that many literatures on, and variants of, the approach exist; and that BLRA method 
(Chuang-Stein, 1994) has been regarded as a reinvention of the MCDA technique (Phillips, 
2010b). Belton and Stewart (2002) labels MCDA as an umbrella term to describe a collection 
of approaches that explicitly take into account multiple criteria in decision making (Belton, 
2002; Mussen, 2009). However, in a 2010 risk-benefit technology review, MCDA is 
specifically referred to the work of Keeney and Raiffa in 1976 based on decision theory 
(Keeney, 1976; Phillips, 2010b), which is essentially the definition I adopt in this thesis. 
 
MCDA breaks the problem down into smaller manageable pieces through the application of 
decision trees to accommodate different criteria. This forces the stakeholders to think about 
the problem or decision to be made in a structured way thus eliminate “gut-feel” decisions on 
the importance of different criteria (Mussen, 2009). There are three main phases of an MCDA 
analysis: (1) problem identification and structuring, (2) model building and use, and (3) 
development of action plan. The detailed stages in building an MCDA model is shown in 
Figure 3.7. 
 
MCDA is very desirable since it can explicitly account for multiple and conflicting criteria 
(Belton, 2002), particularly in making decisions on risk and benefit of drugs. MCDA 
approach can accommodate risks in terms of incidence of adverse events, discontinuation 
rates due to adverse events, as well as other risk factors (Guo, 2010). It can accommodate 
benefits of drugs through clinically relevant outcomes obtained from clinical trials, as well as 
other benefits criteria (Guo, 2010). The readily-available method within MCDA to trade off 
risks and benefits and integrate them into a single measure is what making it attractive, and it 
is conceptually simple (Belton, 2002). It is relatively easy to understand and to be used by 
people who are not familiar with decision analysis techniques (Mussen, 2009). MCDA allows 
the stakeholders to focus on the best data (evidence) available, the scoring of options, and the 
weightings of criteria – without the need to concern heavily about the underlying model itself 
(Mussen, 2009). There are specialised software to facilitate the application of MCDA 
including the underlying model building such as Hiview 3 from Catalyze Ltd (Winchester, 
UK) (Catalyze Ltd., 2010a).   
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MCDA produces better considered, justifiable, and explainable decisions together with an 
audit trail for the decisions, making it transparent (Belton, 2002). However, the internal 
validity of MCDA critically relies on the evidence from clinical trials (Guo, 2010) and the 
quality of qualitative value judgements. Its application in post-approval phase of a drug is 
still limited and threatened by the quality of data available thus remains a challenge (Mussen, 
2009).  
 
Figure 3.7 Detailed stages in MCDA 
 
Extracted and modified from the MCDA manual (Dodgson, 2009) 
 
1. Establish the decision context 
a. to establish the purpose of the analysis, and identify the main stakeholders involved 
b. to design the socio-technical system for conducting the MCDA 
c. to consider the context of MCDA 
2. Identify the options to be appraised 
a. to explicitly list the different options available 
3. Identify objectives and criteria 
a. to identify criteria of each option 
b. to organise the criteria by objectives in a hierarchical fashion 
4. ‘Scoring’ 
a. to describe the consequences of the options 
b. to score each option for each criteria usually on a 0-100 scale 
c. to check the consistency of the scores given relative to each other across different criteria 
5. ‘Weighting’ 
a. to assign weights to the criteria reflecting the relative importance in the decision 
6. Combine the weights and scores for each option to derive an overall value 
a. to calculate overall weighted scores at each level in the hierarchy 
b. to calculate overall weighted scores 
7. Examine the results 
8. Sensitivity analysis 
a. to evaluate how other preference weights affect the ordering of options and the decision 
b. to evaluate and compare the advantages and disadvantages of the options 
c. to determine whether new options are possible and probably better than those considered 
originally 
d. to elicit the best model to be used for making decision 
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3.10 Bayesian statistics 
Main analyses in this thesis use classical regression techniques especially for evidence data 
mining exercise. But some Bayesian analyses are carried out when Bayesian would offer 
clear greater advantage to classical analysis e.g. in mixed treatment comparison described in 
Section 3.4. Some applications of what I call a “hybrid Bayesian”-classical approach are 
explained in Chapter 9. 
 
This section does not intend to give a thorough documentation on Bayesian school of 
thoughts but only a general overview of the concept as applied to case study. Thorough 
discussions on Bayesian statistics can be found in good statistical textbooks (Berger, 1985; 
Bernardo, 1994; Parmigiani, 2002a; Spiegelhalter, 2004b). The use of Bayesian in medical 
decision making has also been discussed elsewhere (Ashby, 2000; Parmigiani, 2002a; 
Spiegelhalter, 2004b). 
 
The history of Bayesian statistics originating from Reverend Thomas Bayes in 1763 has been 
discussed in a recent review on the use of Bayesian statistics in medicine (Ashby, 2006). 
Bayesian statistics has become popular in recent years mainly due to computational advances 
that facilitates its application (Ashby, 2006). This is in some way attributed to the 
development of WinBUGS (Bayesian inference Using Gibbs Sampling for Windows) 
software (Lunn, 2000) which is currently considered as the main tool for performing 
Bayesian analysis. It is being succeeded by OpenBUGS (Lunn, 2009). 
 
For a hypothesis   and data  , the simplest form of Bayes theorem is (Bernardo, 1994), 
where  ( ) denotes the probability: 
 ( | )   ( | )  
 ( )
 ( )
  
 
 ( ) is the subjective probability of the hypothesis independent of the data known as the 
priors, and  ( | ) is the posterior probability of the hypothesis having observed the data. 
This simple principle forms the basis of Bayesian statistics we are now familiar with.  
 
The most problematic issue in Bayesian statistics is the elicitation of priors. Weak priors or 
sometimes known as uninformative or uniform priors are usually used when there is no prior 
knowledge. In this circumstance, the posterior probability of the hypothesis is driven by the 
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data. When informative priors are used in the model, the priors would influence the posterior 
depending on how strong or certain the priors are. This often gets Bayesian analysts in 
trouble when too strong priors are chosen, i.e. being too confident in the judgement of the 
evidence, then the priors would overpower evidence from data. In Bayesian analysis, the 
inferences are made from the examination of posterior distribution. 
 
WinBUGS and OpenBUGS are dedicated to performing Bayesian analysis using Gibbs 
sampler to implement Markov Chain Monte Carlo (MCMC) method. In an application of 
iterative methods such as Gibbs sampling, it is usual that consecutive observations of the 
posterior distributions being sampled are correlated – referred to as autocorrelation in 
WinBUGS/OpenBUGS. The autocorrelation for each stochastic node or parameter is 
inspected using the built-in software diagnostic function to ensure convergence and mixing of 
the MCMC chains. Other diagnostic tools available are the trace plots and the Gelman-Rubin 
plot.  
 
WinBUGS and OpenBUGS also save the (explicitly monitored) estimates at each MCMC 
iteration as Convergence Diagnostic and Output Analysis (CODA) files from each chain 
(Best, 1995). CODA outputs are commonly used for convergence and diagnostic tests when 
the analyses are carried out outside WinBUGS/OpenBUGS software. CODA outputs are used 
in this thesis (Section 9.4) to perform sensitivity analysis of the Bayesian models in Stata 10 
(StataCorp, 2007) to gain computing speed. 
 
“Confidence intervals” (CI) for a parameter from a Bayesian analysis is known as the 
credible intervals (CrI). CrI is the highest posterior density that covers the (   ) 
significance level (in classical sense – see Section 3.11). 
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3.11 Power and sample size determination 
Power and sample size are the two fundamental requirements when designing clinical trials. 
They ensure that the clinical trial to be conducted is large enough to make inference on the 
hypothesis and not too large to be resource inefficient.  
 
Typically a clinical trial requires power at 80% or 90% level. Power indicates how reliably a 
trial could detect the hypothesised difference, and often labelled as (   ). Another 
parameter required is the significance level   which typically is chosen to be 5%. Greater 
power and smaller   lead to larger sample size provided other parameters are constant – 
hypothesised difference and variance. 
 
All illustrative sample size calculations in Chapter 10 are done in classical way in Stata 10 
(StataCorp, 2007). 
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4. Epidemiology of gastro-oesophageal reflux disease 
4.1 Introduction and objective 
This chapter reviews the epidemiology of the medical condition in the case study. We define 
the gastro-oesophageal reflux (GOR) and summarise its public health concerns in children 
population. GOR and gastro-oesophageal reflux disease (GORD) are also differentiated. 
Symptoms, diagnosis and treatment options are reviewed, with focus on the treatment of 
GOR using pro-kinetic drugs, which are being prescribed off-label in the UK. 
 
Finally, I draw up a general conclusion and summarise the content of this chapter in the light 
of forthcoming work in subsequent chapters.  
 
4.2 Gastro-oesophageal reflux in children  
Gastro-oesophageal reflux (GOR) is defined as involuntary passage of gastric contents into 
the oesophagus (Vandenplas, 2000). The contents vary from saliva, ingested food and drinks, 
pancreatic to biliary secretions. 
 
Figure 4.1: Proportion (%) of children who spilled 
 
Extracted from published literature (Martin, 2002). 
 
GOR is common and occurs in about 18% of the general infant population (Boulton, 1979; 
Chouhou, 1992) although the prevalence is more age-dependent but very little is known. 
Figure 4.1 shows that this peaks at around 3 months with majority of children settling by 13 
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or 14 months (Martin, 2002). 50% of infants 0-3 months old regurgitate but only 5% of 10-12 
months old do (Nelson, 1997). 47% one month old infants regurgitate, compares to 29% at 4 
months, 6.4% at 7 months, and down to 0% at one year (Miyazawa, 2002). This shows that 
most regurgitation in younger children improve with time. On the other hand, some GOR 
may be more serious than just regurgitation that gets better with time. Some developed into 
GORD; and some are results of complications of other somatic disorders e.g. vomiting due to 
brain tumours. 
 
The spectrum of reflux is divided into three categories – normal, functional and pathogenic 
GOR (Stephen, 1994). Normal GOR is a minimal degree of acid reflux experienced by 
normal individuals which should cause no concern. Functional GOR is benign.  The example 
of this is frequent regurgitations in infants. As functional GOR is a passive process, it does 
not cause inflammation or lead to long-term complications, therefore medical attention is not 
required. Pathogenic GOR, although similar to functional GOR, usually involves vomiting 
with a nauseous sensation and require medical attention.  
 
The active process of (involuntary) vomiting is a powerful reflex which puts pressure on the 
stomach and forces gastric contents out from the mouth. Pathogenic GOR can be further 
divided as primary and secondary.  
 
Primary pathogenic GOR is associated with complications such as anaemia, oesophagitis, 
dysphagia, weight loss, and failure to thrive which could lead to discomfort, disability or 
impairment of function (Vandenplas, 2000). Primary pathogenic GOR is more commonly 
known as GOR disease (GORD).  
 
Secondary pathogenic GOR is majority reflux caused by other stimuli like injections of 
sclerosant, metabolic disorders and food allergy. Treatment for secondary GOR is based on 
treating the underlying cause. In this research, I shall refer to functional GOR as ‘GOR’ and 
primary pathogenic GOR as ‘GORD’ or ‘GOR’ disease. I shall not look into secondary 
pathogenic GOR further as the clinical pathology deviates from the research interests. 
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4.2.1 Symptoms of GORD 
Clinically, the three classifications of gastro-oesophageal reflux are hard to distinguish due to 
their similar manifestations (Table 4.1). Most common GOR symptoms, regurgitation and 
vomiting may be observed in normal people but are more severe or more frequent in GORD 
patients. 3% of parents to 10-12 months old infants view regurgitation in their children as a 
problem (Nelson, 1997). In addition to those listed in Table 4.1, the symptoms in infants and 
younger children extend to but not necessarily crying, chronic cough, wheezing, aspiration 
pneumonia and abnormal head positioning (Behrman, 1992). 
 
Table 4.1: Symptoms of gastro-oesophageal reflux disease (GORD) 
Usual manifestations Unusual presentations 
Specific manifestations - GOR related to chronic 
respiratory disease (bronchitis, 
asthma, laryngitis, pharyngitis,  
- Regurgitation 
- Nausea 
- Vomiting etc.) 
Symptoms possibly related to complications 
of GOR
†
 
- Sandifer-Sutcliffe syndrome  
- Rumination  
- Symptoms related to iron deficiency 
anaemia 
- Apnoea, apparent life-
threatening event and sudden 
- Haematemesis and melaena infant death syndrome 
- Dysphagia (as a symptom of 
oesophagitis or from stricture formation 
 
- Weight loss and/or failure to thrive  
- Epigastric or retrosternal pain  
- Non-cardiac angina-like chest pain  
- Pyrosis or heartburn, pharyngeal 
burning 
 
- Belching, postprandial fullness  
- Irritable oesophagus  
- General irritability (infants)  
† 
Some of these symptoms may also be caused by other mechanisms.  
This table is extracted and modified from Vandenplas’s paper (Vandenplas, 2000). 
 
4.2.2 Management of GORD 
Several guidelines have been published regarding the management of gastro-oesophageal 
reflux disease in children. Rudolph et al. (2001) conducted a systematic review to develop a 
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guideline for management of suspected GOR in children on behalf of the North American 
Society for Pediatric Gastroenterology and Nutrition. The guideline summarised the 
diagnostic approaches to GOR, available treatments and recommended a management 
approach based on specific symptom presentations in children. Below I discuss the diagnostic 
and treatments for GOR in relation to the headings used in the guideline (Rudolph, 2001) in 
reference to children. 
4.2.2.1 Diagnosis of GORD 
(1) History and physical examination – History should include any previous reflux 
episodes, frequency and pattern of reflux, feeding, medical, exposure to smoke, 
sleeping position, etc. to relate to GOR symptoms. A significant relationship between 
maternal GOR and infant spilling was observed in a prospective cohort study of 693 
infants and suggested that a genetic component may be involved (Martin, 2002). 
Maternal history of GOR may be another variable to be collected when taking history. 
Physical examination could identify any abnormal signs. Some experts thought that 
history and physical examination is sufficient to diagnose GOR, recognise any 
complications and to initiate management (Rudolph, 2001). 
 
(2) Upper GI series – Upper GI series test (barium contrast radiography) is useful to 
detect anatomical abnormalities such as hiatus hernia, pyloric stenosis, malrotation 
and annular pancreas in vomiting infants. Sensitivity ranges from 31% to 86% and 
specificity ranges from 21% to 83% when compared to oesophageal pH monitoring 
(Rudolph, 2001). However, the test is neither sensitive nor specific to GOR, and 
therefore it is not a very useful test for diagnosis of GOR. 
 
(3) Oesophageal pH monitoring is regarded as a first line of investigation for children 
regardless of age (Al Khawari, 2002). It is a valid and reliable way to measure acid 
reflux. This method involves transnasal placement of microelectrode into lower 
oesophagus to measure and record inter-oesophageal pH. Computerised devices are 
normally used to record pH every 4 to 8 seconds, which then calculates the frequency 
and episodes of reflux, usually within a 24-hour period. An episode is defined as 
pH<4 for a minimum of 15 to 30 seconds. A normal episode of acid reflux in normal 
infants is 31 (±21) per day with an upper limit of 73 episodes (Vandenplas, 1991). 24-
hour pH monitoring can detect any abnormal acid reflux and could be used to 
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determine whether the symptoms are temporally associated with GORD. On the other 
hand, non-acidic reflux episodes, for example post-prandial reflux in infants are not 
detected by pH monitoring. In some patients, pH monitoring is within normal range 
but the brief episodes of GOR may also cause complications. A study suggested that 
non-acidic reflux occurs more frequently than acid reflux in infants (Wenzl, 2002) 
thus oesophageal pH monitoring may not be able to detect reflux events in children 
(Condino, 2006). 
 
(4) Impedance monitoring is a new technique to detect non-acid or weak acid reflux. 
Impedance is defined as the ratio of voltage to current. It is used to detect bolus 
volume of the refluxate independently from its pH composition (Condino, 2006). 
Condino et al. (2006) finds that impedance is better at detecting both non-acidic and 
acidic reflux, but a combined pH-impedance monitoring improves the correlation of 
reflux-type events even further (Condino, 2006). A combination of pH-impedance 
monitoring may become a standard test for GOR in the future (Bredenoord, 2008; 
Zerbib, 2006).  
 
(5) Endoscopy is used for diagnosis of complicated GORD for example when 
oesophagitis is suspected or the regurgitation has been persistent (Vandenplas, 2000). 
Endoscopy and biopsy allow visualisation of the oesophageal epithelium for the 
presence and severity of oesophagitis, strictures or Barrett’s oesophagus (not common 
in children). This diagnosis is used to rule out other disorders e.g. Crohn’s disease. A 
normal appearance of oesophagus however does not exclude histopathological 
oesophagitis. The findings from endoscopy are then used to determine the appropriate 
management and/or treatment for the patient. 
 
(6) Empiric medical therapy is an experimental procedure to test whether GOR is causing 
specific symptoms. In empiric medical therapy, a suspected GORD patient is put 
under a trial of GOR medical therapy for a limited time period. Depends on whether 
the symptoms resolve, continue or worsen, the clinician may then make a deduction 
whether GORD is the problem and whether the medication should continue.  
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4.2.2.2 Treatment options 
There is currently no medical treatment targeting the primary mechanism of GOR i.e. 
transient relaxation of the lower oesophageal sphincter. All available treatments available are 
aiming at relieving patient’s symptoms, promoting normal weight gain, healing inflammation 
caused by GOR, and preventing respiratory or other complications associated with chronic 
reflux of gastric contents (Rudolph, 2001). 
 
Diet changes such as use of thickened formulae should be regarded as the first step of 
treatment (Vandenplas, 2000) for infants with GORD symptoms. In children younger than 2 
years, thickeners like starch and bean gum added to normal formulae help reduce symptoms 
of GORD (Craig, 2004). While it reduces the symptoms like vomiting, thickeners do not 
improve reflux index (Rudolph, 2001). Thickened formulae also increase sleep duration 
(Vandenplas, 1997; Vandenplas, 1998) and may also help underweight infants due to GORD 
to gain weight (Ferry, 1983). On the contrary, Huang et al. (2002) conducted a systematic 
review on the efficacy of thickeners for newborn infants with GOR but did not find any 
studies that met the inclusion criteria. She concluded that the use of thickeners should not be 
encouraged for GOR management in neonates in the absence of evidence from randomised 
controlled trials. The use of thickeners may increase coughing during feedings in infants 
(Orenstein, 1992; Rudolph, 2001) and in theory could delay gastric emptying (Huang, 2002). 
 
Infants sleeping in prone position have less GORD symptoms as shown by a pH monitor 
compared to those sleeping in a supine position. However, the risk of sudden infant death 
syndrome (SIDS) is significantly increased when infants sleep in prone position. In the 0-12 
month infant population, this is not advisable as the risk of SIDS outweighs the benefits of 
prone sleeping. It should only be considered if the fatal complications from GORD outweigh 
the risk of SIDS (Rudolph, 2001). Although the benefit of sleep positioning has not been 
studied in the older children population, it is suggested that left side positioning and elevation 
of head of the bed may have some likely benefits (Hamilton, 1988; Johnson, 1981; Stanciu, 
1977). 
 
Lifestyle changes include avoiding food that may cause allergy, caffeine, chocolates and 
spicy food that may provoke GORD symptoms (Chang, 1997; Murphy, 1988; Pehl, 1997; 
Vandenplas, 1986). Obesity and exposure to tobacco and alcohol are also associated with 
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GORD and should be avoided (Fisher, 1999; Locke, 1999). Lifestyle changes apply more to 
older children and adults but not to younger children and infants. However, parents’ lifestyle 
changes like avoiding smoking around children or giving up smoking completely will 
definitely help in avoiding children from exposure to second-hand smoke. In patients who 
already received pharmacological therapy, the benefit of lifestyle changes has not been 
established (Rudolph, 2001). 
 
Acid-suppressant therapy is used to relief symptoms of GORD and promotes mucosal healing 
of the oesophagus. Many acid-suppressants are sold over-the-counter (OTC) in many 
countries. A meta-analysis  of OTC drugs for GOR concluded that they are effective for 
symptomatic GORD when compared to placebo (Strickland, 2007) and reported a number-
needed-to-treat (NNT) of four (95% CI, 2 – 9) for alginate-antacid. However, a trial 
concluded that Gaviscon alginates, which are available OTC, did not improve number of 
reflux events but only marginally improved reflux height up the oesophagus in infants when 
compared to placebo (Del Buono, 2005). Chronic antacids are not generally recommended 
for self-management of GORD as more convenient and safe alternatives are available 
(Rudolph, 2001). However, a BMJ review recognises that the efficacy studies of OTC drugs 
in GORD treatment may be bias as more severe symptoms may be masked or ignored when 
self-managing GORD symptoms (Strickland, 2007). Health professionals should be sought 
when GORD symptoms are observed in younger children and infants. 
 
Pro-kinetic drugs treatment for GORD has initiated some debates of its efficacy and safety. 
Many studies (Cucchiara, 1987; De Loore, 1979; Escobar Castro, 1994; Van Eygen, 1989) 
showed pro-kinetic drugs are effective when used to treat patients with GORD, whilst some 
other studies did not establish that relationship (Carroccio, 1994; Clara, 1979; Cohen, 1999; 
Scott, 1997; Vandenplas, 1991). We shall look at the use of pro-kinetic drugs therapy in 
patients with GORD further in Section 4.2.3 below. 
 
Surgery is the last treatment option to be considered when other medical treatments and 
management do not work. The diagnosis and particular cause of GORD must also be 
confirmed before performing surgery. Several surgical procedure were proposed for GORD 
treatment – Nissen fundoplication, Thal procedure, Toupet posterior wrap, Hill repair, 
Boerema procedure and the Boix-Ochoa balanced procedure (Ashcraft, 1993; Boix-Ochoa, 
1989; Hill, 1967). The most popular surgical procedure for GORD in the paediatric patients is 
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Nissen fundoplication (Dalla Vecchia, 1997; Rudolph, 2001) with 91% success rate (Dalla 
Vecchia, 1997). The procedure involves a construction of a new ‘valve’ between the 
oesophagus and the stomach by wrapping the upper portion of the stomach (fundus) to the 
lowest part on the oesophagus. In Nissen procedure, a short loose wrap is created by 
completely wrapping the fundus around the lower oesophagus. As the stomach becomes 
distended, e.g. during meals, the wrap then compresses the lower oesophagus preventing 
reflux. About 76% of Nissen fundoplication wrap failure in children attributed to vomiting 
has been reported (Dalla Vecchia, 1997). Common adverse effect attributed to surgery is 
raised intragastric pressure (“gas bloat syndrome”) which could disruption to the wrap or 
wrap slippage into the chest as a result of forceful vomiting or retching (Bush, 2005; Saedon, 
2007). In rare situations, complications of surgery also include perforation of the stomach and 
wound infections (Iwanaka, 2004). 
 
4.2.3 Treatment with pro-kinetic drugs for children 
Cisapride (prior to its withdrawal) and domperidone are both widely accepted for treatment 
of GORD. Because the pharmacological mechanisms of action of the two compounds differ, 
their therapeutic activity profiles are bound to be different. Another common pro-kinetic 
treatment for GORD is metoclopramide but it is not very commonly used in younger 
children. 
 
4.2.3.1 Introduction to cisapride and domperidone 
Cisapride is a HT4-agonist. It stimulates the motility of smooth muscle lining in the 
oesophagus, stomach, small intestine and colon, therefore reduces colonic transit time. 
Cisapride was well tolerated, with adverse effects limited to gastrointestinal tract (Barone, 
1994). ESPGAN recommended cisapride as the first line medicine for GORD in children 
(Vandenplas, 1993). Compared to domperidone, cisapride was found to be more effective in 
treating GORD with no major or unexpected adverse events (Halter, 1997). Although 
cisapride was regarded as a safe and effective drug, fatal cardiac arrhythmias and sudden 
deaths had driven its withdrawal in July 2000 by the Medicines Control Agency (MCA). 
Until the end of 2003, cisapride should only be considered after very careful considerations 
of all known risks and benefits where the child condition would be at a greater threat to life if 
cisapride were not given than the potential of cardiac sudden death if it were given (RCPCH, 
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2003). Substantial publication bias was reported in a systematic review of the efficacy of 
cisapride in favour of the studies showing positive effect of cisapride as shown by funnel plot 
asymmetry; but no evidence of cisapride efficacy was found (Augood, 2003). The evidence 
of publication bias was also supported by a report of a large unpublished multi-centre trial of 
children randomised to cisapride and placebo ‘because efficacy results did not reach 
statistical significance (possibly because inclusion criteria were too broadly defined)’ 
(Augood, 2003; Levy, 2001). 
 
Domperidone is a peripheral dopamine D2-antagonist with anti-emetic properties. It affects 
the motility of the upper gastrointestinal tract and effectively improves GORD symptoms. 
Some studies (Agorastos, 1981; De Loore, 1979; Haarmann, 1979; Van Outryve, 1979) 
showed that domperidone has been superior to metoclopramide in treating GORD. In a 
systematic review of four randomised controlled trials of domperidone use in children one 
month old to 11 years old with GORD, no robust evidence of efficacy was found in younger 
children but no adverse reactions were noted. Only the two older trials (Clara, 1979; De 
Loore, 1979) showed any benefits of domperidone in older children (Pritchard, 2005). 
 
4.2.3.2 Drug dosage bioequivalence 
There were oral and rectal formulations of domperidone and cisapride available during our 
observation period. Because there is a substantial difference between dosage recommended 
for rectal and oral administration, we rescale the rectal dose to be equivalent to the oral dose. 
This is to avoid averaging across different dose “units” as coded on GPRD database. 
 
Domperidone 
Different doses for oral vs. rectal formulations were recommended by domperidone 
manufacturers although they have similar bioavailability. This is because there are other 
pharmacokinetic differences between oral and rectal formulations which were taken into 
considerations when choosing dosing. Suppositories (rectal formulations) give a lower peak 
level, and the level plateaus for longer which mean a higher dose is given but there can be a 
longer dosing interval. 
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The summary of product characteristics (SPC) for Motilium® 30mg suppositories indicates 
the pharmacokinetics as:  
 
“After rectal administration of 60mg domperidone suppositories, a plateau is attained 
with domperidone plasma concentrations of about 20ng/ml lasting from 1 to 5 hours 
after administration. Although peak plasma levels are only about one third of that of an 
oral dose, the mean rectal bioavailability of 12.4% is quite similar to that after oral 
administration.” (eMC, 2010) 
 
Following this, we rescaled rectal doses to a third of that prescribed which gives an 
equivalent dosing to that of oral doses.  
 
Cisapride 
Bioavailability of oral cisapride ranges from 35% to 65%, where it is approximately 50% 
under fasting conditions and 65% when taken with a meal. The peak plasma levels (Cmax) are 
achieved after approximately 1-2 hours. 
 
Bioavailability of rectal cisapride is 40%, but there are other differences in pharmacokinetics 
which were taken into considerations. Rectal absorption of a 30mg suppository, which also 
contained hydroxypropyl-beta-cyclodextrine 12%, was slightly slower than after oral 
administration with a tmax of 3 hours. However, Cmax values approximated those seen after an 
oral 10mg dose administered after fasting. Based on the values of AUC (0-∞), the 
bioavailability of the rectally administered form was 50% relative to the oral form 
(McCallum, 1988). 
 
4.2.3.3 Licensing of cisapride and domperidone 
Cisapride was licensed in the UK for the treatment of GORD people over 12 years old in 
1998. It was never licensed for use in children under 12 years old (RCPCH, 1999).  
 
Domperidone is licensed for use in children but restricted to nausea and vomiting following 
cytotoxics or radiotherapy, with an indication for use in GORD and gastric stasis (Paediatric 
Formulary Committee, 2008). 
 
Part II: Epidemiology of gastro-oesophageal reflux disease 
Chapter 4 | 115  
 
4.3 Conclusion 
This chapter presented the epidemiology of GOR in children. The often benign nature of the 
disease can sometimes get worse. In pursuit of the treatment following failure of conservative 
(lifestyle and non-drug) therapy, pro-kinetics such as cisapride and domperidone were used. 
The prescribing of these drugs in children for the treatment of GORD is unlicensed however 
common it becomes, and the efficacy and safety have been questioned. It is also unknown 
how long or how many conservative therapies have been tried until they are considered 
“failed” before starting a child on pro-kinetics therapy. This might have changed over the 
years and may also be an important aspect to study but I will not pursue this further in this 
thesis. 
 
Many different analyses could be carried out to establish the risks and benefits of the drug 
use. But without good data, any results obtained from such data would be under scrutiny. Past 
clinical trials on these drugs in children have many problems; and one of them is 
inconsistency of reporting. Chapter 5 reviews clinical trials of cisapride and domperidone in a 
non-quantitative manner to appraise the design, conduct and reporting of trials. This 
reinforces the need for risk-benefit assessment using alternative evidence to justify off-label 
drug prescribing. 
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5. Narrative review on clinical trials of cisapride and domperidone 
5.1 Introduction 
A narrative
12
 review of the inconsistency of evidence reporting from clinical trials of 
cisapride and domperidone in children is presented here. I summarise and discuss the 
planning of safety data collection and how they are reported in each trial. This chapter does 
not appraise the planning and reporting on benefits because they are usually well defined, and 
not very critical here. They are reviewed in Chapter 7 as part of the quantitative evidence of 
risks and benefits. 
 
Extensive systematic reviews of the treatment of gastro-oesophageal reflux using cisapride 
and domperidone in children have already been conducted (Augood, 2003; Pritchard, 2005). 
Therefore this chapter simply builds on these systematic reviews. 
 
5.2 Rationale for the review 
The reviews on cisapride (Augood, 2003) and domperidone (Pritchard, 2005) seek to explore 
the evidence of efficacy for cisapride and domperidone in reducing symptoms of GOR in 
children. Neither found any clear evidence of efficacy; but both reviews were in agreement 
about the uncertain safety profiles for both drugs.  
 
There were no adverse effects observed from the trials included in the domperidone review 
(Pritchard, 2005). The authors however cited some reported adverse reactions from other 
studies that were not included in the review but treatment effects were not quantified. In the 
cisapride review (Augood, 2003), the authors found no statistically significant difference in 
the occurrence of adverse events between cisapride and placebo group – odds ratio for 
cisapride versus placebo 1.80 (95% CI 0.87-3.70). Only diarrhoea and QTc interval duration 
were mentioned in the review. 
 
The objective of this review is to assess the extent of adverse events planning and assessment 
in randomised clinical trials for cisapride and domperidone, as they were reported in the 
papers. 
 
                                                 
12
 A narrative review is a documentary of reviewed articles subjectively discussed which may or may not 
include quantitative evidence or evidence-based opinions. 
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5.3 Methods 
5.3.1 Literature search strategy 
I identified the primary papers of the randomised controlled trials included in the cisapride 
and domperidone systematic reviews by hand-searching the references. Literature search was 
then rerun to look for new trials between 2005 and May 2010. The Cochrane Central Register 
of Controlled Trials and Database of Systematic Review, Medline, and EMBASE were 
searched using appropriate combinations of the following search terms: cisapride, 
domperidone, gastro-oesophageal reflux, oesophagitis, infantile reflux, and regurgitation. 
Appropriate truncations and variations in spellings of the search terms were also taken into 
considerations. 
 
The studies were selected using the same criteria as the original systematic reviews (Augood, 
2003; Pritchard, 2005), which are: 
(1) Randomised controlled trials comparing a minimum of one week administration of 
oral cisapride/domperidone therapy with either placebo or nonsurgical treatments; and 
were performed in children (<18 years) with a probable diagnosis of GOR, however 
defined. 
(2) The studies must also report at least one of the outcomes: symptoms or change in 
symptoms of GOR; presence of any adverse events,; occurrence of any clinical 
complications of GOR e.g. respiratory symptoms; weight change; episodes of reflux 
measured by oesophageal pH monitoring; lower oesophageal sphincter pressure 
measure by oesophageal manometry; or histological evidence of oesophagitis on 
biopsy. 
 
5.3.2 Methods for narrative review 
A pro forma (see Appendix A.1) was developed to collect information on the extent of which 
safety was reported in publication of clinical trials. The pro forma seeks to find out what were 
mentioned about safety in the introduction, methods, results, and discussion/conclusion. And 
if so, what evidences were used to justify them. The coherence on what aspects of safety 
appeared to be planned explicitly (or implicitly) at design stage and the final reporting is also 
examined.  
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5.4 Results 
Four domperidone trials (Bines, 1992; Carroccio, 1994; Clara, 1979; De Loore, 1979) and 
eight cisapride trials (Cohen, 1999; Cucchiara, 1987; Escobar Castro, 1994; Greally, 1992; 
Levy, 2001; Scott, 1997; Van Eygen, 1989; Vandenplas, 1991) which were previously 
included in the original systematic reviews are included. The information from the trial was 
only extracted from what were reported in the systematic review (Augood, 2003). Two new 
studies were found during the literature search rerun. One study (Cresi, 2008) is excluded 
because it was conducted in neonates (<1 month), and another study (Hegar, 2009) satisfies 
the inclusion criteria and is included in this review.  
 
Of the thirteen trials included, only two (Cohen, 1999; Hegar, 2009) reported sample size 
calculations. Only one paper (Levy, 2001) clearly states in its introduction that cisapride was 
unlicensed for GOR indications in children.  
 
I discuss the aspects of safety planning and reporting from each trial in Section 5.4.1 
(Pritchard, 2005), Section 5.4.2 (Augood, 2003), and Section 5.4.3 for trials of domperidone 
versus non-cisapride therapy, cisapride versus non-domperidone therapy, and domperidone 
versus cisapride therapy respectively. Sections 5.4.1 and 5.4.2 start with short basic 
characteristics of the trials, patients and intervention to aid the interpretation of the work that 
follows in this chapter and in the quantitative review Chapter 7. More detailed characteristics 
of the trials can be found in the original systematic reviews (Augood, 2003; Pritchard, 2005) 
but are not presented here to avoid duplication of work. They are however extracted for 
reference and are available in Appendix A.1. More detailed characteristics for the new trial 
(Hegar, 2009) found through rerunning the systematic search algorithm are given at the 
beginning of Section 5.4.3. 
 
5.4.1 Domperidone versus placebo, other drugs not cisapride, or non-drugs trials 
The characteristics of the trials comparing domperidone to drugs other than cisapride or non-
drugs (including placebo) are shown in Table 5.1. The patients and interventions 
characteristics of the trials are given in Table 5.2. For each domperidone trial being reviewed, 
the planning and reporting of safety aspects of the trial are discussed in Sections 5.4.1.1 to 
5.4.1.4. 
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Table 5.1 Characteristics of trials comparing domperidone to non-cisapride 
Author Study 
year 
Study 
place 
Methods Endpoints Withdrawals 
Clara 
(1979) 
1979 Belgium Randomised 
double-blind 
GORD symptoms none 
De Loore 
(1979) 
~1979 Belgium Randomised 
double-blind 
GORD symptoms none 
Bines 
(1992) 
~1990 Boston, 
USA 
Randomised 
double-blind 
GORD symptoms, 
Reflux index 
none 
Carroccio 
(1994) 
~1993 Italy Randomised 
double-blind 
Reflux index none 
 
Table 5.2 Patients and interventions characteristics in trials comparing domperidone to non-cisapride 
Author Length 
(weeks) 
Dose 
(mg/kg/day) 
        
(months)  
        
(months) 
Clara (1979) 4 0.9 14 48 18 72 
De Loore (1979) 2 0.9 15 9 15 6 
Bines (1992) 4 1.8 8 43.2 9 28.8 
Carroccio (1994) 8 0.9 20 5 20 4 
    number of children in treatment group.  
    number of children in control group. 
      median or mean age in treatment group. Median is presented where available. 
      median or mean age in control group. Median is presented where available. 
 
5.4.1.1 Clara (1979) 
In the introduction, there is a mention of side-effects from other medications used to treat 
GOR, but author suggested that domperidone could be a safe and effective alternative as a 
justification for conducting the trial. 
 
The methods section of the paper mentions that nine signs and symptoms to be monitored in 
the trial, which are nausea or retching, vomiting, projectile vomiting, regurgitation, anorexia, 
abdominal pain, abdominal distension, flatulence, and diarrhoea. Three items 
(nausea/retching, vomiting, regurgitation) were regarded as target items and to be monitored 
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for in the trial. However, the possibilities that the signs and symptoms could also be potential 
adverse reactions were not considered. The author mentioned that side-effects were registered 
but no further details were given. 
 
The results section reports that there was no side-effect observed by the investigator or 
reported by patients/carers. 
 
The paper concludes that the lack of side-effects indicate domperidone as a ‘very promising’ 
drug for treatment of regurgitation and vomiting in children. 
 
5.4.1.2 De Loore (1979) 
The introduction of the paper states that the aim of the trial was to compare efficacy of 
domperidone when compared to metoclopramide and placebo. Domperidone was implicitly 
regarded as a new approach that would be more effective and safer for use in infants and 
children. 
 
There is a mention of the rating for nausea and vomiting, which were treated as symptoms in 
the methods section. With respect to adverse events, the section states that ‘apparent’ side-
effects were to be recorded. What is meant by “apparent” however is ambiguous. 
 
In the results section, the author reported that there was no evidence of any drug-related 
adverse events.  
 
The paper concludes that domperidone is a safe treatment for chronic vomiting and nausea. It 
also stresses that compared to metoclopramide; domperidone does not carry risk of 
extrapyramidal effect. 
 
5.4.1.3 Bines (1992) 
Central nervous system (CNS) side-effect is mentioned in the introduction to the trial. The 
aim of the trial however does not explicitly mention safety. 
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The methods section states that the trial was to give attention to CNS side-effects – 
drowsiness and extrapyramidal reactions; and to gastrointestinal side-effects – increased 
vomiting, diarrhoea, and abdominal pain. The paper also states that adverse events were 
monitored by clinical criteria and laboratory parameters. 
 
Self-limiting diarrhoea, transient neutropenia, and elevated prolactin levels are reported in the 
results section. There were no CNS adverse events reported during the trial. 
 
There is a discussion that there were no CNS adverse events observed in the trial, but other 
studies had observed somnolence and extrapyramidal effects in patients receiving 
domperidone. The author cautioned on prescribing domperidone to infants below six months 
old, in children with CNS disease, and with doses over 0.6mg/kg four times daily. Mild self-
limiting diarrhoea is reiterated as the most common adverse events. Transient neutropenia 
observed is dismissed as being related to domperidone. The paper concludes that there was 
no evidence domperidone is effective in reducing symptoms of GOR, and longer therapy may 
be needed to see improvement.  
 
5.4.1.4 Carroccio (1994) 
The safety of domperidone is not mentioned in the introduction of the paper.  
 
The plan of safety monitoring is unclear from the methods. There is however a mention of a 
repeat assessment of the clinical conditions of the patients after treatment.  
 
It is unclear what is considered to be an adverse event from the results. The paper mentions 
vomiting, retarded growth, serious anorexia, retarded weight increase, recurrent episodes of 
bronchopneumonia, prolonged fits of crying that accentuates after feeding, and apnoeic. 
These are considered as symptoms in the trial. There was no significant difference of these 
symptoms between treatment groups. The author then claims that there was no complain of 
adverse events during the trial period. 
 
The trial focussed on finding the best treatment combination. It concludes that the 
combination of domperidone with magnesium hydroxide plus aluminium hydroxide is the 
best treatment option but safety issues are not addressed. 
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5.4.2 Cisapride versus placebo, other drugs not domperidone, or non-drugs trials 
The characteristics of the trials comparing cisapride to drugs other than domperidone or non-
drugs (including placebo) are shown in Table 5.3. The patients and interventions 
characteristics of the trials are given in Table 5.4. For each cisapride trial being reviewed, the 
planning and reporting of safety aspects of the trial are discussed in Sections 5.4.2.1 to 
5.4.2.8. 
 
Table 5.3 Characteristics of studies comparing domperidone to non-cisapride 
Author Study 
year 
Study 
place 
Methods Endpoints Withdrawals 
Cucchiara 
1987 
~1986 Italy Randomised 
double-blind 
GORD 
symptoms, reflux 
index 
Two from febrile upper 
respiratory infections, and 
one non-compliant 
Van Eygen 
1989a 
~1989 Belgium Randomised 
double-blind 
GORD symptoms none 
Van Eygen 
1989b 
~1989 Belgium Randomised 
double-blind 
GORD symptoms Four early drop-outs, and 
one protocol violation 
Vandenplas 
1991 
~1991 Belgium Randomised 
double-blind 
GORD 
symptoms, reflux 
index 
13 exclusions for 
unexpected weaning, 
withdrawal of permission 
for second pH due to 
improvement, lack of 
improvement and parents 
refusal to continue. 
Greally 
1992 
~1991 Leicester, 
UK 
Randomised GORD 
symptoms, reflux 
index 
none 
Castro 
1994 
~1994 Madrid, 
Spain 
Randomised 
double-blind 
GORD 
symptoms, reflux 
index 
One due to ‘lack of 
motivation’ 
Scott 
1997 
1989-
1993 
Canada Randomised 
double-blind 
GORD 
symptoms, reflux 
index 
Four due to protocol 
violations, 9 did not 
complete follow-up 
Cohen 
1999 
~1999 Australia Randomised 
double-blind 
GORD 
symptoms, reflux 
27 withdrawn due to 
consent being withdrawn, 
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index serious AE, or if change of 
treatment was necessary 
Levy 
2001 
1991-
1994 
USA Randomised 
double-blind 
GORD symptoms 
but not published, 
QTc 
19 excluded because ECG 
was not performed within 
study period 
 
Table 5.4 Patient and intervention characteristics in studies comparing domperidone to non-cisapride 
Author Length 
(weeks) 
Dose 
(mg/kg/day) 
        
(months)  
        
(months) 
Cucchiara (1987) 8 0.9 8 24.7 9 19.5 
Van Eygen 
(1989a) 
4 0.45 12 4.0 11 4.0 
Van Eygen 
(1989b) 
4 0.45 14 5.7 17 3.7 
Vandenplas (1991) 2 0.8 21 3.0 21 3.0 
Greally (1992) 4 0.2 26 4.0 24 4.5 
Castro (1994) 4 0.6 15 27.6 15 27.6 
Scott (1997) 6 0.8 20 8.4 16 8.3 
Cohen (1999) 2 0.8 38 7.3 30 8.3 
Levy (2001) 8 0.6 24 15.0 25 14.0 
    number of children in treatment group.  
    number of children in control group. 
      median or mean age in treatment group. Median is presented where available. 
      median or mean age in control group. Median is presented where available. 
 
5.4.2.1 Cucchiara (1987) 
The introduction gives no reference to any safety issue that may be related to cisapride, or 
other drugs used for the treatment of gastro-oesophageal reflux in children. 
 
The patients and methods section of the paper states that patients were excluded if they had 
infectious, neurologic, metabolic, and renal disorders; abnormalities of the oesophagus, 
stomach, and duodenum. The grounds for the exclusion were not described. There was no 
mention of safety, but author described the use of diary card to record daily signs and 
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symptoms. A scoring system was developed to evaluate vomiting and/or regurgitation, 
pneumonia or asthma, apnoea, haematemesis, heartburn/dysphagia, weight/height ratio, and 
histology of oesophagitis. 
 
In the results section, the author pointed out that two patients were withdrawn from the study 
because of febrile upper respiratory infections but their randomised group was not reported. 
A further two patients on cisapride was reported as ‘unchanged’ or ‘worsened’. ‘Unchanged’ 
may mean that the drug is not working, but ‘worsened’ could potentially mean that the drug 
might be harmful. This was not distinguished in the paper. The paper however reports that 
there were no ‘untoward clinical signs and symptoms’ in the trial. 
 
There was no mention of safety in the discussion. It concludes that cisapride may be effective 
for mild or moderate reflux, but uncertain for severe reflux. 
 
5.4.2.2 Van Eygen (1989) 
There is no specific mention of safety in the introduction. It however describes that cisapride 
does not have antidopaminergic or direct cholinergic effects, which may imply its safety. The 
abstract of the paper does mention that ‘side effects were limited to phenomena of stimulated 
bowel motility’. 
 
The methods section does not mention safety. It reports that severity of condition and 
frequency of regurgitation were assessed at baseline. The study was made up of three trials: 
open study, RCT, and dose-response trial. 
 
The results for the open study report the incidence of diarrhoea and abdominal cramps, each 
in two patients leading to cisapride being withdrawn for the four cases. Additional two 
patients experienced slight transient diarrhoea, and another two became quieter. Becoming 
quieter was regarded as a possible result from a smoother digestion from cisapride 
prescribing. The RCT reported incidence of diarrhoea in two and one patients in placebo-
treated and cisapride-treated group respectively. In the dose-response trial, eructations were 
reported in one child receiving 0.2mg/kg of cisapride three times daily. Abdominal cramps 
with diarrhoea were observed in one two months old infant receiving 0.1mg/kg of cisapride 
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three times daily. Abdominal pain was also observed in one six months old infant receiving 
the same treatment regime. 
 
In the discussion of the paper, the author concluded that cisapride was well-tolerated among 
treated infants. Cisapride was also deemed only responsible for non-dose related stimulation 
of bowel motility, and none of the other side-effects. 
 
5.4.2.3 Vandenplas (1991) 
The introduction bears no mention of the safety of cisapride. The goal of the trial was to 
investigate whether the incidence and duration of GOR would be decreased by adding 
cisapride systematically to positional therapy. 
 
It is unclear in the methods section what was considered to constitute adverse events or the 
safety parameters from the use of symptom diary. 
 
Again, as the trial did not plan to look for adverse events, none were reported in the results. 
 
The discussion states that there was no adverse drug reaction observed during the study.  
However, it recognises that children treated with cisapride can have loose stools and colicky 
pain at the early stage of treatment. The author also mentioned that a group from the Catholic 
University of Leuven had observed severe jaundice was observed in extremely premature 
infants receiving cisapride. Their data was not published. 
 
The paper also cautions about overprescribing, and limiting prescription of cisapride to 
infants who did not respond to non-drug therapy. 
 
5.4.2.4 Greally (1992) 
The trial aims to assess the effectiveness of Gaviscon® plus Carobel versus cisapride. It 
addresses that the mode of action for Gaviscon® is unclear compared to cisapride, but the 
safety aspects of the treatment options were not mentioned. 
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The methods section mentions the use of diary to record daily episodes of vomiting. Severity 
of vomiting was scored in terms of the number of episodes. It does not specify methods for 
safety evaluation. 
 
In the results section, the author commented that cisapride and Gaviscon®/Carobel were 
well-tolerated. In patients receiving cisapride, two children developed mild diarrhoea. 
Another child was diagnosed with oesophagitis (by endoscopy after trial completion) while 
receiving cisapride. 
 
The discussion does not address the safety issue of cisapride (or Gavison®/Carobel). It 
concludes that cisapride was no more effective than Gaviscon®/Carobel, but neither 
treatment had any evidence of efficacy or safety. 
 
5.4.2.5 Scott (1997) 
Safety assessment is mentioned in the abstract as part of the trial focus. The introduction 
however does not reiterate this. 
 
Assessment of safety is the aim of the trial and is mentioned in the methods section. The 
investigators explained the risks involved with the treatment to patients and guardians before 
enrolment into the trial. Withdrawal from the trial criteria include experience of any 
significant adverse reactions, or if patients were adversely affected by trial conditions. These 
were assessed by the investigators but no there is unclear guideline to this in the paper. Daily 
diary of the conditions was also kept by guardians. Adverse events and concomitant illnesses 
were obtained from the daily diary or from non-leading questioning of the parents by the 
investigators. Dates of onset, duration, severity, action taken, and outcome of adverse events 
were recorded. Adverse events relations to cisapride were also assessed. The use of non-
leading questioning may be appropriate in terms of minimising false positive adverse events 
reporting, but it is unclear from the paper how the question was phrased. In an extreme 
situation, a very generic question like “Did your son/daughter experience any adverse 
events?” would not help to improve the rates of adverse events reporting. Additionally, 
laboratory data including haematology, blood chemistry, and urinalysis were performed in all 
patients. Abnormal values were assessed and commented. The author described that adverse 
events were reported descriptively. The trial was powered on the assumption that 70% of 
Part II: Narrative review on clinical trials of cisapride and domperidone 
Chapter 5 | 128  
 
cisapride patient would respond to therapy compared to 30% in the placebo group at 80% 
power and 5% alpha. 
 
The results section reports 14% and 12% recurrent respiratory infections in the cisapride and 
placebo group respectively at baseline. Abnormal biopsies at baseline were observed in 
eleven versus nine patients in cisapride and placebo respectively. This indicates balance in 
the two study arms. Also, none of the patients were on any pro-kinetics therapy at the time of 
referral into the study. At the end of the study, 64% (7/11) children in cisapride group were 
reported to have had abnormal biopsies, compared to 56% (5/9) children in the placebo 
group. However, biopsies were only repeated on the children who had abnormal biopsies at 
baseline, and not on all patients. Therefore it is unknown whether patients who had normal 
biopsies at baseline had the disease worsened. During the trial, 85 adverse events were 
reported in 14 cisapride patients, and 13 placebo patients. The paper gives counts for the most 
common adverse events reported (cisapride/placebo): fever (6/5), diarrhoea (5/5), common 
cold (0/3), insomnia (2/0), nervousness (2/0), cough (1/2), and upper respiratory tract 
infections (2/2). 
 
In the discussion, the author claims the study to be the largest to evaluate efficacy and safety 
of cisapride in children suffering from gastro-oesophageal reflux disease. The paper 
concludes cisapride was well-tolerated because incidences of adverse events were 
comparable in both groups and that no serious adverse events had been reported. 
 
5.4.2.6 Cohen (1999) 
The introduction states that the trial’s aim was to evaluate the efficacy of cisapride in the 
treatment of GOR. No reference to safety of cisapride was given. 
 
In the methods section, the author wrote that parents were requested not to administer other 
medications to children without consulting the investigators. It was not justified in the paper 
whether this was a safety issue of possible drug interactions. Parents were also disallowed to 
administer any other symptomatic relief drugs e.g. metoclopramide or antacids. The reason 
was not justified, but presumably this was to avoid contamination from other drugs 
contributing to reducing in symptoms. The trial monitored, recorded and scored for 
symptoms of vomiting, crying, and gagging. The presence of apnoea, wheezing, nocturnal 
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cough, and haematemesis were also recorded. The author added that any adverse event and 
other illnesses were also recorded when reported by parents or when asked by investigators. 
The trial was powered on a 50% reduction in reflux index in the cisapride group. 
 
The results section reports six and seven patients in cisapride and placebo group respectively 
withdrew from the trial due to adverse events. 42/50 adverse events were reported in the 
cisapride group, and 32/45 adverse events were reported in the placebo group. 30/38 and 
22/30 were among children in cisapride and placebo group respectively who completed the 
trial. The most frequent side-effects were upper respiratory tract infection, irritability, 
diarrhoea, teething, and vomiting. One patient in the cisapride group was hospitalised for 
asthma. Five patients in cisapride group experienced vomiting, compared to only one in the 
placebo group.  
 
The discussion acknowledges the difficulty to attribute adverse events to the underlying 
condition, concomitant illness, or the treatment. It concludes that cisapride could not be 
recommended because the efficacy compared to placebo was not observed. 
 
5.4.2.7 Levy (2001) 
In the introduction, cisapride is described as having an ‘excellent safety profile’, but there 
were raising concerns after cardiac abnormalities were identified from its use. It continues to 
discuss about safety of cisapride in relation to prolongation of QTc interval and ventricular 
arrhythmias which led to warnings being issued by the FDA. The paper aims to identify 
abnormalities in QTc interval associated with cisapride use from an efficacy trial conducted 
between 1991 and 1994. The original trial results were not published due to lack of evidence 
of efficacy. This immediately suggests publication bias among cisapride trials in favour of 
trials showing positive effect of the treatment. 
 
The methods section describes the calculation of QTc interval from the ECG readings taken 
in the original trial. The QTc was the main interest in this paper. The study protocol required 
patients to not taking other drugs that could mask or modify the effects of cisapride. ECG, 
blood count, urinalysis, chemical panels including electrolytes, and liver function panel 
reports were performed at entry, at fourth week, and at the end of the study (week 8). 
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QTc is reported to be normal in all patients in the results section. Other aspects of safety were 
not looked at thus were not reported. 
 
The author recognised that the trial was too small to establish absolute risks of life-
threatening cardiac events. He also pointed out that there is no clear cut for a definition of 
abnormal QTc in premature infants, where cisapride was also used in. The author also 
proposed that a larger and better designed clinical trial to determine actual risks associated 
with cisapride; to define clinical settings when cisapride is best used; and to identify other 
risks factors that should be avoided when using cisapride to ensure its use is as safe as 
possible. 
 
5.4.2.8 Castro (1994) 
In the introduction, the paper suggested that cisapride had been a successful drug in the 
treatment of GOR in children. The trial aim was to assess the efficacy of cisapride in a short 
time period (2-4 weeks). There was no mention of the safety of cisapride. 
 
In the methods section, the paper still does not mention any planning of safety monitoring 
during the trial. 
 
The results section mainly concentrates on the improvement of regurgitation and vomiting 
symptoms, and coughing. It reports that adverse events or complications were not observed 
during the trial. 
 
In the discussion section, the author acknowledged that it was difficult to establish the 
relationship between GOR and coughing in some patients. Whilst other studies had observed 
some improvement or disappearance of respiratory symptoms with cisapride use, this trial 
only showed that improvements were only observed after four weeks therapy. This section 
reinforces that no adverse events were seen in the trial. The author suggested that at least 
three months cisapride treatment is needed before any clinical effectiveness can be expected. 
The paper concludes that cisapride is an effective drug for the treatment of gastro-
oesophageal reflux in children. 
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5.4.3 Domperidone versus cisapride trial 
Table 5.5 Characteristics of studies comparing domperidone to cisapride (Hegar, 2009) 
Study year 2007 
Study place Jakarta, Indonesia 
Methods Randomised investigator-blind (see Intervention below) 
Participants Twenty children aged between 2-9 months old regurgitating at least four 
times a day for longer than two weeks, otherwise healthy. Infants must also 
present the following symptoms: sleep difficulties, back-arching, irritability 
during feeding, and food refusal. 
Interventions 0.8 mg/kg/day of either domperidone or cisapride administered 15 minutes 
before a feeding. Commercialised medications were used, therefore blinding 
was not possible. Investigators were blinded to treatment assignment when 
making evaluations. 
Placebo intervention was not allowed by the ethical committee because 
symptoms suggested GORD in infants where dietary changes have failed. 
Outcomes (a) frequency of regurgitation from symptoms diary; 
(b) pH monitoring – reflux index, number of reflux episodes, duration of 
longest  reflux episode – using Digitrapper pH 100 monitor and 
Polygram 98 pH testing application software; 
(c) cardiac side effects from 12-lead ECG machine. 
Notes (a)           mean and SD of regurgitation per day in the cisapride 
group, and           in the domperidone group at week 4 (p-value 
difference = 0.859). 
(b)           mean and SD reflux index in cisapride group, and 
          in the domperidone group (p-value difference = 0.594). 
(c) During day 3-5, QTc in the cisapride group was             mean 
and SD, and those in domperidone group had mean and SD of 
            (p-value difference = 0.758). One infant randomised 
to cisapride had prolonged QTc interval during the treatment. 
Withdrawals One from QTc prolongation, and one from malrotation. Both were 
randomised to cisapride. 
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The characteristics of the trial directly comparing domperidone to cisapride are shown in 
Table 5.5. The patients and interventions characteristics of the trial are given in Table 5.6. 
The planning and reporting of safety aspects of the trial are further discussed in Section 
5.4.3.1 below. 
 
Table 5.6 Patient and intervention characteristics in studies comparing domperidone to cisapride 
Author Length 
(weeks) 
Dose 
(mg/kg/day) 
        
(months)  
        
(months) 
Hegar (2009) 4 0.8 10 6 10 5 
    number of children in treatment group.  
    number of children in control group. 
      median or mean age in treatment group. Median is presented where available. 
      median or mean age in control group. Median is presented where available. 
 
5.4.3.1 Hegar (2009) 
The introduction states that the aim of the trial was to compare the effects of domperidone 
and cisapride in infants on frequency of regurgitation, pH monitoring, and cardiac 
parameters.  
 
The methods section only mentions monitoring for QTc but it is unclear whether other 
adverse events would also be monitored for. The same dose regime of 0.8 mg/kg/day for both 
cisapride and domperidone was also unjustified. This raises the question that cisapride was 
prescribed at the maximum recommended daily dose, whilst domperidone was only 
prescribed at less than half the maximum recommended daily dose. This makes the safety 
(and efficacy) of the two drugs incomparable. The ethics committee for the trial also disallow 
the use of placebo because the children were selected based on non-responsiveness to other 
non-drug therapy. Therefore, the “real” safety and efficacy profile of cisapride (and 
domperidone) could not be directly measured in this trial. 
 
The results section presents one prolonged QTc interval in one child on cisapride. The author 
reported that symptoms related to reflux (sleep difficulties, back-arching, irritability and food 
refusal) also improved with the decrease of regurgitation frequency. 
 
Part II: Narrative review on clinical trials of cisapride and domperidone 
Chapter 5 | 133  
 
The discussion section criticises the use of domperidone without strong evidence of efficacy. 
The author also cited some extrapyramidal effects, increased prolactin levels, and prolonged 
QTc interval had been reported in other studies. The author then commented that cisapride 
was also associated with QTc prolongation. The paper also discusses the lack of evidence of 
efficacy and safety to use other drugs for the treatment of GOR. The author argued that 
although the sample size is small, the power calculation suggested only six patients per group 
were needed for 90% power and       . It concludes that domperidone cannot be 
recommended as a ‘safe’ drug but it has better safety profile than cisapride. Cisapride 
however was concluded as the more effective therapy in reducing acid reflux. 
 
5.5 Discussion 
The main issue observed in these trials is there are no clear definitions of what constitutes an 
adverse event. Another critical matter is that safety reviews prior to conducting these trials 
were somewhat too focussed in the sense that certain safety aspects is known and therefore 
had chosen to only address them. In cisapride trials, there is unclear justification for safety 
perhaps because earlier trials did not observe any safety issue or most likely did not classify 
any adverse event to be associated with cisapride thus dismissed. In the cases domperidone 
trials, the rare extrapyramidal effects (when compared to metoclopramide) were usually 
“enough” to justify that domperidone is a safe drug. 
 
In these trials, adverse events that may be associated with drugs use are often overlapped with 
the signs and symptoms of the disease. Nevertheless, none of the papers considered 
worsening of signs and symptoms as an adverse event. At the end of the spectrum, one could 
also argue that unchanged in signs and symptoms may also be an adverse event in this 
population because of the benign nature of the disease and that it often resolves itself over 
time. 
 
In general, trials that sought for evidence of safety reported more adverse events. The 1997 
Canadian trial (Scott, 1997) reported adverse events in most detail compared to two other 
trials that observed adverse events (Bines, 1992; Cohen, 1999). The 1999 Australian trial 
(Cohen, 1999) reported higher proportions of children experiencing adverse events but did 
not clearly specify the number of instances or the incidence rates for the different adverse 
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events. Inconsistency in the style of adverse events reporting from different trials makes it 
difficult to compare the rates of specific events.  
 
This review suggests that elements of data collection especially for adverse events need to be 
evidence-based, and justifications on what is considered as an adverse event are to be made 
clear for the benefit of future trials. The formal quantitative results of the outcomes of these 
trials have not been presented, and will form part of the quantitative evidence data (Chapter 
7) after we have considered that there are no further issues with our research questions 
(Section 1.3). Chapter 6 analyses prescribing trends to identify further issues in the 
prescribing of cisapride and domperidone. 
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6. Analysis of prescribing trends 
6.1 Introduction 
Using trends analysis to study the changing in prescribing trends of cisapride and 
domperidone over time may help identify further issues that may be associated with the 
prescriptions we have not considered. Patterns of prescribing between 1990 and 2006 are 
investigated from different angles. 
 
6.2 Aims and objectives 
The first aim of prescribing trends analysis is to provide information on the prescribing 
pattern of cisapride and domperidone in order to illustrate how off-label drugs are being 
prescribed in the absence of robust efficacy and safety evidence. The second aim is to decide 
whether the trends support the need for a well-designed domperidone trial in children with 
GORD at this time. 
 
The aims of trends analysis are accomplished through five specific objectives: 
i. to describe time trends in the rates of prescribing of cisapride and domperidone in 
children; 
ii. to describe the time trends in the rates of prescribing of cisapride and domperidone in 
children by geographical region within the GPRD; 
iii. to describe the trends in prescribing of cisapride and domperidone in children, by age 
and sex; 
iv. to describe the trends of individual prescribing characteristics for cisapride and 
domperidone in children; and 
v. to investigate the impact of cisapride withdrawal on domperidone prescription, 
including any evidence of switching to domperidone. 
 
6.3 Methods 
6.3.1 Study population 
The GPRD data we acquired were under a project commissioned by the MHRA. Under the 
agreement, we obtained patient-level data (Level 4) for our defined cohort i.e. data on 
children aged 0-18 years old from 1990 to 2006 who had at least one prescription of 
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cisapride, domperidone, or metoclopramide who were aged 0-18 years old and never had any 
of cisapride, domperidone, or metoclopramide prescribed between 1990 and 2006. Ideally, 
we would sample the data based on the medical conditions i.e. GORD but because there is no 
clear definition of GORD on primary care records, we used the drugs prescription as a 
surrogate for children with GORD. 
 
For calculation of rates, and related analyses, we obtained denominator populations by age, 
sex, practice and time-period. The rationale for the age group was to include all children, 
although interest was mainly younger children particularly those under the age of two years 
old. The dates were to cover periods when cisapride was used, and the more recent period 
when domperidone was available. The variation in the denominators for children below 18 
years old in the GPRD is shown in Figure 6.1 by practice regions and year. 
 
Figure 6.1 Number of all children <18 years old by GPRD region and practice year 
 
 
A control group (unexposed children) is not needed at this stage as the analysis is purely 
description of the experience in prescribing these drugs. Comparison with unexposed children 
population comes next when I discuss the rates of adverse events and signals in Chapter 8. 
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6.3.2 Exclusion criteria 
We started with the sample of patients identified by GPRD to have had prescriptions of the 
drug. We then applied the following exclusion criteria: 
 
i. Not up-to-standard practices identified through variable     in the original dataset. 
We excluded       /  / 5   and when     is missing.  
ii. Patients from practice 222027 were excluded because the practice failed GPRD data 
warehouse load (Personal communication with Ms. Anna Shafe at the MHRA). 
iii. Patients with ambiguous first registration dates were also excluded. This was 
identified through variable    . We excluded patients with missing     and those 
with     before their date of birth. 
iv. Patients who turned 18 before 1st January 1990 were also excluded. 
v. Data for the patient were valid for less than three months 
vi. Patients whom we did not have drug prescriptions data for, or for whom their 
prescriptions for cisapride or domperidone only started after the age of 18 years old. 
 
6.3.3 Inclusion timeframe 
We also pre-specified a timeframe for our analyses to be between 01/01/1990 and 
31/12/2006. We further define a timeframe for the data to be valid as follows: 
  
          (       ) 
       (                          )  
 
i.e. the timeframe starts on patient’s first registration date     at general practice or the date 
when practice continuously keeping up-to-standard (   ) with GPRD quality control, 
whichever is later. Timeframe ends when patient transferred out of the practice (      ), on 
the last collection date     of data from the practice, when patient died (         ), or when 
patient turns 18 years old (     ), whichever is earliest. 
 
6.3.4 Analysis definition 
In line with objectives i-v, I define the analysis to be undertaken to address the underpinning 
issues. 
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i. Trends of overall prescribing rates 
We characterised time trends in the prescribing of cisapride and domperidone from 
1990 to 2006 by number of prescription, number of patients, age at starting, and age at 
prescription. The time trend for age was broken into those under the age of two years, 
and those over two years old. For those under two years old, age were given in months, 
and in years for over two. We calculated the mean number of prescription per patient 
per year to investigate the trend in the amount of prescription for individual patient. We 
also described the drug use by year in terms of prevalent (current in that year) users, 
and incident (new in that year) users. 
ii. Trends of overall prescribing rates by geographical regions within GPRD 
The overall trends of prescribing were investigated further by broken them down into 
geographical regions within the GPRD where the prescriptions originated. The rates of 
prescribing per million children were given by region over time. Regional variation is 
investigated to find any evidence whether prescribing trends were different in different 
regions and may need to be addressed separately in analysis. 
iii. Trends of prescribing rates by age and sex 
The overall rates of prescriptions were then calculated separately for boys and girls. 
Age was given in years. The rates were given as rates per million from the entire GPRD 
children population by year. This approach estimates the ‘true’ prevalence in GPRD 
children population by age and sex. 
iv. Trends of individual prescribing characteristics 
Individual prescribing trends for cisapride and domperidone were characterised in 
terms of number of prescriptions per patient, mean therapy duration per prescription, 
and doses prescribed per patient. Doses were characterised by mg/kg/day, which were 
then compared to the recommended amount of prescription for each drug. 
v. Temporal effect from the withdrawal of cisapride on domperidone prescriptions 
Due to cisapride withdrawal in July 2000 in the UK, we expect an influx in the 
prescription of domperidone around the same time as those who would have been 
prescribed with cisapride may have been given domperidone instead. I describe number 
of children who switched to domperidone. This is carried out for the subgroup of 
children who had been prescribed both cisapride and domperidone within the study 
time period.  
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6.3.5 Missing data 
As with any longitudinal dataset, missing data is always a problem – GPRD data is no 
exception. A high rate of missingness is anticipated. Most of the times, data that were missing 
could be ignored because they were not used in analysis. We acknowledge that some data 
were missing simply because the GPs did not record them in the first place, but there is no 
way to find out about this type of missingness therefore was also ignored. There were three 
scenarios where missing data mattered critically: missing date of birth, missing weight, and 
missing duration and doses of prescriptions.  
 
GPRD actively anonymise day of birth to protect patient confidentiality. We imputed day of 
birth as first of the month for the person-time to cover the entire month. We imputed missing 
month of birth as “January” to cover the entire year. Figure 6.2 shows the improvement in the 
proportions of missing month of births recorded in GPRD over time.  
 
Weight of patients at the time of prescribing was far from complete. Because we anticipated 
to characterise doses as a function of body weight, we imputed missing weights based on age 
in months using data from Growth Online (Harlow Healthcare, 2003). This is assuming that 
children with missing weight were on average weight for their age. Furthermore, we assumed 
that weight remained constant for the duration of a single prescription. 
 
Some doses are also anonymised by GPRD to govern patients’ confidentiality. Consequently, 
prescription durations are unknown. We impute missing durations by simple mean imputation 
of the non-missing durations for the same drug code on the data set. Where we were unable to 
impute by drug-specific non-missing mean durations, we impute using the overall mean of 
non-missing durations. This is assuming that on average the same drugs are prescribed for the 
same amount of time for children of any age and sex. 
 
Missing doses of prescriptions were imputed using a stratified median imputation approach. 
We calculated the median doses stratified by drug codes, age, and sex initially; and imputed 
missing doses within each stratum. We then relaxed the sex criterion, and imputed median 
doses by drug codes and age. Finally, we relaxed the drug codes criterion, and imputed 
median doses by age. This is recognising that the distribution for dosage of a prescription is 
skewed and that the median of the distribution for a particular drug characterises the dosage 
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prescribed well for children of the same age and sex. This assumes that different GPs 
prescribe cisapride and domperidone according to the same guideline. 
 
Figure 6.2 Change in the proportion (%) of missing month of birth in the background population 
 
 
6.3.6 Multiple prescriptions on the same day 
There was also an issue of multiple prescriptions on the same day for the same drug. This 
glitch in the record might occur because the GP had changed their mind about the amount to 
prescribe or that the GPs had mistyped the earlier entries. However, the unique identifier 
attached to each prescription was not in any incremental order therefore we could not identify 
which was the last prescription entered. As advised by GPRD and MHRA, we assumed that 
when there were more than one prescription for the same drug on the same day, the 
prescription with largest amount was the one the patient received, so not to underestimate the 
effect of dose. 
 
6.3.7 Statistical analysis 
Most of the analyses in this chapter are descriptive. Means and standard deviations, or 
medians and inter-quartile ranges are calculated for variables of interest. Variables on 
analysis of their distributions are approximately normally distributed are characterised by the 
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means and standard deviations. More skewed variables are characterised by medians and 
inter-quartile ranges. Both sets of measures are given where appropriate and for consistency. 
 
Poisson rates of number of children being prescribed with domperidone and cisapride are 
calculated with Poisson regressions adjusted for the year of general practices’ data and offset 
by total number of children patients in the general practices in that year. The Poisson model 
with parameter   is written as follows: 
 
  (    )  
      
  
  
   (  )               (  ) 
 
where    (         ) is the number of new (incident) or currently prescribed (prevalent) 
children in      .    is the total number of children patients in the general practices in       
and   is the number of years (data points) for any particular analysis. Offsetting by 
   (  ) reparameterises the model as    (
  
  
). The parameter of interest is   , which is now 
the annual incidence (referring to incident children) or prevalence (referring to prevalent 
children) rates. 
 
Within-subject correlations over time were not taken into account in this model. However, 
accounting for within-subject correlations is not an issue with this model because this is dealt 
by defining the outcomes of interest which are the incidence and the prevalence. Incidence is 
defined as the year when a child had his/her first ever prescription of domperidone or 
cisapride, and prevalence is defined as the number of children within any particular year. For 
these analyses, the individual patient data were collapsed appropriately to avoid double-
counting the same children in a year. The structure of the collapsed data ensures that for 
annual incidence rates, a child is counted only once within the defined analysis period; and 
for annual prevalence rates, a child is counted only once per year within the defined analysis 
period. 
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6.4 Results 
6.4.1 Data sets 
There were 1,497 and 9,319 children in the cisapride cohort and domperidone cohort 
respectively who met our inclusion and exclusion criteria. Breakdowns by the region of the 
general practices are shown in Table 6.1 and Table 6.2.  
 
Table 6.1 Number of patients who were prescribed with cisapride and number of prescribing practices 
Region Number of 
patients (%) 
Number of 
practices (%) 
Number of patients 
within practices, 
Median (IQR) 
Practice size 
(      ) patients 
per year,  mean (SD) 
Eastern 264 (18%) 42 (14%) 5 (3-9) 2.95 (1.04) 
London 216 (14%) 40 (13%) 4 (2-7) 2.06 (1.05) 
N. Ireland
a 
56 (4%) 10 (3%) 6 (1-8) 3.11 (1.24) 
Northeast 97 (6%) 23 (8%) 4 (2-6) 2.45 (1.03) 
NW/WM
b 
363 (24%) 78 (26%) 4 (2-6) 2.64 (1.14) 
Scotland 78 (5%) 17 (6%) 4 (2-6) 2.45 (1.51) 
Southern 376 (25%) 82 (27%) 3 (2-6) 2.49 (1.48) 
Wales 47 (3%) 12 (4%) 2 (2-4) 2.33 (1.16) 
Total 1497 (100%) 304 (100%) 4 (2-7) 2.54 (1.25) 
a 
Northern Ireland
 
b
 Northwest and West Midlands 
 
Table 6.2 Number of patients who were prescribed with domperidone and number of prescribing 
practices 
Region Number of 
patients (%) 
Number of 
practices (%) 
Number of patients 
within practices, 
Median (IQR) 
Practice size 
(      )  patients 
per year,  mean (SD) 
Eastern 1500 (16%) 56 (14%) 22 (11-32) 2.78 (1.12) 
London 1117 (12%) 59 (14%) 16 (6-27) 1.92 (1.19) 
N. Ireland
a 
268 (3%) 12 (3%) 19 (8-33) 2.96 (1.17) 
Northeast 777 (8%) 31 (8%) 8 (3-31) 2.35 (0.97) 
NW/WM
b 
2657 (29%) 97 (23%) 13 (7-28) 2.51 (1.12) 
Scotland 460 (5%) 21 (5%) 12 (5-30) 2.16 (1.49) 
Southern 2142 (23%) 114 (28%) 14 (6-24) 2.52 (1.45) 
Wales 398 (4%) 23 (6%) 9 (5-19) 2.32 (1.01) 
Total 9319 (100%) 413 (100%) 14 (6-28) 2.44 (1.25) 
a
 Northern Ireland 
b
 Northwest and West Midlands  
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6.4.2 Trends of overall prescribing rates 
The annual incidence rates ratio for children who were prescribed with cisapride were 1.24 
(95% CI 1.11 – 1.38) between 1990 and 1999, and 0.23 (95% CI 0.08 – 0.71) from 2000 
onwards. The annual prevalence rates ratio for children who had prescription of cisapride 
current for that year were 1.29 (95% CI 1.16 – 1.45) before 2000, and 0.18 (95% CI 0.06 – 
0.55) after 2000. The overall rates from 1990 to 2006 were not calculated as cisapride was 
withdrawn in July 2000, and this would have affected the rates and characteristics of patients 
who were prescribed cisapride after 2000.  
 
Table 6.3 shows the annual incidence rates ratio and annual prevalence rates ratio by age 
below and above two years old who were prescribed with cisapride. 
 
Between 1990 and 1999, the annual incidence rates ratio for children who were prescribed 
with domperidone was 1.07 (95% CI 1.05 – 1.09); and that between 2000 and 2006 was 1.08 
(95% CI 1.07 – 1.09) showing a slightly higher increase from previous period. The annual 
prevalence rates ratio before 2000 was 1.09 (95% CI 1.06 – 1.11), and it was 1.12 (95% CI 
1.11 – 1.13) after 2000. The overall annual incidence rates ratio and annual prevalence rates 
ratio between 1990 and 2006 were 1.08 (95% CI 1.07 – 1.08) and 1.11 (95% CI 1.11 – 1.12) 
respectively. Table 6.4 shows the annual incidence rates ratio and annual prevalence rates 
ratio by age below and above two years old who were prescribed with domperidone. Whilst 
the annual incidence and prevalence rates ratios for the older group of children do not suggest 
much temporal effects due to withdrawal of cisapride; those for below two years old showed 
a slower increase in rates of prescription. However, the incidence rates need to be carefully 
interpreted (see 6.5 Discussion). 
 
The following Figure 6.3 – Figure 6.5 suggest that the influx in domperidone prescriptions 
from the withdrawal of cisapride was driven mainly by the prescribing data on children below 
two years old. The growing gap between the rates of domperidone prevalent prescriptions and 
incident prescriptions over time suggests that therapy duration had also increased over the 
years. Therapy duration for individual patient who was prescribed with domperidone is 
investigated in Section 6.4.5. 
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Table 6.3 Annual incidence rates ratios (95% CI) for children below two years old and children two years 
old and older who were prescribed with cisapride between 1990 and 1999 , and between 2000 and 2006 
 Annual ratio < 2 years old ≥   years old 
1990 – 1999 (before 
withdrawal) 
Incidence  1.33 (1.14, 1.55) 1.17 (1.08, 1.26) 
Prevalence  1.37 (1.18, 1.61) 1.26 (1.17, 1.35) 
2000 – 2006 (after 
withdrawal) 
Incidence  0.10 (0.01, 0.99) 0.31 (0.15, 0.64) 
Prevalence  0.04 (0.00, 0.57) 0.24 (0.10, 0.55) 
 
Table 6.4 Annual incidence rates ratios (95% CI) for children below two years old and children two years 
old and older who were prescribed with domperidone between 1990 and 1999 , and between 2000 and 
2006 
 Annual ratio < 2 years old ≥   years old 
1990 – 1999 (before 
withdrawal) 
Incidence  1.32 (1.18, 1.48) 1.06 (1.04, 1.08) 
Prevalence  1.38 (1.23, 1.54) 1.07 (1.05, 1.09) 
2000 – 2006 (after 
withdrawal) 
Incidence  1.23 (1.18, 1.27) 1.05 (1.04, 1.06) 
Prevalence  1.27 (1.23, 1.31) 1.07 (1.06, 1.08) 
1990 – 2006 
(overall) 
Incidence  1.30 (1.26, 1.34) 1.05 (1.04, 1.06) 
Prevalence  1.36 (1.31, 1.41) 1.08 (1.07, 1.08) 
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Figure 6.3 Prevalence and incidence per million children of all ages prescribed with cisapride and 
domperidone by year 
 
 
Figure 6.4 Prevalence and incidence rates per million children two years old and older prescribed with 
cisapride and domperidone by year 
 
 
Year 
Year 
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Figure 6.5 Prevalence and incidence rates per million children below two years old prescribed with 
cisapride and domperidone by year 
 
 
6.4.3 Trends of overall prescribing rates by geographical regions within GPRD 
Prescribing trends of cisapride and domperidone in children by region are fairly reflective of 
the overall trends in children observed in Section 6.4.2. The highest mean total (for all year) 
incidence of cisapride prescribing was in London but the median total was highest in the 
Southern region (Table 6.5). London had the lowest median total incidence and total 
prevalence cisapride prescribing per million children two years old and above (Table 6.6), but 
had the highest mean and median total incidence of cisapride prescribing per million children 
below two years old (Table 6.7). The lowest median total incidence and total prevalence in 
children below two years old prescribed with cisapride were observed in Northern Ireland, 
Northeast, Scotland, and Wales regions at five per million children. When the rates of 
cisapride prescribing were aggregated by year, the trends did not illustrate any marked 
differences among regions (Figure 6.6 – Figure 6.8). 
 
The median total prescribing incidence of domperidone was highest in the Northwest and 
West Midlands region, and was the lowest in London (Table 6.8). London also had the lowest 
median total domperidone prescribing incidence in children two years old and above. The 
Year 
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GPs in the Northwest and West Midlands remained the highest prescribers of domperidone in 
children two years old and above (Table 6.9). In children below two years old, the Eastern 
region had the highest total domperidone prescribing rates. The mean total incidence of 
domperidone prescribing however was the highest in London in children below two years 
old, but also with the largest variance (Table 6.10). Figure 6.9 – Figure 6.11 illustrate the 
trends of prescribing domperidone over time. In general, all regions had the upward overall 
trend. 
 
On examining Figure 6.8 and Figure 6.11, there is a suggestion that Northern Ireland, 
Scotland and Wales did not strongly support the use of domperidone in children below two 
years old and preferred cisapride for children in this age group. There is also a possibility that 
this is the case for any children in the Northeast region where domperidone prescribing rates 
were fairly low prior to 1998 and showed a sudden jump in 1998 when more warnings on the 
safety of cisapride were surfacing around that time. 
 
Table 6.5 Means (SD) and medians (IQR) of rates per million children prescribed cisapride by region  
 Incidence Prevalence 
Regions Mean (SD) Median (IQR) Mean (SD) Median (IQR) 
Eastern 145 (183) 58 (5-252) 722 (877) 231 (5-1272) 
London 166 (203) 59 (5-291) 650 (889) 80 (5-1119) 
N.Ireland 131 (150) 47 (5-219) 494 (560) 181 (5-1010) 
NE 116 (143) 29 (5-234) 757 (959) 134 (29-1384) 
NW/WM 138 (166) 61 (5-267) 733 (936) 168 (9-1388) 
Scotland 115 (133) 62 (5-225) 697 (788) 249 (5-1355) 
Southern 125 (144) 79 (5-191) 544 (652) 257 (40-1074) 
Wales 76 (90) 24 (5-136) 680 (1019) 63 (5-981) 
Total 127 (153) 53 (5-229) 660 (830) 148 (5-1202) 
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Table 6.6 Means (SD) and medians (IQR) of rates per million children two years old and older prescribed 
cisapride by region  
 Incidence Prevalence 
Regions Mean (SD) Median (IQR) Mean (SD) Median (IQR) 
Eastern 67 (65) 45 (5-129) 481 (548) 262 (5-955) 
London 78 (95) 22 (5-118) 361 (506) 64 (5-701) 
N.Ireland 77 (84) 44 (5-152) 368 (428) 203 (5-670) 
NE 50 (56) 33 (5-98) 536 (633) 123 (33-971) 
NW/WM 69 (68) 60 (5-119) 457 (539) 181 (10-826) 
Scotland 62 (70) 24 (5-116) 511 (546) 245 (5-914) 
Southern 58 (51) 53 (5-87) 309 (310) 241 (44-473) 
Wales 49 (57) 27 (5-68) 638 (997) 65 (5-902) 
Total 64 (69) 37 (5-114) 458 (587) 129 (5-847) 
 
Table 6.7 Means (SD) and medians (IQR) of rates per million children below two years old prescribed 
cisapride by region  
 Incidence Prevalence 
Regions Mean (SD) Median (IQR) Mean (SD) Median (IQR) 
Eastern 841 (1272) 109 (5-1187) 2885 (4042) 109 (5-5199) 
London 884 (1146) 328 (5-1180) 3004 (4141) 492 (5-4787) 
N.Ireland 631 (963) 5 (5-1259) 1670 (2569) 5 (5-3566) 
NE 751 (1034) 5 (5-1848) 2894 (4513) 5 (5-5154) 
NW/WM 797 (1147) 65 (5-1563) 3368 (4943) 65 (5-6316) 
Scotland 627 (840) 5 (5-1262) 2551 (3689) 5 (5-4303) 
Southern 736 (1041) 122 (5-1162) 2715 (4182) 122 (5-4426) 
Wales 317 (508) 5 (5-541) 1041 (1789) 5 (5-792) 
Total 698 (1005) 5 (5-1183) 2516 (3828) 87 (5-4298) 
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Figure 6.6 Prevalence rates per million children prescribed cisapride by year and region 
 
 
Figure 6.7 Prevalence rates per million children two years old and older prescribed cisapride by year and 
region 
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Figure 6.8 Prevalence rates per million children below two years old prescribed cisapride by year and 
region 
 
 
Table 6.8 Means (SD) and medians (IQR) of rates per million children prescribed domperidone by region  
 Incidence Prevalence 
Regions Mean (SD) Median (IQR) Mean (SD) Median (IQR) 
Eastern 766 (386) 687 (444-957) 2096 (1915) 1044 (545-3199) 
London 766 (735) 342 (150-1260) 2541 (3055) 439 (241-4605) 
N.Ireland 608 (272) 619 (457-795) 1113 (703) 1019 (598-1615) 
NE 896 (671) 828 (371-1025) 1484 (989) 1645 (459-2462) 
NW/WM 1002 (271) 904 (820-1127) 2048 (1588) 1188 (998-2773) 
Scotland 651 (245) 674 (491-812) 1271 (944) 864 (573-1781) 
Southern 648 (386) 496 (375-812) 1609 (1570) 718 (487-2192) 
Wales 569 (418) 384 (202-863) 1924 (1768) 1185 (302-3739) 
Total 738 (467) 745 (373-955) 1761 (1727) 1085 (487-2448) 
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Table 6.9 Means (SD) and medians (IQR) of rates per million children two years old and older prescribed 
domperidone by region 
 Incidence Prevalence 
Regions Mean (SD) Median (IQR) Mean (SD) Median (IQR) 
Eastern 675 (229) 682 (488-836) 1708 (1318) 994 (579-2902) 
London 534 (416) 356 (167-886) 1506 (1602) 455 (258-2837) 
N.Ireland 629 (277) 611 (454-844) 1099 (659) 1035 (661-1681) 
NE 878 (598) 767 (416-1103) 1392 (851) 1710 (514-1820) 
NW/WM 1003 (160) 967 (913-1076) 1829 (1049) 1316 (1088-2490) 
Scotland 672 (230) 692 (546-851) 1209 (785) 958 (637-1904) 
Southern 573 (236) 544 (419-680) 1221 (974) 742 (534-1539) 
Wales 497 (313) 424 (227-706) 1589 (1312) 1245 (342-2874) 
Total 683 (364) 681 (416-904) 1444 (1107) 1092 (524-2135) 
 
Table 6.10 Means (SD) and medians (IQR) of rates per million children below two years old prescribed 
domperidone by region 
 Incidence Prevalence 
Regions Mean (SD) Median (IQR) Mean (SD) Median (IQR) 
Eastern 1726 (2101) 528 (100-2251) 6043 (8258) 1495 (273-7020) 
London 2829 (3698) 223 (115-5363) 11718 (16018) 447 (164-21164) 
N.Ireland 417 (491) 420 (5-780) 1293 (1939) 420 (5-1712) 
NE 1119 (1724) 234 (5-1232) 2583 (3933) 234 (5-5045) 
NW/WM 1073 (1439) 350 (134-2030) 4387 (7145) 460 (134-5960) 
Scotland 468 (692) 5 (5-505) 1939 (2842) 279 (5-2337) 
Southern 1474 (2026) 277 (5-2588) 5702 (7733) 850 (5-9612) 
Wales 1371 (1932) 5 (5-2000) 5555 (7255) 5 (5-9714) 
Total 1310 (2067) 272 (5-1917) 4903 (8409) 502 (5-6766) 
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Figure 6.9 Prevalence rates per million children prescribed domperidone by year and region 
 
 
Figure 6.10 Prevalence rates per million children two years old and older prescribed domperidone by 
year and region 
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Figure 6.11 Prevalence rates per million children below two years old prescribed domperidone by year 
and region 
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6.4.4 Trends of prescribing rates by age and sex 
Cisapride was mainly used in younger children, particularly in infants below 12 months old, 
and not very common in older children. The incidence rate of cisapride prescriptions was 
highest in 1998 for boys at 3,169 per million boys, which was higher than that in girls at 
2,645 per million girls, peaked in 1997. The trends by age and sex were reflective of the 
overall trends of cisapride prescribing. These are illustrated in Figure 6.12; and support that 
cisapride was prescribed mainly for indications of GOR which are more prevalent among 
younger children and subside with age.  
 
Figure 6.13 tells slightly different story on domperidone prescriptions by age and sex. Similar 
to that of cisapride, more boys below 12 months old were prescribed domperidone compared 
to girls of the same age – incidence rates in 2006 were 5,640 per million and 5,214 per 
million for boys and girls respectively. The graph shows a bimodal distribution along the age 
axis at very young children and older children. This suggests that domperidone may have 
been prescribed for different indications in younger and older children. GOR would be the 
primary indication for prescribing domperidone in younger children similar to cisapride. In 
older children, the incidence rates were higher in girls, probably driven by prescribing 
domperidone for indications such as migraine and nausea which are known to be more 
common in older girls than boys. 
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Figure 6.12 Incidence rates per million children prescribed cisapride by age and sex 
 
 
Figure 6.13 Incidence rates per million children prescribed domperidone by age and sex 
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6.4.5 Trends of individual prescribing characteristics 
At individual level, mean number of prescriptions per patient per year (referred as “number 
of prescriptions” in this section for simplicity) increased rapidly in the early  99 ’s in 
children two years old and older, and then levelled between three and four until it was 
withdrawn (Figure 6.14). Children below two years old also shared similar trend with slightly 
less cisapride prescribing per year (between two and three). The mean therapy duration per 
prescription (Figure 6.15) for cisapride did not change much over time. Table 6.11 shows the 
overall means for number of cisapride prescriptions, and length of cisapride therapy duration 
by age group and total. 
 
Table 6.11 Mean (95% CI) number of prescriptions per patient per year, and length of therapy duration 
per prescription among children prescribed with cisapride 
 Number of 
prescriptions per 
patient per year 
Therapy duration in 
days per prescription 
             2.25 (1.64, 2.86) 37.0 (33.2, 40.9) 
             3.02 (2.49, 3.55) 32.2 (30.5, 33.9) 
All children 2.84 (2.36, 3.32) 32.4 (30.2, 34.6) 
 
Table 6.12 shows the overall means for number of domperidone prescriptions, and length of 
domperidone therapy duration by age group and total. Although the mean number of 
prescriptions among all children prescribed with domperidone was lower than that of 
cisapride; the number of domperidone prescriptions for children below two years old had 
already surpassed the number of cisapride prescriptions in the same age group. Mean therapy 
durations were still low among children prescribed with domperidone when compared to 
cisapride. 
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Table 6.12 Mean (95% CI) number of prescriptions per patient per year, and length of therapy duration 
per prescription among children prescribed with domperidone 
 Number of 
prescriptions per 
patient per year 
Therapy duration in 
days per prescription 
             2.33 (1.93, 2.73) 24.4 (21.3, 27.4) 
             1.59 (1.32, 1.86) 13.2 (10.8, 15.5) 
All children 1.71 (1.38, 2.04) 15.8 (12.8, 18.8) 
 
Number of domperidone prescriptions was also increasing over time and did not show very 
promising signs of levelling off (Figure 6.16). The mean therapy duration per prescription 
was also increasing (Figure 6.17). The increasing trends were more apparent for children 
below two years old who were prescribed with domperidone, particularly after the year 2000. 
 
The following Table 6.13 and Table 6.14 list the average dose each child was prescribed with 
for cisapride and domperidone cohorts respectively. Detailed breakdown by age and year are 
given in Appendix A.2. The amounts were somewhat consistent over the years but with 
slightly larger variance in the younger group of children. When compared to the Guy’s and 
St. Thomas’s paediatric formulary guideline (Guy's and St Thomas's and Lewisham 
Hospitals, 1990), 40% of children below two years old had at least one cisapride prescription 
exceeded the maximum daily dosage for their age and weight; and 20% in the remaining 
children on cisapride therapy. For those on domperidone therapy, only 4% of children below 
two years old and 0.5% of children two years old and older had exceeded the maximum 
recommended guideline (Paediatric Formulary Committee, 2007) in this cohort. However, 
this might be because guidelines for prescriptions are inconsistent and do not always provide 
clear cut recommendations for age and/or weight (see Appendix A.3). 
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Figure 6.14: Mean (and 95% confidence intervals) number of cisapride prescription per patient by year 
 
 
Figure 6.15: Mean therapy duration of cisapride per prescription by year 
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Figure 6.16: Mean (and 95% confidence intervals) number of domperidone prescriptions per patient by 
year 
 
 
Figure 6.17: Mean therapy duration of domperidone per prescription by year 
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Table 6.13 Mean (SD) of daily dose of cisapride prescribed in mg/kg/day by age group and year 
Year                           Total 
1990 n/a 0.07 (0.03) 0.07 (0.03) 
1991 n/a 0.13 (0.15) 0.13 (0.15) 
1992 0.57 (0.17) 0.15 (0.19) 0.17 (0.20) 
1993 0.67 (0.21) 0.23 (0.25) 0.31 (0.29) 
1994 0.72 (0.38) 0.33 (0.29) 0.44 (0.36) 
1995 0.57 (0.41) 0.42 (0.29) 0.48 (0.35) 
1996 0.47 (0.24) 0.41 (0.24) 0.44 (0.24) 
1997 0.63 (0.49) 0.47 (0.30) 0.52 (0.38) 
1998 0.65 (0.46) 0.45 (0.28) 0.53 (0.37) 
1999 0.65 (0.76) 0.46 (0.29) 0.51 (0.47) 
2000 0.60 (0.26) 0.42 (0.32) 0.46 (0.32) 
2001 n/a 0.29 (0.15) 0.29 (0.15) 
2002 n/a 0.39 (0.08) 0.39 (0.08) 
2003 n/a 0.46 (0.35) 0.46 (0.35) 
2004 n/a 0.30 (n/a) 0.30 (n/a) 
Total 0.60 (0.46) 0.42 (0.29) 0.47 (0.36) 
Coefficient of variation 0.77 0.70 0.77 
 
Table 6.14 Mean (SD) of daily dose of domperidone prescribed in mg/kg/day by age group and year 
Year                           Total 
1990 0.71 (0.28) 0.60 (0.25) 0.61 (0.25) 
1991 1.33 (1.44) 0.61 (0.22) 0.64 (0.37) 
1992 0.74 (0.11) 0.56 (0.17) 0.57 (0.17) 
1993 0.76 (0.25) 0.60 (0.24) 0.60 (0.24) 
1994 1.76 (3.10) 0.57 (0.19) 0.60 (0.47) 
1995 0.52 (0.14) 0.61 (0.24) 0.61 (0.24) 
1996 0.66 (0.28) 0.57 (0.19) 0.57 (0.20) 
1997 0.94 (0.58) 0.57 (0.21) 0.60 (0.27) 
1998 1.02 (0.40) 0.62 (0.31) 0.65 (0.33) 
1999 0.77 (0.35) 0.64 (0.28) 0.65 (0.29) 
2000 0.74 (0.41) 0.64 (0.31) 0.66 (0.33) 
2001 0.63 (0.33) 0.59 (0.34) 0.59 (0.33) 
2002 0.70 (0.31) 0.60 (0.33) 0.62 (0.32) 
2003 0.67 (0.30) 0.64 (0.34) 0.65 (0.33) 
2004 0.81 (0.54) 0.62 (0.31) 0.67 (0.39) 
2005 0.71 (0.36) 0.62 (0.30) 0.64 (0.31) 
2006 0.84 (0.55) 0.63 (0.33) 0.68 (0.41) 
Total 0.77 (0.49) 0.61 (0.30) 0.64 (0.34) 
Coefficient of variation 0.64 0.48 0.53 
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6.4.6 Temporal effect from the withdrawal of cisapride on domperidone 
There were 114 children who had been on both cisapride and domperidone therapy during the 
observation period. I conduct a descriptive analysis of children who switched drug therapy 
between cisapride and domperidone, restricted to the 114 children only.  
 
Figure 6.18 shows, in a particular year, when a child was only on cisapride therapy, on only 
domperidone therapy, and on both therapy. The shift upwards in the ‘cloud’ pattern provides 
some visual indications that children were switching from cisapride to domperidone over 
time.  
 
Figure 6.18 Clouds of drugs use per child by year 
 
Note: The traffic-light scheme to the graph does not imply any relative safety or efficacy between the drugs 
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I’ve broken down further the evidence of switching drugs therapy illustrated in Figure 6.18 in 
terms of nine possible states, expressed as a state in that year compared to state in previous 
year:  
DC Domperidone (only) to cisapride (only) 
BC Both to cisapride 
C Cisapride only 
DB Domperidone to both (domperidone/cisapride) 
CB Cisapride to both 
B Both domperidone and cisapride 
BD Both to domperidone 
CD Cisapride to domperidone 
D Domperidone only 
 
The states “B” and “CB” may also include children on cisapride who completely switched 
to domperidone in that year, as well as children who were prescribed cisapride and 
domperidone concomitantly in the same year.  
 
On top of that, 29/114 children had prescription of both cisapride and domperidone recorded 
on the same day. It is expected that only one of the prescriptions was actually issued whilst 
the other was recorded in error e.g. because the GP changed his/her mind. However, from the 
data available, there is no way to tell which one was the correct prescription, or which one 
was the latter or the former. Here, I just assume that both prescriptions were issued for 
simplicity; and so not to underestimate the number of prescriptions for either drug. 
 
Table 6.15 shows the proportions (and number) of children moving between the nine states of 
cisapride-domperidone therapy when compared to the previous year.  
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Table 6.15 Percentages (number) of children in that year who switched from or remained on the 
prescribed drug from previous year 
 
DC BC C DB CB B BD CD D 
1990 - - - - - - - - - 
1991 - - - - - - - - 100 (1) 
1992 - - - - - - - - - 
1993 - - 100 (1) - - - - - - 
1994 - - 55 (6) - - 18 (2) - - 27 (3) 
1995 - - 50 (9) 6 (1) 6 (1) 28 (5) - - 11 (2) 
1996 7 (2) 4 (1) 39 (11) 4 (1) 4 (1) 43 (12) - - - 
1997 3 (1) 5 (2) 38 (15) 3 (1) 15 (6) 36 (14) - - - 
1998 - 5 (2) 49 (20) - 10 (4) 32 (13) 5 (2) - - 
1999 - 2 (1) 49 (25) - 4 (2) 35 (18) 4 (2) 2 (1) 4 (2) 
2000 - 2 (1) - 3 (2) 40 (25) 47 (29) 5 (3) - 3 (2) 
2001 - - - - - 5 (2) 84 (37) - 11 (5) 
2002 - 3 (1) - 3 (1) - 3 (1) 3 (1) - 88 (29) 
2003 - - 4 (1) 4 (1) - 8 (2) - - 84 (21) 
2004 - - 6 (1) - - - 6 (1) - 89 (16) 
2005 - - - - - - 17 (2) - 83 (10) 
2006 - - - - - - - - 100 (10) 
“-” represents 0% (omitted for clarity) 
 
The series of prescriptions for each of the 114 children were examined manually to determine 
the pattern of their cisapride and domperidone use. The analysis suggests that 15.8% (18/114) 
children were using cisapride and domperidone interchangeably over the years. A small 
proportion of children,  7.5% (  /  4), who were on cisapride therapy “experimented” 
domperidone did not completely switch to domperidone. They either remained (2/20) on 
cisapride or had stopped completely (18/20) from the therapy by the time cisapride was 
withdrawn. Majority of the children, 66.7% (76), switched to domperidone completely as an 
alternative to cisapride. Of these, 57.9% (44/76) switched in 2000 (Figure 6.19) and it is 
highly likely that it was in response to cisapride withdrawal from the market. 
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Figure 6.19 Relative proportions of children who switched to domperidone from cisapride by year among 
those who switched to domperidone 
 
 
6.5 Discussion 
The analyses carried out in this chapter clearly indicate that the practice of prescribing 
domperidone to children is increasing. Whilst there is little evidence that the trends of 
prescribing differ from region to region, the differences observed may be due to the number 
of general practices (hence number of GPs) within the region who contributed their data to 
GPRD. It is possible that some GPs are more supportive than others of the use of 
domperidone (or cisapride) in children.  
 
The increasing trends in individual prescribing characteristics were possibly largely due to 
the build-up of experiences in prescribing domperidone in the general practices. However, 
this may also suggest that the treatment at the given dosage and duration simply did not work. 
A well-designed clinical trial is needed to determine the correct dose and duration of therapy 
for this population. Because there is no solid evidence to support the guideline for cisapride 
and domperidone, the amount prescribed to children can be very variable, some of which had 
exceeded the recommended maximum daily dose. However, the exceeded proportions are 
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only indicative and would vary depending on which guidelines they were compared to. 
Nevertheless, it is indicative that they do happen in real clinical practice. 
 
Whilst it is still questionable whether domperidone (and cisapride) actually works for the 
treatment of GORD, the data could not provide the answer. The improvement in GORD 
symptoms is just not recorded in the general practices and the GPRD (as are improvements in 
other medical conditions). Section 8.6 discussed the type of “benefit” outcomes that are 
present in routine healthcare data that could be investigated further but is not possible for this 
case study.  
 
Based on the increasing trends in almost all aspects of prescribing characteristics, the data are 
supportive of the need for a domperidone trial for the treatment of gastro-oesophageal reflux 
disease in children at this point in time. A well-designed trial is needed to justify the 
prescribing trend; and it needs to seek to answer how effective and safe domperidone is, and 
to be able to advise the best treatment regime when used in children. 
 
The more challenging and important aspect to study is the risks that may be associated with 
the prescription (hence use) of domperidone in children. It is important to point out that even 
though there is no robust evidence that the benefit of cisapride or domperidone outweighs the 
risks from previous trials, ESPGAN has recommended both drugs as a ‘phase  ’ treatment for 
GORD (Vandenplas, 1993; Vandenplas, 1997). Such guidelines do influence the decision 
GPs make in deciding treatment options for their patients. But for GPs to react positively to 
or rely upon these guidelines is not fully warranted. Pritchard et al. also warns in their review 
that when considering domperidone, the experience with cisapride must also be considered 
(Pritchard, 2005). 
 
Clinical trials of cisapride and domperidone in children have been done and published as 
reviewed in Chapter 5. There are inconsistencies of the outcomes reported from these trials, 
but some trials did investigate common risk and benefit outcomes which could be evaluated 
together in a meta-analytic framework. Meta-analysis of results from different clinical trials 
can be very valuable since it can combine results from similar trials thus makes pooled 
inference on the outcomes based on larger sample. Chapter 7 performs classical and Bayesian 
meta-analysis to combine evidence from different trials whilst addressing uncertainties 
around different parameters in the models. 
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7. Quantitative review meta-analysis of risks and benefits evidence from trials 
7.1 Introduction 
Literatures reviewed in Chapter 5 provide some evidence of risks and benefits for 
domperidone and cisapride when used in children with gastro-oesophageal reflux disease. 
This chapter explores the quantitative evidence of risk and benefit outcomes from clinical 
trials and analyses the data using methods of meta-analysis. The rationale for conducting this 
quantitative review is discussed in Section 7.2. The review methods and meta-analytic 
models used are discussed in Section 7.3. The results of the meta-analyses are presented and 
discussed in Section 7.4 by outcome. Finally the overall discussion of the results from the 
meta-analyses and the level of certainty that these results can contribute to risk-benefit 
analysis are discussed in Section 7.5. 
 
7.2 Rationale for the review 
Although other reviews have looked at quantitative results of cisapride (Augood, 2003) and 
domperidone (Pritchard, 2005) using meta-analysis, these are separate and compared to 
placebo or other drugs. There are no direct comparisons of cisapride and domperidone until a 
small pilot trial was conducted in 2009 to study drug-induced prolongation of QTc interval 
(Hegar, 2009). This review aims to quantify the risks and benefits of cisapride compared to 
domperidone indirectly, as well as improving the results on the effects of these drugs when 
compared to placebo. 
 
The objectives are to estimate:  
(1) the efficacy of domperidone using the common outcomes where data permits; and  
(2) the rates of adverse events where data permits. 
 
7.3 Methods 
7.3.1 Literature search strategy 
Literature search strategy has been described in Chapter 5. The same papers are included in 
this quantitative review. 
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7.3.2 Methods for quantitative review 
Outcomes similar to those in the Cochrane review of cisapride (Augood, 2003) are 
investigated. These are: 
A. Improvement in gastro-oesophageal symptoms however defined, characterised by 
“moderate or excellent improvement” (“improved” for simplicity) versus “worse, 
same, or slight improvement” (“not improved” for simplicity) 
B. Difference in reflux index 
C. Reported number of patients with adverse events 
 
Data extraction is limited to comparison of cisapride or domperidone against placebo, or each 
other only. Combination therapies, e.g. domperidone plus alginates, are also excluded. Study 
characteristics are described in Section 5.4, and published data for the three outcomes used in 
the analyses in this chapter are given in Appendix A.4.  
 
7.3.3 Statistical analysis 
7.3.3.1 Model   – classical meta-analysis 
The classical meta-analyses were performed separately for cisapride versus placebo trials, 
and domperidone versus placebo trials using random effect meta-analyses. Meta-analyses for 
this model along with cumulative meta-analyses (Lau, 1992) were performed in Stata 10 
under model assumptions described below. 
 
Let          be the treatment arms placebo, cisapride and domperidone respectively where 
available in studies          . Within-study variability   
  is assumed known, and the 
between-study variability    is the DerSimonian and Laird estimator (DerSimonian, 1986). 
Then we define: 
 
                           (    
 ) 
                           (   
 ) 
 
Also, let      
     be the total variance in study  . Then, the pooled estimate  ̂ and 
variance    ( ̂) are: 
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For binary outcomes and     is the control arm in study   where available, we also define: 
 
   
   (       )
   (       )
 
 
7.3.3.2 Model    – Bayesian meta-analysis with binary outcomes 
For binary outcomes improvement in GORD symptom (Section 7.4.1) and experiencing 
adverse events (Section 7.4.3), logistic regression was used to estimate the odds ratio of 
treatment effects. 
 
Let          be the treatment arms placebo, cisapride and domperidone respectively where 
available in studies          , and let          as in   be the control treatment in study  . 
Then we define 
 
    {
       
       
 
    
    
 
(             )
(                )
 
 
             (       ) 
     (   )             
          (        ) 
 
The control group in study   is identified in the dataset when     , and the active treatment 
group in study   is identified when      (Lu, 2004). The number of “successes”,      is 
assumed Binomially-distributed with probability     and observed total    ; and that     has a 
logit link.    is the trial-specific log odds and is treated as a “nuisance” parameter.      is the 
trial-specific log odds ratio of active treatment versus control, and is assumed to be normally-
distributed with log odds ratio       for treatment   compared with a comparative treatment 
    , with precision   .  
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7.3.3.3 Model    – Bayesian meta-analysis with continuous outcomes 
For the continuous outcome reflux index (Section 7.4.2), linear regression was used to 
estimate the difference in treatment effects.  
 
Indexes   and   are as previously described in model    above. Parameter     has also been 
described in Section 7.3.3.2 above, and follows the same reasoning here. Then, we define 
 
          (       ) 
               
          (        ) 
 
    is the observed reflux index and is assumed to be Gaussian normally-distributed with 
mean     and the observed precision    .    is the reflux index in control group for study   and 
is treated as a nuisance parameter.     is the trial-specific difference of active treatment 
versus control, and is assumed to be normally-distributed with mean      , the difference 
between treatment   and a comparative treatment     , with precision   .  
 
7.3.3.4 Model   – Bayesian covariates-adjusted models for    and    
Adjustments for study level covariates were done as extensions to model    and model    by 
further modelling            against mean or median age (where available median is 
preferred), duration of trial, and log of dose prescribed in the trial. Age and duration were 
centred at their respective means. Then, the adjustments were defined as (Nixon, 2007): 
 
    (      )         (         )     (                   )                
 
and 
          (        ) 
 
    is the trial-specific adjusted log odds ratio (for    ) or treatment difference (for    ) which 
is assumed to be normally-distributed with mean      , the log odds ratio (for    ) or treatment 
difference (for    ) between the treatment   and a comparative treatment     , with precision 
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  .       and      are regression coefficients for age centred at mean     , duration centred 
at mean          , and log-transformed doses. The regression coefficient      is set to zero to 
eliminate dose effect when placebo was used (   ). For the continuous reflux index 
outcome (   ), the regression was further adjusted for reflux index at baseline to account for 
regression-adjusted changes from baseline.  
 
7.3.3.5 Model-fitting 
Under the classical meta-analysis framework, an unadjusted indirect treatment comparison 
model was calculated. Classical meta-analyses were performed in Stata® 10 (StataCorp, 
2007) for each outcome as a starting point. Indirect treatment comparison of the estimates 
was calculated manually from the results of the two separate meta-analyses for cisapride and 
domperidone using the formula described in Section 3.4. Forest plots from cumulative meta-
analysis by year are presented instead of the standard forest plot to illustrate the building of 
evidence over time. These apply to model  . 
 
An unadjusted indirect treatment comparison model was fitted in a connected network of 
evidence under Bayesian framework where there was no direct evidence involved. This 
model allows “feedbacks” between the two separate meta-analyses through the indirect 
treatment comparison parameter between domperidone and cisapride. Covariance was 
assumed to be exchangeable among cisapride studies, and among domperidone studies; but 
not across them. These apply to models            . 
 
When there was direct evidence, unadjusted mixed treatment comparison was fitted allowing 
for exchangeable covariance across all studies. The mixed treatment comparison model thus 
allows the direct evidence to be complemented by available indirect evidence. These also 
apply to models            . 
 
The analyses for model             were carried out under Bayesian framework in 
WinBUGS (Lunn, 2000) to accommodate all sources of variability and the complex structure 
of the models. WinBUGS codes for mixed treatment comparisons fitted are that for the 
simple (univariate) random-effects model of Ades (MPES, 2010). 
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In all Bayesian models, vague priors were used to allow the data to drive the results. 
Sensitivity analyses were performed ad hoc by varying the priors on the precision parameters 
with gamma priors or using uniform priors on the standard error parameters. Two MCMC 
chains were used to assess the sampler sensitivity to initial values. The second initial values 
chain was built from the “Model→Save State” function in WinBUGS after running the 
sampler with one chain. The initial values were also randomly changed in each chain to 
assess the impact on the final results. Convergence for each model was assessed visually 
using auto-correlation plots, density plots, and Gelman-Rubin statistic plots but the plots are 
not presented in this thesis.  
 
7.4 Results 
The results are presented in three sub-sections according to the outcomes. The numerical 
results from the meta-analyses are summarised in Table 7.1 to Table 7.3 in their respective 
sub-sections. The cumulative meta-analysis forest plots corresponding to classical meta-
analysis to show how evidence of risks and benefits accumulated over time when trials were 
conducted are shown in Figure 7.1 to Figure 7.3 in their respective sub-sections.  
 
7.4.1 Improvement in gastro-oesophageal symptoms however defined, characterised by 
“improved” versus “not improved”  
The most frequently used efficacy outcome for GORD treatments is the reduction in 
symptoms. However, the definitions vary from study to study. Assuming that the definitions 
for improvement were reasonable and comparable in these trials, three meta-analytic models 
were fitted and assessed. 
 
The first model   is the unadjusted classical meta-analysis (first column in Table 7.1). The 
cumulative of evidence on efficacy of cisapride and domperidone as and when new trial 
results were published are shown in Figure 7.1. Interestingly, the evidence that cisapride 
improved GORD symptoms when compared to placebo were statistically significant from the 
very first trial included in this review. However, the strength of association grew weaker with 
additional trials in general to an odds ratio of 3.57 (95% CI 1.00, 12.80) when compared to 
placebo. Furthermore, publication bias has been reported when a published trial (Levy, 2001) 
reported a large (134 subjects) industrial-sponsored trial conducted between 1991 and 1994 
was not published ‘because efficacy results did not reach statistical significance’ (Augood, 
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2003). The true effect of this publication bias is unknown but any trial with the size and 
direction of treatment effect could bring down the treatment odds ratio towards favouring 
placebo, and would almost certainly shift the 95% confidence intervals to straddle the point 
of no difference (OR=1.00). 
 
The unadjusted meta-analysis for domperidone versus placebo (first column in Table 7.1) 
also shows treatment effects on the efficacy of domperidone in similar direction with slightly 
greater improvements in GORD symptoms of 5.30 (95% CI 1.74, 16.17). The cumulative 
meta-analysis plot (Figure 7.1) also suggests that additional trial is starting to shift the 
treatment effects towards favouring placebo, particularly due to one larger trial in 1994 
(Carroccio, 1994). Because there are very few domperidone trials, the pooled estimates from 
these trials can be misleading especially with the small sample sizes within trials and low 
statistical power. 
 
Simple calculations as described in Section 3.4 estimate that the indirect odds ratio 
comparison of domperidone against cisapride is 1.49 (95% CI 0.27, 8.09); suggesting that 
although on average domperidone may be slightly better at reducing GORD symptoms than 
cisapride, the greater improvement is not statistically significant (Table 7.1).  
 
Allowing the two meta-analyses to interact and learn from each other under model    
specifications, the Bayesian estimates of odds ratios are lower than those produced in 
classical analysis. Table 7.1 (second column) shows cisapride improves GORD symptoms by 
about three times compared to placebo – odds ratio 2.75 (95% CrI 0.91, 8.14); and 
domperidone improves GORD by three and half times compared to placebo – odds ratio 3.46 
(95% CrI 0.83, 11.99). The indirect odds ratio estimates comparing domperidone to cisapride 
was also slightly lower than that of classical analysis estimate at 1.25 (95% CrI 0.21, 6.63). 
The 95% credible intervals for all odds ratio estimates obtained through this model did not 
show strong evidence to support the increase. 
 
The study-level covariates adjusted model   (third column Table 7.1) shows a slightly less 
improvement than in model    for cisapride treatment of about 2.4-times compared to 
placebo – odds ratio of 2.39 (95% CrI 0.84, 7.13). The odds ratio of domperidone compared 
to placebo was estimated to be 3.87 (95% CrI 0.78, 16.08), and the corresponding indirect 
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odds ratio comparison was 1.61 (95% CrI 0.24, 9.05). The odds ratios for the covariates 
suggested that increase in age is associated with improvement, but conversely true for 
increase in dose. Study duration did not affect the odds ratio for seeing an improvement. An 
increase in age was associated with increased odds ratio of improvement, but increase in 
doses was associated with a decrease in odds ratio of improvement. The increase in duration 
of treatment neither increased nor decreased the odds ratio of improvement. However, the 
95% credible intervals for all covariates suggest that the effects were weak and could go in 
either direction. 
 
Figure 7.1 Cumulative random-effects meta-analysis for odds ratio of improved vs. not improved 
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Favours placebo  Favours treatment 
1.2 .5 2 5 10 50 100
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Table 7.1 Pooled odds ratios comparing “improved” to “not improved” 
 Classical Bayesian
a 
Bayesian
b 
Cisapride vs. placebo 3.57 (1.00, 12.80) 2.75 (0.91, 8.14) 2.39 (0.84, 7.13) 
Domperidone vs. placebo 5.30 (1.74, 16.17) 3.46 (0.83, 11.99) 3.87 (0.78, 16.08) 
Domperidone vs. cisapride (indirect 
comparison) 
1.49 (0.27, 8.09) 1.25 (0.21, 6.63) 1.61 (0.24, 9.05) 
Increase in age by one month n/a n/a 1.07 (0.99, 1.18) 
Increase in log dose of cisapride by one 
log mg/kg/day 
n/a n/a 0.37 (0.07, 2.13) 
Increase in log dose of domperidone by 
one log mg/kg/day 
n/a n/a 0.87 (0.12, 6.09) 
Increase in study duration by one week n/a n/a 1.00 (0.67, 1.47) 
Bayesian odds ratio estimates for treatment is given as 
a
unadjusted and 
b
study level covariates adjusted 
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7.4.2 Change in reflux index 
Similar to the symptoms improvement outcome in Section 7.4.1, the cumulative evidence for 
the role of cisapride and domperidone in reducing reflux index in children with GORD were 
shifting towards favouring placebo (Figure 7.2). Model   (first column in Table 7.2) shows 
that reflux index in children treated with cisapride was 6.48 (95% CI 2.85, 10.12) points 
lower than those received placebo; and those treated with domperidone reduced their reflux 
index by 1.93 (95% CI -2.96, 6.81) points compared to placebo. The indirect treatment 
comparison indicates that cisapride reduced reflux index by 4.56 (95% CI -1.53, 10.64) 
points when compared to domperidone. 
 
The unadjusted mixed treatment analysis in model    (second column in Table 7.2) shows 
cisapride reduces reflux index by 5.46 (95% CrI 2.94, 8.06) points when compared to 
placebo. The reflux index was reduced by 4.94 (95% CrI 1.70, 8.34) points in children who 
were treated with domperidone when compared to placebo. Under this model’s assumptions, 
both cisapride and domperidone were effective at reducing reflux index. The indirect 
treatment comparison model    indicates that cisapride reduced reflux index by 4.24 (95% 
CrI -2.43, 11.15) points more than domperidone, similar to indirect effect from the classical 
analysis model  . The additional evidence providing direct comparison of domperidone to 
cisapride in reducing reflux index (Hegar, 2009), decreases the difference in treatment effect 
between cisapride and domperidone to 0.50 (95% CrI -2.12, 3.13) points. The inconsistency 
measure   (back-calculation method described in Section 3.4) between direct and indirect 
effects of domperidone compared to cisapride is -4.59 (95% CrI -11.77, 2.39) suggesting 
some evidence of inconsistency but it is difficult to say which direction the inconsistency 
might be from 95% credible interval. 
 
When adjusted for study-level covariates in model   using mixed treatment comparison 
specifications (third column in Table 7.2), the reductions in reflux index remained strongly 
associated with the active treatments compared to placebo at 4.04 (95% CrI 0.72, 7.45) points 
and 2.52 (95% CrI 1.91, 7.03) for cisapride and domperidone respectively. The indirect 
treatment comparison shows reduction of reflux index in those receiving cisapride 2.07 (95% 
CrI -8.13, 12.43) points greater than those receiving domperidone but the 95% credible 
interval suggests that it could also be an increase as much as 8.13 points or much greater 
reduction of 12.43 points. Under the mixed treatment comparison specifications, cisapride 
reduces reflux index by 1.50 (95% CrI -2.35, 5.50) points more when compared to 
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domperidone, but cisapride could also increase the reflux index by 2.35 points or greater 
reduction up to about 5.50 points could be observed. The consistency measure   suggests 
there were -2.41 (95% CrI -12.96, 7.98) points inconsistency between the direct and indirect 
evidence of domperidone against cisapride, but the magnitude could be as much as 12.96 
smaller in the direct evidence or could be as much as 7.98 larger in the direct evidence, 
relative to the indirect evidence. Increase in age was associated with more reduction in reflux 
index, whilst increase in doses and increase duration of treatments were associated with 
increasing reflux index. However, the 95% credible intervals for all covariates suggest that 
the effects were weak and could go in either direction. 
 
Figure 7.2 Cumulative random-effects meta-analysis for weighted mean difference of reflux index at the 
end of study (labelled as treatment vs. control) 
  
Cisapride vs. placebo
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Scott
Cohen
Domperidone vs. placebo
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Carroccio
Domperidone vs. cisapride
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1987
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1992
1994
2009
Year
-12.02 (-23.74, -0.30)
-7.72 (-13.98, -1.45)
-9.00 (-12.49, -5.52)
-8.72 (-12.08, -5.36)
-6.48 (-10.12, -2.85)
-4.10 (-13.03, 4.83)
-1.93 (-6.81, 2.96)
-0.34 (-2.31, 1.63)
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Table 7.2 Average treatment effects compared to control (placebo or cisapride) for reflux index 
 Classical Bayesian
b 
Bayesian
c 
Cisapride vs. placebo -6.48 (-10.12,-2.85) -5.46 (-8.06,-2.94) -4.04 (-7.45,-0.72) 
Domperidone vs. placebo -1.93 (-6.81,2.96) -4.94 (-8.34,-1.70) -2.52 (-7.03,1.91) 
Domperidone vs. cisapride 
(indirect comparison)
a 
4.56 (-1.53,10.64) 4.24 (-2.43,11.15) 2.07 (-8.13,12.43) 
Domperidone vs. cisapride 
(mixed treatment  comparison) 
n/a 0.50 (-2.12,3.13) 1.50 (-2.35,5.50) 
Increase in age by one month n/a n/a -0.24 (-0.88,0.29) 
Increase in log dose of cisapride 
by one log mg/kg/day 
n/a n/a 5.90 (-1.88,13.65) 
Increase in log dose of 
domperidone by one log 
mg/kg/day 
n/a n/a 5.40 (-7.08,18.71) 
Increase in study duration by one 
week 
n/a n/a 0.19 (-4.11,4.43) 
a
 Data from Hegar (2009) that give direct comparison is excluded from these models. Domperidone vs. placebo 
effect = -2.00 (95% CrI -8.21, 4.42); cisapride vs. placebo effect = -6.26 (95% CrI -9.03, -3.42) from unadjusted 
model. Domperidone vs. placebo effect = -2.27 (95% CrI -11.78, 7.40); cisapride vs. placebo effect = -4.32 
(95% CrI -8.17, -0.42) from covariates-adjusted model.  
Bayesian estimates for treatment difference is given as 
b
unadjusted and 
c
study level covariates adjusted 
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7.4.3 Reported number of patients with adverse events 
Figure 7.3 shows that the cumulative odds ratio of adverse events was shifting towards 
favouring placebo over cisapride or domperidone from the classical meta-analyses model  . 
The odds ratio of a child experiencing an adverse event when prescribed with cisapride was 
1.76 (95% CI 0.87, 3.58) compared to placebo; and when prescribed with domperidone, the 
odds ratio against placebo was 3.07 (95% CI 0.60, 15.81). The indirect treatment comparison 
under model   suggests that twice as many children prescribed with domperidone 
experienced an adverse event when compared to cisapride – odds ratio of 1.75 (95% CI 0.29, 
10.41) (first column in Figure 7.3). None of the odds ratios in model   were statistically 
significant at 5% level. 
 
The unadjusted mixed treatment comparison model    (second column in Table 7.3) 
estimates very similar odds ratios for cisapride and domperidone versus placebo of 1.96 (95% 
CrI 0.53, 7.39) and 1.95 (95% CrI 0.28, 13.87) respectively. Consequently, the mixed 
treatment comparison of domperidone versus cisapride shows no difference, with odds ratio 
of 1.00 (95% CrI 0.11, 8.75). The unadjusted indirect treatment comparison reported odds 
ratio of experiencing adverse events of 1.94 (95% CrI 0.14, 29.14), nearly twice as larger 
than when the study with direct comparison (Hegar, 2009) was included. The back-
calculation method estimated the inconsistency   to be of magnitude 0.05 (95% CrI 0.00, 
4.52) on the odds ratio scale. None of the odds ratios in model    for experiencing adverse 
events, including the measure of inconsistency, had convincingly strong associations to the 
treatments since the 95% credible intervals suggest the odds could be the same – where odds 
ratio is 1.00 – in both groups. 
 
On the other hand, having adjusted for study-level covariates in model   (third column in 
Table 7.3), the estimated odds ratio suggested that children prescribed with cisapride 
experienced adverse events over twice as much when compared to placebo – odds ratio of 
2.25 (95% CrI 0.47, 11.29); but children who were prescribed with domperidone experienced 
adverse events with lower odds ratio of 1.60 (95% CrI 0.17, 13.54), about 60% more than 
children who were on placebo. Thus, it follows from the adjusted mixed treatment 
comparison that 28% fewer children (95% CrI OR 0.05, 8.18) experienced adverse events 
when treated with domperidone compared to cisapride. The adjusted indirect treatment 
comparison still suggests that domperidone was almost twice worse than cisapride in terms of 
adverse events with odds ratio 1.95 (95% CrI 0.08, 53.01). The estimated inconsistency (odds 
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ratio) measure    between direct and indirect estimates is 0.05 (95% CrI 0.00, 6.42). Model 
  also suggested that increase in age and increase in doses were associated with increased in 
odds of experiencing adverse events, but increase in treatment or study duration was 
associated with decrease in odds of experiencing adverse events. Similar to previous models, 
none of the odds ratios in model   for experiencing adverse events, including the covariates 
effects, were convincingly strong to favour any particular treatment. 
 
Figure 7.3 Cumulative random-effects meta-analysis for odds ratio of experiencing adverse events vs. not 
experiencing adverse events (Stratified meta-analyses labelled as treatment vs. control) 
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Table 7.3 Pooled odds ratios comparing “experienced adverse events” to “not experienced adverse event” 
 Classical Bayesian
b 
Bayesian
c 
Cisapride vs. placebo 1.76 (0.87, 3.58) 1.96 (0.53, 7.39) 2.25 (0.47, 11.29) 
Domperidone vs. placebo 3.07 (0.60, 15.81) 1.95 (0.28, 13.87) 1.60 (0.17, 13.54) 
Domperidone vs. cisapride (indirect 
comparison)
a 
1.75 (0.29, 10.41) 1.94 (0.14, 29.14) 1.95 (0.08, 53.01) 
Domperidone vs. cisapride (mixed 
treatment  comparison) 
n/a 1.00 (0.11, 8.75) 0.72 (0.05, 8.18) 
Increase in age by one month n/a n/a 1.02 (0.94, 1.12) 
Increase in log dose of cisapride by one 
log mg/kg/day 
n/a n/a 1.11 (0.16, 7.71) 
Increase in log dose of domperidone by 
one log mg/kg/day 
n/a n/a 1.31 (0.20, 8.45) 
Increase in study duration by one week n/a n/a 0.91 (0.49, 1.67) 
Note: Continuity correction of +0.5 was added to all cells to account for zero cell counts in the classical analysis 
a
 Data from Hegar (2009) that give direct comparison is excluded from these models. Domperidone vs. placebo 
OR = 3.16 (95% CrI 0.35, 33.32); cisapride vs. placebo OR = 1.63 (95% CrI 0.41, 6.63) from unadjusted model. 
Domperidone vs. placebo OR = 2.62 (95% CrI 0.27, 28.21); cisapride vs. placebo OR = 1.35 (95% CrI 0.23, 
7.87) from covariates-adjusted model. 
Bayesian estimates for treatment difference is given as 
b
unadjusted and 
c
study level covariates adjusted 
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7.5 Discussion 
The review confirms that there is no robust evidence of efficacy and safety for cisapride and 
domperidone when used in children for treatment of gastro-oesophageal reflux disease. The 
inconsistency in trial reporting and lack of high quality trials are the two main issues 
accountable for the uncertain risk and benefit evidence of domperidone in children. Therefore 
the evidence currently available from clinical trials on these drugs is not good enough for 
risk-benefit decision-making assessment. 
 
On the efficacy front, both efficacy outcomes considered in this review supported the efficacy 
of cisapride when compared to placebo, particularly for the reflux index outcome that reached 
statistical significance at the 5% level. However, reflux index is a weak clinical marker and 
does not correlate well with clinical symptoms in children. Therefore the reduction in reflux 
index may not actually indicate any treatment benefit. On the other hand, in the light of 
known publication bias (Augood, 2003), the results presented should be treated cautiously. 
The issue of bias including reporting bias and publication bias, as well as quality and size of 
trials should also be acknowledged when the results are referred to. The evidence of benefit 
of prescribing domperidone to children with GORD is less clear due to lack of trials in this 
population. The available evidence does point to some benefit in symptoms reduction, which 
may be greater than cisapride. 
 
Authors tend to report adverse events collectively in very broad categories or to dichotomise 
them into experiencing adverse events or not. Individual adverse event rates from clinical 
trials are not usually reported (Section 5.5). Adverse events that are less common i.e. those 
with small incidence rates are often the ones given less attention to. Consistent and 
transparent reporting is important because some adverse events are more serious than others 
although rarely occur. The same kind of adverse event could also differ in its severity but 
severity of adverse events is even more infrequently reported.  
 
The meta-analysis illustrates that when trials reported only serious adverse events (Hegar, 
2009; Levy, 2001) and trials also reported other adverse events are to be combined, the 
results can be very inconsistent especially when the number of trials is small. For example, 
the odds of adverse events for domperidone are almost twice as much when compared to 
cisapride using an indirect treatment comparison (Table 7.3). In an unadjusted mixed 
treatment comparison suggested there were no difference between the two. This is largely 
Part II: Quantitative review meta-analysis of risks and benefits evidence from trials 
Chapter 7 | 183  
 
driven by the additional trial that compares cisapride to domperidone which only reported the 
rates of QTc prolongation adverse events and nothing else was mentioned (Hegar, 2009). 
 
The effects of the covariates from the presented meta-analyses should be interpreted carefully 
and within the context of the trial conditions. I discuss some issues when interpreting these 
effects for the benefit (improvement in GORD symptoms) and risk (experienced AE) 
endpoints, omitting observed change in reflux index for the reason described earlier (weak 
clinical marker). Increase in age was associated with increased benefit (Section 7.4.1) and 
increased risk (Section 7.4.3). This could be interpreted either as there is weak evidence that 
cisapride or domperidone might be beneficial in older children, or that it may be that GOR 
symptoms naturally subside in older children and the treatment did not contribute to this 
change.  
 
An increase in daily dose was associated with decreased benefit (Section 7.4.1) and increased 
risk (Section 7.4.3) for both cisapride and domperidone – this is analogous to unmitigated 
failure scenario described in Section 3.9.1. The only probable interpretation may be that 
higher doses worsen the symptoms and are associated with more adverse events. However, 
the children populations may be very different between studies and some trials only reported 
selected adverse events e.g. focus on QTc prolongation. Furthermore, in all four trials, 
domperidone was prescribed below the recommended daily doses (2 mg/kg/day); but of the 
nine trials involving cisapride, two prescribed below the recommended daily doses (0.6 
mg/kg/day), two prescribed at the recommended daily doses, and five over-prescribed. 
 
Increase in duration of trial, hence the length of therapy, was associated with decreased risk 
(Section 7.4.3) but had no effect on benefit (Section 7.4.1). An explanation for this could be 
that the longest trials of eight-week therapy were either focussed on establishing efficacy and 
ignoring adverse events, or focussed only on specific adverse events and ignoring the others. 
The inconsistency and selective reporting of adverse events in the trials in this review have 
been major drawbacks on obtaining the evidence for risks in children prescribed with 
cisapride or domperidone. Therefore any effects associated with adverse events arising from 
these trials should be interpreted with caution, and suitable alternative evidence should be 
sought in order to establish better understanding of benefit-risk balance of these drugs when 
used in children with GORD. 
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In all mixed treatment comparison meta-analyses, there might be inconsistency in direct and 
indirect evidence. It is difficult to disentangle which study might be aberrant because there is 
only one study that provides direct comparison of cisapride to domperidone which was 
carried out to investigate QTc prolongation. This is complicated further by the fact that there 
are very few studies and that they are small, and those providing evidence for domperidone 
are mostly old. 
 
The exploration of meta-analysis results by changing prior assumptions in models 
            did not materially alter the results. Changes to initial values for the MCMC 
sampler, provided they are sensible, did not materially alter the final results. Hence, they are 
not presented in this thesis. 
 
Because the evidence for and against the efficacy and safety of domperidone in this 
population is limited and uncertain, it is important that domperidone is studied further to 
ensure that its current and future use is appropriate. Future trials should seek to collect 
evidence on both efficacy and safety of domperidone when used in children with GORD in 
the light of current evidence. In particular, past prescribing experience as recorded on the 
GPRD database may be able to inform whether certain safety issues had already been 
encountered but missed; and whether conducting a trial is justified at this time and if it were 
safe enough to conduct. Additionally, there is also a pressing need to determine a better 
efficacy endpoint to be measured as the primary outcome in trials to allow more direct 
comparisons, inferences, and decisions to be made. 
 
Chapter 8 attempts to find alternative evidence of risks and benefits through the application 
of data mining technique on GPRD database followed by assessment of causality to solicit 
unknown risks that are worthwhile to take forward into formal quantitative risk-benefit 
assessment. 
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8. Evidence data mining and verification using longitudinal routine healthcare data 
8.1 Introduction 
Most healthcare databases such as the GPRD database (Sections 2.6 and 2.7) can be used for 
this purpose, but GPRD data is used here for the reasons explained in the introduction 
(Section 1.4). GPRD stores large longitudinal data on patients in the primary care and are rich 
sources of evidence for risks and benefits. These data include clinical events information and 
drug prescription data, which is central to the arguments of evidence-based safety in this 
thesis. General practices in the United Kingdom record their patients’ reasons for visiting as 
“clinical events”, and additionally record adverse drugs reactions, and deaths; among other 
variables.  
 
It is not prejudiced to say that recorded adverse drugs reactions would only contain the events 
that were known to be the side-effects from the drugs; which GPs had suspected to be caused 
by particular drugs use with some degree of certainty. These were categorised as either 
“allergy” or “intolerant” to the drugs on the database. The recorded ADRs and deaths were 
assumed to be accurate – there was no reason to assume otherwise. “Clinical events” data 
particularly hold the key to the evidence-based safety we sought for. Whilst some events 
might be identified as adverse events from evidence in other literature, some could only be 
flagged up as signals as the associations to the drugs have not been established. 
 
There are several main signal detection methodologies that have been implemented by 
different pharmacovigilance authorities: the proportional reporting ratios (PRRs) (Evans, 
2000) by the Yellow Card scheme (YCS) in the UK until 16
th
 February 2006, Empirical 
Bayes Gamma-Poisson Model (EBGM) (DuMouchel, 1999) by the YCS from 17
th
 February 
2006, EBGM and Multi-item Gamma-Poisson Shrinkage (MGPS) (DuMouchel, 2001) by the 
FDA AERS/SRS in the US, and Bayesian Confidence Propagation Neural Network 
(BCPNN) (Bate, 1998) by WHO UMC. Different methods may raise different signals, and 
may have different detection and false positive rates based on the database and/or signal 
selection criteria used for the data mining. 
 
The strengths and weaknesses of the methods have been described in a 2003 review on signal 
detection in pharmacovigilance (Hauben, 2003); and our approach shared these features. For 
our data mining exercise, the PRRs method was chosen where details were described in 
Section 3.7. From our point of view, it is easier to communicate the findings to other parties 
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who do not have extensive statistical knowledge. In a study on drug-induced pancreatitis, 
PRRs outperformed MGPS on several counts of the analysis both in number of true signals 
generated and the timing of signals (Hauben, 2004). This demonstrates that although PRRs 
method is the simplest, it does not necessarily mean that it performs the worst. Because this 
chapter (or this thesis) does not seek to compare the performance of the different methods for 
signal detection, we did not attempt to generate signals using methods other than PRRs. 
However we expect that should other methods were chosen to perform data mining, 
reasonably similar results would be obtained. 
 
8.2 Aims and objectives 
The aims of this chapter are to evaluate the viability of the GPRD clinical events data to 
provide evidence of risks from the use of drugs in the general population in the form of safety 
signals; and to describe the practical aspects of automated signal detection using the database. 
 
Specific objectives of this chapter are: 
(i) To describe and quantify previously known adverse events; 
(ii) To develop an algorithm for signal detection and validation of previously 
unknown adverse events using GPRD; 
(iii) To describe and quantify raised signals from objective (ii);  
(iv) To investigate the effect of dosage, concomitant drugs use, and concomitant 
illnesses associated with the raised signals via matched case-controls studies for 
those who were prescribed with cisapride or domperidone;  
(v) To discuss the signals’ causal relations to the prescribed drugs with specific 
attention given to domperidone; and 
(vi) To comment on and generalise the algorithm with an extension to evidence of 
benefits. 
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8.3 Methods 
8.3.1 Working definitions for adverse events 
In order to describe and analyse safety issues that may be associated with cisapride and 
domperidone, AEs are classified into those that are already known, and those previously 
unknown side-effects (or AEs). Previously-unknown AEs are subdivided into those that were 
explicitly recorded as adverse events, and those that were implicitly recorded (as clinical 
events). Because metoclopramide was originally included as part of GORMET, the working 
definitions reflect this. The results for metoclopramide are omitted from this thesis but 
presented in full in the GORMET report (Mt-Isa, 2010). 
 
a. Previously-known adverse events 
i. Recorded AEs: There are three recorded adverse outcomes in the GP records. 
These are allergy to drugs, intolerance to drugs, and deaths. Although deaths are 
not recorded as an adverse drug reaction, they are explicitly recorded and therefore 
classified as recorded outcome here. For this reason we also describe recorded 
deaths among those who were prescribed cisapride or domperidone as part of 
“recorded AEs”. 
 
ii. Recognised and possible AEs: BNF 53 (Joint Formulary Committee, 2007) was 
used to define recognised AEs for domperidone and metoclopramide from the list 
of side-effects of the drug; and those listed in BNF 39 (Joint Formulary 
Committee, 2000) as side-effects for cisapride were defined as recognised AEs for 
the drug. Let               (            ) be the elements in AEs sets   which 
contain recognised AEs for cisapride (C), domperidone (D), and metoclopramide 
(M) respectively. Then we write these as                 .  
 
Thence,   {     |    }     {    |    }  and    {    |    } are 
the possible AEs for cisapride, domperidone and metoclopramide respectively. 
However, analyses with regards to metoclopramide are omitted throughout this 
thesis.  
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b. Previously-unknown adverse events 
iii. Signals for potential ADRs are clinical events recorded during a clinic visit that 
have not yet been recognised as side-effects for cisapride, domperidone, and 
metoclopramide. Let    be the raised signals for potential ADRs for drug    then 
  {  (     )}  where U denotes the universal set of all clinical events 
recorded on GP data for the selected cohorts. 
 
8.3.2 Development of signal detection algorithm for use with GPRD clinical events data 
Data mining algorithms for signal detection in pharmacovigilance have been developed and 
applied in many countries. The main ones have been introduced in Section 8.1. The intention 
here is not to develop a new algorithm of the sort, but to implement a chosen data mining 
algorithm (e.g. PRRs) in this new setting. Therefore, the signal detection algorithm to be 
presented here consists of a finite proposition of steps that are required to meet the aims and 
objectives specified in Section 8.2 above. Figure 8.1 summarises the signal detection 
algorithm. 
 
Step 1: Initial data setup, and analyses of previously-known adverse events 
The time at risk (exposure period) for the two cohorts of children prescribed with cisapride 
and domperidone are matched by their time period to their matched unexposed children as 
described in Section 3.4. Any exposed child without a matched unexposed child and vice 
versa were excluded. Scenario 3 (Section 3.5.1) of the time at risk for exposed patients was 
used as it has the most suitable assumptions in this situation. It assumes that when prescribed, 
a child would adhere to the drug therapy for the duration of the therapy; and that an adverse 
drug reaction could occur during the therapy duration or within a week after therapy ends. 
Any event outside the defined risk period was assumed to be unrelated to the drugs. 
 
Adverse events that were already known (recorded, recognised, and possible AEs) should be 
excluded from the data set to be used for signal detection. There are two advantages for doing 
this. First, in line with good practice in pharmacovigilance, by excluding these events the 
denominators would not be inflated by their presence. Therefore the data have greater ability 
to raise other signals that are not yet known. The second advantage is from the mechanics 
point of view that is smaller data sets are much easier to process. 
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Broad keywords from the previously-known AEs were searched in the MedDRA lowest level 
term (LLT) fields in the dataset, e.g. “prolactinaemia” was searched as “prolactin”. All 
resultant MedDRA-LLTs were reviewed for their relevance to the adverse events described. 
Non-relevant terms were excluded. Additionally, NHS CT Browser was also searched using 
the keywords and the associated Read codes were extracted. The associated Read codes were 
also used to search for previously-known AEs in the data sets.  
 
The previously-known adverse events were then analysed to give the idea of how GPRD data 
record them, and the risks associated with cisapride and domperidone were described. They 
were then excluded from the dataset to be used in signal detection. 
 
Step2: Data setup for hypothesis testing and validation 
The Read clinical classification codes (Read codes) of the clinical events within the exposure 
period for exposed and unexposed children were truncated at 3-byte. For example, Read 
codes “R 9  ” for “[D]Abdominal colic” was truncated to “R 9” which is the higher 
hierarchy for “[D]Other abdominal and pelvic symptoms”. Read codes that were already 
recorded at 3-byte e.g. “  J” for “O/E – dead” won’t be affected, but its lower hierarchies 
would also be truncated to “  J”. Read codes that were originally recorded shorter than 3-
byte e.g. “R ” for “[D]Symptoms” in essence are also not affected, but treated as “R .” 
consistent with the notation used in the NHS Clinical Terminology (CT) Browser. Therefore, 
“R .” is truncated at  -byte and does not include its descendants. This assumes that a too 
general recorded clinical event does not add any value to the signal detection algorithm, 
unless they are found to be in excess at that level. 
 
Exposed children were then randomly split into two data sets based on the patient identifiers 
taking into account the age at first prescription and the number of their matched unexposed 
children to ensure balance. With probability of 0.5, one dataset was randomly selected and 
assigned to be the Test data, and the other one was assigned to be the Validation data. Their 
matched unexposed children naturally followed. Stata codes snippets for data split are given 
in Appendix A.6.1. 
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Step 3: Hypothesis testing 
Using the Test data, PRRs were applied to each truncated Read codes as described in Section 
3.7. The Read codes that were found to be disproportionate at 95% significance level using 
   tests with at least three recorded cases were hypothesised to be candidate signals for 
potential ADRs. Stata codes snippets to calculate PRRs are given in Appendix A.6.2. 
 
As previously acknowledged, these candidate signals were nonclinical and were only based 
on statistical principle of disproportionality given the data and assumptions. Therefore, we 
subjected the candidate signals to clinical experts’ evaluation.  
 
Step 4: Evaluation of raised signals 
The panel of clinical experts for GORMET consisted of a consultant paediatric 
gastroenterologist (Dr. Nick Croft), a chair in primary care research, a consultant pharmacist, 
and an honorary consultant in child health. Professor Deborah Ashby and I participated in the 
meeting to go through the candidate signals raised from PRRs. Based on the discussion, some 
signals were excluded and the rests were deemed to be potentially feasible to be associated 
with cisapride or domperidone therapy. 
 
The candidate signals that passed our clinical experts’ evaluations were then explored further. 
We examined their actual Read codes (as recorded by GPs) and made further exclusions 
where necessary, and regroup them into more descriptive categories (“signal groups”). Using 
keywords from the category names, the Read codes description, and appropriate truncations 
and wild cards, I search for other associated Read codes in the NHS CT Browser that were 
described by the categories. A list of other associated Read codes were reviewed and agreed 
by GORMET clinical experts. The final lists of Read codes (listed in Table 8.5) were then 
used to validate the hypothesis that the signal groups were present in excess relative to the 
data available. 
 
Step 5: Hypothesis validation 
The signal groups were validated in the Validation data via the Read codes. To make better 
use of the patient-level data, number of events in each signal group was counted for each 
child during the exposure period. Random-effects Poisson regression (Section 3.6.2) was 
performed on the signal groups in turn to estimate the incidence rates ratio among those who 
were exposed when compared to those who were not exposed to cisapride or domperidone. 
Part II: Evidence data mining and verification using longitudinal routine healthcare data 
Chapter 8 | 191  
 
The regressions were adjusted for time of exposure within patients. Further adjustment for 
age and sex were made using forward stepwise regressions. Best model was selected for each 
outcome. 
 
Signal groups with incidence rates ratios that reached 95% statistical significance level were 
then confirmed to be in excess, and selected for further confirmatory analysis in case-controls 
setting to learn more about the effects of other covariates. As a rule of thumb, death events 
were also selected to be investigated further in case-controls studies regardless of the IRRs. 
 
Figure 8.1 Signals detection and validation algorithm flow diagram 
 
  
Split data into two 
halves: (1) Test data, (2) 
Validation data 
Set Validation data 
aside 
Apply PRRs to truncated 
Read codes in Test data 
Some signals generated 
Signals checked for 
relevance by clinicians 
Relevant signals are 
grouped as necessary 
Test hypothesis of 
excess events using 
random effects Poisson 
regression in Validation 
data set 
Confirmed signals i.e. 
statistically significant 
at 95% level 
Confirmed signals 
investigated further in 
case-control studies 
adjusting for covariates 
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8.3.3 Further confirmatory analysis under case-controls design 
Signals for potential ADRs that were confirmed from the five-step algorithm above were 
investigated further in nested case-controls studies. Effects of three variables were 
investigated: dosage of prescriptions, concomitant use of other drugs known to be associated 
with the signals, and underlying concomitant illnesses. 
 
In terms of dosage of prescriptions, I present the effects of increasing cumulative dose by 
50%. Cumulative dose is chosen here because evidence from trends analysis in Chapter 6 
suggests that domperidone was prescribed with increasing frequency and longer duration. 
Mean daily doses however were generally low for domperidone and in line with the guideline 
for cisapride. For this reason, I do not present the results from the investigation of daily dose 
in this thesis. Initially, univariable conditional logistic regressions were performed to 
determine the signals association with increasing dose. A sensitivity analysis was performed 
by excluding children who had any prescription of other drugs that antagonise the effects of 
cisapride or domperidone (obtained from the BNF, see Section 8.3.1 for respective BNF 
editions) because concomitant use of these drugs may alter the pharmacokinetics of cisapride 
or domperidone. In effect, children who were on drug antagonists would have different risks 
to those who were not. The regression model for conditional logistic regression used in this 
chapter was described in Section 3.6.2. 
 
There are drugs that are already known to be associated with certain clinical events. We used 
DRUGDEX® System (Thomson Reuters (Healthcare) Inc., 2010) to perform “reverse” 
search for drugs with a specified side-effect. The drugs lists were then compiled and used to 
identify children who were using them concomitantly with cisapride or domperidone. If we 
found them to be statistically significant at 95% level in the univariable analysis, we then 
performed multivariable analysis of cisapride or domperidone cumulative dose adjusted for 
their concomitant use. Children who were prescribed with drugs that antagonise the effects of 
cisapride or domperidone as previously described were excluded from multivariable analyses. 
 
It was our initial intention to develop a strategy to study concomitant illnesses in the children 
population that may confound the effect of domperidone. However, because GORD 
symptoms have been associated with variety of other illnesses, it was inefficient for us to 
specify a priori a list of concomitant illnesses which may be associated to signals with the 
resources available. The signals themselves might also be associated with variety of other 
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illnesses, thus a simple task such as making a list of concomitant illness became more 
difficult (and not robust or reproducible because it would be dependent on the clinical experts 
producing the list). Because individual circumstances differ, and that the same illnesses or co-
morbidities may affect another individual differently, we anticipated that this task would be 
laborious. Considering these points, we ruled out the worthiness to develop such list for this 
study.  
 
The obvious way forward was to manually assess every clinical event for each child who 
experienced the signal for a potential ADR. To put the clinical events into context, we split 
the events into those occurred before and after the first prescription of the suspected drug 
(e.g. domperidone) leading up to the first occurrence of the signal. Every clinical event was 
evaluated and any concomitant illnesses that were clinically related to the signal were 
identified. Based on what is known about the medical conditions, we judged whether the 
signal could still be associated with prescription of domperidone in the presence of 
concomitant illnesses, or whether it was mainly due to the generally poor health state of the 
child. This approach was still difficult in practice. I only illustrate how concomitant illnesses 
can be addressed through one of the confirmed signals, selected because of feasibility and out 
of clinical interest (see Section 8.4.5.2). 
 
8.4 Results 
The results for adverse events that were already known to be associated with cisapride and 
domperidone are described and quantified in Sections 8.4.1 and 8.4.2. However, because of 
the nature of the drugs being prescribed off-label in children, the known adverse events 
associations were mostly established in adults. Some of them have also been observed in 
children in previous trials – the narrative review in Chapter 5 highlighted them. 
 
8.4.1 Previously-known recorded adverse events 
Among the children who were prescribed with cisapride or domperidone, 9.8% (147/1497) 
and 0.5% (44/9319) had recorded AEs respectively. The medians age for children with 
recorded AEs were 5.1 (IQR 1.7 – 9.4) and 8.1 (IQR 2.2 – 15.1) years old for cisapride and 
domperidone respectively.  
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Only 10% (14/142) had AEs recorded within the cisapride exposure timeframe. Possible 
reasons of intolerance and allergy within this period were recorded in three children on 
cisapride therapy as “allergic drug reaction”, rash, and vomiting. Among children on 
domperidone therapy, 44% (4/9) had AEs recorded within the domperidone exposure 
timeframe – tremor and urticaria were recorded in two children as possible reasons. 
 
Additionally, five deaths were recorded among children on cisapride therapy; where one was 
recorded within the cisapride exposure timeframe for a six-month old girl in 1997. Thirty-five 
deaths were recorded among children on domperidone therapy between 2000 and 2006; 
where 42.9% (15/35) were recorded within the time of exposure to domperidone. The age and 
sex for children who died within the exposure period of domperidone are given in Table 8.1. 
 
The recorded death for children on domperidone demonstrates an interesting but questionable 
pattern. None of the deaths in these children were recorded before year 2000. This may 
trigger an alert about safety of domperidone, but this may also be due to the quality of death 
records in the GPRD in the earlier years. Although the number of deaths (Figure 8.2) and 
rates of deaths per 10,000 children on domperidone therapy (Figure 8.3) were relatively low, 
the data show that deaths are increasing over time. Death is investigated further in case-
control studies to learn more about individual circumstances (Section 8.4.5.2). 
 
Table 8.1 Age and sex for children on domperidone therapy who died within domperidone exposure 
period 
Year of death Age (Sex, M=Male F=Female) 
2002 17.7 (M) 
2003 0.5 (M), 5.9 (F) 
2004 1.8 (F), 13.9 (F), 15.5 (F), 15.9 (M) 
2005 2.6 (F), 3.1 (M), 16.0 (F) 
2006 0.8 (F), 1.0 (F), 1.8 (F), 4.4 (F), 7.6 (M) 
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Figure 8.2 Stacked bar graph of the number of children who died, were allergic or intolerant to cisapride 
or domperidone by year 
 
 
Figure 8.3 Stacked bar graph of the rates per 10,000 children who died, were allergic or intolerant to 
cisapride or domperidone by year 
 
Note that the two vertical axes (“rates per   ,    children on therapy”) do not share common scale  
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8.4.2 Previously-known recognised and possible adverse events 
As defined in Section 8.3.1, previously-known recognised and possible adverse events were 
extracted from the sources mentioned (Joint Formulary Committee, 2000; Joint Formulary 
Committee, 2007). The recognised and possible AEs are represented in the Venn diagram in 
Figure 8.4 where the reactions listed within the square for a drug are the recognised AEs for 
the particular drug, and those outside the square are the possible AEs. 
 
The rates per thousand and the associated number of children with particular adverse events 
are given in Table 8.2. Among the recognised adverse events, we were only able to quantify 
seven for cisapride, and three for domperidone (Table 8.3). Of the seven quantifiable 
recognised AEs for cisapride, only “convulsions” reached 95% statistical significance level. 
The data also suggested that cisapride had protective effect against “diarrhoea” and “rashes”. 
All three quantifiable recognised adverse events for domperidone – “cramps”, 
“extrapyramidal effects”, and “rashes” – reached 95% statistical significance level.  
 
We were unable to observed any statistically significant (at        level) possible adverse 
events for cisapride; but nine of those for domperidone were statistically significant at 95% 
level. The possible adverse events significantly (at        level) associated with 
domperidone were “anxiety”, “arrhythmias”, “bronchospasms”, “convulsions”, “depression”, 
“diarrhoea”, “drowsiness”, “headaches”, and “light-headedness”. 
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Figure 8.4 Recognised and possible adverse drug reactions for cisapride, domperidone, and 
metoclopramide 
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Table 8.2 Rates per 1,000 person-months (number of events) for previously-known adverse reactions for 
cisapride and domperidone 
 Cisapride
a 
Domperidone
a 
 Exposed Unexposed Exposed Unexposed 
(Abdominal) cramps 0.00 (0) 0.04 (1) 0.42 (9) 0.02 (1) 
Anxiety 0.35 (3) 0.21 (6) 2.50 (53) 0.27 (17) 
Arrhythmias 0.00 (0) 0.04 (1) 0.19 (4) 0.03 (2) 
Bronchospasm 0.00 (0) 0.14 (4) 0.24 (5) 0.03 (2) 
Convulsions 1.06 (9) 0.28 (8) 0.71 (15) 0.31 (20) 
Depression 0.47 (4) 0.11 (3) 2.83 (60) 0.36 (23) 
Diarrhoea 5.65 (48) 10.40 (294) 32.12 (681) 10.28 (653) 
Drowsiness 0.24 (2) 0.07 (2) 0.14 (3) 0.02 (1) 
Extrapyramidal effect 0.12 (1) 0.00 (0) 0.42 (9) 0.05 (3) 
Headaches 0.35 (3) 0.50 (14) 16.70 (354) 0.98 (62) 
Light-headedness 0.00 (0) 0.04 (1) 0.90 (19) 0.16 (10) 
Oedema 0.35 (3) 0.07 (2) 0.38 (8) 0.19 (12) 
Pruritus 0.24 (2) 0.50 (14) 0.61 (13) 0.31 (20) 
Rashes 4.24 (36) 11.25 (318) 16.09 (341) 14.20 (902) 
Urinary Frequency 0.24 (2) 0.18 (5) 0.33 (7) 0.13 (8) 
Urticaria 0.71 (6) 1.56 (44) 0.75 (16) 0.60 (38) 
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Table 8.3 Incidence rates ratios (95% confidence intervals) for previously-known adverse reactions for 
cisapride and domperidone 
 Cisapride
a 
Domperidone
a 
(Abdominal) cramps .n/e* 21.32 (2.70, 168.53)*
 †
 
Anxiety 1.08 (0.23, 5.13) 7.96 (4.61, 13.76)
 †
 
Arrhythmias .n/e* 6.42 (1.17, 35.10)
 †
 
Bronchospasm .n/e* 8.02 (1.55, 41.38)
 †
 
Convulsions 4.74 (1.60, 14.04)*
† 
2.46 (1.26, 4.81)
 †
 
Depression 1.82 (0.36, 9.20) 6.22 (3.84, 10.06)
 †
 
Diarrhoea 0.60 (0.43, 0.83)*
‡ 
3.27 (2.94, 3.65)
 †
 
Drowsiness 2.76 (0.31, 24.71) 9.89 (1.03, 95.08)
 †
 
Extrapyramidal effect .n/e* 9.25 (2.50, 34.25)*
 †
 
Headaches 0.98 (0.25, 3.79)* 14.27 (10.89, 18.69)
 †
 
Light-headedness .n/e* 4.77 (2.21, 10.27)
 †
 
Oedema 2.07 (0.25, 16.90) 1.94 (0.79, 4.77) 
Pruritus 0.40 (0.08, 1.89)* 1.89 (0.94, 3.81) 
Rashes 0.35 (0.24, 0.50)*
‡ 
1.24 (1.09, 1.40)*
 †
 
Urinary Frequency 1.33 (0.22, 8.08)* 2.40 (0.87, 6.63) 
Urticaria 0.49 (0.20, 1.19)* 1.30 (0.73, 2.34) 
a 
Incidence rates ratio of exposed vs. unexposed from random-effects Poisson regression, adjusted for practice 
regions, age and sex.  
“ n/e” represents Non-estimable in regression due to very small numbers. 
* marked the recognised AEs whilst those without are the possible AEs.  
†
 AE is significant at 95% level. 
‡
 AE is significant at 95% level but in the opposite direction (protective effect). 
Known reactions that were not observed in both cohorts were excluded from the table. 
 
8.4.3 Previously-unknown signals for potential adverse drug reactions 
The characteristics of Test and Validation data in terms of proportions and number of 
children by age group are given in Table 8.4. Test and Validation data sets for domperidone 
were well-balanced, but those for cisapride were not. However, the mean and standard 
deviation summary of age at first prescription by age group were reasonably balanced 
between the Test and Validation data sets for cisapride and domperidone. 
 
Proportional reporting ratios technique (Evans, 2001) raised 19 signals for cisapride, and 46 
signals for domperidone. Following clinical evaluations, 37% (7/19) and 50% (23/46) were 
dismissed as signals for cisapride and domperidone respectively (Figure 8.5). After further 
evaluation, regrouping (Table 8.5) and hypothesis testing, two signals for cisapride and ten 
for domperidone were statistically significant at 95% level (Table 8.6).  
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Table 8.4 Percentage (number of children) by age group in the Test and Validation data sets 
 Cisapride Domperidone 
 % (n) 
Age in years, 
mean (SD) 
% (n) 
Age in years, 
mean (SD) 
Test data     
<2 years old 63 (165) 0.6 (0.4) 43 (600) 0.6 (0.4) 
≥  years old 37 (95) 8.3 (4.4) 57 (788) 12.6 (4.9) 
Validation data     
<2 years old 71 (138) 0.6 (0.4) 44 (559) 0.6 (0.4) 
≥  years old 29 (56) 7.8 (4.2) 56 (709) 12.9 (4.6) 
 
Figure 8.5 Signals processing flow chart for cisapride and domperidone 
Cisapride 
 
Domperidone 
 
See Appendix A.4 for details of signals raised and those preliminarily excluded by clinical judgement 
  
19 signals  
raised 
•Two GOR related codes excluded 
•Two comorbidity codes excluded 
•Two procedure codes excluded 
•One general code excluded 
12 signals 
investigated 
•One 3-byte signal excluded because 
too broad on that level; and not 
enough cases (<3) on examination of 
individual lower level codes 
10 groups 
identified 
•Seven groups did not achieve 95% 
statistical significance 
•One signal (coughing) was significant 
in favour of cisapride 
2 groups 
confirmed 
•Two signal groups confirmed to be 
investigated further in case-controls 
analyses 
•Coughing was also investigated 
further in case-controls study as an 
endpoint of clinical interest 
46 signals 
 raised 
•Three GOR related codes excluded 
•Six comorbidity codes excluded 
•12 procedure codes excluded 
•Two administrative codes (sociological 
status) excluded 
23 signals 
investigated 
•One 3-byte signal excluded on 
examination of lower level codes 
because of known association with 
domperidone 
21 groups 
identified 
•11 groups did not achieve 95% 
statistical significance 
10 groups 
confirmed 
•Ten signal groups confirmed to be 
investigated further in case-controls 
analyses 
Part II: Evidence data mining and verification using longitudinal routine healthcare data 
Chapter 8 | 201  
 
Table 8.5 Read codes associated with identified signals from cisapride and domperidone by signal group 
Signals group Associated Read Codes 
Abdominal pain group (any of the subgroups below) 
Constipation J520 19C E2645  
Gastritis and duodenitis J15 J4z J43  
GIT Colic 1962 1965 1966 R0901 R0902 
Indigestion symptoms 195 J16y4 R071  
Other GI pain 
196 (excluding 1961 1962 1965 1966) 197 F2622 J52 
R090 (excluding R0901 R0902) 25C 
Anorexia and weight loss R030 R032 1612 E271 1D1A 1625 
Bronchitis and bronchiolitis H06 H30 H31  
CAT scan 567 
Chest X-ray 535 536 68C1 ZV725 
Coughing R062 171 (excluding 1711) A33 E2611 Ey435 173B  
Death 22J R21 8HG G5751 949  
Dysmenorrhoea K583  
Dysphagia R072 194 (excluding 1941)  
Epilepsy F25 1O30  
Flatulence, eructation and gas pain R073  
Infectious colitis, enteritis and 
gastroenteritis 
A080 A081  
Influenza vaccination 65E  
Local infection of skin NOS M07yz M07z 
Migraine F26 (excluding F2622) 
Osteoporosis N330 N3313 N3315 N3316 N3318 N3319 N331A  
Other digestive symptoms R07z 19D (excluding 19D1)  
Physiological development failure R034 2291 22A1 
Pneumonia H26 AB24 H5302 H5303  
Polydipsia R035 1644 1645 
Post-coital contraception 61A 61F 614F  
Sleep disorders E274 Fy0 1B1Q R005 Eu51 H5B 
Urinary tract infection Q40y1 K190 
Wound exudates 4I2D 
See GORMET report (Mt-Isa, 2010) for more detailed description of Read codes used   
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Table 8.6 Incidence rates ratios (95% confidence intervals) of experiencing events in signal groups for 
being exposed to versus not being exposed to cisapride or domperidone from Validation dataset 
Signals group Cisapride
a 
Domperidone
a 
Abdominal pain
 
1.10 (0.57, 2.14)
c 
5.68 (4.16, 7.77)
b †
 
Constipation 0.90 (0.35, 2.28) - 
Gastritis and duodenitis - n/e 
GIT Colic
 
1.14 (0.35, 3.69) 2.27 (1.07, 4.84)
 †
 
Indigestion symptoms - n/e 
Other GI pain 3.41 (1.57, 7.43)
b† 
6.62 (4.77, 9.19)
bc†
 
Anorexia and weight loss - 4.10 (1.83, 9.16)
 b†
 
Bronchitis and bronchiolitis 1.53 (1.11, 2.11)
 † 
3.71 (3.07, 4.48)
 bc†
 
CAT scan - n/e 
Chest X-ray n/e - 
Coughing 0.55 (0.35, 0.84)
bc‡
 - 
Death
 
- n/e 
Dysmenorrhoea - 5.58 (1.88, 16.52)
 b†
 
Dysphagia - n/e 
Epilepsy - 16.90 (3.84, 74.39)
 †
 
Flatulence, eructation and gas pain - n/e 
Infectious colitis, enteritis and 
gastroenteritis 
- 1.09 (0.34, 3.53) 
Influenza vaccination - 10.97 (2.37, 50.76)
 †
 
Local infection of skin 1.92 (0.43, 8.57) - 
Migraine - 32.96 (12.10, 89.80)
 b†
 
Osteoporosis - n/a 
Other digestive symptoms n/a - 
Physiological development failure - 3.25 (0.73, 14.51) 
Pneumonia - 14.69 (1.77, 122.05)
 †
 
Polydipsia - n/e 
Post-coital contraception - 8.11 (2.40, 27.37)
 b†
 
Sleep disorders - 2.59 (1.21, 5.51)
 †
 
Urinary tract infection 1.70 (0.28, 10.20) - 
Wound exudates n/a - 
a
 Incidence rates ratios adjusted for time of exposure, 
b
age, and/or 
c
sex (best model fit).  
 “n/e” indicates that IRRs were non-estimable in regression due to very small numbers; “n/a” indicates that 
signal group was raised in Test data but not observed in Validation data; “-” indicates that signal group was not 
raised for that drug in Test data. 
†
 Signal group is significant at 95% level 
‡
 Signal group is significant in the opposite direction (protective effect). 
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The confirmed signals for potential ADRs in Table 8.6 were further classified into 
MedDRA’s system organ class (SOC). Due to the multi-axial property of MedDRA, certain 
signals may come under more than one SOC in the MedDRA terminology dictionary. We 
used clinical judgement to determine the most likely SOC classification for these signals with 
respect to the population in question. 
 
The classifications into MedDRA-SOC clarify the origin of the signals from clinical point of 
view (Figure 8.6). The choices were made based on what is already known about the drugs 
and the characteristics of children with GORD. The classifications can be used to help focus 
the discussion and arguments on causality (see Section 8.5).  
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Figure 8.6 Signals for potential ADRs and MedDRA system organ classes 
 
Legend:   
Signals for potential ADRs 
System organ class 
  
More likely classification 
Less likely classification 
a
 Coughing was not a “real” signal because it was statistically significant in the opposite direction 
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8.4.4 Effects of cumulative dose on confirmed signals 
Number of children included in the case-control analyses of signals for potential ADRs are 
shown in Table 8.7 and Table 8.8 for cisapride and domperidone respectively against their 
matched controls. The same case-control populations were used in analyses in the following 
Section 8.4.5. 
 
Table 8.9 and Table 8.10 show the odds ratios and 95% confidence intervals for the effect of 
increasing dose of cisapride and domperidone by 50% respectively.  
 
Bronchitis and bronchiolitis, and coughing were significantly associated with increasing 
cumulative dose of cisapride for all children at 95% level (Table 8.9). 
 
For domperidone, only the signal for bronchitis and bronchiolitis was statistically significant 
at 95% level where every 50% increase in cumulative dose of domperidone prescribed, the 
odds ratio of bronchitis and bronchiolitis was increased by 27% (95% OR CI 1.14 – 1.41). In 
the older group of children, abdominal pain, other GI pain, bronchitis and bronchiolitis, and 
epilepsy were significantly associated with increasing cumulative dose of domperidone. For 
all children, additional to those statistically significant in the subgroups, signals for anorexia 
and weight loss, death, influenza vaccination, pneumonia, and sleep disorders were also 
significantly associated with cumulative dose of domperidone (Table 8.10). 
 
The signals found to be statistically significant overall for each drug were then investigated 
further in multivariable conditional logistic model adjusted for use of other drugs that are 
known to be associated with the signals, where applicable (see Section 8.4.5.1 below). 
 
Sensitivity analyses described in Section 8.3.3 were performed but did not materially alter the 
odds ratios so were not presented here; but can be found in the GORMET study report (Mt-
Isa, 2010). 
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Table 8.7 Number of cases and controls by age group and signal for potential ADRs of cisapride 
 < 2 years old ≥   years old 
 Cases Controls Cases Controls 
Other GI pain
a 
2 8 21 57 
Bronchitis and bronchiolitis 46 116 24 64 
Coughing
b 
32 92 26 64 
 
Table 8.8 Number of cases and controls by age group and signals for potential ADRs of domperidone 
 < 2 years old ≥   years old 
 Cases Controls Cases Controls 
Abdominal pain 363 411 512 2036 
GIT colic 10 30 6 22 
Other GI pain
a 
14 46 105 419 
Anorexia and weight loss 10 34 14 56 
Bronchitis and bronchiolitis 160 469 95 302 
Death 7 25 3 12 
Dysmenorrhoea n/a n/a 13 52 
Epilepsy 13 36 18 55 
Influenza vaccination 5 19 9 29 
Migraine 6 24 35 140 
Pneumonia 5 20 8 25 
Post-coital contraception n/a n/a 9 36 
Sleep disorders 8 26 7 28 
 
Table 8.9 Odds ratios (95% confidence intervals) of observing a confirmed signal for every 50% increase 
in cumulative dose of cisapride from conditional fixed effect logistic regressions 
 < 2 years old ≥   years old Overall 
Other GI pain
a 
1.03 (0.32, 3.33) 1.14 (0.96, 1.37) 1.14 (0.96, 1.36) 
Bronchitis and bronchiolitis 1.18 (1.00, 1.38)
† 
1.62 (1.21, 2.16)
†
 1.32 (1.16, 1.50)
†
 
Coughing
b 
1.91 (1.38, 2.65)
†
 1.70 (1.25, 2.30)
† 
1.80 (1.44, 2.26)
† 
a
 not including constipation, gastrointestinal colic, and indigestion symptoms 
b
 IRR of exposed versus unexposed from original signal was in the opposite direction 
†
 statistically significant at 95% level  
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Table 8.10 Odds ratios (95% confidence intervals) of observing a confirmed signal for every 50% increase 
in cumulative dose of domperidone from conditional fixed effect logistic regressions 
 < 2 years old ≥   years old Overall 
Abdominal pain 0.96 (0.90, 1.04) 1.28 (1.23, 1.34)
†
 1.20 (1.16, 1.24)
†
 
GIT colic 0.69 (0.43, 1.09) 2.31 (0.24, 4.38) 1.08 (0.85, 1.38) 
Other GI pain
a 
1.09 (0.77, 1.54) 1.34 (1.22, 1.46)
†
 1.32 (1.22, 1.44)
†
 
Anorexia and weight loss 1.34 (0.85, 2.12)
 
1.38 (0.97, 1.96)
b 
1.34 (1.06, 1.69)
†
 
Bronchitis and bronchiolitis 1.27 (1.14, 1.41)
†
 1.96 (1.64, 2.34)
†
 1.51 (1.39, 1.65)
†
 
Death 2.62 (0.92, 7.47) 2.45 (0.81, 7.43) 2.91 (1.09, 7.79)
†
 
Dysmenorrhoea n/a See overall
c 
1.34 (0.93, 1.94) 
Epilepsy 1.01 (0.73, 1.40) 3.08 (1.41, 6.74)
†
 1.56 (1.21, 2.02)
†
 
Influenza vaccination 0.83 (0.51, 1.37) n/e
 
1.58 (1.13, 2.23)
†
 
Migraine n/a 1.19 (0.96, 1.48)
b
 1.11 (0.93, 1.34) 
Pneumonia 1.27 (0.70, 2.32) 2.04 (0.91, 4.58) 1.63 (1.10, 2.43)
†
 
Post-coital contraception n/a See overall
c 
1.12 (0.81, 1.57) 
Sleep disorders 1.67 (0.89, 3.13) 7.00 (0.11, 435.90) 2.24 (1.29, 3.86)
†
 
a 
not including gastritis and duodenitis, gastrointestinal colic, and indigestion symptoms 
b
 only restricted to, or 
c
 only observed in children over 12 years old 
 “n/a” indicates that the signal was not observed in that age group; and “n/e” indicates that model did not 
converge due to small numbers 
†
 statistically significant at 95% level 
 
8.4.5 Effects of other factors on confirmed signals 
8.4.5.1 Effects of concomitant use of other drugs with known positive associations to the 
signals  
Using DRUGDEX®, we identified drugs that are recognised to have bronchitis and 
bronchiolitis, coughing, abdominal pain (general), anorexia and weight loss, bronchitis and 
bronchiolitis, epilepsy, or pneumonia as their recognised adverse reactions. For signal “other 
GI pain”, we used the list as that for general abdominal pain for simplicity. 
 
The results for univariable analysis of these other drugs, together with multivariable analyses 
(see Section 8.3.3; and Section 3.6.2 for general description of the models) results with 
cumulative dose, where applicable, are presented in Table 8.11 and Table 8.12 for cisapride 
and domperidone respectively. The effects of cumulative dose when random effect logistic 
regressions are used are given in Appendix A.8 but did not materially alter the results.  
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Table 8.11 Odds ratios (95% confidence intervals) of observing a confirmed signal for every 50% increase 
in cumulative dose of cisapride further adjusted for concomitant use of other drugs for all children 
 Cumulative dose
c 
Other drugs
c 
Other drugs
d 
Other GI pain
a 
- - 2.82 (1.04, 7.64)
† 
Bronchitis and bronchiolitis 1.28 (1.11,1.46)
† 
5.83 (1.75,19.47)
†
 9.43 (3.03, 29.35)
†
 
Coughing
b 
1.75 (1.40, 2.19)
† 
1.65 (0.67, 4.04)
 
 2.60 (1.24, 5.44)
†
 
a
 not including constipation, gastrointestinal colic, and indigestion symptoms 
b
 IRR of exposed versus unexposed from original signal was in the opposite direction 
c
 from multivariable, and 
d
 univariable conditional logistic regressions 
 “-” indicates that multivariable analysis was not performed 
†
 statistically significant at 95% level 
 
Table 8.12 Odds ratios (95% confidence intervals) of observing a confirmed signal for every 50% increase 
in cumulative dose of domperidone further adjusted for concomitant use of other drugs for all children 
 Cumulative dose
c 
Other drugs
c 
Other drugs
d 
Abdominal pain 1.15 (1.11,1.20)
† 
2.26 (1.85,2.76)
†
 2.66 (2.21, 3.21)
†
 
GIT colic - - n/a 
Other GI pain
a 
1.28 (1.17, 1.39)
† 
1.85 (1.16, 2.96)
† 
2.83 (1.87, 4.28)
† 
Anorexia and weight loss
b 
- 
- 
3.15 (0.43, 23.36) 
Bronchitis and bronchiolitis 1.43 (1.31,1.57)
†
 3.72 (1.81,7.64)
†
 7.33 (4.14, 12.99)
†
 
Dysmenorrhoea
b 
- - n/a 
Epilepsy - - n/a 
Migraine
b 
- - n/a 
Pneumonia 1.56 (0.95, 2.57) 0.84 (0.06, 11.94) 10.28 (1.21, 87.62)
 †
 
a 
not including gastritis and duodenitis, gastrointestinal colic, and indigestion symptoms 
b
 restricted to children over 12 years old due to the clinical nature of the event 
c
 from multivariable, and  
d
 univariable conditional logistic regressions 
 “n/a” indicates that other drugs with known association to the respective signal was not observed; and “-” 
indicates that multivariable analysis was not performed 
Death, influenza vaccination, post-coital contraception, and sleep disorders were omitted because we did not 
feel it was clinically relevant to enlist other drugs with known associations to these signals 
†
 statistically significant at 95% level 
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8.4.5.2 Investigations into individual concomitant illnesses for death outcome: an 
illustration of the proposed process 
Careful examination of the children’s clinical record (see Appendix A.9) showed that the 
children who died were generally sicker and some had been diagnosed with known fatal 
illnesses either before or after the first prescription of domperidone. These include Krabbe’s 
disease
13, Edward’s syndrome Trisomy 1814, Williams’s syndrome15, chronic obstructive 
airways disease, congenital cardiovascular disorders, anoxic brain damage
16
, and 
lissencephaly
17
.  
 
Examination of clinical events closer to date of death suggests that the causes might include 
difficulty in breathing, cardio-respiratory failure, congestive heart failure, MRI-related 
conditions, chest infection, viral illness, shortness of breath leading to terminal care, 
pneumonia, and possible wound. The true underlying cause of death was, of course, 
unknown. The matched controls did not have any of the fatal illnesses mentioned above 
recorded during the same time period. 
 
Therefore, our case-control analyses of deaths established that children who died whilst on 
domperidone therapy were sicker than their matched controls, and that deaths could not be 
attributed to the use of domperidone. Because of poorer health and that the symptoms of 
some of the illnesses such as vomiting and seizure-like events – which might be the reason 
                                                 
13
 Krabbe’s disease is an inherited degenerative disorder of the central and peripheral nervous system which is 
generally fatal before age two years old. Symptoms include irritability, stiffness, seizures, feeding difficulties, 
and vomiting (http://www.ninds.nih.gov/disorders/krabbe/krabbe.htm accessed on 15/09/2010)  
14
 Trisomy  8 (Edward’s syndrome) is a condition caused by chromosomal defects and life-threatening in the 
early months and years of life. Typical characteristics of Trisomy 18 include heart defects, kidney problems, 
oesophageal atresia, delayed growth, and umbilical or inguinal hernia (http://www.trisomy18.org accessed on 
15/09/2010). 
15
 Williams’s syndrome is a rare genetic disorder characterised by over-friendly personality, but can lead to 
many medical complications. The most common problem associated with Williams syndrome is cardiovascular 
disease caused by narrowed arteries. Ongoing medical monitoring is required to prolong lifespan 
(http://www.ninds.nih.gov/disorders/williams/williams.htm accessed on 15/09/2010). 
16
 Anoxic brain damage refers to damage to the brain caused by complete interruption of oxygen supply. It could 
be caused by several factors including cardiac or respiratory arrest, irregular heart rhythm resulting in inefficient 
supply of blood to the brain, suffocation, severe asthma attack, poisoning, and drug overdose 
(http://www.headway.org.uk/Hypoxic-anoxic-brain-injury.aspx accessed on 15/09/2010). 
17
 Lissencephaly (“smooth brain”) is a rare genetic brain malformation characterised by the absence of “folds” 
in the cerebral cortex and abnormally small head (microcephaly). Symptoms include difficulty swallowing, 
failure to thrive, muscle spasms, seizures and severe psychomotor retardation. Depends on the degree of the 
malformation, many children will die before the age of two years old, most commonly from respiratory disease 
or from aspiration of food or fluids (http://www.ninds.nih.gov/disorders/lissencephaly/lissencephaly.htm 
accessed on 15/09/2010). 
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domperidone was prescribed for in the first place – this could explain the positive association 
we observed with increasing dosage of domperidone. 
 
From this analysis, we conclude that deaths among children who were prescribed with 
domperidone were coincidence and most probably caused by other underlying terminal 
illnesses.  
 
8.5 Assessment of causality 
More often, the main interest in safety signals data mining is the evidence of causal linkage to 
the drugs prescribed. Disproportionality methods cannot provide this evidence. Based on the 
findings in this study so far, as well as findings from other literature, I formally assess the 
causality of the confirmed signals under the Bradford Hill causal inference, below. The nine 
criteria as laid by Sir Austin Bradford Hill (Hill, 1965) are italicised in the texts for clarity. 
 
The strength of association is the first criterion and is based on the observed associations 
from statistical analysis. Here, the odds ratios which have reached statistical significance at 
5% level in their respective analysis provide this information. Ten odds ratios ranging from 
2.6 to 33.0 are to be classified (Figure 8.7) to aid the discussions in this section. I then define 
the strength of association according to the odds ratios into four subjective categories with 
the aim to have equal number in each category. The categories defined are shown in Table 
8.13. The naming convention for the categories is chosen to be non-controversial with no 
direct implications on the epidemiology of the drug-disease causal relations. 
 
Figure 8.7 The order of odds ratios to be classified 
 
 
Table 8.13 Odds ratios by categories of strength of association 
Modest Moderate High Very high 
                                          
 
0 5 10 15 20 25 30 35
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8.5.1 Gastrointestinal disorders 
Strength of association was moderate for signals in the abdominal pain for domperidone with 
odds ratios of 5.7. Gastrointestinal colic and “other” GI pain signals for domperidone for 
domperidone, and “other” GI pain for cisapride had low, moderate, and low strength of 
associations respectively (Table 8.6). There is no robust evidence for consistency from 
previous studies. However, consistency was observed across the three cohorts of cisapride, 
domperidone, and metoclopramide (results omitted). The signals were not specific since 
gastrointestinal disorders are common medical problems and can be caused by various 
factors. The temporality criterion was met because of the restrictions we set that “signals” 
must occur within two weeks of the prescriptions. However, there may still be reverse 
causality issue since cisapride and domperidone were prescribed for gastrointestinal 
problems. The biological gradient was weak for cisapride, but it was strong for domperidone 
i.e. reached 95% significance level mainly driven by children older than two years old (Table 
8.10). The signals were plausible because the drugs may exacerbate the pre-existing 
symptoms, or it could be an indication that the drugs did not work at the given doses. 
Coherence was harder to call since there is no data on trends of paediatric gastrointestinal 
disorders by year when literature search was performed. Given more resources, it is possible 
to go back to the GPRD to extract the relevant data on all children using the Read codes list 
shown in Table 8.5. Experimental evidence from previous studies was weak (Chapter 5). 
Analogy is available in the sense that drugs that are prescribed to treat the symptoms can also 
worsen them for example in the case of prescribing selective serotonin reuptake inhibitor 
anti-depressant drugs which led to an increased risk of non-fatal self-harm when compared to 
tricyclic anti-depressants (Martinez, 2005). 
 
8.5.2 Infections and infestations 
The strength of association was modest for bronchitis and bronchiolitis (                
and                  ), and high for pneumonia with odds ratio of 14.7 (Table 8.6). 
External evidence of consistency was sparse but consistency was demonstrated across 
cisapride, domperidone and metoclopramide drug cohorts. The specificity criterion was not 
met because there are many factors such as weather that can trigger viral infection leading to 
bronchitis and bronchiolitis, and pneumonia. Temporality was met by definition. Strong 
biological gradient was observed ranging between 18% and 96% increase in odds ratios per 
50% increase in dose (Table 8.9 and Table 8.10). Increased risk of infections and infestations 
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were plausible in this generally sicker group of children. However, reverse causality cannot 
be ruled out. Children who did not respond to cisapride or domperidone treatment may 
experience severe refluxing that cause inflammation, and consequently contribute to the 
excess signals being raised. We did not find any direct evidence of coherence between the 
incidence of the signals and the prescriptions (see also Section 8.5.1). However, population-
based study in the Netherlands from the GP practices indicates that incidence of pneumonia 
was significantly increasing by 16%, 12% and 7% annually for 0-4 years old, 5-14 years old, 
and 15-24 years old respectively between 2001 and 2007 (van Gageldonk-Lafeber, 2009). 
There is no direct robust experimental evidence that linked these signals to cisapride or 
domperidone. Chapter 5 showed that infection and infestations adverse events had been 
reported (Carroccio, 1994; Cohen, 1999; Cucchiara, 1987; Greally, 1992; Scott, 1997). 
Analogy was available but unclear. Increased risks of gastroenteritis or community-acquired 
pneumonia were observed in a multi-centre trial of omeprazole, another drug also used to 
treat GOR, in children with GORD (Canani, 2006). Their choice of comparing the treated 
group to healthy controls however is questionable. 
  
8.5.3 Respiratory, thoracic, and mediastinal disorders 
Only signals for sleep disorders were in classified in this SOC, and the strength of association 
to domperidone was modest with odds ratio of 2.6 (Table 8.6). We could not find any 
evidence of consistency and did not attempt to formally analyse sleep patterns for these 
children. Sleep pattern is poorly recorded on GPRD, but it is not the same as sleep disorders 
or sleep disturbances, but may be a good proxy if the data were there. Specificity criterion 
was not met. There are many other medical conditions that can cause sleep disorders, for 
example asthma, coughing and GOR itself. Again, temporality was met by definition as these 
signals occurred within two weeks of domperidone prescription. Strong biological gradient 
was observed in the case-controls study for sleep disorders for overall children, but these 
were not statistically significant in the subset of children below two years old, and those who 
were older (Table 8.10). High variability was observed in the older group of children. The 
signals were plausible to be drug-induced; therefore domperidone is not an exception. It 
could also be caused by other infections (also a signal), therefore may be more closely related 
to the medical condition rather than the drug. Reverse causality cannot be ruled out here. 
Because sleep disorders can vary greatly in children population, coherence is harder to call 
(see also Section 8.5.1). A proper definition of sleep disorders is needed for future trial 
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monitoring this outcome. There is no direct experimental evidence that established the link 
between sleep disorders and domperidone. Previous studies have observed respiratory 
infections which are potential confounders for these signals (see Section 8.5.2). There is no 
obvious analogy of drug-induced sleep disorders. 
 
8.5.4 Nervous system disorders 
Signals classified as nervous system disorders were epilepsy and migraine. Both had very 
high strength of association to domperidone with odds ratios of 16.9 and 33.0 respectively 
(Table 8.6). We did not find any evidence of consistency from other trials because migraine 
was considered as symptoms that may lead to prescribing of domperidone; whilst epilepsy 
(which may include seizures in this case) may lead to other symptoms of GOR such as 
vomiting which may also lead to prescribing of domperidone. Signal for migraine during 
domperidone therapy was consistent with the results from the metoclopramide cohort. Since, 
migraine is also an indication for domperidone and metoclopramide as well, reverse causality 
was possible. The signals were not specific – the obvious counter-example is that it was also 
flagged up in children on metoclopramide cohort. Temporality was met by timeframe 
definition for signals. Biological gradient evidence in terms of cumulative dose was strong 
for epilepsy but weak for migraine (Table 8.10). We were disinclined to suggest that signals 
under nervous system disorders were true positive findings, but it is plausible that epilepsy 
and migraine was manifested by chance after domperidone therapy started. Nevertheless, a 
case series has suggested some positive association between intravenous domperidone and 
occurrence of grand mal seizure (Weaving, 1984). However, intravenous domperidone 
preparations were withdrawn due to high risks of cardiac arrests and arrhythmias, and were 
no longer in use during our study time period. The evidence of coherence was weak. A 
systematic review on incidence of epilepsy and unprovoked seizures between 1966 and 1999 
concluded that the incidence of epilepsy in children was decreasing over time (Kotsopoulos, 
2002). There was no experimental evidence supporting domperidone association to nervous 
system disorders. There was no analogy available for epilepsy, but for migraine it would be 
similar to the one given in Section 8.5.1. 
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8.5.5 Metabolism and nutrition disorders 
Modest strength of association was observed for signals for anorexia and weight loss with an 
odds ratio of 4.1 (Table 8.6). Evidence of consistency was not present, and anorexia and 
weight loss were not specific to being on domperidone therapy, as mentioned earlier it could 
be a general psychiatric problem. Criterion for temporality was met because they were 
defined to be within two weeks after a domperidone prescription. A strong biological 
gradient was observed for overall children with an increase of 34% for every 50% additional 
dose of domperidone, but it was weak for the subsets of younger and older children (Table 
8.10). Although anorexia could be considered as psychiatric disorders in older children, it 
was also plausible that persisting or worsening of GOR symptoms after domperidone therapy 
could be causing this. We are uncertain whether long-term domperidone therapy could 
eventually trigger anorexic behaviour in children. Weight loss in younger children may just 
be false signals and could be attributed to children with GORD not responding to 
domperidone therapy. There is very weak evidence of coherence from an observational study 
using the GPRD which found that the incidence of anorexia nervosa and bulimia nervosa in 
children aged 10-19 years old remained consistent over time (Currin, 2005). However, the 
timeframe covered by the study was between 1994 and 2000. Forward citation search did not 
yield any related study. We were not aware of and did not find any experimental evidence or 
any obvious analogy. 
 
8.5.6 Surgical and medical procedures 
Strength of association for influenza vaccination was high (       ), and moderate for 
post-coital contraception (      ) as shown in Table 8.6. These signals were neither 
consistent nor specific. Temporality criterion was met by the timeframe defined for signals. 
Biological gradient was strong for influenza vaccination but weak for post-coital 
contraception (Table 8.10). The plausibility for signals under “surgical and medical 
procedures” category was more debatable. Children who were sicker may visit the GPs more 
frequent than their more healthy controls, concurrently may have greater probability of being 
vaccinated. It is less clear why girls prescribed with domperidone might find themselves in 
greater need of post-coital contraception. Possible hypotheses include a role for domperidone 
in affecting their judgment in sexual encounters; or that, girls who are more mature for their 
age might be more likely to be prescribed domperidone and to be in greater need of post 
coital contraception (Prof. Martin Underwood, personal communication). Another possibility 
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is domperidone might be prescribed to girls prior to post-coital contraception to prevent 
vomiting, especially those with previous history of vomiting following post-coital 
contraception (Webster, 2010). Therefore, reverse causality was also possible. Another 
explanation could be vomiting might interfere with the absorption of contraceptive pills – 
nausea and vomiting were also recognised side effects of oral contraceptive pills (Joint 
Formulary Committee, 2010). Evidence for coherence is difficult to find for this signal. It is 
possible that an upwards trends would be observed over time simply because the medical 
procedures have become more accessible. Over time, public awareness and perceptions on 
getting vaccinated or having a post-coital contraception have also improved with better (risk-
benefit profile) drugs available on the market e.g. the levonorgestrel contraceptive (Task 
Force on Postovulatory Methods of Fertility Regulation, 1998). Since these signals were 
medical procedures, there was no experimental evidence or any analogy available. Although 
it was not demonstrated here (or available in literature elsewhere), it could be also 
hypothesised that domperidone may be a proxy marker to surgical GORD treatment, and thus 
there is a chance that surgery might be raised as a signal in a different exercise to ours. 
Because children with more severe GORD would have been prescribed with domperidone 
and failed to respond before surgery was considered, this signal should be regarded as false 
signal. 
 
8.5.7 Reproductive system and breasts disorders 
An odds ratio of 5.6 was observed for signals for dysmenorrhoea, demonstrating a moderate 
strength of association to prescriptions of domperidone (Table 8.6). The signals were neither 
consistent nor specific considering these were signals and had not been robustly associated 
with domperidone, and that it is a common medical condition in adolescent with a high 
prevalence of up to 90% (Durain, 2004). Therefore false positive association could not be 
dismissed. Temporality criterion was satisfied by definition that the signals occurred within 
two weeks after domperidone prescription. Evidence of biological gradient was weak (Table 
8.10). A known side-effect for domperidone was cramps (see Section 8.4.2). This might 
include dysmenorrhoea, but it was not specifically listed in the BNF (Joint Formulary 
Committee, 2010) – therefore the signals were plausible. On the other hand, reverse causality 
may also be possible since domperidone could have been prescribed for nausea and vomiting 
associated with dysmenorrhoea. Coherence was not available (see also Section 8.5.1). To 
date, there is no experimental evidence showing the causal link between dysmenorrhoea and 
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domperidone prescription. Direct analogy was not available; but considering domperidone 
can cause abdominal cramps and may accentuate during menstrual period, signals for 
dysmenorrhoea should be monitored when domperidone is prescribed to adolescent girls. 
 
8.6 Discussion and conclusion 
8.6.1 Signal detection and validation 
GPRD clinical events data can be used to raise important safety signals as demonstrated in 
this chapter. However, it must be emphasised that the raised signals from the case study were 
only generated from a pool of small number of clinical events – 3,754 unique clinical events 
in the cisapride data, and 16,979 clinical events in the domperidone data.  
 
Using truncated Read codes is not the only (or even the best) way to perform signal detection 
on GPRD database. Other options have been suggested and discussed; including the use of 
structured MedDRA’s “preferred-terms” and “high level terms”, although not specifically for 
data mining on GPRD data (Brown, 2002). But it is conceptually possible. However, because 
MedDRA terminologies recorded on GPRD database are matched internally by the GPRD 
and not originally selected by the GPs who recorded them, their use for this purpose would be 
less accurate compared to using Read codes. Due to the fact that MedDRA is multi-axial i.e. 
the lower level terms can belong to more than one higher level terms, duplications of the 
same clinical events are inevitable. 
 
It is well-known that very strong signals can influence PRRs for other signals (Hauben, 
2003). The presence of very strong signals overwhelms the data, increases the denominators, 
and thus reduces sensitivity of PRRs to detect other less strong signals. The obvious way to 
overcome this issue is to exclude very strong signals when they are raised and rerun the 
disproportionality algorithm. This would be an iterative process as other strong signals may 
be raised in subsequent iterations. By performing the disproportionality algorithm iteratively, 
it also induces multiplicity problems therefore not undertaken here. Defining “very strong 
signals” can also be very subjective. Strong signals demonstrated by high PRRs scores may 
not be the same illustrated by the associated p-values. Both would be valid; but more work 
may be required to properly justify the best option. 
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As I previously mentioned, PRRs and other data mining algorithms are nonclinical and could 
not replace clinical experts’ opinions. Therefore, a fully-automated signal detection algorithm 
is far from possible with what is currently available. Presenting the PRRs with the ranks of 
how significant they are for example can certainly aid clinical experts’ efforts in evaluating 
them. 
 
In short, proportional reporting ratios method is fit for this purpose. Being easy to understand 
and to implement, PRRs method does have appeal. Although it is not commonly used in 
pharmacovigilance, the same signal detection algorithm presented here can also be applied to 
mine the evidence for benefits of a drug treatment. Efficacy outcomes for GOR were simply 
not recorded in GP data. This is also to some extent true for other efficacy outcomes for other 
drugs. Nevertheless, major clinical outcomes such as type II diabetes and deaths can be 
identified from GPRD data when talking about prevention. Benefits would then be measured 
in terms of effectiveness of drugs rather than the typical measure of efficacy under the ideal 
controlled conditions. Signal detection algorithm presented here can be readily applied in 
such situations, but the PRRs would need to be interpreted in the opposite direction. 
 
8.6.2 Confirmatory analysis 
Section 8.4.5 demonstrates that odds ratios were raised by other factors such as the use of 
other drugs that have known associations to the signals, and other illnesses that may give rise 
to the signals. For example, after adjusted for the use of these concomitant drugs with 
cisapride or domperidone, the significant effect of domperidone on signal of pneumonia 
disappeared. Therefore the analysis down-weighed the significant association of pneumonia 
to domperidone observed previously. Odds ratios of other signals remained similar to those 
from the univariable analyses. 
 
We were able to examine individual clinical events for children who died because of the 
small incidence and relatively short clinical records compared to other domperidone children. 
For other less serious outcomes that occurred in many children e.g. abdominal pain, manually 
examining individual clinical events can be a very exhaustive process, where the effort put in 
pre-specifying a list of possible concomitant illnesses may outweigh the effort of reviewing 
individual clinical record. We suggest that future trials planning to evaluate concomitant 
illnesses to adopt the arguments we present in the methods (see Section 8.3.3) in order to 
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decide whether a list of concomitant illnesses is worth to be pre-specified. Therefore we 
recognise this as a limitation of this study and encourage future research to develop a better 
procedure to deal with concomitant illnesses more efficiently. 
 
8.6.3 Causal inference 
The role of causal inference in this process is vital to provide the evidence of causality for the 
signals confirmed in the previous stage. Bradford Hill criteria for causation are used to 
further verify the status of the signals and their degree of association to the drugs 
incorporating the evidence found, other evidences and current knowledge. 
 
Most of the confirmed signals satisfied some of the nine Bradford Hill criteria through the 
analysis definition. The classifications of the strength of association defined in Section 8.5 
should not be used to determine which signal for potential ADRs is most causally related to 
domperidone. The actual odds ratios after considerations of the baseline odds should be taken 
into account when any conclusion is to be made. However, there is no direct impact of this 
classification on the conclusion of causal relationship to domperidone since the statistical 
significance of the odds ratios, which have been met initially, were used as guidance. 
 
The aspects of associations these signals fulfilled are summarised in Table 8.14. There is no 
strong evidence of causation for the signals to be associated with cisapride or domperidone. 
However weak the causal relationship between the signals and the drugs, studying the safety 
issues from routine healthcare data such as that held in the GPRD, could identify stronger 
signals in different indications; and even weak signals provide clues for further investigation 
in prospectively planned studies.  
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Table 8.14 Summary of signals for potential ADRs versus Bradford Hill criteria for causation 
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A Abdominal pain 
B 
Bronchitis & bronchiolitis 
Pneumonia 
C Anorexia and weight loss 
D 
Epilepsy 
Migraine 
E Dysmenorrhoea 
F 
Coughing
a 
Sleep disorders 
G 
Influenza vaccination 
Post-coital contraception 
A – Gastrointestinal disorders; B – Infections and infestations; C – Metabolism and nutrition disorders;  
D – Nervous system disorders; E – Reproductive system and breasts disorders; F – Respiratory, thoracic, and 
mediastinal disorders; G – Surgical and medical procedures 
a
 Coughing was not a “real” signal because it was statistically significant in the opposite direction 
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8.6.4 Conclusion 
The evidence synthesis method presented and applied here did not raise any serious events 
directly related to or potentially related to domperidone prescription in children. Therefore 
the analysis and data support the need for a domperidone trial in children. We showed that 
there are clues to safety issues in the GPRD that should be monitored and confirmed in future 
trials. 
 
In terms of data monitoring, our evidence synthesis approach points to rash, diarrhoea, 
arrhythmia, abdominal pain, bronchitis and bronchiolitis, pneumonia, epilepsy, and sleep 
disorders. The signals were chosen as important outcomes to monitor based on our inability 
to completely dismiss them through Bradford Hill causality criteria. Additionally, the data 
indicate that the use of other drugs concomitantly with domperidone significantly increased 
the risk of abdominal pain, and bronchitis and bronchiolitis. This should be taken into 
account when prescribing domperidone. 
 
Whilst so far the method we proposed is aimed at informing future trials where risk/benefit 
evidence was inadequate for making robust assessment, it is also useful for risk-benefit 
assessment in its own right. In the next Chapter 9, I discuss the conceptual development of 
risk-benefit decision-making models that naturally follow through the evidence synthesis 
process presented to this point. 
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9. Assessment and integration of evidence-based risks and benefits for decision-
making 
9.1 Introduction 
The issues surrounding the finding risks and benefits from the case study were discussed in 
Part II of this thesis. So far, risks and benefits of drugs are analysed separately in their 
respective dimensions and have not been compared head-to-head. Overall assessment of a 
drug requires that both risks and benefits be weighed against each other to decide on whether 
a drug is safe and/or effective for use. Comparison between treatment options can then be 
made by comparing the risk-benefit profiles of the drugs under consideration. 
 
Throughout this chapter, I compare domperidone to no treatment and cisapride. This is 
implicitly assuming cisapride is still an option, which in this case is not true because it has 
been withdrawn from the market in July 2000 due to serious arrhythmic adverse events and 
deaths (mainly in adults). The reason for its inclusion is to assess how domperidone compares 
to an alternative drug that used to be its competitor and is of the same pharmacological class. 
It is also because cisapride was available for over half the time period in the study. 
 
9.2 Aims and objectives 
The overall aim of this chapter is to bring together the evidence of risks and benefits in the 
earlier chapters into a quantitative risk-benefit decision-making framework. The issues of 
integrating risks and benefits for decision-making are discussed. It is also difficult to specify 
all the necessary values required for risk-benefit assessment but nevertheless they are needed 
in order to make a rational decision (Spiegelhalter, 2004c). 
 
This chapter specifically address the following objectives: 
i. to evaluate risk-benefit profiles of treatment options;  
ii. to describe the issues in choosing input values in risk-benefit assessments; and 
iii. to discuss, in general, the difficulties that might be encountered or need to be 
considered when assessing risks and benefits of medicines. 
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9.3 Decision problems and available evidence 
There are three questions to be answered for this case study in terms of risk-benefit 
assessment: 
(1) what is the risk-benefit profile for domperidone? 
(2) how does it compare to risk-benefit profiles of not being treated, or when treated with 
cisapride? 
(3) how does the choice of preference values affect the comparison metrics? 
 
These questions are dealt with in Section 9.4 below. 
 
9.3.1 Evidence of benefits 
At this point for the current case study, the best estimates for benefits of domperidone and 
cisapride came from the indirect treatment comparison meta-analysis in Chapter 7. The 
Bayesian model is modified to also calculate the adjusted incidence rates in person-month 
and shown in Table 9.1. 
 
Table 9.1 Estimates of benefits for improvement in GOR symptoms (treatment 1 versus treatment 2) 
Treatment 1 Treatment 2 Odds ratio of improved 
versus not improved 
symptoms
 
Adjusted incidence 
rates per person-month 
for treatment 1
 
Placebo Placebo 1.00 0.46 (0.04, 0.97) 
Cisapride Placebo 2.39 (0.84, 7.13) 0.73 (0.51, 0.87) 
Domperidone Placebo 3.87 (0.78, 16.08) 0.78 (0.42, 0.94) 
Domperidone Cisapride 1.61 (0.24, 9.05) n/a 
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9.3.2 Evidence of risks 
Previously-known recognised and possible adverse events (see Section 8.3.1 for definitions) 
are listed in Table 9.2. Except for diarrhoea and rashes in domperidone cohort, other known 
AEs were based on very small absolute numbers and small incidence rates per person-month. 
Under the fitted Poisson model, it is expected that a very large clinical trial is needed to 
observe just one of these adverse events among exposed patients. For example, 1000 patients 
exposed for two months are needed to observe one case of anxiety. Diarrhoea and rashes are 
of acceptable magnitude for considerations in clinical trials. 
 
The results for the two potential adverse events from analysis in Chapter 8 that are found to 
be worth considering in the assessment of unknown potential risks of domperidone are 
extracted and listed in Table 9.3. Similar results for cisapride are also shown as comparisons. 
Abdominal pain is realised to be somewhat clinically associated to the underlying condition 
but because it may also be associated with domperidone use, we decided to bring it forward 
as potential risk to be assessed. 
 
For the purpose of illustration in this thesis, I take forward potential ADR signals in Table 9.3 
as attributes to be assessed using the quantitative risk-benefit approaches described in Section 
3.9. Therefore, by no means that the risk-benefit profiles of domperidone and cisapride in 
Section 9.4 provide complete assessment of the drugs. They would however demonstrate how 
the current choices of attributes contribute to the risk-benefit profiles of domperidone and 
cisapride, and the difficulties that are associated when multiple attributes are involved in risk-
benefit decision-making. 
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Table 9.2 Estimates of incidence rates in 1000 person-months of previously-known AEs that reached 95% 
statistical significance level and associated ratios using age-adjusted Poisson regression for domperidone 
and cisapride cohorts 
 IRunexposed (95% CI) IRexposed (95% CI) IRR (95% CI) 
Domperidone    
Anxiety 0.06 (0.01,0.10) 0.45 (0.13,0.77) 7.96 (4.61, 13.76) 
Arrhythmias 0.04 (-0.02,0.10) 0.26 (-0.05,0.57) 6.42 (1.17, 35.10) 
Bronchospasm 0.04 (-0.02,0.11) 0.35 (0.02,0.68) 8.02 (1.55, 41.38) 
Convulsions 0.52 (0.27,0.78) 1.27 (0.57,1.96) 2.46 (1.26, 4.81) 
Cramps 0.00 (-0.01,0.01) 0.06 (-0.10,0.22) 21.32 (2.70, 168.53) 
Depression 0.02 (-0.00,0.04) 0.11 (-0.02,0.23) 6.22 (3.84, 10.06) 
Diarrhoea 14.77 (13.22,16.31) 47.25 (42.34,52.15) 3.27 (2.94, 3.65) 
Drowsiness 0.03 (-0.03,0.08) 0.27 (-0.03,0.57) 9.89 (1.03, 95.08) 
Extrapyramidal 
effects 
0.05 (-0.02,0.12) 0.46 (-0.05,0.97) 9.25 (2.50, 34.25) 
Headaches 0.16 (0.09,0.23) 2.26 (1.43,3.10) 14.27 (10.89, 18.69) 
Light-
headedness 
0.02 (-0.00,0.05) 0.12 (-0.02,0.26) 
4.77 (2.21, 10.27) 
Rashes 23.46 (21.52,25.40) 29.09 (25.68,32.51) 1.24 (1.09, 1.40) 
Cisapride    
Convulsions 0.36 (0.08,0.64) 1.36 (0.35,2.37) 4.74 (1.60, 14.04) 
 
Table 9.3 Estimates of incidence rates in 1000 person-months of potential ADR signals and associated 
ratios using age-adjusted Poisson regression for domperidone and cisapride cohorts 
 IRunexposed (95% CI) IRexposed (95% CI) IRR (95% CI) 
Domperidone    
Abdominal Pain 2.5 (2.1,2.9) 35.8 (31.5,40.1) 14.40 (12.77, 16.24) 
Bronchitis And 
Bronchiolitis 
11.5 (10.1,12.8) 54.2 (48.4,59.9) 4.73 (4.25, 5.27) 
Cisapride    
Abdominal Pain 3.8 (2.8,4.7) 6.9 (4.8,8.9) 1.83 (1.36, 2.47) 
Bronchitis And 
Bronchiolitis 
15.5 (13.1,17.8) 32.8 (27.3,38.2) 2.12 (1.80, 2.50) 
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9.4 Quantitative evidence-based risk-benefit profiles 
Quantitative risk-benefit approaches described in Section 3.9 are summarised below in terms 
of the parameters involved and the level of complexity in application of each method 
subjectively judged based on my experience and understanding (Table 9.4).  
 
Risks and benefits evidences are assessed using NNT-based approaches, benefit-less-risk 
analysis, decision tree, and MCDA approaches to illustrate how the approaches work, and in 
order to demonstrate the difficulties associated with them. Basic NNT approach is chosen to 
represent probability-based risk-benefit assessment method. The extended NNT and MCE 
approaches are example when there is a “bridging” between probabilities and utilities. The 
other approaches are utility-based approaches stemmed from the decision theory. 
Conventional approaches (e.g. incidence rates ratio, odd ratio) have been discussed and have 
their results examined in previous chapters, therefore are not repeated here. A brief 
discussion on the applications of CUI and DI in risk-benefit assessment is presented because 
they are similar to BLRA. Time trade-off approaches favoured by health economists are 
beyond the scope of this thesis, therefore only a brief discussion on the approaches is made. 
The usefulness of TURBO model is unconvincing (see Section 3.9.7), therefore it is not 
applied. 
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Table 9.4 Comparison summary table 
   U S w I T   G 
Resultant 
metric 
Level of 
complexity 
Conventional 
approach 
X        
Rates/Odds 
(ratios) 
Easy 
NNT/NNH X        Rates threshold Easy 
AE-NNT X    X    Rates threshold Easy 
RV-
NNT/NNH 
X X X      
Rates threshold 
Medium 
MCE X X X  X    Rates threshold Medium 
CUI X  X X X  X X Expected utility Medium 
DI X X X X X  X X Expected utility Complex 
BLRA X X X X X  X  Weighted utility Complex 
QALY/DALY  X X X  X   Expected utility Medium 
RVALY  X X X  X   Expected utility Medium 
INB  X X X X X X  Expected utility Medium 
TURBO X  X  X   X Utility Easy 
Decision tree X X X  X   X 
Expected utility Easy – 
complex 
MCDA X X X X X O X X Weighted utility Complex 
  = probability; S = Scoring; U = Utility; w = weights; I = Integrated risk and benefit; T = integrate time trade-
off;    = explicit sensitivity analysis; G = Graphical methods readily available 
  indicates required parameters; O indicates optional parameters 
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9.4.1 Basic NNT approach to risk-benefit analysis 
The incidence rates from Table 9.1 are used to calculate number needed to treat for treatment 
options, and presented in Table 9.5. The results from NNT analysis suggest that domperidone 
is a more effective drug than cisapride. On average as smaller number of patients needs to be 
treated with domperidone than with cisapride to see an improvement in GOR symptoms i.e. 
                           . Using the indirect treatment comparison estimates in the 
calculations, we would expect to see one additional patient improved GOR symptoms when 
treated with domperidone compared to cisapride only after treating 21 patients.  
 
Table 9.5 Number needed to treat to get one improved outcome (NNT) measured in person-months at age 
one year under Bayesian indirect treatment comparison framework 
  Domperidone vs. 
placebo 
Cisapride vs. placebo Domperidone vs. 
cisapride 
            0.46 (0.04, 0.97) n/a 
         
 0.78 (0.42, 0.94) 0.73 (0.51, 0.87) n/a 
IRD
 
0.30 (-0.26, 0.74) 0.25 (-0.25, 0.69) 0.05 (-0.33, 0.32) 
NNT   ((   )  (     ))   ((   )  (     ))    ((   )
 (     )) 
NNT
a 
3 (NNTB 1, NNTH 4) 4 (NNTB 1, NNTH 4) 21 (NNTB 3, NNTH 3) 
a
 Alternative representation of CI for NNT. NNTB = NNT to benefit, NNTH = NNT to harm 
 
The risks profiles for domperidone and cisapride using NNT approach are calculated using 
the estimates of incidence rates in Table 9.3. Domperidone appears to be slightly inferior to 
that for cisapride for the two safety attributes (potential ADRs) as suggested by the NNH in 
Table 9.6. However, comparing NNT to NNH for both drugs, on average their benefits seem 
to have outweighed their risks i.e.        . This example demonstrates the too 
simplistic approach of NNT-based approaches that heavily rely on point estimates (mean or 
median). Figure 9.1 – Figure 9.4 demonstrate that the estimates of NNT and NNH also vary 
with age (under fitted model) – that less younger children was expected to benefit from the 
treatments. 
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Table 9.6 Number needed to treat to get one adverse outcome (NNH) measured in person-months at age 
one year 
 Domperidone cohort Cisapride cohort 
 Abdominal pain Bronchitis and 
bronchiolitis 
Abdominal pain Bronchitis and 
bronchiolitis 
            0.0025 
(0.0021,0.0029) 
0.0115 
(0.0101,0.0128) 
0.0038 
(0.0028,0.0047) 
0.0155 
(0.0131,0.0178) 
         
 0.0358 
(0.0315,0.0401) 
0.0542 
(0.0484,0.0599) 
0.0069 
(0.0048,0.0089) 
0.0328 
(0.0273,0.0382) 
IRD 0.0333 
(0.0293,0.0373) 
0.0427 
(0.0376,0.0479) 
0.0031 
(0.0013,0.0050) 
0.0173 
(0.0124,0.0222) 
NNH 30 (26,34) 23 (21,27) 320 (200,769) 58 (45,81) 
 
Figure 9.1 IRD and NNT in person-months for an improvement for domperidone (Bayesian indirect 
treatment comparison) 
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Figure 9.2 IRD and NNT in person-months for an improvement for cisapride (Bayesian indirect 
treatment comparison) 
 
 
Figure 9.3 NNH for domperidone 
Abdominal pain 
 
Bronchitis and bronchiolitis 
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Figure 9.4 NNH for cisapride 
Abdominal pain 
 
Bronchitis and bronchiolitis 
 
 
Interpretation of NNT and NNH can also be a problem. Take the benefit of domperidone for 
example; the average NNT is three person-months. This could either mean treat three patients 
for a month, or treat one patient for three months to see an improvement. The concept of 
person-months in the latter would have to be interpreted as “on average three months 
treatment is required to see an improvement in GOR symptoms”. However, extrapolating 
beyond the available data can be misleading and threatens its clinical logic. It would be 
implausible to extrapolate that if a patient is treated for six months, then twice the 
improvement in symptoms would be expected. However, it may be a sensible interpretation 
in the case of ADRs that more ADRs would be expected if a patient were treated for longer 
duration. As the duration of the treatment plays important role in NNT and NNH measures, it 
needs to be factored in properly but it is not pursued in details here.  
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One weakness of NNT that is often criticised is in the construction of its confidence intervals 
(CI). A typical way to obtain this is to invert the CI for the IRD as I did in Table 9.5. 
However, because the CI for the IRD includes zero, the respective CI for NNT would include 
infinity resulting in disjoint intervals. Using mathematical notation to show this: let      be 
the mean IRD,       and       be the lower bound and the upper bound of the 95% 
confidence intervals. Then, 
                   
The reciprocals would be 
 
     
 
 
    
       
 
     
 
 
    
 
provided that                       are all positive. However,       take negative value in 
this case. Hence, it follows that 
 
 
     
 
 
    
 
 
Altman ( 998) describes this phenomenon as ‘strange’ (Altman, 1998) as the mean NNT is 
bounded by two lower bounds. He rethinks the consequences of presenting such confidence 
intervals and adopted the idea that negative NNT is regarded as an adverse outcome i.e. NNH 
(McQuay, 1997). The reciprocal of       can then take positive values and remain the upper 
bound for NNT as it should be, which is termed as NNTH (number needed to treat to harm), a 
naming convention consistent with the paper (Altman, 1998). NNT is also relabelled as 
NNTB (number needed to treat to benefit). The confidence intervals for NNT thus can be 
presented as shown in Figure 9.1 and Figure 9.2 with the axes reversed to properly depict the 
NNT values. Value of  .  is considered as the ‘extreme and unattainable’ value when all 
patients do not improve if not given the treatment and all improve with it for NNTB; and all 
patients improve unless given the treatment for NNTH (Altman, 1998). 
 
Obviously, the CI is very wide and not statistically significant. A method to derive exact 
confidence intervals for NNT is available in the form of exact posterior density in Bayesian 
framework (Grieve, 2003). When taking the 95% confidence intervals into account, the 
comparison of NNT to NNH in the illustration above becomes unfair as the NNTs were not 
statistically significant at 95% level but the NNHs were. A naive way to get around the over-
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reliance on comparing mean/median estimates of NNT and NNH is to also compare the lower 
and upper bounds of their confidence intervals. If we were to take these into account, then for 
an NNT approach of comparison to be meaningful, we also need             and 
            conditions to be met. For the domperidone and cisapride example above, 
the condition on the lower bounds was not met. This is not easily seen from mathematical 
notations alone, but requires conceptual reasoning. A negative NNT value is still less than a 
positive NNH value but conceptually –        and larger NNH values are more 
desirable, therefore the condition that needs to be satisfied need to be reversed i.e. –    
            . 
 
While IRR and OR are unitless metrics, IRD and NNT (and NNH) are not. IRD and NNT 
take the unit of the incidence rates. By definition, they can only be calculated when the time 
period is defined, otherwise they do not exist. It has been criticised that NNT approach 
violates logical soundness and lacks clinical relevance (Phillips, 2010b). For example, an 
NNT of 20 for deaths and an NNT of 20 for abdominal pain are not equal, and can be 
misleading if carelessly presented, or blindly compared. The basic NNT approach neither can 
address the highly desired joint assessment of an integrated risk-benefit measure, nor can it 
deal with multiple risks or benefits at the same time. 
 
9.4.2 Extended NNT and MCE approach to risk-benefit analysis 
A rather interesting concept of ‘unqualified success’ and ‘unmitigated failure’ described in 
Section 3.9.1 provide a simple way of integrating risk and benefit into a single measure. For 
the purpose of illustration and simplicity, I am assuming independence among all attributes 
and that the evidence of risks and benefits came from the same population. 
 
Table 9.7 shows the results from a “hybrid” Bayesian indirect treatment analysis of 
improvement of GOR symptoms. The “hybrid” here is referring to the inclusion of the mean 
and variance of IRD estimates for AEs from classical analysis, shown in Table 9.6, as 
stochastic nodes in the Bayesian analysis. These results were used to calculate     and     
in OpenBUGS (Lunn, 2009). AE-NNT is then calculated manually as the inverse of    , as 
proof of concept, under the strong assumptions that improvement of symptoms is 
independent of experiencing an AE with the rates observed from GPRD data. The correct 
application of AE-NNT is to use marginal probabilities based on individual-level data. 
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Table 9.7 Unmitigated failure, unqualified success and AE-NNT for improvement in GOR symptoms at 
age one year 
 Domperidone vs. 
placebo 
Cisapride vs. placebo Domperidone vs. 
cisapride 
IR with no treatment
a 
0.46 (0.04, 0.97) 0.46 (0.04, 0.97) 0.25 (-0.25, 0.69) 
IRDimprovement of symptoms  
with treatment
b 
0.30 (-0.26, 0.74) 0.25 (-0.25, 0.69) 0.30 (-0.26, 0.74) 
Abdominal Pain (AP)    
IRDAP 0.033 (0.029,0.037) 0.003 (0.001,0.005) 0.030 (0.026, 0.035) 
umfAP 0.016 (0.002, 0.032) 0.001 (0.000, 0.003) 0.022 (0.015, 0.028) 
uqsAP 0.282 (-0.255, 0.706) 0.246 (-0.249, 0.687) 0.046 (-0.323, 0.313) 
AE-NNTAP 4 (NNTB 1, NNTH 4) 4 (NNTB 1, NNTH 4) 22 (NNTB 3, NNTH 3) 
Bronchitis and 
bronchiolitis (BB) 
   
IRDBB 0.043 (0.038,0.048) 0.017 (0.012,0.022) 0.025 (0.018, 0.032) 
umfBB 0.020 (0.002, 0.041) 0.008 (0.001,0.017) 0.018 (0.012, 0.025) 
uqsBB 0.279 (-0.252, 0.699) 0.242 (-0.246, 0.677) 0.046 (-0.325, 0.315) 
AE-NNTBB 4 (NNTB 1, NNTH 4) 4 (NNTB 1, NNTH 4) 22 (NNTB 3, NNTH 3) 
a
 Refers to IR for cisapride and 
b
 to IR for domperidone in domperidone vs. cisapride comparison 
 
The idea of NNT is also extended to include relative values derived from the utilities of AE 
and improvement with treatment. RV is calculated using the following formula: 
 
   
     
                                    
 
 
Because utility values cannot be determined without proper consolidation of experts’ 
opinions or patient-preferences, I show RV-NNH over a range of utility values via 
simulation. It is impractical to generate large matrices in OpenBUGS to collect the results. To 
overcome the problem, again I used another “hybrid” Bayesian approach by extracting 
CODA chains (see Section 3.10) from the OpenBUGS analysis of AE-NNT into Stata 10 
(StataCorp, 2007) to perform the simulations.  
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The median estimates from posterior densities of IRDs were used to calculate RV-NNH using 
the following formula:  
 
        {∑(    )     
 
   
}
  
   {
                
                              
 
 
Confidence intervals can also be simulated from the CODA chains from the 95% Bayesian 
credible intervals, but are not shown here due to the volume of results to be presented. 
 
Figure 9.5 and Figure 9.6 show the RV adjusted NNH for being treated with domperidone 
and cisapride respectively compared to being untreated over a range of utilities. Higher utility 
value is more preferred; where higher AE utility represents lower severity, and higher utility 
of improvement with treatment represents better efficacy of treatment. Utilities of AE range 
between 0.00-1.00 and utilities of improvement with treatment range between 0.50-1.00. 
Utility of improvement with treatment less than 0.50 is undesirable since they produce very 
small RV-NNH, and were omitted from the graphs for visual clarity. The x- and y-axes on 
Figure 9.5 and Figure 9.6 relate to (     ) thus treating utility of improvement with 
treatment as a constant within 0.50-1.00, smaller values of RV is associated with larger 
utilities of AE, therefore are more preferred. 
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Figure 9.5 RV-NNH for domperidone compared to placebo by relative values of AE attributes 
 
 
Figure 9.6 RV-NNH for cisapride compared to placebo by relative values of AE attributes 
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RV-NNH approach can also be used to compare treatment options (Holden, 2003). RV-NNH 
for domperidone compared to cisapride can be calculated in the same way using the IRD 
between domperidone and cisapride for the respective AEs. The IRDs can be calculated using 
indirect treatment comparison method from data in Table 9.6. The “head-to-head” 
comparison in RV-NNH is not done here; instead I show the minimum clinical efficacy 
(MCE) for a domperidone treatment to be worth considering over cisapride in the following 
Figure 9.7. 
 
MCE of domperidone compared to cisapride,     , was simulated from the same CODA 
chains data used in the simulation of RV-NNH using the formula (see Section 3.9.2): 
        ∑
        
  
 
   
 
 
Naturally, the credible intervals for MCE are available for this analysis from the MCMC 
sampling but are not shown here. Figure 9.7 the effect of trading between the two attributes 
of risks on the minimum clinical efficacy for domperidone to be worth considering over 
cisapride (this is assuming cisapride is still around). For someone to be more willing to accept 
“more” abdominal pain, say with relative values of 5, and only half the amount of bronchitis 
and bronchiolitis at relative values of 2.5, then domperidone needs to show a relative risk 
reduction of at least 0.39 compared to the untreated group. Other MCEs with different 
relative values for each risk attribute can be obtained by cross-checking the MCE-RV plane 
after considering the utility of improvement.  
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Figure 9.7 Minimum clinical efficacy to be worth considering domperidone over cisapride 
 
 
9.4.3 Benefit less risk approach 
The uniqueness of Chuang-Stein’s BLRA approach is that it explicitly considers the different 
body functions (Chuang-Stein, 1994). However, the choice of which body functions to 
include is still of subjective nature and heavily dependent on the researchers/clinicians 
making the assessment. In Chapter 8, I proposed a systematic approach on how to derive the 
list of body functions that matter from a mixture of data mining technique and experts’ 
opinions. Naturally, the approach only addresses post-marketed drugs that are already 
(commonly) used in the general practices where the data on their use are available (see 
discussion in Chapter 11). 
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In order to apply BLRA to our data, I consider the system organ class (SOC) for potential 
ADRs classified in Section 8.4.3, which are the gastrointestinal disorders (SOC1), and 
infections and infestations (SOC2). Suppose that the two SOCs are scored from 1 – 10, and let 
the scores be      (        ). Also let the relative magnitudes between SOCs be    for 
gastrointestinal disorders (   ) and infections and infestations (   ). Weights are defined 
as          and ∑     ( )    . The combined risk profile (see Section 3.9.3) is  
 
   ∑∑        
 ( )
   
 
   
            {
                                            
                                                                  
 
 
The formulation of    came from evaluation of risks in clinical trial patients, but for this case 
study, the application of BLRA is not very straightforward as the severity of an AE is 
unavailable from GP records. Even if severity were available, the scoring would be extremely 
inconsistent. A slightly different interpretation of      is then used here because of 
unavailability of patient-level data. At population level,      simply refers to whether AE   
was observed in cohort   (domperidone or cisapride) at some specified level  ; it is treated as 
a constant 1 here having observed the AEs. The combined risk profile is therefore simply 
   ∑ ∑     
 ( )
   
 
   . 
 
The relative magnitudes of SOCs can be estimated from seriousness of an AE; where 
seriousness of an AE can be judged by experts from the types of AEs. An example of ranking 
seriousness of AEs was performed by CIOMS Working Group IV members and illustrated in 
section 4 of their report (CIOMS Working Group IV, 1998). 
 
The CIOMS IV Working Group 2 assigned an average seriousness score of 2.33 for diarrhoea 
which I take as the proxy to gastrointestinal pain. An average score of 6.38 was assigned for 
“bronchial asthma”. I would value bronchial asthma to be more serious, thus consider a 
seriousness score of 6 for infections and infestations. Therefore, for our case study,     
(    )       since ∑            . The weights for varying severity scores in the two 
SOCs are shown in Figure 9.8. Individual weighted scores can be calculated in each cohort if 
individual severity scores were available.  
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In order to compare the treatment options in the population, I propose to modify the 
seriousness score by the probability of an AE happening in the treated group compared to 
untreated group (relative risk), and weight them accordingly. This axiom implies that if an 
AE is scored to be serious but does not occur very often in a study population, then the 
seriousness score is weighted down, and vice versa. The reasoning for the modification is that 
an AE that is valued half as serious as another AE but occurs twice as much should really be 
valued the same. The modified seriousness score    with relative risk     for SOC   is  
 
          
 
The modified weight is therefore defined as         . From the results shown in Table 
9.3, the modified weighted risks for domperidone and cisapride respectively are: 
 
                   (           )  
    
(                   )    
 
 
    
(            )    
 
 (      )       
 
                 (         )  
    
((                   )    )
 
 
    
(            )    
 
 (      )       
 
Figure 9.9 and Figure 9.10 show the modified risk profiles for domperidone and cisapride 
respectively at various score combinations for gastrointestinal disorders, and infections and 
infestations. 
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Figure 9.8 Risk profile at different scores of SOCs 
 
 
Figure 9.9 Risk profile for domperidone at different scores for SOCs using proposed modifications 
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Figure 9.10 Risk profile for cisapride at different scores for SOCs using proposed modifications 
 
 
Having estimated the risk profiles for both drugs, the next step in BLRA is to discount the 
benefit of the treatment using a proportionality constant   to arrive at the risk-adjusted 
benefit    (Section 3.9.3). Sensible choice of   is crucial for this exercise. The idea is to find 
  such that efficacy equals risk (Chuang-Stein, 1994).  
 
We learnt that improvement in GOR symptoms when untreated was 0.46 (0.04, 0.97) (Table 
9.5). Then   can be estimated by solving the equation          (
    
 
), where   is 
619.32 and 169.84 for domperidone and cisapride respectively (Chuang-Stein, 1994).  Figure 
9.11 shows different values of   that could be chosen to solve the equation for   . Higher 
score for SOCs result in smaller   i.e. smaller penalty is required to reduce the efficacy 
measure. However this reasoning is only a guideline to acquire reasonable values of  ; and 
once   is chosen, the same   is to be used in every calculation. 
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Figure 9.11 Possible choices of   values within at different scores for SOCs 
 
SOC 2 scores refer to scores in SOC Infections and infestations 
 
The risk-adjusted efficacies        (
    
 
) for domperidone and cisapride are then 
calculated from the incidence rates of improvement of                   and            
     (Table 9.5).    values over a range of   are plotted in Figure 9.12 (domperidone) and 
Figure 9.13 (cisapride) for extreme situations of scores    in SOCs gastrointestinal disorders 
and infections and infestations. The figures show that rate of change in    for domperidone is 
affected more by increase in SOC1 scores, but increase in SOC2 scores affects    for cisapride 
more with greater difference in rates as indicated by much steeper slope. On the downside, 
the    measure lacks intuitive interpretation when only one active treatment is involved 
(Chuang-Stein, 1991). 
 
In comparing two active treatments, domperidone and cisapride in this case, BLRA approach 
takes the difference in    values. The difference between risk-adjusted efficacies is illustrated 
in Figure 9.14 over a range of   and when different scores were given to the two risks 
attributes (without any reference to which drugs). 
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Figure 9.12 Risk-adjusted efficacy    for domperidone over a range of   
 
 
Figure 9.13 Risk-adjusted efficacy    for cisapride over a range of   
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Figure 9.14 Risk-adjusted efficacy difference between domperidone and cisapride over a range of   
 
Shaded areas represent the effect of increasing scores in the two risks attributes when the other was fixed 
arbitrarily. The dashed line marked with “x” represents the difference in    when same scores were assigned to 
both attributes. 
  
Figure 9.14 also illustrates that when both drugs to be compared have very similar risk-
benefit profile, e.g. in the extreme cases when the same scores are given to the attributes, an 
optimal choice between two drugs cannot be made. At the extreme end (same scores in both 
SOCs) using this case study,             
  exceeds that of cisapride by 0.05 suggesting that 
domperidone has a slightly better safety profile, and unaffected by the choice of  . The 
difference in    varies from being (more) in favour of domperidone to being (more) in favour 
of cisapride when one is unwilling to tolerate more severe gastrointestinal disorders adverse 
events i.e. scored higher
18
. 
 
However, the weakness in BLRA approach lies in addressing uncertainty in patients’ 
response, as well as uncertainty in the final estimates of   . Furthermore, the correlations 
                                                 
18
 The scoring scheme used here is in reverse to that used in the NNT approach 
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between the body functions have not been addressed under the current BLRA approach. It is 
also questionable whether treating the entire body function as the “same” adverse event is 
appropriate as oppose to treating each adverse event within a body function separately 
(Mussen, 2009). The work example illustrated how I treated gastrointestinal colic and other 
abdominal pain as the same potential ADR under gastrointestinal disorders system organ 
class. It may not matter in this situation as the two conditions cannot be well distinguished or 
very similar in younger children population, but care must be taken when dealing with 
clinically more different AEs within the same body function. Berry and Berry (2004) has 
suggested a Bayesian hierarchical approach to better model the relationship among adverse 
events within and between body functions (Berry, 2004). The hierarchical model allows the 
AEs to ‘borrow strengths’ from each other based on their “biological correlations”. Therefore 
in principle Berry’s model can be incorporated into BLRA to improve its risk component, 
therefore the overall risk-benefit profile but I have not seen this approach being used. 
 
9.4.4 Clinical utility index and desirability index approach 
CUI has the same flavour as BLRA based on the concept of discounting benefit measure by 
risks albeit in a slightly different formulation and focus. CUI explicitly uses utilities for both 
risks and benefits to be weighted. It shares many of the limitations of BLRA. One is when the 
benefit and safety profiles of a drug are very similar (or identical), which led to the 
suggestion of desirability index approach as an alternative (Renard, 2009). This problem 
however is general to any risk-benefit approach with linear combination scores. 
 
Desirability index approach requires choosing an appropriate desirability functions to convert 
the responses into desirability indices. As well as the issues in choosing appropriate scoring 
schemes and weights, proper desirability functions are also needed. For categorical responses 
like the severity of AEs, a function based on probit models might be appropriate but the 
elicitation of the specific desirability functions requires multitudes of clinical inputs and 
perhaps large psychometric studies. Therefore, an illustration of DI approach can only be 
discussed as a “concept” approach here given the resources available. 
 
Sources of uncertainty in DI can be dealt with as in CUI via bootstrapping, Monte Carlo 
simulations, or under Bayesian framework. When log-normal distributions of the attributes 
can be validly assumed, correlations among attributes can also be readily taken into account 
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(Schwartz, 1982). Sensitivity analysis for DI comes in the form of visualisations using a 3-
dimensional surface plot for risk-benefit-desirability trade-offs (together with the 
uncertainties), and an equi-desirable contour plot of safety against efficacy for the assessment 
of weightings choice (Renard, 2009). 
 
Desirability index approach provides a framework to define lower and upper boundaries for 
the desirability functions; hence it has the capabilities to detect “out-of-control” values. In 
principle, in the risk-benefit assessment of drugs, clinical experts can elicit these boundaries 
for their patients as guidance for choices of utilities. Drug regulatory agencies could also pre-
specify the boundaries based on past experience to define a more uniform and explicit 
acceptable risk-benefit profiles for new drugs.  
 
9.4.5 Time trade-off approaches 
The time trade-off approaches described in Section 3.9.6 are favoured by health economists. 
Cost criteria can be added to the models, and it is a common practice to do so in cost-
effectiveness analyses. I have not illustrated time trade-off approaches as I regard them as 
somewhat different from other risk-benefit decision-making approaches and beyond the 
scope of this thesis. Their applications are not critical and not too relevant to this case study.  
Their advantages and limitations lie along the line the concept of time trading, and have 
strong link to psychometric discipline. 
 
QALY-based models have been criticised of potential bias and inadequacies in the various 
measures being used in its construction (Phillips, 2010b). For example, two QALYs for the 
same drug cannot be compared head-to-head when different measures were used in their 
construction. Because QALY models are not usually differentiated by specific therapeutic 
area or disease state, these models can be ‘insufficiently comprehensive’ (Phillips, 2010b). In 
principle, it is possible to use any criteria e.g. measures of efficacy on outcomes, health 
consequences, and time; but for most parts, QALY-based models are weak in acknowledging 
uncertainty and rely heavily on point estimates (Phillips, 2010b). 
 
In a parallel publication, Lynd (2010) shows that INB model with explicit and transparent 
data elements can quantify uncertainty surrounding decisions given available data (Lynd, 
2010). He demonstrates how the INB framework through the application of RVALYs can be 
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used for regulatory decision-making of the treatment of irritable bowel syndrome using 
alosetron through simulations (Lynd, 2010). The simulations were based on data from seven 
published RCTs of alosetron versus placebo, and incorporated conjoint patient-preference 
weights on the outcomes obtained through a discrete choice experiment (see Section 9.5). He 
concludes that the INB framework is a strong candidate for use in real-life decision-making; 
but its practicality is yet to vindicate. 
 
9.4.6 Decision tree approach 
The options and consequences are assembled into a simple tree diagram as shown in Figure 
9.15 for the case study.  
 
 
 
From data in Table 9.5, the expected utilities for the three options are: 
 
No treatment:  [ (  )]       (    )                        
Cisapride:  [ (  )]       (    )                        
Domperidone:  [ (  )]       (    )                        
 
Figure 9.15 Decision tree for treatment options for gastro-oesophageal reflux 
Decision Event? Utility of consequences 
None 
d0 
  𝜋  
Not improved 
Cisapride 
d1 
Domperidone 
d2 
𝜋  
Improved 
  𝜋  
Not improved 
𝜋  
Improved 
U1 – c2 
U0 – c2 
U1 – c0 
U0 – c0 
  𝜋  
Not improved 
𝜋  
Improved 
U1 – c1 
U0 – c1 
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The utilities          for still having GOR symptoms and having improved GOR symptoms 
respectively are measured on some scale from 0 to 1 where 1 indicates perfect health 
(assuming this state can actually be reached). ci (i=0,1,2) refer to monetary costs (Ashby, 
2000). An orthodox decision tree approach requires further branches to be built into the tree 
with the relevant probabilities and utilities as illustrated in Figure 9.16 with one of the 
options. The full decision tree diagram would contain      branches for   options and   
number of attributes i.e. 24 branches. The calculations of expected utilities can be very 
messy; and require joint utilities and conditional probabilities for later attributes given the 
option and earlier attributes. Under independence assumptions among probabilities, the 
expected utilities can be calculated by multiplying the probabilities along each branch with 
their respective joint utilities, and then combined by discounting expected utility of perfect 
outcome i.e. improved with no adverse events, by the sum of the other expected utilities. 
 
 
 
Grey triangles indicate that the branch branches out from previous grey circles.         are 1 or 2 denoting the 
upper and lower branches from previous branch 
  
Figure 9.16 Illustration of full decision tree expansion for one of the options 
  𝜋  𝑚 𝑛  
𝜋  𝑚 𝑛  
  𝜋  𝑚  
𝜋  𝑚  
None 
d0 
Cisapride 
d1 
Domperidone 
d2 
  𝜋  
Not improved 
𝜋  
Improved 
AE 1 AE 2 
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As an alternative, ci from the earlier formulations can be considered as a mixture of monetary 
cost
19
 and utilities of AEs instead. Separate decision trees can be built for each adverse event 
with utilities    (   )       (   ) for experiencing and not experiencing AE   where     
for abdominal pain and     for bronchitis and bronchiolitis. Their expected utilities of AEs 
are shown in Table 9.8, assuming when untreated, an overall rate of abdominal pain is 3 per 
thousand, and an overall rate of bronchitis and bronchiolitis is 20 per thousands. 
 
Table 9.8 Expected utilities of adverse events by treatment options 
 Abdominal pain Bronchitis and bronhiolitis 
No treatment:         (   )          (   )         (   )          (   ) 
Cisapride:         (   )          (   )         (   )          (   ) 
Domperidone:         (   )          (   )         (   )          (   ) 
 
The weighted utilities of AEs can be calculated using the seriousness scores used in BLRA 
(see Section 9.4.3). Having weighted the utilities of AEs, under linear combination and 
appropriate choice of weighting factor   for risk and benefit, the utilities for the treatment 
options are: 
 
No treatment: (             )      ((        (   )          (   ))  
(        (   )          (   )))  
 
Cisapride: (             )      ((        (   )          (   ))  
(        (   )          (   )))  
 
Domperidone: (             )      ((        (   )          (   ))  
(        (   )          (   )))  
 
  
                                                 
19
 Monetary costs as an attribute in risk-benefit decision analysis models is beyond the scope of this thesis. 
Although I acknowledge they are important and do contribute to the final model, any costs when mentioned are 
treated as arbitrary constants. There are no real values associated with any costs attributes throughout this thesis. 
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The results for the decision tree model are left in terms of the three formulae, where the 
solutions are dependent on choices of input values for the various utilities, weights and 
monetary costs. The extended use of decision tree approach in a multi-criteria analysis 
framework is discussed in Section 9.4.7. 
 
The technology is straightforward and logically sound but building a decision tree diagram is 
a work of art (Phillips, 2010b). With more and more nodes (options and consequences) 
involved, the diagram can expand exponentially and quickly becoming very complex. 
Without computer software, building complex decision tree for decision-making is far too 
impractical. Popular decision tree software include DPL (Syncopation, 2010), Precision Tree 
for Microsoft Excel (Palisade, 2010), and Analytica (Lumina Decision Systems, 2010). 
However, once the decision tree model for a problem is set up, the parameters along the 
branches can easily be changed to accommodate different modelling assumptions; and can be 
used for sensitivity analysis. Advanced decision tree model approach involves Bayesian 
belief network and neural network. 
 
9.4.7 MCDA approach 
MCDA approach puts the good practice of evidence-based decision-making into a natural 
framework through the eight-step process described in Section 3.9.9. As natural and fluid as 
the MCDA framework goes, it did not explicitly specify the choice of parameters to be 
considered when an MCDA model is to be built. Our case study suggests the parameters for 
inclusion in MCDA models for drug treatment options – and their sources – where good 
clinical trials data are unavailable. 
 
All MCDA analysis and diagrams were conducted and produced by an evaluation version of 
Hiview3 software from Catalyze Ltd, Winchester UK (Catalyze Ltd., 2010a).  The evaluation 
version has full capabilities as a fully-licensed version for a 20-day period, which provides 
enough time for conducting MCDA in this section. 
 
A decision tree is built (Figure 9.17) with three treatment options – no treatment, cisapride, 
and domperidone – and important attributes (‘criteria’ in Hiview3) from previous analyses. 
Figure 9.17 illustrates that there is one benefit criterion i.e. improvement, and two risks 
criteria i.e. abdominal pain and bronchitis (and bronchiolitis). The two risks criteria are 
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placed under a parent node labelled as “Risks”. The criteria are assumed to be mutually 
preference independent i.e. preference value for each criterion can be scored independently 
without knowing the scores assigned to the other criteria. Consequently, this is also assuming 
that preference values on one criterion are not affected by another. 
 
Figure 9.17 Decision tree for case study generated by Hiview3 
 
 
The preference values are obtained from the probabilities (as percentages) of improvement in 
Table 9.5 for each option, and ‘probabilities to preferences’ value function in Hiview3 was 
used to convert to preference values. Risks are obtained from the incidence rates ratios (IRR) 
in Table 9.3 for domperidone and cisapride. Natural logarithmic-transformed IRRs were 
used, and inversed linear value functions were used to convert to preference values so that 
higher        corresponds to lower preference value. These processes are shown in Figure 
9.18. After preference values have been elicited, the criteria are weighted, initially for the 
risks criteria at the parent “Risks” node, and then between risks and benefit criteria. 
 
Importance weights for each risk criterion are derived from the elicited adverse events 
seriousness scores from CIOMS Working Group IV report (CIOMS Working Group IV, 
1998), as used in BLRA (Section 9.4.3) and decision tree (Section 9.4.6) approaches above. It 
follows that abdominal pain criterion is weighted 39% as important as bronchitis and 
bronchiolitis criterion at the parent “Risks” node level. As elicited weights for risks and 
benefit are not available, I assigned several choices of weights to illustrate the change in 
overall expected utilities of each option. Table 9.9 shows the results for different weights 
choices. During the weighting process, Hiview3 implements the ‘swing-weighting’ methods 
(Dodgson, 2000) to calibrate the relative importance between criteria ensuring that the 
preference values between criteria are comparable. 
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The last column in Table 9.9 demonstrates how each criterion contributes to the weighted 
differences between domperidone and cisapride after swing-weighting. The more important 
the adverse events are compared to the improvement in GOR symptoms, the more they will 
contribute to the total utility scores. 
 
Figure 9.18 Evidence-based data and their associated preference values 
Data Converted preference values 
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Table 9.9 Utility scores for each option at different risk-benefit weights and snapshot of weighted 
comparison of domperidone to cisapride by attributes 
Risk:Benefit 
weights 
No treatment Cisapride Domperidone 
Weighted difference
a 
 
by attributes
 
100:100 58 71 42 
 
Improvement 
Abdominal pain 
Bronchitis 
50:100 41 76 59 
 
Improvement 
Abdominal pain 
Bronchitis 
10:100 12 84 88 
 
Improvement 
Abdominal pain 
Bronchitis 
5:100 6 86 94 
 
Improvement 
Abdominal pain 
Bronchitis 
a
 domperidone-cisapride by attributes: Green = positive differences, red = negative differences 
Optimal option is highlighted for each risk:benefit weights choice 
 
Figure 9.19 Sensitivity analysis graph of expected utilities for treatment options against total weight on 
risks attributes 
 
Vertical red line represents the total weight on risks in current model  
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A sensitivity analysis on “Risks” node can also show – graphically – how the expected 
utilities change with different weights. The frontiers of the green-shaded areas in Figure 9.19 
show when the choice of weights given to risks and benefits can shift the optimal treatment 
option. For example, when the total weight on risks is small relative to benefit at about 18, 
domperidone would be the optimal treatment option; when the total weight on risks is large at 
about 66, no treatment would be the optimal option; otherwise, cisapride would be the 
optimal treatment option. In the absence of cisapride as an option, domperidone should only 
be considered as optimal option when total weight on risks is less than 50 relative to benefit 
under current model data and assumptions. 
 
Ideally, preference values for each criterion should be composed of two sub-criteria: (1) the 
stakeholder’s value judgement, and ( ) the evidence data. However, proper stakeholder’s 
input is infeasible at this stage given the resources and focus of this thesis. It is unwarranted 
to assume the same values for different options as the severity of the same AE, for example, 
would be different depending on treatment options. Although MCDA framework allows 
theoretical value judgement to be inputted, the software used does not provide a 
straightforward infrastructure to do so. The same applies to the assessment of uncertainty in 
preference values and data. Therefore this limitation is of the software due to its “point-and-
click” implementation, rather than the limitation of the approach itself. 
 
The MCDA manual (Dodgson, 2000) explicitly stated that at the sensitivity analysis stage, 
the options and criteria used in the model should be revised to verify whether different ones 
or additional ones are needed. In my opinion, it is not a good practice as like any other 
statistical analyses, it would introduce multiplicity problems and should not be encouraged. 
All options and criteria should be well-defined and pre-specified before any analysis is 
undertaken. 
 
The application of MCDA can be too burdensome for simple problems (Guo, 2010) when 
there is small number of options and criteria involved. Clear guidelines are not set in stone as 
to when an MCDA approach would add any value to decision-making when compared to the 
other easier approaches.  
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9.5 Choice of input values in risk-benefit assessments 
Quantitative risk-benefit approaches are only as good as the available data, the preference 
scores, and the weightings. There is not much more to say about available data and their 
quality which have been discussed thoroughly in Chapter 2. The usual hierarchy of evidence 
sources applies here in which randomised clinical trials’ evidences are universally regarded 
as the gold standard. For certain drugs used in certain population, data from clinical trials are 
not available, very limited, or of poor quality. In our case study, we were able to find a good 
quality surrogate data for domperidone and cisapride when clinical trials evidences of their 
use in children population are scarce. This to some extent helps to address the issue on 
available data for use in risk-benefit assessments of post-marketing drugs that are commonly 
used in general practices. 
 
The main challenges in any quantitative risk-benefit assessment are in assigning numeric 
values to attributes that are typically considered qualitative (most of the times, ordinal in 
scale), and in combining multiple attributes without proper unit of measurements or any 
known scaling method. Only the time trade-off approaches are able to circumvent these 
complexities just because the approaches trade risks and benefits attributes in terms of 
monetary values (cost-utility analysis) and time (QALY-based analysis), which are real 
numeric values and well-defined units of measurements. Conversion to monetary values and 
trading the willingness to pay for goods is referred to as contingent valuation (Phillips, 
2010b). 
 
In theory, contingent valuations can be used as part of any risk-benefit approach by assessing 
how much money an individual is willing to pay to obtain certain benefits, or how much an 
individual is willing to pay avoid certain risks. Although contingent valuation technique 
might seem like an attractive and sensible approach to obtain preference scores and choices 
of weights, it also comes at a price. Monetary costs might be fixed on their face values, but 
the interpretation and the value worth of the same amount of money mean different things to 
different individuals. A £20 note would obviously have less value to a very rich individual 
but worth more to more unfortunate individuals. The state of illness could also affect how the 
face value of money is worth to that individual. The extra amount of money an individual is 
willing to pay or to trade is also dependent on the amount he/she is already willing to pay. 
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Willingness to pay trading strategy is subjected to lack of scope sensitivity
20
, strategic 
biases
21
, and warm glow
22
 (Ryan, 2001). Therefore careful considerations of contingent 
valuations and robust formulations of the questions about willingness to pay are required to 
ensure the method provides fair trading values. 
 
More generally, elicitation of preference values associated with a problem is done 
qualitatively as a group where members are representatives of the stakeholders – patient 
representatives, clinical experts, regulators, etc. More formal qualitative methods of 
elicitation such as Nominal Group Technique (NGT) and Delphi technique are preferred.  
 
NGT involves a structured face-to-face meeting where important criteria for a problem are 
discussed and agreed using an iterative process (Finkler, 2007). The iterative process includes 
defending individual ideas, identifying candidate ideas, and ranking and rating them for the 
next iteration (Van de Ven, 1972). The outcome of NGT can be biased by the personalities of 
the group members. For example, when there is a dominant member, agenda can be pushed 
forward thus influencing outcome. Some individuals might also be reluctant to share their 
ideas and judgements for various reasons in a face-to-face meeting (Finkler, 2007). Three 
methodological difficulties have been recognised and discussed, which are the selection of 
target group members, the specification of the question to be used, and the transformation of 
raw data into standardised measurements (Van de Ven, 1972). The selection of target group 
members should be comprehensive enough to address different perspectives from different 
stakeholders. The main question, and crucial and essential information needed from target 
group should be clear. Transformations of raw data into standardised measurements are 
subjective and often involve further elicitation process e.g. that of the focus of decision 
conferencing (Catalyze Ltd., 2010b) for elicitation of MCDA preference values. 
 
Delphi technique is very similar to NGT but the members of the group never actually meet 
(Finkler, 2007). The entire process is done anonymously and most of the times by written 
mails. A group leader is responsible to summarise and disseminate the ideas from all group 
members iteratively as carried out in NGT. Delphi requires the same members to refocus on 
                                                 
20
 willingness to pay is valued to act in a “market-like” manner where costs are associated with differing 
quantities and qualities of purchased good (Chilton, 2000) 
21
 strategic bias occurs when respondent’s valuation does not represent truthful preference revelation e.g. due to 
random responses (Carson, 2000) 
22
 valuing the willingness to pay as equally for private or environmental purchase (Chilton, 2000) 
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the same problems several times, therefore is very demanding in terms of time and larger 
group members required. Delphi technique can avoid confrontation by avoiding face-to-face 
meetings, and avoid bias due to group members’ personalities and positions (Finkler, 2007). 
However, the group leader should be impartial when disseminating the results at each 
iteration otherwise selection and reporting bias can easily occur. 
 
Quantitative method for eliciting preferences is formally performed using conjoint analysis 
(CA) after the final attributes have been elicited e.g. using one of the qualitative elicitation 
methods above. Discrete choice experiment (DCE) is a choice-based form of CA, with the 
attributes and the level of attributes organised into scenarios to be evaluated by stakeholders 
(Ryan, 2001). The scenarios are chosen to be orthogonal in designs; and factorial designs are 
usually used in the experiment itself but is time-consuming (Phillips, 2010b). Statistical 
models such as multiple logistic and probit models are performed to derive the change in risk 
or benefit between options. As much can CA be used as a risk-benefit assessment approach in 
its own right, it can also be used to quickly derived scores and weights associated with 
attribute levels for use in another approach such as the MCDA (Phillips, 2010b). 
 
It has now become apparent that many techniques are available both for integrating risks and 
benefits, as well as for acquiring input values to contribute to the integrated risk-benefit 
models. However, in most parts, input values elicitations such as attributes selection, scoring 
and weighting are still subjective – and not much can be done about it. They are very much 
dependent on the members of the group making the judgements, and the size of the group. 
The consensus reached at the end of an elicitation process would be more affected by who are 
in the group when the size of the group is small, but may not make any difference least when 
it is large. The uncertainty in measurements would also be greater with small group size. 
Another downside with membership and small group size is that in an iterative or serial 
elicitation process, auto-correlations between the preceding and subsequent iterations would 
be high, thus longer time is needed to obtain stability or a consensus. In an extreme scenario 
when the membership of the group only contain one person, then the group elicitation process 
simply falls apart. 
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9.6 Discussion 
Many of the approaches share similar requirements involving appropriate probabilities, 
scoring, weighting and mathematical operators. The first three have been discussed in 
previous sections (see also Table 9.4 for comparison). Operators may not be regarded as 
having important roles in risk-benefit assessment, but this is far from the truth. Operators play 
the crucial role in risk-benefit trading. Addition (also subtraction) operator is the most 
common and its use implies that the function of the resultant metric is linear. Multiplication 
(also division) operator carries the flavour of risk-benefit ratio (Chuang-Stein, 1991) and may 
be preferred in some circumstances. As described in Section 3.9.5, when multiplication 
operator is used, any unacceptable attribute in an option will cause the option to be 
unacceptable as a whole. 
 
The risk-benefits assessment illustrated here did not take into account any correlations 
between attributes. In real world situations, correlations do exist between any two attributes 
but small correlations can be ignored without any impact to the model. Highly-correlated 
attributes indicate some redundancy in one or more of the attributes and may be treated as a 
single attribute. The extra attributes would only add variations but not extra information if 
included but incorrectly treated. The directions of the correlations also need to be properly 
addressed. Positive correlations (   ) reduces overall uncertainties, and negative 
correlations (   ) increases overall uncertainties of estimates. In a decision analysis 
model, the weights of positively correlated attributes are greater than what it should be when 
independence is assumed; therefore incorrectly value the importance of the attributes, and 
vice versa for negatively correlated attributes. Methods for finding objective weights for 
correlated attributes have been suggested but are not discussed here (Diakoulaki, 1995).  
 
Clinical issues of integrating risks and benefits evidences have not been addressed here but it 
is imperative to note that they need to be taken into account. There are issues related to 
diagnosis of a medical condition which might affect what gets diagnosed and recorded. These 
also vary over time as definition for certain medical conditions change over time, as well as 
the advances in medical technology available. In the context of medicines, sicker individuals 
tend to present more and variety of other medical conditions. They also tend to consume 
more drugs for the various conditions giving rise to the issue of drug-drug interactions. 
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Broadly, the risk-benefit assessment approaches can be categorised into those that are based 
on probability theory, and those that are based on decision theory. Probability theory 
approaches are those in the line of NNT approach. Although the later extension of NNT 
approaches incorporates the idea from decision theory, the resultant metrics are still being 
interpreted in terms of probabilities. From decision theory point of view, probability-based 
approaches lack logical soundness (Phillips, 2010b). Those rooted from decision theory have 
more direct interpretations when used in decision analysis. From my perspective, both 
schools of thoughts have their place in decision-making, and have been used successfully in 
the past. However, the approaches which are too reliant on point estimates without taking the 
uncertainty into account should be least preferred because good decisions could not be made 
on point estimates alone.  
 
Of the quantitative benefit-risk approaches demonstrated in this chapter, the benefit-less-risk 
analysis (BLRA) approach (introduced in section 3.9.3 and applied in Section 9.4.3) provides 
the most intuitive framework for assessing the risks of drugs from the observed ADRs. The 
methodology is simple and directly address risks of drugs in terms of ADRs classification by 
body functions. Its application may be too simplistic, but can be improved by taking into 
account the issues of statistical uncertainties in point estimates and correlated body functions 
through appropriate statistical modelling as addressed in Section 9.4.3. The interpretation of 
the results is sensible and easily understandable which follows the familiar notion of net 
benefit. The transparency in BLRA is rather weak, but better documentation of the decisions 
made throughout the process as practiced in MCDA applications would help improve this. 
 
Finally, it is important to reiterate that decision-analysis models only exist to aid decision-
making process but do not actually make the decisions as illustrated by the examples above. 
It is up to the decision-makers which option(s) is ultimately chosen. 
 
The structured evidence data mining framework presented in the last Chapter 8 can be used 
for risk-benefit assessment in its own right, or more importantly can contribute to future trials 
of medicines in children. Chapter 10 presents dissemination of results from the evidence-
synthesis approach so far into a planned future trial, and discusses other possibilities, and 
further difficulties including communication of the risk-benefit assessment results. 
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10. Propagating evidence-based risk-benefit to medicine and future trials 
10.1 Introduction 
In Section 1.3, I mentioned that the purpose of this thesis is to improve decision-making of 
drugs use and prescription through evidence-based risk-benefit research. A variety of 
methods have been used and discussed at different stages of this study. The amalgamation of 
these methods and stages form a framework and is discussed in Section 10.3. The results 
from the analysis in previous chapters point to uncertainty in evidence of risk-benefit balance 
of domperidone which requires further data collection through clinical trials. The risks and 
benefits assessed previously are disseminated into a planned future trial of domperidone in 
Section 10.4. The value of information for decision-makers is addressed in Section 10.5, and 
the challenges faced in the communication of evidence-based risks and benefits are discussed 
in Section 10.6. Further difficulties are addressed in Section 10.7. 
 
10.2 Aims and objectives 
This chapter aims to take the evidence-based risk-benefit decision-making using systematic 
reviews and GPRD a final step further by inputting the results directly into planned future 
clinical trial of medicines. Specifically, the evidence gathered, assessed and weighed in a 
multi-stage framework encountered in Part II and Chapter 9 are encapsulated into designing a 
clinical trial of domperidone in children for the treatment of gastro-oesophageal reflux 
disease (Section 1.4). 
 
Four objectives are set, and they are: 
iv. to summarise the stages in the risk-benefit evidence synthesis framework proposed 
with reference to case study; 
v. to demonstrate how evidence of risks and benefits from this study would benefit 
future trials of paediatric medicines through a work example;  
vi. to elucidate the value of information this study adds to different stakeholders; and 
vii. to discuss anticipated challenges in communicating evidence-based risks and benefits 
to clinical trials, and general audience 
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10.3 Framework for evidence-based risk-benefit decision-making of medicines for 
children 
Earlier chapters have presented a novel framework to improve evidence-based risk-benefit 
decision-making of medicines for children by way of application to a case study. It may be 
difficult to see how the multiple stages come together in the framework, so I summarise them 
in this section as a walkthrough of Figure 10.1 – depicting the process flow – with references 
to the case study. 
 
The decision problem to be investigated is whether the use of domperidone in children and 
conducting TRI-Domp is justifiable. The research questions are to assess the evidence of 
risks and benefits of domperidone, to investigate the risk-benefit balance of domperidone, 
and to determine the next course of action on the status of its use in children population. 
 
In order to strengthen the argument for the need and appropriateness of a domperidone trial in 
children, firstly, trends analysis and systematic reviews were performed. There were no new 
issues found associated with domperidone prescription from the trends analysis; otherwise 
the research questions need to be reviewed. The trends analysis (Chapter 6) supports the 
decision problem and research questions identified a priori. Systematic review of evidence 
from RCTs found insufficient and inconsistent findings on benefits, and poor reporting of 
risks thus pointed to the need of an alternative high quality evidence source. If there were 
sufficient and robust high quality evidence for domperidone use in children, then risks and 
benefits balance can be immediately assessed. 
 
Observational data from the GPRD was judged to be of high quality and was a suitable 
alternative source for obtaining individual patient data based on their clinical activities in 
primary care. Due to the nature of data collection in primary care and the medical condition 
of interest (GORD), there was only potential for assessing evidence of risks associated with 
domperidone prescriptions (assuming prescription implies usage) in the database. Therefore 
the best available evidence for benefits of domperidone comes from the meta-analysis of 
systematic review data. In different circumstances, for example when drug benefits are 
clearly defined major events like death or stroke, GPRD is anticipated to be a good 
alternative source of evidence. Alternative source of evidence data for risks and benefits do 
not necessarily need to be from the same source, but it is necessary that they have the similar 
patient characteristics e.g. age structure and pattern of drug use. However it would be most 
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ideal if the same data source can provide both risks and benefits evidence. This would ensure 
that any systematic bias resulting from the data source, e.g. methods used to collect data, can 
be minimised. 
 
Benefit outcomes associated to drug use are usually known to investigators. Subject to proper 
encoding translation into Read codes or MedDRA terminologies, the evidence of benefits can 
be obtained from GPRD and assessed using standard statistical techniques. The Bradford Hill 
causal framework can then be used to exclude chance findings of drug benefits. On the other 
hand, risks (adverse events) of a drug therapy are not comprehensive (see Chapter 2), and 
continuous safety monitoring is required e.g. through YCS (Section 2.3) and legal 
requirement for drug risk management plan (see Section 11.1). 
 
Known adverse events were obtained and assessed following encoding into Read codes or 
MedDRA terminologies (Chapter 8), whilst unknown adverse events were mined to generate 
signals using disproportionality data mining technique and then validated (Section 3.7). 
Validated signals were consistent and occurred less by chance alone; and further investigated 
to confirm their association to drug use (Section 8.4). Because association does not imply 
causation, their causal relations to drug were argued through the application of Bradford Hill 
causal framework (Section 8.5). 
 
In a real-life decision-making exercise, patients’ or other relevant utilities would have to be 
elicited systematically and thoroughly for any rational decision to be made (Section 9.5). 
Having elicited utilities for attributes of a decision problem, the evidence of risks and benefits 
of a drug treatment were assessed simultaneously using an appropriate risk-benefit 
assessment approach (Section 9.4). 
 
At the end of the process, three scenarios are possible. First, the benefits outweigh risks 
(positive R-B balance) thus supports the use of the drug given the research questions. Second, 
the risks outweigh the benefits (negative R-B balance) thus does not warrant drug use given 
research questions. Third, the evidence of risks and benefits balance is uncertain therefore 
requires new clinical trial to collect more evidence to address the uncertainty. The case study 
of domperidone as a treatment for GOR in children thus fell into the third scenario, and 
supports the proposal to conduct TRI-Domp. 
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Figure 10.1 Framework for evidence-based risk-benefit synthesis for future trials of medicines 
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10.4 Dissemination of evidence-based risks and benefits 
Robust evidence of safety and efficacy of domperidone for GORD in children have not been 
established (Pritchard, 2005). Previous trials are old, small (and possibly underpowered) and 
used very low doses of domperidone (Bines, 1992; Carroccio, 1994; Clara, 1979; De Loore, 
1979). In most parts of this section, the reference will be specific to TRI-Domp trial. TRI-
Domp was planned to investigate the safety and efficacy of domperidone in the treatment of 
gastro-oesophageal reflux disease (GORD) in infants 0 – 18 months old. As domperidone is 
regarded as the best recommended drug treatment option for severe GORD when alternatives 
have failed, TRI-Domp plans to randomise participants to domperidone and placebo from 
infants attending the paediatric gastroenterology units in London, Cheshire, Trent and North 
Wales Local Research Networks. Domperidone daily dose regime of 1.6 mg/kg was 
proposed. More detailed description of the planned trial TRI-Domp sits in the introduction 
(see Section 1.4). 
 
This thesis only focuses on conveying risks and benefits to the development of clinical trials. 
Other aspects of clinical trial planning may also be advised from this kind of study but is not 
discussed here – see GORMET report for discussion on advising other aspects of trial (Mt-
Isa, 2010). There are three key aspects of clinical trial development that are directly related to 
the work of this research, which are discussed in Sections 10.4.1 to 10.4.3 below. 
 
10.4.1 Evidence-based dose selection agreement 
The first aspect this study addresses is the selection of treatment dosage regime in the new 
trial. Mean daily dose of 0.8 mg/kg (Section 6.4.5) was observed among children below two 
years old in the GPRD domperidone cohort with mean duration of exposure period of about 
4.5 months. Previous trials included in the systematic review in Chapter 7 (extracted data is 
available in Appendix A.4) mostly used much lower doses of domperidone than the 
suggested 1.6 mg/kg/day (Carroccio, 1994; Clara, 1979; De Loore, 1979), except for one trial 
that administered slightly higher doses (Bines, 1992). Both results from case study and meta-
analysis suggest that the doses that have been used might be too low to be effective. Our 
analyses neither have sufficient evidence to argue for a lower dose than 1.6 mg/kg/day, nor 
have the evidence to suggest a much higher dose regime. 
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In our analysis of dose effect (Section 8.4.4), we found some evidence suggesting that 
increase in cumulative dose was associated with occurrence of abdominal pain and bronchitis 
and bronchiolitis. This implied that the length of exposure to domperidone may have an 
effect on safety. However, we did not investigate length of exposure comprehensively to be 
able to come to a definite conclusion on its association to domperidone.  
 
TRI-Domp however may need to be more vigilant in order to capture the occurrences of 
adverse events as trial progresses when children have accumulated higher dose. Based on the 
odds ratio for cumulative dose, we could estimate the risks of the events as the trial progresses, 
for example using those in Table 8.10. For children below two years old, the odds ratio of 
bronchitis and bronchiolitis was estimated to be 1.27 (95% CI 1.14 – 1.41) for every 50% 
increase in cumulative dose. We can use the odds ratio to estimate that children in the trial are at 
three times increased risk of bronchitis and bronchiolitis at the end of week one, and seven times 
increased risk at the end of week four, when compared to day one. Figure 10.2 illustrates 
theoretical extrapolations of the risk of bronchitis and bronchiolitis over the period of a 4-week 
trial. 
 
Figure 10.2 Theoretical extrapolations of increasing odds ratio of bronchitis and bronchiolitis in children 
below two years old compared to day 1 as a 4-week trial progresses 
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10.4.2 Evidence-based risk-benefit profiles of treatment option 
The primary outcome for the improvement of GOR symptoms that was proposed in TRI-
Domp is similar to the benefit outcome from the systematic review (Chapter 7). The 
dichotomisation of the clinical response into “improved” and “not improved” is regarded as 
appropriate because it closely matches the clinical scenario in which decisions on whether a 
treatment is successful are made (Croft, 2007). 
 
Basic NNT approach suggests that one improvement is expected to be observed for every 
three children treated with domperidone (Section 9.4.1). An abdominal pain event and a 
bronchitis and bronchiolitis event are expected for every 30 and 23 exposed children 
respectively. Slightly higher number is required if the age of children in the trial population is 
younger to observe an improvement and abdominal pain, but less is required to observe a 
bronchitis and bronchiolitis in younger children. AE-NNT offers a method to integrate risk 
and benefit into a single measure (Section 9.4.2). In this situation, the adjustment for risk of 
abdominal pain and bronchitis and bronchiolitis separately did not penalise the original NNT 
very much. Only one extra child is needed to expect one “unqualified success” of 
domperidone treatment i.e. observing an improvement without observing any abdominal pain 
(or bronchitis and bronchiolitis) adverse events in the same children. 
 
Patients’ utilities may also have an impact on the outcomes considered. Minimum clinical 
efficacy approach provides a simple method to incorporate the utilities into the decision 
metric. MCE is an intuitive measure that is directly related to the “delta” ( ) of the minimum 
difference between treatments typically used to power a clinical trial. Through this evidence-
based research, where data available, MCE would be a more appropriate measure than the 
simple   to be used in sample size calculations as discussed in Section 10.4.3. The advantage 
of MCE over   is that it takes into account the efficacy and safety of an active comparator as 
well as utilities of the attributes (see further discussion in Section 10.6).  
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Similar arguments of the results from BLRA approach can also be used to feed into TRI-
Domp. I do not show this here as specific results for BLRA are not currently available, and 
there are still further uncertainties to be addressed e.g. the choice of proportionality constant 
 . The mathematical rigour of decision tree and MCDA approaches have not been studied 
thoroughly in this thesis. From the results of the analysis conducted (Sections 9.4.6 and 
9.4.7), their contribution to the development of clinical trial at this stage is somewhat limited 
to deciding whether a planned trial could go ahead.  
 
In general, the evidence of risk-benefit balance of domperidone when used in children is 
uncertain. There were no alarming adverse events related to the prescription of domperidone 
observed in the study. Most of the AEs we observed were based on very low incidence rates 
per person-month, and some could be dismissed because they were assessed to be unrelated 
to domperidone prescription. Clinical trials’ evidence of benefits on the other hand had been 
uncertain from the beginning and no alternative evidence source was appropriate for further 
exploration on the outcomes. At this stage only a new clinical trial can address these 
uncertainties by collecting more data on appropriate risks and benefits of domperidone. 
 
10.4.3 Evidence-based consensus for additional elements of data collection 
The research questions have established that the population of interest is children younger 
than 18 months old. So the next most appropriate question to ask is how big of a sample. In 
section 10.4.2, MCE is acknowledged as a more sensible choice of “delta” for sample size 
determination. MCE are calculated for different relative values as described in Section 9.4.2. 
The sample size requirements assuming that children in the placebo group would improve at 
a rate of 0.46 person-months are graphed in Figure 10.3 for integer RVs. Allowing worst RVs 
in both attributes, only 18 children are required to show the efficacy of domperidone. On the 
other hand, 10,397 children in each arm are required to attain the best possible scenario when 
both AEs are possible. 
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Figure 10.3 Sample size requirement based on relative values (RV) of risks attributes for domperidone 
 
 
There is a large literature (Adcock, 1997; Berger, 1985; Lindley, 1997) on sample size 
calculations in medical decision-making using different models and assumptions which will 
not be reviewed here. Choosing sample size for a trial is naturally a decision problem in this 
context. Considerations are to be given to the trade-off between carrying a larger study and 
improving final decision with respect to some further criteria (Parmigiani, 2002b). One way 
to do this is to find the smallest sample size that guarantees the parameter to be observed e.g. 
expected utility; and another is to explicitly model the cost and utility of the experimentation 
(Parmigiani, 2002b).  
 
A fully Bayesian approach to sample size calculation using the maximisation of expected 
utility method has been proposed (Lindley, 1997), and takes the form (Adcock, 1997; 
Lindley, 1997): 
 [ (   )]          (   ) 
Although the equation looks disarmingly simple, it shares the difficulties in using utilities in 
any context. The choice of constants   and   would have an impact on the sample size   
when a fixed cost   is involved at statistical level   (say 0.05).   and   also affects  , the 
function of data, when it is arbitrary in the utility maximisation (Adcock, 1997).   
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Data elements to be collected can also be justified from this research. Although many 
researchers are tempted to collect vast amount of data to address every single suspicion, this 
is not possible. It is sensible to assume that any clinical trial conducted is restricted to the 
budget amount. A trial cost needs to be properly managed to ensure that the planned trial runs 
smoothly. Certain amount of trial budget is usually allocated to aspects of data collection 
because the size of database can cost more to set up and to maintain, and measuring certain 
outcomes can be very costly e.g. ECG monitoring. There are the “must-haves” and the “nice-
to-haves” data in every clinical trial. Evidence-based risk-benefit research can address this 
issue for items directly related to risks and benefits. Table 10.1 lists the data elements that 
TRI-Domp should explicitly collect in order to confirm the safety issues that have surfaced 
through the risk-benefit analysis; and the grounds for the proposition. 
 
Table 10.1 Proposed data elements to be collected during TRI-Domp trial and the grounds of the 
propositions 
Proposed data collection Grounds of proposition 
Rash It is a recognised ADR of domperidone and it is associated 
to domperidone with OR 1.24 (95% CI 1.09-1.40) among 
exposed children. 
Diarrhoea It is a possible ADR of domperidone and it is associated to 
domperidone with OR 3.27 (95% CI 2.94-3.65) among 
exposed children. 
Arrhythmias It is a possible ADR of domperidone (which was a genuine 
safety issue for cisapride driving its withdrawal) and it is 
associated to domperidone with OR 6.42 (95% CI 1.17-
35.10) among exposed children. However, this was based 
on a low incidence rate of 0.04 per 1000 person-month. 
Abdominal pain It is a potential ADR of domperidone and it is associated to 
domperidone with OR 14.40 (95% CI 12.77-16.24) among 
exposed children. 
Bronchitis and bronchiolitis It is a potential ADR of domperidone and it is associated to 
domperidone with OR 4.73 (95% CI 4.25-5.27) among 
exposed children. 
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Furthermore, there was some evidence that concomitant use of other drugs causing 
abdominal pain significantly increased the abdominal pain adverse events with OR 1.74 (95% 
CI 1.19-2.56). Also, other drugs causing bronchitis and bronchiolitis significantly increased 
the risks of the adverse events with OR 2.75 (95% CI 1.20-6.24). These results suggested that 
the use of these drugs must be avoided for safety reasons as well as to minimise bias and 
contamination to the results. The list of these drugs is available in GORMET study report 
(Mt-Isa, 2010). 
 
10.4.4 A brief remark on cisapride as treatment option from the evidence-based risk-benefit 
framework 
Although cisapride has been withdrawn from the UK market due to safety concerns (Chapter 
4), a future trial may wish to evaluate the risk-benefit evidence in comparison to available 
treatment options. Similar to domperidone, the benefit of cisapride in the treatment of GOR 
in children was not established. Based on the data from the GPRD used in this case study 
alone, the evidence of risks was uncertain. Explanations include that children with severe 
GOR are usually treated in hospitals where cisapride was prescribed thus was not captured on 
GPRD database.  
 
NNT-based analyses under indirect treatment comparison model suggest that cisapride is less 
effective than domperidone on average but is accompanied by large variance i.e. not 
statistically significant (Section 9.4.1 and 9.4.2). Adjustment for relative values as functions 
of patients’ utilities, the balance can go both ways. The BLRA approach suggests similar 
conclusion (Section 9.4.3) but is also very dependent on patients’ utilities. The decision tree 
and MCDA also indicates uncertainty in optimal decision based on the importance weights 
assigned to risk and benefit attributes (Section 9.4.6 and 9.4.7). 
 
Had cisapride not been withdrawn, a suitable trial to conduct would have been a three-arm 
double-blinded randomised controlled trial comparing cisapride, domperidone, and placebo. 
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10.4.5 Remarks 
The elaborate work involved may seem unjustified for a simple decision problem. However, 
in a situation where past evidence of risk and benefit is poor or non-existent, it is necessary to 
meticulously synthesise the best available evidence to ensure no trial subject is placed in 
harm’s way.  
 
10.5 Value of information for decision-making 
The plethora of risk-benefit measures and approaches available are overwhelming, however 
so, are based on the simple idea of maximising benefits and minimising risks. Although they 
are simple in idea, they are not necessarily simple in practice. In addition, each approach has 
its own advantages and disadvantages as discussed in Section 3.9 and in Chapter 9. The term 
“value of information” is used loosely here to describe the degree of usefulness and relevance 
of an approach to stakeholders and has no relation to the economic concept with the same 
name. 
 
The most debated topic related to these approaches is their values and usefulness to different 
stakeholders. The EMA has conducted a thorough review of the values of these approaches to 
drug regulators (Phillips, 2010b), which I tend to agree with. I attempt to summarise the 
(relative) values of information each approach has to different stakeholders in Table 10.2 
based on my experience applying them to the case study with the help of other literatures. 
The approaches are also valued by their characteristics of being easy to use, good 
mathematical foundations and easy to understand. 
 
In general, the usefulness of these approaches to different stakeholders is low when the 
application is difficult and the interpretations of the results or assumptions are not 
straightforward. For example, CUI has low usefulness to patients and carers because their 
applications require data most people do not have access to and the concept of utility index is 
not within familiar territories. The usefulness is classified as medium when the application 
might be easier which could be because of available support software for the implementation, 
and when the interpretations of the results or assumptions are more straightforward or easier 
to understand or to relate to. For example, CUI is of medium usefulness to healthcare 
professionals because they have the medical knowledge necessary for the interpretations and 
communications of the results when compared to patients or carers. The usefulness is 
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classified as high when the application of an approach is most desirable to the relevant 
stakeholders. This could be because of the simplicity in its application, its ability to address 
important issues, its assurance for transparency, or its straightforward interpretations and 
communications of the results and assumptions. For example, CUI is highly useful to drug 
developers because data required are accessible and the application could help to enhance 
safety in drug development process; and the MCDA is highly useful to the regulators because 
it enhances the transparency in decision-making process. An approach is not useful when its 
application is too simplistic for the purpose of decision-making to the stakeholders. For 
example, TURBO is not useful to the regulators due to lack of transparency, and the 
interpretations of the results are not straightforward and may not be consistent due to many 
ad hoc elements in the application of the approach. 
 
Table 10.2 Value of information encompassing the degree of usefulness for stakeholders 
 
Patients and 
carers 
Healthcare 
professionals 
Researchers Regulators 
Drug 
developers 
Conventional 
approach
23
 
Medium Medium High None Medium 
NNT/NNH High High Medium None Medium 
AE-NNT High High Medium None Medium 
RV-NNT/NNH High High High Low Medium 
MCE Medium High High Medium Medium 
CUI Low Medium Medium Low High 
DI Low Medium High Medium High 
BLRA Medium Medium High High High 
QALY/DALY High High High High High 
RVALY High High High High High 
INB High High High High High 
TURBO Medium Medium Low None Low 
Decision tree Medium Medium High High High 
MCDA Medium Medium High High High 
 
                                                 
23
 Statistical measures from epidemiological tables and statistical regressions such as incidence rates, odds and 
their ratios are referred as conventional approach 
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Hiview3 software (Catalyze Ltd., 2010a) has a useful feature that incorporates MACBETH
24
 
allowing multiple attributes to be valued based only on qualitative judgements of their 
attractiveness (Bana e Costa, 2005). As visual extension to the usefulness classification in 
Table 10.2, a simple decision tree (MCDA model) is built to value different risk-benefit 
approaches to the stakeholders, where MACBETH was used. MACBETH checks the 
consistency of the “attractiveness” scores given.  
Figure 10.4 illustrates my judgements on the value and relevance of each approach to 
different stakeholders (overall weighted utilities are omitted from the display as they do not 
have a meaning in this context). 
 
Figure 10.4 Value and relevance of risk-benefit approaches to stakeholders produced by MACBETH for 
Hiview3 
 
 
For patients and carers of patients, risk-benefit assessment can provide useful information in 
making well-informed decisions about drugs to take. However, it is not reasonable to assume 
that patients or carers would find the evidence by themselves. Patients’ and carers’ 
understanding of risks and benefits also very variable, and it is fair to say that many might 
misunderstand interpretations or magnitude of risks and benefits hence contradicting good 
clinical evidence-based decisions made for them. Common methods the evidence of risks and 
                                                 
24
 Measuring Attractiveness by a Categorical Based Evaluation TecHnique 
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benefits reach patients and carers are through the news (television or newspapers headline) 
and the internet. The internet is a “danger zone” for patients and carers to be seeking 
information on risks and benefits of drugs simply because it is not always done through the 
right channel, and advices can come from unqualified individuals who just happened to be 
active and outspoken, and much of the times, misunderstood. Therefore it is the responsibility 
of the professional parties who have good clinical knowledge and understanding of risks and 
benefits of drugs to communicate these results to the wider audience, than just scientific 
journals, so that they are properly understood. 
 
Healthcare professionals like doctors and nurses are the knowledgeable and trusted parties 
who have the closest and most direct contact with patients. It is expected that healthcare 
professionals would make the best healthcare choices or decisions on behalf of their patients. 
Many healthcare professionals would have some statistical knowledge in evidence-based 
risks and benefits research (see also Section 10.6). Therefore they could act as the educators 
to their patients on the importance of considering evidence-based risks and benefits and on 
the understanding of why certain drug is only prescribed to certain individuals. In aspects of 
individual patient care, it is anticipated that risk-benefit approaches that simpler and easier to 
communicate are most useful and practical to healthcare professionals. More complex risk-
benefit approaches are more useful in making management decisions on the healthcare 
system or when making decisions for a group of patients or population. On the other hand, 
many healthcare professionals are also researchers who often are the “idea factories” behind 
drug trials. 
 
Medical researchers (in non-profitable organisations) like statisticians and epidemiologists 
are the ones responsible in carrying out the ideas of evidence-based research, which means 
that they find quantitative risk-benefit approaches are most useful. This may be out of clinical 
interest or simply methodological interest but most of the times the latter. It is fair to say that 
researchers are neutral to whether drugs being on the market (while pharmaceutical 
companies benefiting from them) and whether patients were prescribed with drugs that are 
not beneficial. However, for ethical reasons if a drug with negative or uncertain risk-benefit 
profile were known, it is the responsibility of the researchers to make the fact known – at 
least through peer-reviewed journals. It is already known and discussed elsewhere that 
scientific journals suffer publication bias due to unpublished clinical trials that failed to show 
positive risk-benefit balance. This has direct effect on evidence-based risk-benefit analysis 
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such as meta-analysis. Chapter 7 discusses the evidence of publication bias in clinical trials of 
domperidone. Despite being on neutral ground, researchers are bound to good clinical 
practice set by regulatory agencies, therefore implies that evidence-based risk-benefit 
analysis is crucial to justify any human or non-human experiments to be conducted. 
 
Regulators such as the EMA, the MHRA and the National Institute for Health and Clinical 
Excellence (NICE) (NHS/NICE, 2010) make important decisions on which drugs should be 
on the market and to which population they apply to. Regulators like EMA and MHRA value 
complex decision-analysis approaches because of their ability to simultaneously address 
multiple attributes of risks and benefits. Monetary aspects are not generally relevant to 
regulators. On the other hand, NICE specifically makes recommendation for the technologies 
that should be used within the NHS, therefore is closely governed by available national 
healthcare budget. Therefore risk-benefit approaches that address this issue e.g. QALY and 
INB are generally most useful to NICE. 
 
Pharmaceutical companies need to profit from drug development, as well as to improve 
health of the consumers. In order to establish positive risks and benefits balance, 
pharmaceutical companies are always on the front row of drug-related methodology research. 
Many literatures and risk-benefit approaches are dedicated to drug development. I have not 
investigated the specific approaches used in drug development, but the risk-benefit 
approaches discussed in this thesis are useful in some way for pharmaceutical companies. 
However, the acceptance of certain approaches varies from company to company.  
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10.6 Challenges in communication of risks and benefits 
In terms of risks and benefits communication from this research, there are three aspects to 
consider: communicating probability-based measures including simple probabilities, 
incidence rates, and odds; communicating utilities; and communicating action to take.  
 
Probability is an easy concept to understand and many people would have been exposed to it 
in their daily life as well as part of the school curriculum. These were taught initially as 
fractions in general in early school days and later percentages are introduced which build on 
the understanding of probabilities. Specifically probabilities are bounded by the interval [0,1] 
(see Section 3.9) but however presented they are still probabilities. The more advanced 
concept of probabilities in the various forms of epidemiological measures e.g. incidence 
rates, incidence rates ratio (relative risks), odds, and odds ratios requires more depth of 
understanding. This is not seen as a hindrance to communicating probabilities of risks and 
benefits for the purpose of clinical trials development because most researchers are already 
familiar with them, so long as they are presented correctly and clearly. The danger in 
communicating probability-based measures such as incidence rates ratio and odds ratio is that 
they can easily be misleading without their baseline risks (Gigerenzer, 2010). Risks and 
benefits tend to get overestimated as illustrated by example in a BMJ editorial on the 20% 
risk reduction of breast cancer mortality when screened; but this really corresponds to a 
reduction of five to four in 1000 women i.e. 0.1% (Gigerenzer, 2010). Unfortunately, 31% of 
gynaecologists surveyed were also misled to think the risks as 25 or 250 fewer will die 
(Gigerenzer, 2010). Mismatched reporting of risks and benefits is also condemned, and 
transparent reporting is encouraged (Gigerenzer, 2010). 
 
Utility (Section 3.9) is an alien concept for many people but it is used informally to judge 
“usefulness” of certain matters albeit not in the decision-theoretic sense. Quantitative risk-
benefit assessment approaches that are heavily derived from decision theory like decision tree 
and MCDA should be of more direct use if conducting a trial is regarded as a decision to be 
made. For a decision that is an “action”, i.e. whether to conduct a trial or not, the results of 
such analyses prove extremely useful or at least helpful. On the other hand, when the decision 
problem is to make inferences for a clinical trial from the evidence, direct contribution of the 
results from analysis of utilities in Sections 9.4.6 and 9.4.7 is unclear. It may seem logical to 
give feedback to future trials in terms of the expected utilities which are directly available 
from these analyses, but how expected utilities are to be used in this context is hard to 
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envisage. Nevertheless, if they were communicable for the purpose of clinical trial 
development, then their use is more justified. The use of utility in Bayesian sample size 
determination is briefly discussed in Section 10.4.3. Importantly, care must be taken if 
expected utilities from evidence-based research to be used in some way in future trials that 
the same method to derive utilities are used, otherwise the validity of the new trial is in peril. 
 
Communicating action to be taken from a risk-benefit analysis is straightforward as decision 
analyses are mostly carried out for a “go-no go” decision. In evidence-based management 
decision-making, the decision has been finely broken down into ‘starting starting right’, 
‘stopping starting’, ‘starting stopping’, and ‘slowing starting’25 to reflect the true clinical 
scenario (Gray, 2009). Their definitions are self-explanatory from the terminologies, 
otherwise Section 2.5 of Muir Gray is a good reference (Gray, 2009). For the case study we 
looked at, ‘starting stopping’ and ‘slowing starting’ are the most appropriate scenarios 
because domperidone is already in routine use in children when there is lack of risks and 
benefits evidence. An example of ‘slowing starting’ is the ‘Dear Doctor’ letters; which was 
illustrated to have an impact in the prescribing trend of cisapride in Chapter 6 when this was 
issued in June 1998. So perhaps what this risk-benefit research is meant to contribute to is in 
the territory of ‘slowing stopping’ until more high quality evidence is acquired through new 
clinical trials. Most important of all, risk-benefit decision-making methods do not explicitly 
make and communicate the decisions directly, but rather help to clarify the thinking of 
decision problems, and should be used as what they are. 
  
                                                 
25
 ‘Slowing starting’ refers to slowing the starting process of stopping in the absence of good evidence 
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10.7 Discussion 
10.7.1 Visual representations as aid of communication  
A familiar saying “a picture is worth a thousand words” perfectly describes the place of 
visual representations in the communication of risks and benefits. Many technologies are 
available when it comes to visual display. An excellent visual display should be able to 
communicate complex ideas clearly, precisely and efficiently (Tufte, 2006).The display must 
convey the data, induce thinking on the substance, and avoid distortion of real data, among 
others (Tufte, 2006). This thesis uses static two- and three-dimensional graphs to 
communicate the results. 
 
Two-dimensional (2-D) graphs are most common. They are easy to produce and easy to 
understand. Clarity of the data can be enhanced for communication in various ways including 
colour-coding, different symbols or patterns, and through the use legends and labels. 
However, the aspect ratio
26
 of a 2-D graph should be taken into consideration when it is 
presented. Stretching the axis of the graph may impose a different perception to the 
relationship of the variables plotted when a square graph
27
 of the same variables is presented. 
The issue is unique to each graph as square graphs may not be appropriate for all 2-D graphs.  
 
Three-dimensional (3-D) graphs are used when a three-way relationship is to be shown. 
There are many forms of 3-D graphs but the ones used in this thesis – surface plot (e.g. 
Figure 6.1), 3-D line graphs (e.g. Figure 6.3) and wireframe graphs (e.g. Figure 9.5) – are the 
common ones. The clarity of 3-D graphs however is dependent on the axis rotation, 
especially for surface plots and wireframe graphs. Different axis rotations can only convey 
certain aspects of the graphs therefore a full 360° rotation may be required to see the full 
picture (not illustrated). Interpolation and extrapolation on a 3-D graph are also not as easy as 
on a 2-D graph. Similar techniques of enhancement can be used as in 2-D graphics. 
 
More advanced and modern visualisation techniques come as dynamic and interactive visual 
displays
28
. Hiview3 has the capabilities to export the parameters used in an MCDA model 
into Microsoft Excel, which could be used to create an interactive graph of the weighted 
                                                 
26
 Aspect ratio is the ratio of the total length on the y-axis to the total length on the x-axis on a 2-D graph 
27
 Graph with aspect ratio of 1 is often referred to as a square graph 
28
 Dynamic visual displays refer to animated visual display without permitting inputs from users. Interactive 
visual displays allow users to change input values but are not necessarily animated. 
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utilities by varying these parameters (Phillips, 2010a). However, on papers these visual 
displays are not useful other than providing snapshots of the dynamic visual displays. Some 
examples of these techniques can be found on the internet (Rosling, 2010; Spiegelhalter, 
2010).  
 
10.7.2 The difficulties in simplicity 
Being simple is good but being too simplistic can lead to many problems. This section 
addresses simple sample size determination, simple treatment versus placebo trials, and some 
issues in study design that can make simple matters difficult. These issues need to be 
considered when assessing the evidence of risks and benefits of drugs or when advising 
future trials from evidence-based research. 
 
Section 10.4.3 illustrates how sample size determination in clinical trials can be taken a step 
forward by incorporating integrated risk-benefit measure. Typically, clinical trials consider 
several outcomes but only choose one outcome (primary outcome) in determining the size the 
trial should be. This can be insufficient if other parameters in the complex system of disease-
treatment were not carefully thought through, and especially when the other outcomes also 
need to be tested. By doing so, other outcomes that may be relevant to the answer being 
sought from running the trial are ignored and analyses of other outcomes are underpowered.  
 
A simple way often practised to get around this is to assume independence among all 
important outcomes, and to calculate sample size for the trial from each outcome. An 
outcome that gives the largest sample size can then be chosen to power the trial. The largest 
sample size would ensure that inferences can also be made with reasonable certainty on the 
other outcomes, provided the underlying assumptions were sensible. However, the 
disadvantage of this approach is that although it is satisfactory, it may not be the most 
resource efficient. 
 
Clinical trials comparing an active treatment to placebo are simplistic in principle and can be 
very tempting especially to pharmaceutical companies in order to acquire a marketing 
authorisation for a new drug. The Helsinki declaration (World Health Organisation, 2000) 
recommends that a comparison should be made to the best available treatment option. Despite 
the recommendation, placebo is still being used as a comparator because there is greater 
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chance that the new drug would appear effective, the trial requires smaller number of 
patients, and consequently less costly to run (Garattini, 2008). However, comparing 
domperidone to placebo in TRI-Domp is appropriate because the best standard treatment of 
the same indication is not available, and that domperidone is not proven to be more effective 
than having no treatment. 
 
In the situation when there is more than one active treatment being compared, as illustrated 
(Chapter 9), risks and benefits should not only be given for the drugs but also from when no 
treatment is given. Otherwise, the risk-benefit profile will be incomplete. Other clinical 
parameters should also be considered carefully. For example, response-time of two drugs 
might be different therefore different timeframes of response (risk or efficacy) may be 
required in the assessment. Certain drugs may cause long terms adverse events but others 
may only be associated with short term adverse events. Although long term versus short term 
risks cannot be evaluated in relatively short clinical trials, the issue should be acknowledged 
and revised (see also Section 11.1) when there is more data available. Seriousness, severity 
and frequency of adverse events are also different for different drugs even though they are the 
same clinical event. It might be questionable how the judge of seriousness and severity is to 
be made considering not many individuals have actually experience the same adverse event 
from using the different drugs being compared. Therefore, there is further uncertainty issue, 
say in obtaining patients’ utilities, to be addressed when there are more than one active 
treatment involved. 
 
This leads to the complexities that arise from drug trial designs both from statistical and 
pharmacological point of views. Different trial designs are available using different 
assumptions and to accommodate variety of resources. Bias and confounding are the usual 
problems encountered in clinical trials (and other analyses). Bias can occur at any stage of a 
trial from the sampling of the population to the analysis of data. Similarly for confounding; 
but statistical trial design e.g. using incomplete block design can be used to address this issue. 
Not all trials are randomised – patient-preference studies are also valid in providing risks and 
benefits data for assessment, or to gather more evidence. Patient-preference studies are 
unique that they reflect the real life scenario of drug use. However, when a patient chose a 
preferred drug, it is less likely that the patient would report minor adverse events and may 
also overestimate the benefit (Underwood, 2008b).  
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A cross-over trial design is conducted to estimate the risks and benefits of comparative drugs 
treatments in the same individual but is weaken by the carryover effects in between drugs 
switching. Longer washout period may be required to allow the carryover effects to diminish. 
The question is how long needs a washout period be. If there were long term risk and benefit 
of a drug, then a wrong washout period specified can result in the analysis getting 
contaminated. A too long washout period may be unjustified especially in trials of younger 
children because their physiology changes rapidly. 
 
Clinical trials are sometimes designed to study the effect of combination drugs therapy. Risks 
and benefits of combination drugs therapy can vary greatly based on the proportions of active 
treatments in a combined drugs therapy. Different proportions of active substance in 
combined drugs can also have impact on the synergistic or antagonistic effects. 
 
10.7.3 Conclusion 
The key to communication of risks and benefits lies in the understanding of statistics. This 
applies to the person who communicates and the person they are communicated to. 
Transparency is vital as well as flexibility and clarity of the communication. The Royal 
Statistical Society (RSS Homepage, 2010) launched a 10-year ‘getstats’ campaign (RSS, 
2010) on educating statistics to public at 2010 hours on 20/10/2010. Getstats aims to improve 
the understanding of statistics so that well-informed life choices and sound decisions can be 
made when modern daily life is drowned with information (RSS, 2010). 
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11. Conclusion 
Specific discussions and conclusions are already made at the end of each chapter to address 
the issues directly related to the topic in that chapter. The intention here is to be brief and to 
conclude this study as a whole.  
 
Recognising that no pragmatic clinical trials – especially in the early phases – can capture the 
entire risks and benefits profile of drugs, regulatory agencies require pharmaceutical 
companies to develop a risk management plan for each drug to be authorised for marketing. 
The risk management plans form the legal basis of the importance of risk-benefit assessments 
for drugs which I address in Section 11.1.  
 
Section 11.2 discusses the contributions of this study to risks and benefits research in 
evidence-based medicine and decision-making.  
 
The framework proposed (Section 10.3) is not exclusive to off-label drugs for paediatric use. 
I thus discuss in Section 11.3 the possibilities to generalise this framework in other settings.  
 
The limitations of this study are addressed in Section 11.4, and topics identified for further 
research related to risks and benefits assessment for medical decision-making are discussed in 
Section 11.5. 
 
I made concluding remarks on the issues studied in this thesis in the final Section 11.6. 
 
11.1 Risk Management Plans in the European Union 
Risk Management Plan (RMP) is a prospective strategy designed to identify, characterise, 
prevent, and minimise risks of medicines over the life-cycle of the products. RMP is carried 
out through post-marketing pharmacovigilance activities including the conduct of extra 
studies to resolve uncertainties in the risk-benefit balance of medicines during the pre-
marketing phase.  
 
In the European Union (EU), it is a legal obligation of the pharmaceutical companies to 
produce RMP for the management of drugs to be authorised for marketing (CHMP/EMA, 
2005). The EMA is responsible for centralised marketing authorisation (MA) for the EU, 
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whilst country-specific MA applications are handled by respective country’s regulatory 
agency e.g. the MHRA in the UK. This is required for new applications of drugs MA 
including for changing the current status or indications of drugs already authorised for 
marketing. 
 
Article 8(3)(a) of the Directive 2001/83/EC forms the legal basis of the EU-RMP 
requirements (CHMP/EMA, 2005), states: 
 
“a detailed description of the pharmacovigilance and, where appropriate, 
of the risk management system which the applicant will introduce” 
 
MA applications must also clearly state the details of conditions and restrictions under which 
the MA of the drugs should be imposed on the supply and use of the drugs to be authorised 
for marketing. Details of recommended conditions and restrictions of drug use when they 
might not be safe or effective, and populations not studied in pre-marketing phase must also 
be supplied.  
 
EU-RMP requires explicit discussions on the implications of drugs on populations not studied 
or those only studied to a limited degree when they become available on the market. Explicit 
populations to be addressed include children, the elderly and pregnant and lactating women. 
In addition, the EU requirements explicitly state that potential for off-label use and potential 
off-label paediatric use must also be addressed. 
 
11.2 General discussion of the study 
This study makes several recommendations along the way including the contribution of a 
general framework for evidence-based risk-benefit decision-making of medicines which is 
generalisable to more than just the context explored through the case study (Section 11.3). It 
demonstrates that in the absence of clinical trials evidence, other data not collected in the 
same way as in a controlled clinical trial can also be used to retrieve risks and benefits 
evidence through data mining techniques. Although there are more uncertainties in the results 
obtained in this way, the Bradford Hill criteria for causation can be used to help reduce these 
uncertainties. 
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The main strength of this study is it provides a general transparent framework for risk-benefit 
assessment which allows explicit outcomes to consider based on available evidence. In 
particular, it helps future clinical trials to plan and focus their resources to what matters most 
in collecting further risks and benefits evidence whilst ensuring that participants in the trials 
are not exposed to unmeasured risks of the trial drugs. 
 
It must be emphasised that although the methods considered in this thesis can be used for 
risk-benefit assessment of drugs in its own right, the results could not make objective 
decisions about the risk-benefit balance of the drugs. The actual decisions are made by the 
persons to whom these results are communicated. Therefore the subjective elements of 
decision-making still play important role in the final decisions made. This may be more of an 
issue if the risk-benefit profiles of the treatment options are very similar, or even uncertain. 
 
Importantly, a study on experience of drugs prescriptions using alternative data in the lack of 
clinical trials evidence is of great importance to better understand the safety aspects of drugs 
use in the population, especially in children. They can better inform the planning of future 
trial and to justify their current use, but in no way it should be used as a substitute for a 
clinical trial in children, or in other populations not usually studied extensively (Mt-Isa, 
2010). 
 
11.3 Generalisability of the study 
The framework for evidence-based risk-benefit synthesis (Section 10.3) is general and is 
anticipated to be generalisable in any situation. However it is not entirely generalisable to 
drugs in the pre-marketing phase simply because evidence data on trends and clinical trials 
data would be extremely limited; and alternative data sources are unavailable. Part of the 
framework particularly steps from causality assessment onwards can be adopted for use in 
pre-marketed drugs to improve the risks and benefits evidence from trials. 
 
The methods proposed in this thesis are not only limited to evidence synthesis of paediatric 
drugs but may be generalised to other populations e.g. in the elderly, pregnant women, 
patients with chronic diseases, or patients undergone certain medical or surgical procedures 
(also see limitations of using GPRD as data source in Section 11.4). It is also generalisable in 
scenarios when risks and benefits of non-drug therapies or medical devices are to be assessed 
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provided that they are clearly defined and properly recorded in alternative data source. Given 
suitable data sources are available, the methods could be generalised to assess the risks and 
benefits balance associated with ethnic group research, to alternative medicines or to non-
prescription drugs. 
 
11.4 Limitations of the study 
The main limitation of the framework is that it does not address pre-marketed drugs as 
previously acknowledged in Section 11.3. Other limitations include non-specific 
recommendations of which statistical methods to be used during the process, but the methods 
chosen and described in Chapter 3 are some of the appropriate choices. Other methods may 
be more appropriate based on the data. 
 
Further limitations of this study are data-dependent. The quality of risk-benefit evidence is 
heavily dependent on the data source; for example how specifically, how frequently and how 
promptly clinical events and drug prescriptions are recorded. In the case of studying 
paediatric drug safety, the reported evidence may be confounded by more concerned 
parents/carers. This is because more concerned parents/carers may report incidence of 
adverse events more frequently than others or may exaggerate the conditions, however minor 
they are. This can lead to inflation of the number of events reported by these parents/carers. 
 
Other limitations are down to the assumptions and methods chosen for this study. Imputation 
strategy for missing data described in Section 6.3.5 may influence the results of this study 
especially when quantifying the effect of dose on the rates of adverse events. The analyses 
are also limited to the reliability in the assumption that prescribed drugs are taken as 
prescribed.  
 
The risks and benefits assessments for decision-making illustrated in Chapter 9 are also 
incomplete in the sense that they do not take into account all necessary attributes from the 
available evidence – therefore should not be taken as definite risk-benefit profiles of cisapride 
and domperidone in children. The choice of weights given to attributes in risk-benefit 
assessment may not reflect the correct weights for the case study. 
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I did not attempt to integrate evidence of risks and benefits obtained through the systematic 
review of clinical trials in Chapter 7 with those from the alternative source. However, 
Chapter 7 also addressed that evidence from the systematic review suffers from publication 
bias, thus integrating biased evidence would be more of a challenge. Integrating evidence 
from different sources could strengthen the argument on risk-benefit balance of drugs but 
methods for doing so are currently under-studied. 
 
11.5 Topics for future research 
In the order of what I find more important to assess risk-benefit balance of drugs, I list some 
further research topics that would extend and complement the work of this thesis, and overall 
make the use of medicines safer. 
 
1. Study of methods to obtain patient utilities and importance weights 
Risk-benefit decisions for medicines are often made from judgements of clinical and 
research experts. Involvement of patients who are the potential consumers of the 
medicines to contribute to this issue is seldom taken into account. General methods 
for patient involvement
29
 are available as described in Section 9.5 but future studies 
specifically need to: 
i. identify relevant stakeholders for different scenarios; 
ii. address the feasibility of conducting such studies including the issues of 
conflicting interests; 
iii. address the uncertainties in the responses from different stakeholders 
including the strategy used in sampling the stakeholders;  
iv. identify suitable methods to address and resolve uncertainties especially those 
arising from understanding and perception as well as responders’ 
personalities; and 
v. identify suitable statistical methods to combine the responses from different 
stakeholders. 
  
                                                 
29
 Ms. Kimberley Hockley (PhD student) working with Professor Deborah Ashby is currently working on issues 
in patient involvement in clinical trials through discrete choice experiments 
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2. Study of methods for integrating different sources of evidence 
Evidence of risks and benefits do not usually come from just one source (Chapter 2). 
Therefore when different sources of evidence are available to hand, it is questionable 
how these sources of evidence of differing quality are to be integrated to provide a 
coherent risk-benefit drug profile. Many aspects of quality of evidence need to be 
considered in future methodological studies, including: 
i. the statistical designs that underlie the evidence data including the interactions 
of study drugs with other interventions (drugs and non-drugs); 
ii. the biases associated with the available evidence data, as well as the bias that 
are associated with other evidence data that are available but not accessible 
e.g. data from confidential pharmaceutical companies’ trials; and 
iii. the possibilities of over-counting evidence from different sources. 
 
3. Study of presentation and communication of risks and benefits of evidence 
The difficulties in communicating the idea of risks and benefits were addressed in 
Section 10.6. A collaborative research project PROTECT
30
 (EMA, 2010) 
commissioned by the European Innovative Medicines Initiative (IMI, 2010), of which 
Professor Deborah Ashby and I are also members, are currently taking place to 
address limitations of current methods in pharmacoepidemiology and 
pharmacovigilance. Work package 5 (WP5) of PROTECT specifically aims to 
investigate the best methods in presentation and communication of risks and benefits 
of medicines. Some of the work in this thesis could directly contribute to the work of 
PROTECT-WP5 but the ideal presentations and communications techniques for 
different scenarios and to different stakeholders will be investigated further through 
methodological reviews and applications to case studies. Specific recommendations 
are to be made at the end of the study. 
  
                                                 
30
 Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium 
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11.6 Concluding remarks 
The assessment of risks and benefits of drug treatment is difficult but necessary especially 
when off-label drugs are prescribed to vulnerable populations like children. More clinical 
trials, having thoroughly considered potential safety issues, in this population are needed so 
that these medicines can be properly authorised for their use; and ultimately to ensure safer 
and more beneficial use of medicines in children. 
 
I hope that the strategies and methods proposed in this thesis are a contribution to doing this 
more efficiently. 
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Appendices 
Main texts of the thesis have omitted some specific details to ensure fewer interruptions were 
experienced while reading. This appendix gives some of the details omitted that may be 
useful for future reference to clarify certain process in this thesis. The appendices are given in 
the order when they were mentioned in the thesis. 
 
A.1 Qualitative review pro forma and trial characteristics 
 
Study ID  
Study reference  
 
Merits given to benefits/risks by section: 
Section What was mentioned? 
Aim / Objective  
Methods  
 
Results  
 
Discussion/conclusion  
 
 
Coherence between planning (objectives/methods) and end results (results/discussion): 
Planning  
 
End results  
 
Outstanding issues: 
 
 
 
 
Comments: 
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The following tables of trial characteristics were reproduced from the original systematic review 
papers (Augood, 2003; Pritchard, 2005). 
 
Cisapride trials (Augood, 2003) 
Appendix Table 1 Trial characteristics for Cucchiara 1987 
Methods Randomised, double-blind, placebo-controlled trial 
Participants Age 75 days – 47 months 
Reflux oesophagitis in all (endoscopy and biopsy) 
Diagnosis of GOR made by oesophageal pH (pH<4 for    ”) and 
manometry. 
Exclusion criteria: infections neurologic, metabolic, renal disorders, 
abnormalities of the GI tract. 
Interventions 8 weeks of either: 
Cisapride syrup (1mg/ml) 0.3 mg/kg tid 
Placebo group 
Outcomes Assessed at 8 weeks by investigator: 24-h pH, LES pressure, oesophagitis 
at biopsy. 
Improvement at end of treatment: cured (clinical, pH-metric and 
histological variables normalised), improved (at least one of the three 
variables had improved), unchanged, worsened. 
Notes 3 patients were withdrawn: 2 febrile URTI, 1 failed to take drug 
continuously. 
Other outcomes measured: peristalsis amplitude, clinical score. 
Allocation concealment Unclear 
 
Appendix Table 2 Trial characteristics for Van Eygen 1989 
Methods Three tirals: 
I open trial (n=69) 
II (Van Eygen, 1989) randomised, double-blind, placebo-controlled trial 
(n=23) 
III (Van Eygen, 1989) dose-response trial (n=50) 
Participants Age 5 days – 12 months 
Excessive regurgitation and vomiting at least twice a day in all children. 
In trial II: GOR at radiology or pH monitoring in all children. 
In trial III: GOR at radiology, endoscopy or pH monitoring in all children. 
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Non-pharmacologic measures (e.g. positioning, food thickening) had failed 
to improve the reflux. 
Interventions 4 weeks of either: 
Trial II: Cisapride oral suspension 0.15 mg/kg tid (n=12) 
Placebo oral suspension (n=11) 
Trial III: Cisapride 0.1 mg/kg tid (n=14) (not used in the analysis) 
Cisapride 0.2 mg/kg tid (n=14) 
Placebo tid (n=17) 
Outcomes Assessed at 2 and 4 weeks by the investigator: AE, global therapeutic 
result (poor=no change, fair=distinct but slight improvement, good-marked 
reduction in regurgitation, excellent=virtually complete symptomatic cure). 
Notes In trial III analysis based on 45 of 50 patients. There were 4 early drop-outs 
and 1 protocol violation and a further 10 drop-outs (4 in the Cisapride 0.2 
mg/kg group and 6 in the placebo group). 
Other outcomes assessed at 2 and 4 weeks by investigator: severity of 
regurgitation (severe=the major part of the meal is regurgitation, 
moderate=effortless regurgitation of a mouthful of feeding, slight= 
regurgitation of rather excessive saliva only, no regurgitation); frequency 
of regurgitation (after each meal, at least twice a day, once a day or several 
times a week, never). 
Allocation concealment Unclear 
 
Appendix Table 3 Trial characteristics for Vandenplas 1991 
Methods Randomised, double-blind, placebo-controlled trial 
Participants Age 2 – 4 months 
Pathological GOR of vomiting and regurgitation for >2 weeks, >6 
times/day AND abnormal oesophageal pH monitoring. 
Exclusion criteria: reflux secondary to diseases (e.g. infections, allergy, 
pyloric stenosis). 
Interventions 13-16 days of positional therapy and either: 
Cisapride (1 mg/ml) 0.2 mg/kg tid (n=21) 
Placebo (n=21) 
Outcomes Parental evaluation of GOR severity at 2 weeks: 0 (no vomiting at all), 1 
(1-3 episodes/day), 2 (4-6 episodes/day), 3 (>6 episodes/day). NB: all had 
grade 3 at the beginning. 
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Investigator evaluation at 2 weeks: 24-h pH. 
Notes None of the infants received milk-thickening products. 
29 completed the study, 13 exclusions post-randomisation: unexpected 
weaning (3,3), withdrawal of permission for second pH monitoring 
because symptoms had improved (4,1), lack of improvement & parents 
refused to continue (0,2). 
Allocation concealment Unclear 
 
Appendix Table 4 Trial characteristics for Greally 1992 
Methods Randomised study. Double-blind design was not feasible 
Participants Age 2-18 months 
Chronic vomiting and GOR confirmed by 24-h pH oesophageal monitoring 
(pH<4 for 5% of the recording period). 
No neurological, respiratory, metabolic, GI disease, treatment with H2 
antagonists, theophylline, anticholinergic drugs. 
Interventions 4 weeks of either: 
Cisapride p.o. 0.2 mg/kg qid (n=26) 
Gaviscon ½ sachet to each 90 ml feed qid (n=24, 21 also had Carobel) 
Outcomes Parental evaluation at 4 weeks of improvement (improved, not improved). 
Investigator evaluation at 4 weeks of 24-h pH (RE was defined as pH<4 for 
  5”). 
Notes All 50 infants completed the study. 
Other outcomes measured at 4 weeks: daily parental evaluation of severity 
of vomiting: 0 (absent), 1 (1-4 episodes/day), 2 (>4 episodes/da7y), leading 
to a final symptoms score (range 0-1), improvement in diary scores. 
Allocation concealment Unclear 
 
Appendix Table 5 Trial characteristics for Castro 1994 
Methods Randomised, double-blind, placebo-controlled trial 
Participants Age 3 months – 5 years 
Vomiting and regurgitation present. 
GOR at oesophageal pH monitoring (RI<3.5% considered normal). 
No organic pathology to justify reflux. 
Interventions 4 weeks of either: 
Cisapride 0.2 mg/kg (n=15) 
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Placebo (n=15) 
Outcomes Assessment at 2 and 4 weeks (probably by parents) of digestive symptoms: 
severe (regurgitation and/or vomiting after each meal of an important part 
of the meal), moderate (regurgitation of a small quantity more than once a 
day), mild (regurgitation of a very small quantity once a day or sometime 
during the week), absent. 
Investigator assessment at 4 weeks: 24-h oesophageal pH, AE, 
complications. 
Notes 1 drop-out in the cisapride group (“lack of motivation”) 
Other outcomes measured: radiological image, endoscopy, respiratory 
symptoms improvement (nil, slight, good, excellent). 
Allocation concealment Unclear 
 
Appendix Table 6 Trial characteristics for Scott 1997 
Methods Randomised, double-blind, placebo-controlled trial 
Participants Age 6 weeks – 2 years. 
Daily regurgitation or vomiting during a 1 week baseline period 
AND  1 episode of GOR (pH<4 for >  ”) at  8-h pH monitoring. 
Exclusion criteria: not meeting the inclusion criteria, premature, previous 
GI surgery (excluding for appendicitis), illnesses & drugs that could 
interfere with cisapride, reflux due to known anatomic abnormalities, 
underlying disease, infection of the GI tract, parents who couldn’t express 
concern, comply with the study, complete diaries. 
Interventions 6 weeks of positioning and thickened feeds (where appropriate) and either: 
Cisapride suspension (1 mg/ml) 0.2 mg/kg qid (n=23) 
Placebo suspension (n=26) 
Outcomes Assessed at 2,4, 6 weeks by parent and investigator: global evaluation of 
overall treatment (deterioration=symptoms worse, poor=no improvement, 
fair-slight improvement, persistence of some symptoms, good 
=improvement, occasional symptoms, excellent=complete relief of 
symptoms). 
Assessed at 6 weeks by investigator: 24-h pH, LES pressure, oesophagitis 
at biopsy. 
Notes 45 patients (21 cisapride, 24 placebo) were evaluable (4 were 
noncompliant or had violated protocol). 
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Other outcomes: various at 24-h pH, swallow pressure, daily diary 
recording of each episode (none, mild, moderate, severe), score for 
regurgitation and vomiting. 
Allocation concealment Adequate 
 
Appendix Table 7 Trial characteristics for Cohen 1999 
Methods Randomised, double-blind, placebo-controlled trial 
Participants Age <36 months 
Clinical diagnosis of GOR: frequent vomiting or regurgitation often 
associated with feeding difficulties and/or excessive crying. 
Baseline 24-h oesophageal pH monitoring: RI  50. 
Exclusion criteria: anatomic abnormality of the GI tract, previous GI 
surgery, treatment with anticholinergics, theophylline, other diagnosis 
which could explain vomiting. 
Interventions 2 weeks of either: 
Cisapride suspension (1 mg/ml) 0.2 mg/kg qid (n=50) 
Placebo (n=45) 
Outcomes Parental evaluation at 2 weeks: overall symptoms intensity on VAS 0-
10cm (0=absence of symptoms, 10=could not be worse), improvement 
(marked=complete or near complete resolution of symptoms, 
moderate=partial resolution, minimal=slight improvement, unchanged, 
deterioration). 
Evaluation during the 2 weeks of treatment: presence of vomiting, 
gagging, crying (score 0-3). 
AE: any, withdrawals due to AE. 
Investigator assessment at 2 weeks: 24-h oesophageal pH, oesophagitis at 
biopsy. 
Notes 68 patients (38, 30) completed the trial. 
Withdrawn if: consent was withdrawn, serious AE, further investigations 
necessitated a change in treatment. 
A high proportion of patients had received prior treatment with: thickened 
feeds, positional therapy, cisapride, H2 antagonists, antacids, 
metoclopramide, other. 
Allocation concealment Adequate 
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Appendix Table 8 Trial characteristics for Levy 2001 
Methods Randomised, double-blind, placebo-controlled study. 
Participants Age 6 months – 4 years (mean age 14.4 months). 
Minimum 3 months of symptomatic GOR with failure to respond to at 
least 6 weeks of non-surgical treatment other than cisapride. 
Interventions 3-8 weeks of either Cisapride 0.6 mg/kg/day or placebo 
Outcomes Data on QTc retained in 4 (68 patients) of 7 study centres (134 patients in 
total) in the trial. 19/68 excluded as ECGs recorded after 8 weeks of 
treatment. Mean QTc reported at 3-8 weks of treatment and mean 
difference in QTc from baseline. 
Notes Data on symptoms of GOR not published “because efficacy results did not 
reach statistical significance”. 
Allocation concealment Unclear 
 
  
Appendices 
Appendices | 324  
 
Domperidone trials (Pritchard, 2005) 
Appendix Table 9 Trial characteristics for Clara 1979 
Methods Randomised, double-blind, placebo-controlled trial 
Participants Aged 2.5 months – 10 years. 
Chronic regurgitation and vomiting diagnosed clinically – GORD not 
diagnosed. 
Interventions 2 weeks of either: 
Domperidone 0.3 mg/kg tid 
Placebo 
Outcomes Investigator rated nausea, vomiting, retching and regurgitation. After 2 
weeks of medication, the dose was doubled, because of poor results in 7 
out of 14 patients. After 4 weeks, there was a statistical and clinical 
difference between the domperidone group and the placebo group, a good 
or excellent result was obtained in 93% of the domperidone group 
compared with 33% of the controls (P < 0.05). 
Notes Very small trial. Some evidence of efficacy of domperidone for the 
symptomatic relief of nausea and vomiting in older children (median age 
of 5 years). Evidence of efficacy in 50% of patients only at higher dose 
(0.6 mg/kg). The median age in the domperidone group was 4 years, 
compared with 6 years in the control group. No adverse effects. 
Allocation concealment Unclear 
 
Appendix Table 10 Trial characteristics for De Loore 1979 
Methods Randomised, double-blind, placebo-controlled trial 
Participants Aged 3 weeks – 7 years. 
Chronic, excessive regurgitation and vomiting. 
Diagnosis of GORD made clinically. 
Interventions 2 weeks of either: 
Domperidone 0.3 mg/kg t.i.d.  
Metoclopramide 0.3 mg/kg tid (not used in analysis) 
Placebo tid 
Outcomes Raw data not provided. Symptoms of nausea and vomiting were rated by 
an investigator. The cumulative percentage of patients after 2 weeks of 
treatment was plotted on a graph. After 2 weeks of treatment, 75% of 
patients treated with domperidone were found not to be vomiting, 
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compared with 43% in the metoclopramide group and 7% in the placebo 
group. No adverse effects reported. 
Notes Baseline ages different; domperidone group had a median age of 9 months, 
whereas the placebo and metoclopramide groups had a median age of 6 
months. Nausea would be difficult to assess in a preverbal child of 6–9 
months. Very small trial, inadequately powered. However, some efficacy 
for the symptomatic relief of vomiting shown. 
Allocation concealment Unclear 
 
Appendix Table 11 Trial characteristics for Bines 1992 
Methods Randomised, double-blind, placebo-controlled trial 
Participants Aged 5 months – 11.3 years 
17 children (including 7 with other significant disease) with GORD 
diagnosed clinically, radiologically and by pH-metric methods 
Interventions 4 weeks of either: 
Domperidone 0.6 mg/kg tid 
Placebo tid 
Outcomes No significant difference in investigator assessment of symptoms 
(vomiting, spitting, irritability, heartburn, coughing, choking) between 
domperidone and placebo after 4 weeks of therapy. The total number of 
reflux episodes within 2 h of eating was decreased by more than 25% in all 
7 patients receiving domperidone who underwent a second pH study 
compared with only 1 of 8 patients receiving placebo ( P < 0.01). The 
pretreatment pH monitoring lasted 17– 24 h and the monitoring after 4 
weeks lasted 8–12 h. Analysing only the 2 h within eating was not a 
prespecified outcome. The data beyond 2 h were not reported 
Notes There were striking baseline differences in the two groups. The mean age 
was 3.6 years in the domperidone group and 2.4 years in the placebo 
group. The total number of reflux episodes at baseline was 69 for the 
domperidone group and 16 for the placebo group. The mean age and age 
range is not representative of the commonest age group for which 
treatment for GOR and GORD is prescribed (under 18 months). The trial 
was very small 
Allocation concealment Unclear 
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Appendix Table 12 Trial characteristics for Carroccio 1993 
Methods Randomised, double-blind, placebo-controlled trial 
Participants Aged 1 – 18 months. 
Diagnosis of GOR confirmed by radiological and pH-metric criteria. 
Interventions 8 weeks of either:  
A. Domperidone 0.3 mg/kg plus magnesium hydroxide plus 
aluminium hydroxide (not used in analysis) 
B. Domperidone 0.3 mg/kg plus alginate (not used in analysis) 
C. Domperidone 0.3 mg/kg alone 
D. Placebo 
Outcomes No clinical data provided, with the exception of the number of reflux 
episodes. Authors reported that all patients had severe symptoms, but no 
details given. In group C, there was a reduction in the number of reflux 
episodes from a median of 59 to 48.5 (P < 0.009). In the placebo group 
(D), the number of reflux episodes changed from a median of 65 to 68. 
There was no decrease in the total percentage reflux time in either placebo 
or domperidone groups. 
Notes Groups A and B not included in this systematic review, as they included 
other therapies. Authors concluded that there was no significant difference 
in the degree of improvement between the patients receiving domperidone 
alone and those receiving placebo alone. No reported adverse effects. 
No evidence of efficacy for symptomatic relief with domperidone. 
Allocation concealment Unclear 
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A.2 Dose of cisapride and domperidone prescribed in mg/kg/day by age and year 
Appendix Table 13 Mean (SD) of daily dose of cisapride prescribed in mg/kg/day by age and year 
 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Total 
1990 n/a n/a n/a n/a 0.06 
(n/a) 
n/a 0.13 
(n/a) 
n/a n/a n/a n/a 0.08 
(n/a) 
n/a n/a n/a 0.07 
(n/a) 
n/a 0.04 
(0.02) 
0.07 
(0.03) 
1991 n/a n/a n/a 0.07 
(n/a) 
n/a n/a n/a 0.10 
(0.02) 
n/a 0.40 
(0.20) 
n/a 0.04 
(n/a) 
0.07 
(0.00) 
n/a 0.06 
(n/a) 
n/a 0.05 
(0.00) 
0.05 
(0.02) 
0.13 
(0.15) 
1992 0.41 
(n/a) 
0.65 
(0.14) 
0.47 
(0.06) 
n/a n/a n/a 0.66 
(n/a) 
0.08 
(0.04) 
0.39 
(0.19) 
n/a 0.29 
(0.25) 
0.08 
(n/a) 
0.04 
(0.02) 
0.04 
(0.02) 
0.25 
(0.16) 
0.05 
(0.00) 
0.06 
(0.02) 
0.06 
(0.01) 
0.17 
(0.20) 
1993 0.64 
(0.25) 
0.69 
(0.18) 
0.72 
(0.41) 
0.25 
(0.22) 
0.42 
(0.13) 
0.49 
(n/a) 
0.85 
(n/a) 
n/a 0.24 
(0.20) 
0.36 
(0.25) 
0.84 
(n/a) 
0.31 
(0.24) 
0.14 
(0.12) 
0.25 
(0.29) 
0.04 
(0.01) 
0.05 
(0.00) 
0.04 
(0.01) 
0.05 
(0.00) 
0.31 
(0.29) 
1994 0.73 
(0.45) 
0.69 
(0.29) 
0.63 
(0.10) 
0.40 
(0.08) 
0.66 
(0.31) 
0.39 
(0.03) 
0.64 
(0.36) 
0.56 
(0.14) 
0.32 
(0.32) 
0.05 
(0.00) 
0.35 
(0.37) 
0.24 
(0.38) 
0.24 
(0.21) 
n/a 0.23 
(0.19) 
0.08 
(0.09) 
0.24 
(0.00) 
0.07 
(0.06) 
0.44 
(0.36) 
1995 0.55 
(0.39) 
0.64 
(0.45) 
0.54 
(0.23) 
0.49 
(0.12) 
0.43 
(0.24) 
0.60 
(0.31) 
0.57 
(0.34) 
0.55 
(0.16) 
0.57 
(0.07) 
0.43 
(0.24) 
0.89 
(0.47) 
0.17 
(0.18) 
0.16 
(0.15) 
0.29 
(0.17) 
0.11 
(0.11) 
0.18 
(0.16) 
0.05 
(0.01) 
0.31 
(0.28) 
0.48 
(0.35) 
1996 0.46 
(0.23) 
0.49 
(0.25) 
0.49 
(0.19) 
0.47 
(0.27) 
0.44 
(0.06) 
0.55 
(0.25) 
0.67 
(0.17) 
0.47 
(0.15) 
0.55 
(0.05) 
0.52 
(0.11) 
0.46 
(0.05) 
0.45 
(0.20) 
0.32 
(0.29) 
0.08 
(0.11) 
0.28 
(0.26) 
0.13 
(0.17) 
0.13 
(0.14) 
0.11 
(0.14) 
0.44 
(0.24) 
1997 0.62 
(0.52) 
0.67 
(0.41) 
0.49 
(0.23) 
0.67 
(0.38) 
0.52 
(0.21) 
0.70 
(0.25) 
0.65 
(0.28) 
0.47 
(0.21) 
0.58 
(0.34) 
0.45 
(0.24) 
0.57 
(0.23) 
0.19 
(0.18) 
0.52 
(0.03) 
0.07 
(0.00) 
0.09 
(0.14) 
0.27 
(0.26) 
0.36 
(0.16) 
0.21 
(0.17) 
0.52 
(0.38) 
1998 0.66 
(0.51) 
0.64 
(0.36) 
0.54 
(0.21) 
0.57 
(0.23) 
0.61 
(0.30) 
0.58 
(0.19) 
0.82 
(0.17) 
0.60 
(0.02) 
0.43 
(0.24) 
0.47 
(0.29) 
0.50 
(0.35) 
0.45 
(0.22) 
0.19 
(0.17) 
0.07 
(0.01) 
0.23 
(0.11) 
0.07 
(0.10) 
0.28 
(0.25) 
0.33 
(0.13) 
0.53 
(0.37) 
1999 0.76 
(1.02) 
0.54 
(0.26) 
0.78 
(0.43) 
0.47 
(0.22) 
0.50 
(0.20) 
0.66 
(0.24) 
0.54 
(0.16) 
0.51 
(0.21) 
0.53 
(0.07) 
0.27 
(0.15) 
0.33 
(0.27) 
0.20 
(0.23) 
0.30 
(0.20) 
0.06 
(0.03) 
0.22 
(0.23) 
0.36 
(0.21) 
0.04 
(0.02) 
0.33 
(0.20) 
0.51 
(0.47) 
2000 0.62 
(0.26) 
0.59 
(0.25) 
0.75 
(0.63) 
0.83 
(0.54) 
0.51 
(0.23) 
0.76 
(0.35) 
0.52 
(0.19) 
0.54 
(0.15) 
0.37 
(0.12) 
0.48 
(0.06) 
0.29 
(0.19) 
0.16 
(0.09) 
0.21 
(0.10) 
0.37 
(0.28) 
0.17 
(0.23) 
0.14 
(0.20) 
0.13 
(0.10) 
0.04 
(0.01) 
0.46 
(0.32) 
2001 n/a n/a 0.24 
(n/a) 
n/a n/a n/a n/a n/a n/a n/a n/a 0.39 
(0.01) 
n/a n/a 0.06 
(n/a) 
0.05 
(n/a) 
n/a n/a 0.29 
(0.15) 
2002 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0.35 
(0.01) 
n/a n/a 0.55 
(0.00) 
n/a n/a 0.39 
(0.08) 
2003 n/a n/a 1.45 
(n/a) 
n/a n/a n/a n/a 0.47 
(0.07) 
n/a n/a n/a n/a n/a 0.31 
(0.01) 
n/a n/a n/a n/a 0.46 
(0.35) 
2004 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0.30 
(n/a) 
n/a n/a n/a 0.30 
(n/a) 
Total 0.60 
(0.52) 
0.59 
(0.33) 
0.56 
(0.29) 
0.55 
(0.30) 
0.52 
(0.24) 
0.62 
(0.25) 
0.59 
(0.24) 
0.48 
(0.20) 
0.48 
(0.23) 
0.44 
(0.21) 
0.49 
(0.31) 
0.30 
(0.25) 
0.23 
(0.19) 
0.20 
(0.21) 
0.19 
(0.20) 
0.19 
(0.21) 
0.18 
(0.19) 
0.24 
(0.19) 
0.47 
(0.36) 
CV 0.87 0.55 0.53 0.54 0.46 0.40 0.40 0.42 0.47 0.46 0.64 0.83 0.82 1.04 1.07 1.10 1.07 0.80 0.77 
Appendices 
Appendices | 328  
 
Appendix Table 14 Mean (SD) of daily dose of domperidone prescribed in mg/kg/day by age and year 
 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Total 
1990 0.22 
(n/a) 
0.84 
(0.04) 
1.01 
(0.69) 
0.82 
(0.30) 
1.02 
(0.24) 
1.29 
(0.33) 
0.94 
(0.33) 
0.68 
(0.31) 
0.55 
(0.02) 
0.49 
(0.16) 
0.77 
(0.21) 
0.68 
(0.17) 
0.65 
(0.18) 
0.54 
(0.18) 
0.59 
(0.18) 
0.50 
(0.13) 
0.47 
(0.09) 
0.53 
(0.12) 
0.61 
(0.25) 
1991 2.67 
(1.99) 
0.66 
(0.34) 
0.54 
(n/a) 
1.10 
(0.18) 
0.84 
(0.21) 
0.77 
(0.03) 
0.69 
(0.03) 
0.61 
(0.10) 
0.88 
(0.46) 
0.57 
(0.32) 
0.38 
(0.33) 
0.63 
(0.20) 
0.63 
(0.16) 
0.63 
(0.20) 
0.61 
(0.17) 
0.57 
(0.18) 
0.52 
(0.16) 
0.57 
(0.22) 
0.64 
(0.37) 
1992 0.75 
(0.16) 
0.72 
(0.08) 
0.78 
(0.41) 
0.60 
(0.23) 
0.60 
(0.26) 
0.48 
(0.22) 
0.50 
(0.19) 
0.61 
(0.02) 
0.71 
(0.38) 
0.58 
(0.18) 
0.54 
(0.14) 
0.60 
(0.20) 
0.53 
(0.18) 
0.59 
(0.10) 
0.59 
(0.16) 
0.56 
(0.18) 
0.53 
(0.09) 
0.54 
(0.13) 
0.57 
(0.17) 
1993 n/a 0.76 
(0.25) 
1.02 
(0.56) 
0.82 
(0.26) 
0.57 
(0.29) 
0.73 
(0.34) 
0.60 
(0.13) 
0.62 
(0.22) 
0.70 
(0.48) 
0.51 
(0.04) 
0.61 
(0.20) 
0.65 
(0.22) 
0.60 
(0.18) 
0.60 
(0.15) 
0.51 
(0.18) 
0.52 
(0.16) 
0.59 
(0.21) 
0.54 
(0.15) 
0.60 
(0.24) 
1994 8.08 
(n/a) 
0.50 
(0.11) 
0.51 
(0.20) 
0.47 
(0.05) 
0.80 
(0.50) 
0.63 
(0.12) 
0.66 
(0.22) 
0.51 
(0.16) 
0.86 
(0.33) 
0.46 
(0.13) 
0.48 
(0.30) 
0.51 
(0.21) 
0.60 
(0.20) 
0.63 
(0.15) 
0.57 
(0.16) 
0.56 
(0.16) 
0.58 
(0.18) 
0.54 
(0.12) 
0.60 
(0.47) 
1995 0.36 
(n/a) 
0.60 
(0.06) 
0.79 
(0.63) 
0.68 
(0.25) 
1.11 
(0.26) 
0.70 
(0.27) 
0.67 
(0.28) 
0.57 
(0.11) 
0.52 
(0.10) 
0.62 
(0.28) 
0.51 
(0.15) 
0.64 
(0.33) 
0.63 
(0.25) 
0.66 
(0.20) 
0.57 
(0.15) 
0.54 
(0.11) 
0.61 
(0.19) 
0.56 
(0.19) 
0.61 
(0.24) 
1996 0.51 
(0.08) 
0.74 
(0.32) 
0.56 
(n/a) 
0.59 
(0.30) 
0.79 
(0.44) 
1.02 
(0.38) 
0.58 
(0.12) 
0.61 
(0.18) 
0.47 
(0.19) 
0.50 
(0.08) 
0.46 
(0.22) 
0.53 
(0.18) 
0.56 
(0.26) 
0.56 
(0.18) 
0.57 
(0.14) 
0.57 
(0.12) 
0.58 
(0.18) 
0.53 
(0.12) 
0.57 
(0.20) 
1997 1.09 
(1.11) 
0.90 
(0.40) 
0.72 
(0.32) 
0.73 
(0.31) 
0.78 
(0.25) 
0.76 
(0.14) 
0.64 
(0.22) 
0.57 
(0.19) 
0.61 
(0.18) 
0.71 
(0.32) 
0.49 
(0.20) 
0.56 
(0.27) 
0.58 
(0.28) 
0.52 
(0.22) 
0.52 
(0.16) 
0.49 
(0.16) 
0.55 
(0.18) 
0.52 
(0.11) 
0.60 
(0.27) 
1998 0.86 
(0.32) 
1.14 
(0.42) 
0.81 
(0.32) 
0.83 
(0.34) 
0.97 
(0.90) 
0.79 
(0.12) 
0.81 
(0.11) 
0.80 
(0.10) 
0.65 
(0.16) 
0.63 
(0.19) 
0.57 
(0.33) 
0.55 
(0.25) 
0.62 
(0.30) 
0.52 
(0.21) 
0.52 
(0.28) 
0.57 
(0.21) 
0.55 
(0.19) 
0.56 
(0.17) 
0.65 
(0.33) 
1999 0.82 
(0.40) 
0.73 
(0.29) 
0.78 
(0.17) 
0.70 
(0.23) 
0.72 
(0.29) 
0.75 
(0.25) 
0.68 
(0.15) 
0.62 
(0.18) 
0.67 
(0.23) 
0.47 
(0.15) 
0.53 
(0.15) 
0.53 
(0.28) 
0.84 
(0.59) 
0.67 
(0.33) 
0.62 
(0.25) 
0.61 
(0.31) 
0.64 
(0.30) 
0.56 
(0.21) 
0.65 
(0.29) 
2000 0.70 
(0.39) 
0.79 
(0.43) 
0.67 
(0.21) 
0.73 
(0.17) 
1.04 
(0.59) 
0.71 
(0.37) 
0.66 
(0.11) 
0.53 
(0.36) 
0.78 
(0.27) 
0.49 
(0.26) 
0.61 
(0.32) 
0.51 
(0.24) 
0.55 
(0.27) 
0.67 
(0.33) 
0.62 
(0.28) 
0.65 
(0.35) 
0.62 
(0.29) 
0.63 
(0.26) 
0.66 
(0.33) 
2001 0.66 
(0.32) 
0.59 
(0.34) 
0.63 
(0.28) 
0.74 
(0.69) 
0.56 
(0.28) 
0.71 
(0.13) 
0.66 
(0.29) 
0.55 
(0.23) 
0.36 
(0.16) 
0.46 
(0.17) 
0.78 
(0.49) 
0.54 
(0.28) 
0.74 
(0.39) 
0.53 
(0.37) 
0.65 
(0.37) 
0.56 
(0.24) 
0.54 
(0.28) 
0.56 
(0.23) 
0.59 
(0.33) 
2002 0.71 
(0.31) 
0.67 
(0.30) 
0.62 
(0.20) 
0.45 
(0.11) 
0.51 
(0.14) 
0.46 
(0.22) 
0.70 
(0.02) 
0.76 
(0.30) 
0.45 
(0.14) 
0.43 
(0.31) 
0.75 
(0.51) 
0.69 
(0.32) 
0.62 
(0.28) 
0.66 
(0.34) 
0.62 
(0.46) 
0.65 
(0.39) 
0.65 
(0.29) 
0.58 
(0.30) 
0.62 
(0.32) 
2003 0.67 
(0.30) 
0.67 
(0.28) 
0.84 
(0.67) 
0.64 
(0.20) 
0.47 
(0.16) 
0.48 
(0.16) 
0.72 
(0.33) 
0.63 
(0.31) 
0.67 
(0.29) 
0.55 
(0.20) 
0.74 
(0.31) 
0.59 
(0.27) 
0.74 
(0.36) 
0.56 
(0.20) 
0.74 
(0.36) 
0.72 
(0.45) 
0.58 
(0.30) 
0.62 
(0.32) 
0.65 
(0.33) 
2004 0.86 
(0.61) 
0.69 
(0.27) 
0.80 
(0.31) 
0.79 
(0.32) 
0.69 
(0.21) 
0.55 
(0.37) 
0.64 
(0.31) 
0.67 
(0.45) 
0.55 
(0.32) 
0.61 
(0.27) 
0.61 
(0.38) 
0.67 
(0.29) 
0.67 
(0.24) 
0.71 
(0.33) 
0.57 
(0.29) 
0.58 
(0.34) 
0.58 
(0.32) 
0.52 
(0.21) 
0.67 
(0.39) 
2005 0.74 
(0.32) 
0.68 
(0.39) 
0.53 
(0.19) 
0.70 
(0.29) 
0.72 
(0.25) 
0.85 
(0.32) 
0.72 
(0.34) 
0.76 
(0.30) 
0.64 
(0.42) 
0.51 
(0.27) 
0.54 
(0.27) 
0.64 
(0.24) 
0.70 
(0.31) 
0.60 
(0.23) 
0.62 
(0.29) 
0.60 
(0.31) 
0.57 
(0.29) 
0.54 
(0.25) 
0.64 
(0.31) 
2006 0.83 
(0.40) 
0.85 
(0.71) 
0.69 
(0.31) 
0.60 
(0.22) 
0.53 
(0.34) 
0.71 
(0.51) 
1.19 
(0.64) 
0.79 
(0.29) 
0.73 
(0.38) 
0.51 
(0.37) 
0.55 
(0.28) 
0.70 
(0.43) 
0.71 
(0.26) 
0.58 
(0.23) 
0.53 
(0.20) 
0.58 
(0.18) 
0.54 
(0.17) 
0.56 
(0.21) 
0.68 
(0.41) 
Total 0.78 
(0.51) 
0.75 
(0.48) 
0.68 
(0.34) 
0.69 
(0.34) 
0.69 
(0.40) 
0.67 
(0.33) 
0.75 
(0.38) 
0.67 
(0.30) 
0.62 
(0.33) 
0.53 
(0.27) 
0.60 
(0.33) 
0.62 
(0.29) 
0.67 
(0.31) 
0.60 
(0.26) 
0.60 
(0.28) 
0.60 
(0.30) 
0.58 
(0.25) 
0.56 
(0.22) 
0.64 
(0.34) 
CV 0.64 0.64 0.50 0.50 0.58 0.49 0.51 0.45 0.53 0.51 0.55 0.46 0.46 0.43 0.48 0.50 0.44 0.40 0.53 
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A.3 Inconsistencies in prescribed daily dose against unit weight in the absence of 
evidence for appropriate dosage required in children 
Appendix Figure 1 Prescribed daily dose of cisapride in mg/kg for children in different age groups 
 
RDD = Recommended daily dose 
 
Appendix Figure 2 Prescribed daily dose of domperidone in mg/kg for children in different age groups 
 
RDD = Recommended daily dose 
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A.4 Quantitative review data 
Appendix Table 15 Trial level characteristics of studies in safety review meta-analysis 
Author Comparison Duration Dose 
(mg/kg/day) 
                
Cucchiara (1987) Cis vs. Pl 8 0.9 8 24.7 9 19.5 
Van Eygen (1989a) Cis vs. Pl 4 0.45 12 4 11 4 
Van Eygen (1989b) Cis vs. Pl 4 0.45 14 5.7 17 3.7 
Vandenplas (1991) Cis vs. Pl 2 0.8 21 3 21 3 
Castro (1994) Cis vs. Pl 4 0.6 15 27.6 15 27.6 
Scott (1997) Cis vs. Pl 6 0.8 20 8.4 16 8.3 
Cohen (1999) Cis vs. Pl 2 0.8 38 7.3 30 8.3 
Clara (1979) Dom vs. Pl 4 0.9 14 48 18 72 
De Loore (1979) Dom vs. Pl 2 0.9 15 9 15 6 
Bines (1992) Dom vs. Pl 4 1.8 8 43.2 9 28.8 
Carroccio (1994) Dom vs. Pl 8 0.9 20 5 20 4 
Hegar (2009) Dom vs. 
Cis
a 
4 0.8 10 6 10 5 
Cis = Cisapride, Dom = Domperidone, Pl = Placebo. T denotes treated group, and C denotes control group 
a
 Cisapride is the control group 
 
Appendix Table 16 Reported number of children who had worse, same, or slight improvement (r) versus 
moderate or excellent improvement (n-r) 
Author             
Cucchiara (1987) 2 8 7 9 
Van Eygen (1989a) 2 10 7 11 
Van Eygen (1989b) 5 12 8 11 
Vandenplas (1991) 7 21 11 21 
Castro (1994) 1 14 14 15 
Scott (1997) 10 20 7 16 
Cohen (1999) 27 38 15 30 
Clara (1979) 0 14 2 18 
De Loore (1979) 1 15 7 15 
Carroccio (1994) 4 20 10 20 
T denotes treated group, and C denotes control group 
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Appendix Table 17 Reflux index 
Author                      
Cucchiara (1987) Baseline 25.68 11.65 8 32.71 18.35 9 
Cucchiara (1987) End of 
trial 
11.83 11.07 8 23.85 13.57 9 
Vandenplas (1991) Baseline 29.7 11.97 14 33.1 13.56 15 
Vandenplas (1991) End of 
trial 
12.5 8.61 14 18.5 11.62 15 
Castro (1994) Baseline 12.85 8.96 15 13.73 12.38 15 
Castro (1994) End of 
trial 
3.84 3.47 14 13.42 7.47 15 
Scott (1997) Baseline 17 15 18 22 25 15 
Scott (1997) End of 
trial 
15 20 18 20 17 15 
Cohen (1999) Baseline 8.9 6.6 50 9.1 6.6 45 
Cohen (1999) End of 
trial 
7.1 7.9 38 10 7.8 30 
Bines (1992) Baseline 15.9 - 8 15.2 - 9 
Bines (1992) End of 
trial 
11.8 - 8 15.9 - 9 
Carroccio (1994) Baseline 10 - 20 9 - 20 
Carroccio (1994) End of 
trial 
8 - 20 9 - 20 
Hegar (2009) Baseline 4.44 6.1 10 5.68 5.34 10 
Hegar (2009) End of 
trial 
2.19 1.2 10 2.53 2.95 10 
T denotes treated group, and C denotes control group. “–” denotes missing data. 
 
Appendix Table 18 Reported number of children with any adverse events 
Author             
Cucchiara (1987) 0 8 0 9 
Castro (1994) 0 14 0 15 
Scott (1997) 14 23 13 26 
Cohen (1999) 42 50 32 45 
Clara (1979) 0 14 0 18 
Bines (1992) 5 8 2 9 
Carroccio (1994) 0 20 0 20 
Hegar (2009) 0 10 1 10 
T denotes treated group, and C denotes control group 
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A.5 WinBUGS codes for quantitative review 
Appendix Table 19 WinBUGS codes for Model    
# Logistic regression model 
for(i in 1:N)  { # N = number of rows in dataset 
 logit(p[i])<-mu[s[i]]+ delta[i]  * (1-equals(t[i],b[i])) 
r[i]~dbin(p[i],n[i]) 
delta[i] ~ dnorm(md[i],tau) 
md[i] <- d[t[i]] - d[b[i]] 
} 
 
# pairwise odds ratios 
for (c in 1:(NT-1)) { # NT = number of treatments in dataset 
for (k in (c+1):NT) { 
lor[c,k] <- d[k] - d[c] 
log(or[c,k]) <- lor[c,k]  
} 
} 
} 
 
# Consistency check - Bucher's method for binary endpoints using data from direct evidence 
indirect <- lor[2,3] 
direct <- lor.domcis 
logit(p.d) <- m.c + lor.domcis 
logit(p.c) <- m.c 
r.d ~ dbin(p.d,n.d) 
r.c ~ dbin(p.c,n.c) 
m.c ~ dnorm(0,0.1) 
lor.domcis ~ dnorm(0,0.1) 
omega <- direct – indirect 
 
# Priors 
for(j in 1:NS) { # NS =  number of studies in dataset 
mu[j]~dnorm(0,0.0001)  
} 
d[1]<-0 
for (k in 2:NT) { 
d[k] ~ dnorm(0,0.0001) 
}    
tau ~ dgamma(10,10) 
sd <- 1/sqrt(tau) 
# Priors for sensitivity analyses 
#tau<-1/pow(sd,2) 
#sd~dunif(0,2) 
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Appendix Table 20 WinBUGS codes for Model    
# Linear regression model 
for (i in 1:N) { # N = number of rows in dataset 
 y[i] ~ dnorm(mu[i],tau[i]) 
 mu[i] <- gamma[s[i]] + lambda[i]*(1-equals(t[i],b[i])) 
 lambda[i] ~ dnorm(lambda.t[i], tau.lambda) 
 lambda.t[i] <- eff[t[i]] - eff[b[i]] 
} 
   
# Pairwise difference 
for (c in 1:(NT-1)){ 
 for (k in (c+1):NT){ 
  trt.diff[k,c] <- eff[k] - eff[c] 
 } 
} 
 
# Consistency check - Bucher's method for continuous endpoints using data from direct 
evidence 
indirect <- trt.diff[3,2] 
direct <- ri.dom - ri.cis 
ri.dom ~ dnorm(2.19, t.dom) 
ri.cis ~ dnorm(2.53, t.cis) 
t.dom <- 1/var.dom 
var.dom <- 1.2*1.2/10 
t.cis <- 1/var.cis 
var.cis <- 2.95*2.95/10 
omega <- direct - indirect 
 
# priors 
for (i in 1:N) { 
 tau[i] <- 1/var[i] 
 var[i] <- (sde[i]*sde[i])/ne[i] 
 sde[i] ~ dnorm(pooled.sde,tau.sde)I(0,) 
} 
pooled.sde ~ dunif(0,20) 
tau.sde ~ dgamma(1,1) 
tau.lambda ~ dgamma(10,10) 
 
for (j in 1:NS) { # NS = number of studies in dataset 
 mu[j] ~ dnorm(0,0.0001) 
} 
 
eff[1] <- 0 
for (k in 1:NT) { # NT = number of trials in dataset 
 eff[k] ~ dnorm(0,0.0001) 
} 
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Appendix Table 21 WinBUGS codes amendments for Model   
# Covariates adjustment for logistic regression model 
for (i in 1:N){ 
delta[i] <- theta[i] + beta.age*(age[i]-m.age) + beta.dose[t[i]]*(logdose[i]) + 
beta.dur*(dur[i]-m.dur)  
theta[i] ~ dnorm(md[i], tau) 
} 
 
# Covariates adjustment for linear regression model 
for (i in 1:N){ 
lambda[i] <- theta[i] + beta.age*(age[i]-m.age) + beta.dose[t[i]]*(logdose[i]) + 
beta.dur*(dur[i]-m.dur)  
theta[i] ~ dnorm(lambda.t[i], tau) 
} 
 
# log-transform dose 
for (i in 1:N) { 
logdose[i] <- log(dose[i]) 
} 
 
# Means for centering 
m.age <- mean(age[]) 
m.dur <- mean(dur[]) 
   
# Priors 
beta.age ~ dnorm(0,0.00001) 
beta.dur ~ dnorm(0,0.00001) 
for (j in 1:2){ 
 beta.dose[j] ~ dnorm(0,1) 
} 
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A.6 Stata codes  
A.6.1 Codes snippets to split data in halves 
 
 
************************************** 
* Split data in halves by patient ID * 
************************************** 
 
encode caseid, gen(cid) 
bys caseid (exposed): gen N=_N 
 
local cl = 2 
forvalues x=1/`cl'{ 
    preserve 
    keep if exposed==1 
    singleout idno, clear 
  
    if `x'>1{ 
        local y = `x'-1 
   forvalues r=1/`y'{ 
       sort cid 
  merge cid using "CandidatePotentialDom`r'.dta" 
  drop if _merge==3 
  drop _merge 
   } 
    } 
 
    set seed `x' 
    local pct = 100/(`cl'+1-`x') 
    sample `pct', by(ageh N) 
    keep cid 
    sort cid 
    save "CandidatePotentialDom`x'.dta", replace 
    restore 
} 
 
gen finalsample = . 
qui forvalues x=1/`cl'{ 
    sort cid 
    merge cid using "CandidatePotentialDom`x'.dta", _merge(sample`x') 
    recode sample`x' 1=0 3=1 
    replace finalsample = `x' if sample`x'==1 
} 
bys finalsample: tab ageh exposed,mis sum(indexage) mean 
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A.6.2 Codes snippets to calculate PRR 
 
 
  
************************************************************ 
* calculate PRR for each reaction                          * 
*----------------------------------------------------------* 
* note: each row contains number with and without one type * 
*       of reaction for exposed and unexposed              * 
************************************************************ 
 
local row = 1 
local total = _N 
while `row'<=`total'{ 
    local a = Nreac_exp[`row'] 
    local b = Nreac_unexp[`row'] 
    local c = Nnoreac_exp[`row']  
    local d = Nnoreac_unexp[`row'] 
    cap csi `a' `b' `c' `d' 
    foreach x in rr rd{ 
        qui replace `x' = r(`x') in `row' 
        foreach y in lb ub{ 
            qui replace `y'_`x' = r(`y'_`x') in `row' 
        } 
    } 
    qui replace pval = r(p) in `row' 
    qui replace chi2 = r(chi2) in `row' 
 
    local ++row 
} 
 
********************************* 
* PRRs criteria MHRA            * 
* ------------------------------* 
* PRR≥2,  2  4                  * 
* no. of (exposed) cases ≥3     * 
********************************* 
 
gen meetcriteria = ((rr>=2 & rr!=.) & (chi2>=4 & chi2!=.) /// 
& (Nreac_exp>=3 & Nreac_exp!=.)) 
 
*********************************** 
* Rank raised signals by p-values * 
*********************************** 
 
egen rank = rank(pval) if meetcriteria==1 , unique 
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A.7 Raised signals from PRRs algorithm 
Appendix Table 22 Domperidone raised signals 
Read Term Details 3-byte Notes from teleconference on 07 
Aug 2009 
Housing dependency scale 13F exclude - sociological status 
Social/personal history NOS 13Z exclude - sociological status 
H/O: regular medication 14Q exclude - procedure codes 
Feeding problem symptom 163 exclude - GOR related 
Fluid intake symptom 164 OK 
Indigestion symptoms 195 OK 
Type of GIT pain 196 OK 
Site of GIT pain 197 OK 
O/E - dead 22J OK 
Sample sent to lab for test 414 exclude - procedure codes 
Full blood count - FBC 424 exclude - procedure codes 
Computerised axial tomography 567 OK 
Other diagnostic ultrasound 585 exclude - procedure codes 
Post-coital contraception 61A OK 
Ultrasound scan 58D exclude - procedure codes 
Maturity of baby 635 exclude - comorbidity 
Influenza vaccination 65E OK 
Stomach and pylorus operations 761 exclude - procedure codes 
Other miscellaneous operations 7L1 exclude - procedure codes 
Dressing of wound 81H exclude - procedure codes 
Drug therapy 8B3 exclude - procedure codes 
Prophylactic drug therapy 8B6 exclude - procedure codes 
Other misc. Therapy 8BA exclude - procedure codes 
Ill-defined intestinal tract infections A08 OK 
Iron deficiency anaemias D00 exclude - comorbidity 
Hereditary haemolytic anaemias D10 exclude - comorbidity 
Psychogenic syndromes NEC E27 OK 
Specific delays in development E2F exclude - GOR related 
Epilepsy F25 OK 
Migraine F26 OK 
Acute bronchitis and bronchiolitis H06 OK 
Pneumonia due to unspecified organism H26 OK 
Disease of oesophagus J10 exclude - GOR related 
Gastritis and duodenitis J15 OK 
Disorders of stomach function J16 OK 
Inguinal hernia J30 exclude - comorbidity 
Functional gastrointestinal tract disorders 
NEC 
J52 OK 
Intestinal malabsorption J69 OK 
Female genital organ symptoms K58 OK 
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Other bone and cartilage disorders N33 OK 
Ventricular septal defect P54 exclude - comorbidity 
Patent ductus arteriosus P70 exclude - comorbidity 
[D]Nutrition, metabolic and developmental 
symptoms 
R03 OK 
[D]Digestive system symptoms R07 OK 
Other abdominal and pelvic symptoms R09 OK 
Other procedure complication NEC SP2 exclude - procedure codes 
 
Appendix Table 23 Cisapride raised signals 
Read Term Details 3-byte Notes from teleconference on 07 
Aug 2009 
Feeding problem symptom 163 exclude - GOR related 
Site of GIT pain 197 OK 
Constipation 19C OK 
Type of sample 4I2 OK 
Standard chest X-ray 535 OK 
Maturity of baby 635 exclude - comorbidity 
Drug therapy 8B3 exclude - procedure codes 
Prophylactic drug therapy 8B6 exclude - procedure codes 
Specific delays in development E2F exclude - GOR related 
Acute bronchitis and bronchiolitis H06 OK 
Functional gastrointestinal tract disorders 
NEC 
J52 OK 
Other urethral and urinary tract disorders K19 OK 
Other local infections of skin and 
subcutaneous tissue 
M07 OK 
Other fetal and newborn respiratory 
conditions 
Q31 exclude - comorbidity 
[D]Symptoms affecting skin and other 
integumentary tissue 
R02 OK 
[D]Respiratory system and chest symptoms R06 OK 
[D]Digestive system symptoms R07 OK 
Other abdominal and pelvic symptoms R09 OK 
[V]Persons with a condition influencing their 
health status 
ZV4 exclude - general 
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A.8 Effects of cumulative dose from random-effects logistic regressions 
Appendix Table 24 Odds ratios (95% confidence intervals) of observing a confirmed signal for every 50% 
increase in cumulative dose of cisapride from random-effects logistic regressions 
 < 2 years old ≥   years old Overall 
Other GI pain
a 1.03 (0.29,3.71) 1.07 (0.94,1.23) 1.08 (0.94,1.23) 
Bronchitis and bronchiolitis 1.07 (0.95,1.21) 1.84 (1.37,2.48)
 †
 1.21 (1.10,1.33)
 †
 
Coughing
b 1.50 (1.21,1.86)
† 
1.64 (1.29,2.08)
† 
1.46 (1.27,1.67)
† 
a
 not including constipation, gastrointestinal colic, and indigestion symptoms 
b
 IRR of exposed versus unexposed from original signal was in the opposite direction 
†
 statistically significant at 95% level 
 
Appendix Table 25 Odds ratios (95% confidence intervals) of observing a confirmed signal for every 50% 
increase in cumulative dose of domperidone from random effects logistic regressions 
 < 2 years old ≥   years old Overall 
Abdominal pain 0.97 (0.91,1.03) 1.26 (1.21,1.31)
 †
 1.09 (1.06,1.12)
 †
 
GIT colic 0.75 (0.53,1.06) 1.63 (1.06,2.50)
 †
 1.03 (0.85,1.24) 
Other GI pain
a 1.01 (0.79,1.29) 1.30 (1.20,1.40)
 †
 1.27 (1.18,1.37)
 †
 
Anorexia and weight loss 1.19 (0.80,1.77) 1.31 (1.05,1.64)
b† 
1.28 (1.06,1.56)
 †
 
Bronchitis and bronchiolitis 1.14 (1.05,1.24)
 †
 1.73 (1.54,1.94)
 †
 1.34 (1.26,1.42)
 †
 
Death 1.39 (0.98,1.98) 2.01 (1.13,3.55)
 †
 1.51 (1.13,2.02)
 †
 
Dysmenorrhoea n/a See overall
c 
1.37 (0.93,2.01) 
Epilepsy 0.95 (0.75,1.22) 1.98 (1.43,2.74)
 †
 1.39 (1.17,1.64)
 †
 
Influenza vaccination 0.86 (0.56,1.32) 3.18 (1.36,7.45)
 †
 1.58 (1.19,2.11)
 †
 
Migraine n/a 1.19 (0.97,1.47)
b 
1.11 (0.93,1.34) 
Pneumonia 1.11 (0.76,1.62) 1.98 (1.19,3.31)
 †
 1.47 (1.14,1.89)
 †
 
Post-coital contraception n/a See overall
c 
1.13 (0.80,1.59) 
Sleep disorders 1.19 (0.86,1.63) 2.06 (1.25,3.40)
 †
 1.48 (1.18,1.86)
 †
 
a 
not including gastritis and duodenitis, gastrointestinal colic, and indigestion symptoms 
b
 only restricted to, or  
c
 only observed in children over 12 years old 
“n/a” indicates that the signal was not observed in that age group; and “n/e” indicates that model did not 
converge due to small numbers 
†
 statistically significant at 95% level 
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A.9 Clinical events for children who died within domperidone exposure time period 
 Events before first 
prescription of 
domperidone 
Date of 
event 
Events after the first 
prescription of 
domperidone 
Date of 
event 
1 O/E - weight 05JAN2006 Krabbe's disease 13APR2006 
 Child exam.: hearing 19JAN2006 Constipation 21APR2006 
 Exam. of cardiovascular 
system 
19JAN2006 Myoclonic encephalopathy 21APR2006 
 Immunisation 
contraindicated 
19JAN2006 Upper respiratory infection 
NOS 
15MAY2006 
 O/E - height 19JAN2006 Cough 23MAY2006 
 Snuffles 02FEB2006 Chest infection 31MAY2006 
 Crying 18FEB2006 Thrush 06JUN2006 
  . Oral thrush 12JUN2006 
  . Tearful 28JUN2006 
  . [D]Fit (in non epileptic) 
NOS 
01JUL2006 
  . Vomiting 17JUL2006 
  . O/E - weight 20JUL2006 
  . Difficulty breathing 14SEP2006 
  . Death 31OCT2006 
2  . Edward's syndrome - 
trisomy 18 
04NOV2005 
  . Terminal care 04NOV2005 
  . Echocardiogram 09DEC2005 
  . Primary pulmonary 
hypertension 
09DEC2005 
  . Ventricular septal defect 09DEC2005 
  . Gastro-oesophageal reflux 
with oesophagitis 
19JAN2006 
  . Prescription not collected 20JAN2006 
  . O/E - weight 23JAN2006 
  . Congestive heart failure 31JAN2006 
  . [D]Cardiorespiratory failure 31JAN2006 
  . Death 31JAN2006 
3 Neonatal snuffles 04APR2006 Jaundice - symptom 15AUG2006 
 Vomiting 30APR2006 Terminal care 15AUG2006 
 Registered blind 09MAY2006 Death 30AUG2006 
 Nystagmus 15JUN2006  . 
 Optic atrophy 07JUL2006  . 
4 Child exam.: hearing 20NOV2003 Chest infection 30SEP2004 
 Exam. of cardiovascular 
system 
20NOV2003 Death 13OCT2004 
 O/E - weight 20NOV2003  . 
 Chickenpox - varicella 10JUN2004  . 
 Croup 22JUN2004  . 
 [D]Abnormal weight gain 29JUL2004  . 
 Magnetic resonance 
imaging 
09SEP2004  . 
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 Events before first 
prescription of 
domperidone 
Date of 
event 
Events after the first 
prescription of 
domperidone 
Date of 
event 
5 Normal delivery 12FEB2003 O/E - weight 22APR2003 
 O/E - weight 12FEB2003 O/E - height 04JUN2003 
 Perinatal conditions 12FEB2003 Blue - symptom 05JUL2003 
 Coryza - acute 09APR2003 Nasal congestion 04SEP2003 
  . Chest infection 25SEP2003 
  . Upper respiratory infection 
NOS 
29SEP2003 
  . Cardiac catheterisation 06JAN2004 
  . Head injury 08MAR2004 
  . O/E - blood pressure 
reading 
08MAR2004 
  . O/E - pulse rate 08MAR2004 
  . Feels unwell 15APR2004 
  . Allergic reaction 17APR2004 
  . Congenital cardiovascular 
disorders in 
preg/childb/puerp 
01MAY2004 
  . Constipation 09AUG2004 
  . Weight decreasing 11OCT2004 
  . Ventricular septal defect 22OCT2004 
  . Insulin dependent diabetes 
mellitus 
04NOV2004 
  . Vomiting 19NOV2004 
  . Chesty cough 07DEC2004 
  . Patient's condition 
improved 
09DEC2004 
  . Nasal catarrh - acute 11DEC2004 
  . Acute left otitis media 14FEB2005 
  . Undescended testicle 30MAR2005 
  . Other development delays 25APR2005 
  . Viral illness 07MAY2005 
  . Minor head injury 29JUN2005 
  . Cardio-respiratory arrest 04JUL2005 
  . Died 05JUL2005 
6  . Blepharitis 14JUN2001 
  . Chest infection NOS 14JUN2001 
  . C/O - catarrh 09AUG2001 
  . Patient's condition 
improved 
22AUG2001 
  . Patient's condition 
deteriorating 
29NOV2001 
  . Learning difficulties 05JUL2002 
  . Nocturnal cough / wheeze 23JUL2002 
  . Shortness of breath 02SEP2002 
  . Terminal care 06SEP2002 
  . Chronic obstructive 
airways disease 
10SEP2002 
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 Events before first 
prescription of 
domperidone 
Date of 
event 
Events after the first 
prescription of 
domperidone 
Date of 
event 
  . Death 10SEP2002 
7 Hearing test abnormal 12JUL2004 Crying, excessive 28JUL2004 
  . Cardiac failure 03AUG2004 
  . Edward's syndrome - 
trisomy 18 
14AUG2004 
  . Death 26AUG2004 
8 Horseshoe kidney 27DEC2002 Health visitor visits 12MAY2004 
 Infant feeding problem 27DEC2002 Epilepsy 26OCT2004 
 William syndrome 27DEC2002 Vomiting 15NOV2004 
 O/E - hyperventilating 05JAN2003 Influenza vaccination 26NOV2004 
 Acute bronchiolitis 20JAN2003 Cough 25MAY2005 
 Inguinal hernia 19FEB2003 [D]Fever NOS 16SEP2005 
 Health visitor visits 20FEB2003 H/O: pneumonia 17DEC2005 
 Infantile spasms 04MAR2003 Death 17DEC2005 
 Seizures in newborn 11APR2003  . 
 Urinary tract infection, 
site not specified NOS 
18MAY2003  . 
 Eye infection 23JUL2003  . 
 Primary repair of inguinal 
hernia NOS 
01SEP2003  . 
 Cough 29SEP2003  . 
 O/E - a rash 03DEC2003  . 
 Epilepsy 08DEC2003  . 
 Perinatal cyanotic attacks 
NOS 
16JAN2004  . 
 Chest infection 01APR2004  . 
9 Gastroenteritis 06AUG2004 Physiotherapy/remedial 
therapy 
21JAN2005 
 General symptom NOS 08SEP2004 Visual loss NOS 21JAN2005 
 Viral infection NOS 08SEP2004 Acute upper respiratory 
tract infection 
28JAN2005 
 O/E - weight 01OCT2004 Medication increased 09MAR2005 
 Abdomen examined - 
NAD 
06OCT2004 Cough 21MAR2005 
 CVS examined - NAD 06OCT2004 O/E - weight 13APR2005 
 O/E - chest examination 
normal 
06OCT2004 Infant feeding problem 22APR2005 
 Anoxic brain damage 19NOV2004 General symptom NOS 20JUL2005 
  . Nonsuppurative otitis media 
+ eustachian tube disorders 
15AUG2005 
  . Chest infection 23SEP2005 
  . Removal of suture of skin 24NOV2005 
  . Excessive granulation tissue 06JAN2006 
  . Death 31JAN2006 
10  . Child 6 week exam. normal 05AUG2003 
  . Child exam.: hearing 05AUG2003 
  . Exam. of cardiovascular 05AUG2003 
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 Events before first 
prescription of 
domperidone 
Date of 
event 
Events after the first 
prescription of 
domperidone 
Date of 
event 
system 
  . Lissencephaly 01SEP2003 
  . Bronchopneumonia due to 
unspecified organism 
31OCT2003 
  . Died 31OCT2003 
 
 
 
 
- End of thesis - 
